1. Patent Search
  2. Details

TEAD INHIBITORS AND METHODS OF USE

20250223306 ยท 2025-07-10

    Inventors

    Cpc classification

    International classification

    Abstract

    The present disclosure provides, in part, compounds of formula (I), wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, such as proliferative disorders, mediated by TEA domain transcription factors.

    Claims

    1. A compound having the chemical formula (I): ##STR00401## or a pharmaceutically acceptable salt thereof, wherein: X is N or CH; R.sup.1 is selected from the group consisting of C(O)OR.sup.5, C(O)NR.sup.6R.sup.2, S(O).sub.2N(R.sup.6).sub.2, S(O).sub.m(C.sub.1-6alkyl), and S(O)N(R.sup.6).sub.2; R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.0-C.sub.4 alkylene)-phenyl, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2, 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), (C.sub.0-C.sub.4 alkylene)-C.sub.3-C.sub.10cycloalkyl, and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned phenyl, 5-6 membered heteroaryl, C.sub.3-C.sub.10cycloalkyl, and 3-10 membered heterocyclyl are optionally substituted; m is 1 or 2; n is 0, 1, or 2; R.sup.3 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 haloalkyl), O(C.sub.1-C.sub.6 alkyl), and O(C.sub.1-C.sub.6 haloalkyl); R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens; each R.sup.5 is independently hydrogen or C.sub.1-C.sub.6 alkyl; each R.sup.6 is independently hydrogen or C.sub.1-C.sub.6 alkyl; each R.sup.x is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, CN, and N(R.sup.6).sup.2; each R.sup.y is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, CN, and N(R.sup.6).sub.2; s is 0, 1, or 2; and t is 0, 1, 2, or 3.

    2. A compound having the chemical formula (I): ##STR00402## or a pharmaceutically acceptable salt thereof, wherein: X is N or CH; R.sup.1 is selected from the group consisting of C(O)OR.sup.5, C(O)NR.sup.6R.sup.2, S(O).sub.2N(R.sup.6).sub.2, S(O).sub.m(C.sub.1-6alkyl), and S(O)N(R.sup.6).sub.2; R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with CN or OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.0-C.sub.4 alkylene)-phenyl, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7), (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2, 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), (C.sub.0-C.sub.4 alkylene)-C.sub.3-C.sub.10cycloalkyl, and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned phenyl, 5-6 membered heteroaryl, C.sub.3-C.sub.10cycloalkyl, and 3-10 membered heterocyclyl are optionally substituted with one or more R.sup.w; m is 1 or 2; n is 0, 1, or 2; R.sup.3 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 haloalkyl), O(C.sub.1-C.sub.6 alkyl), and O(C.sub.1-C.sub.6 haloalkyl); R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens; each R.sup.5 is independently hydrogen or C.sub.1-C.sub.6 alkyl; each R.sup.6 is independently hydrogen or C.sub.1-C.sub.6 alkyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C(O)(C.sub.1-6 alkyl), C(O)N(R.sup.6).sub.2, C(O).sub.2(C.sub.1-6 alkyl), S(O).sub.n(C.sub.1-C.sub.6 alkyl), and S(O).sub.nNR.sup.6(C.sub.1-C.sub.6 alkyl); each R.sup.w is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, N(R.sup.6).sub.2, and oxo, wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with OH; each R.sup.x is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, and CN; each R.sup.y is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, and CN; s is 0, 1, or 2; and t is 0, 1, 2, or 3.

    3. The compound of claim 1 or 2, wherein X is N.

    4. The compound of any one of claims 1-3, wherein R.sup.1 is C(O)NHR.sub.2.

    5. The compound of any one of claims 1-3, wherein R.sup.1 is C(O)OH.

    6. The compound of any one of claims 1-3, wherein R.sup.1 is S(O)CH.sub.3.

    7. The compound of any one of claims 1-3, wherein R.sup.1 is S(O).sub.2CH.sub.3.

    8. The compound of any one of claims 1-3, wherein R.sup.1 is S(O).sub.2NHCH.sub.3.

    9. The compound of any one of claims 1-8, wherein R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S).

    10. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene)-5-6 membered heteroaryl.

    11. The compound of any one of claims 1-10, wherein R.sup.2 is CH(CH.sub.3)-5-6 membered heteroaryl.

    12. The compound of any one of claims 1-10, wherein R.sup.2 is CH.sub.2-5-6 membered heteroaryl.

    13. The compound of any one of claims 1-12, wherein the 5-6 membered heteroaryl is optionally substituted with C.sub.1-C.sub.6alkyl or N(R.sup.a).sub.2, wherein each R.sup.a is independently hydrogen or C.sub.1-C.sub.6alkyl.

    14. The compound of any one of claims 1-13, wherein the 5-6 membered heteroaryl is pyridyl.

    15. The compound of any one of claims 1-14, wherein the 5-6 membered heteroaryl is ##STR00403##

    16. The compound of any one of claims 1-13, wherein the 5-6 membered heteroaryl is oxazolyl.

    17. The compound of any one of claims 1-13 and 16, wherein the 5-6 membered heteroaryl is ##STR00404##

    18. The compound of any one of claims 1-9, wherein R.sup.2 is C.sub.1-C.sub.6 alkyl.

    19. The compound of any one of claims 1-9 and 18, wherein R.sup.2 is isopropyl.

    20. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5).

    21. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OR.sup.5).

    22. The compound of any one of claims 1-9, 20, and 21, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH).

    23. The compound of any one of claims 1-9 and 20, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH and OCH.sub.3).

    24. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl).

    25. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-CN.

    26. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5.

    27. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2.

    28. The compound of any one of claims 1-9, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2.

    29. The compound of any one of claims 1-28, wherein R.sup.3 is (C.sub.1-C.sub.6 haloalkyl).

    30. The compound of any one of claims 1-29, wherein R.sup.3 is trifluoromethyl.

    31. The compound of any one of claims 1-28, wherein R.sup.3 is halogen (e.g., F).

    32. The compound of any one of claims 1-31, wherein R.sup.4 is hydrogen.

    33. The compound of any one of claims 1-31, wherein R.sup.4 is halogen (e.g., F).

    34. The compound of any one of claims 1-28, wherein R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens (e.g., F).

    35. The compound of any one of claims 1-34, wherein s and t are both 0.

    36. A compound of formula (Ia): ##STR00405## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein the 5-6 membered heteroaryl is optionally substituted; n is 0, 1, or 2; R.sup.3 is selected from the group consisting of halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, and O(C.sub.1-C.sub.6 alkyl); R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the 3-7 membered carbocyclic ring is optionally substituted with one or more halogens; each R.sup.5 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl; and each R.sup.6 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl.

    37. A compound of formula (Ia): ##STR00406## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with CN or OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7), (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein the 5-6 membered heteroaryl is optionally substituted with one or more R.sup.w; n is 0, 1, or 2; R.sup.3 is selected from the group consisting of halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, and O(C.sub.1-C.sub.6 alkyl); R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the 3-7 membered carbocyclic ring is optionally substituted with one or more halogens; each R.sup.5 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl; and each R.sup.6 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C(O)(C.sub.1-6 alkyl), C(O)N(R.sup.6).sub.2, C(O).sub.2(C.sub.1-6 alkyl), S(O).sub.n(C.sub.1-C.sub.6 alkyl), and S(O).sub.nNR.sup.6(C.sub.1-C.sub.6 alkyl); each R.sup.7 is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, N(R.sup.6).sub.2, and oxo, wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with OH.

    38. The compound of claim 36 or 37, wherein the compound is a compound of formula (Ib): ##STR00407## or a pharmaceutically acceptable salt thereof.

    39. The compound of claim 36 or 37, wherein the compound is a compound of formula (Ic): ##STR00408## or a pharmaceutically acceptable salt thereof.

    40. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene)-5-6 membered heteroaryl.

    41. The compound of any one of claims 36-39, wherein R.sup.2 is CH(CH.sub.3)-5-6 membered heteroaryl.

    42. The compound of any one of claims 36-39, wherein R.sup.2 is CH.sub.2-5-6 membered heteroaryl.

    43. The compound of any one of claims 36-42, wherein the 5-6 membered heteroaryl is optionally substituted with C.sub.1-C.sub.6alkyl or N(R.sup.a).sup.2, wherein each R.sup.a is independently hydrogen or C.sub.1-C.sub.6alkyl.

    44. The compound of any one of claims 36-43, wherein the 5-6 membered heteroaryl is pyridyl.

    45. The compound of any one of claims 36-44, wherein the 5-6 membered heteroaryl is ##STR00409##

    46. The compound of any one of claims 36-43, wherein the 5-6 membered heteroaryl is oxazolyl.

    47. The compound of any one of claims 36-43 and 46, wherein the 5-6 membered heteroaryl is ##STR00410##

    48. The compound of any one of claims 37-39, wherein R.sup.2 is selected from the group consisting of (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7).sub.2, (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned 5-6 membered heteroaryl and 3-10 membered heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of methyl, NH.sub.2, and oxo.

    49. The compound of any one of claims 37-39, wherein R.sup.2 is selected from the group consisting of (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein any aforementioned 5-6 membered heteroaryl and 3-10 membered heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of methyl, NH.sub.2, and OXO.

    50. The compound of any one of claims 36-39, wherein R.sup.2 is C.sub.1-C.sub.6 alkyl.

    51. The compound of any one of claims 36-39 and 50, wherein R.sup.2 is isopropyl.

    52. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5).

    53. The compound of any one of claims 36-39 and 52, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OR.sup.5).

    54. The compound of any one of claims 36-39, 52, and 53, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH).

    55. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH and OCH.sub.3).

    56. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl).

    57. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-CN.

    58. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5.

    59. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2.

    60. The compound of any one of claims 36-39, wherein R.sup.2 is (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2.

    61. The compound of any one of claims 36, 37, and 40-60, wherein R.sup.3 is C.sub.1-C.sub.6 haloalkyl.

    62. The compound of any one of claims 36, 37, and 40-61, wherein R.sup.3 is trifluoromethyl.

    63. The compound of any one of claims 36, 37, and 40-60, wherein R.sup.3 is halogen.

    64. The compound of any one of claims 36, 37, 40-60, and 63, wherein R.sup.3 is F.

    65. The compound of any one of claims 36, 37, and 40-64, wherein R.sup.4 is hydrogen.

    66. The compound of any one of claims 36, 37 and 40-64, wherein R.sup.4 is halogen.

    67. The compound of any one of claims 36, 37, 40-64, and 66, wherein R.sup.4 is F.

    68. The compound of any one of claims 36, 37 and 40-60, wherein R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens (e.g., F).

    69. The compound of claim any one of claims 1-68, wherein the compound is selected from Table 1.

    70. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof of any one of claims 1-69; and a pharmaceutically acceptable excipient.

    71. A method of treating a disease or condition mediated by hyperactivation of a TEAD isoform selected from TEAD1 and TEAD 4 in a subject in need thereof comprising administering to the subject, a compound or pharmaceutically acceptable salt of any one of claims 1-69 or a pharmaceutical composition of claim 70.

    72. The method of claim 71, wherein the disease or condition is a cancer characterized by hyperactivation of a TEAD isoform selected from TEAD1 and TEAD4.

    73. The method of claim 72, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer including pancreatic adenocarcinoma, mesothelioma including malignant mesothelioma, hepatocellular cancer, prostate cancer, head and neck cancer, renal cell carcinoma, and medulloblastoma.

    74. The method of claim 72 or 73, wherein the cancer is selected from the group consisting of hepatocellular cancer, breast cancer, pancreatic adenocarcinoma, and malignant mesothelioma.

    75. The method of any one of claims 72-74, wherein the cancer is malignant mesothelioma.

    76. The method of any one of claims 72-75, wherein the cancer is metastatic.

    Description

    BRIEF DESCRIPTION OF THE DRAWINGS

    [0014] The disclosure can be more completely understood with reference to the following drawings.

    [0015] FIG. 1 is a diagram showing the domain architecture of human TEAD1, TEAD2, TEAD3, and TEAD4. The percent values represent the identity of the N-terminal DNA binding domain (DNA-BD) and C-terminal YAP/TAZ binding domain (YAP/TAZ-BD) of TEAD2-4 compared to the respective binding domains of TEAD1. Post translation modifications including palmitoylation and phosphorylation as well as the p38 binding D domain of DNA-BD are also shown.

    [0016] FIG. 2A is a diagram showing the upstream signaling and downstream transcriptional outputs of TEAD in cancer biology, which regulate critical functions in tumorigenesis, stem cell maintenance, cancer immunology, and metabolism, as well as formation of signaling feedback loops. Oncogenic signal transduction pathways include EGFR signaling, TGF signaling, WNt signaling, GPCR signaling, and cancer genes (indicated with *), such as KRAS, BRAF, LKB1, APC, and GNAQ/11.

    [0017] FIG. 2B is a diagram showing the role of TEAD in multiple stages of tumorigenesis.

    DETAILED DESCRIPTION

    [0018] Provided herein, in certain embodiments, are compounds (e.g., compounds of formula (I) or formula (I), e.g., compounds of formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2), or pharmaceutically acceptable salts thereof. Further provided herein, in certain embodiments are compositions comprising a compound of formula (I) or formula (I), e.g., a compound of formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient). Also provided herein, in certain embodiments, are methods of use of compounds and compositions disclosed herein. The contemplated compounds and compositions disclosed herein are inhibitors of transcriptional enhancer factor domain (TEAD) activity and thus are useful in methods of treating certain diseases or disorders such as cancer characterized by abnormal TEAD transcriptional complex activity (e.g., hyperactivation).

    [0019] The present disclosure provides compounds (e.g., compounds of formula (I) or formula (I), e.g., compounds of formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2)) that can selectively bind certain TEAD isoforms associated with therapeutic efficacy (e.g., TEAD1 and/or TEAD4). Such selective binding is advantageous because less selective and/or non-selective TEAD isoform binding may result in an increase in undesirable effects (e.g., toxicity and/or cancer cell proliferation).

    Certain Terminology

    [0020] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. Generally, nomenclatures utilized in connection with, and techniques of, immunology, oncology, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

    Chemical Definitions

    [0021] Definitions of specific functional groups and chemical terms are described in more detail below.

    [0022] In some embodiments, compounds described herein comprise one or more asymmetric centers, and thus exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, in some embodiments, the compounds described herein are in the form of an individual enantiomer, diastereomer or geometric isomer, or are in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. In some embodiments, isomers are isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers are prepared by asymmetric syntheses. The disclosure additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

    [0023] In some embodiments, compound described herein also comprise one or more isotopic substitutions. For example, in some embodiments, H is in any isotopic form, including .sup.1H, .sup.2H (D or deuterium), and .sup.3H (T or tritium); C is any isotopic form, including .sup.12C, .sup.13C, and .sup.14C; O is in any isotopic form, including .sup.16O and .sup.18O; F is in any isotopic form, including .sup.18F and .sup.19F; and the like.

    [0024] The articles a and an are used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article.

    [0025] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, C.sub.1-6 alkyl is intended to encompass, C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-6, C.sub.1-5, C.sub.1-4, C.sub.1-3, C.sub.1-2, C.sub.2-6, C.sub.2-5, C.sub.2-4, C.sub.2-3, C.sub.3-6, C.sub.3-5, C.sub.3-4, C.sub.4-6, C.sub.4-5, and C.sub.5-6 alkyl.

    [0026] As used herein, alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group, e.g., having 1 to 20 carbon atoms (C.sub.1-20 alkyl). In some embodiments, an alkyl group has 1 to 10 carbon atoms (C.sub.1-10 alkyl). In some embodiments, an alkyl group has 1 to 9 carbon atoms (C.sub.1-9 alkyl). In some embodiments, an alkyl group has 1 to 8 carbon atoms (C.sub.1-8 alkyl). In some embodiments, an alkyl group has 1 to 7 carbon atoms (C.sub.1-7 alkyl). In some embodiments, an alkyl group has 1 to 6 carbon atoms (C.sub.1-6 alkyl). In some embodiments, an alkyl group has 1 to 5 carbon atoms (C.sub.1-5 alkyl). In some embodiments, an alkyl group has 1 to 4 carbon atoms (C.sub.1-4 alkyl). In some embodiments, an alkyl group has 1 to 3 carbon atoms (C.sub.1-3 alkyl). In some embodiments, an alkyl group has 1 to 2 carbon atoms (C.sub.1-2 alkyl). In some embodiments, an alkyl group has 1 carbon atom (C.sub.1 alkyl). Examples of C.sub.1-6 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, and the like.

    [0027] As used herein, alkylene, refers to a divalent radical of an alkyl group. When a range or number of carbons is provided for a particular alkylene group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. In some embodiments, alkylene group is substituted or unsubstituted with one or more substituents as described herein.

    [0028] As used herein, aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (C.sub.6-14 aryl).

    [0029] As used herein, heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (5-10 membered heteroaryl). In some embodiments, in heteroaryl groups that contain one or more nitrogen atoms, the point of attachment is a carbon or nitrogen atom, as valency permits.

    [0030] In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heteroaryl). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

    [0031] Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.

    [0032] The term cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-10, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as C.sub.3-C.sub.10cycloalkyl, derived from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclopentanes, cyclobutanes and cyclopropanes.

    [0033] As used herein, heterocyclyl or heterocyclic refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (3-10 membered heterocyclyl). In some embodiments, in heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment is a carbon or nitrogen atom, as valency permits. In some embodiments, a heterocyclyl group is either be monocyclic (monocyclic heterocyclyl) or a fused, bridged or spiro ring system such as a bicyclic system (bicyclic heterocyclyl), and is saturated or is partially unsaturated. In some embodiments, heterocyclyl bicyclic ring systems include one or more heteroatoms in one or both rings. Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more phenyl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. The terms heterocycle, heterocyclyl, heterocyclyl ring, heterocyclic group, heterocyclic moiety, and heterocyclic radical, are used interchangeably.

    [0034] The term carbocyclyl or carbocyclic refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (3-10 membered carbocyclic ring) and zero heteroatoms in the non-aromatic ring system. In some embodiments, carbocyclyl or carbocyclic ring is a 3-7 membered carbocyclic ring.

    [0035] In some embodiments, a heterocyclyl group is a 3-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (3-10 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 4-7 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (4-7 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (5-10 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-8 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heterocyclyl). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.

    [0036] Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. In some embodiments, hetero is applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl; cycloalkyl, e.g., heterocyclyl; aryl, e.g., heteroaryl; and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.

    [0037] The terms halo and halogen as used herein refer to an atom selected from fluorine (fluoro, F), chlorine (chloro, Cl), bromine (bromo, Br), and iodine (iodo, I). In certain embodiments, the halo group is either fluoro or chloro.

    [0038] The term haloalkyl includes mono, poly, and perhaloalkyl groups substituted with one or more halogen atoms where the halogens are independently selected from fluorine, chlorine, bromine, and iodine.

    [0039] The term oxo refers to O.

    [0040] In general, the term substituted, whether preceded by the term optionally or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a substituted group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.

    [0041] Nitrogen atoms are substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.

    [0042] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims. The disclosure is not intended to be limited in any manner by the above exemplary listing of substituents.

    Other Definitions

    [0043] As used herein, pharmaceutically acceptable excipient refers to any substance in a pharmaceutical formulation other than the active pharmaceutical ingredient(s). Exemplary pharmaceutical excipients include those that aid the manufacturing process; protect, support or enhance stability; increase bioavailability; or increase patient acceptability. They may also assist in product identification or enhance the overall safety or function of the product during storage or use.

    [0044] As used herein, pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

    [0045] As used herein, a subject to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms human, patient, individual and subject are used interchangeably herein. None of the terms require the supervision of medical personnel.

    [0046] The terms disease, disorder, and condition are used interchangeably herein.

    [0047] As used herein, and unless otherwise specified, the terms treat, treating and treatment contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition.

    [0048] As used herein, and unless otherwise specified, a therapeutically effective amount of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition. In some embodiments, the term therapeutically effective amount encompasses an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.

    Compounds

    [0049] Disclosed herein, in certain embodiments, are compounds of formula (I):

    ##STR00005##

    or a pharmaceutically acceptable salt thereof, wherein: [0050] X is N or CH; [0051] R.sup.1 is is selected from the group consisting of C(O)OR.sup.5, C(O)NR.sup.6R.sup.2, S(O).sub.2N(R.sup.6).sub.2, S(O).sub.m(C.sub.1-6alkyl), and S(O)N(R.sup.6).sub.2; [0052] R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.0-C.sub.4 alkylene)-phenyl, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2, 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), (C.sub.0-C.sub.4 alkylene)-C.sub.3-C.sub.10cycloalkyl, and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned phenyl, 5-6 membered heteroaryl, C.sub.3-C.sub.10cycloalkyl, and 3-10 membered heterocyclyl are optionally substituted; [0053] m is 1 or 2; [0054] n is 0, 1, or 2; [0055] R.sup.3 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 haloalkyl), O(C.sub.1-C.sub.6 alkyl), and O(C.sub.1-C.sub.6 haloalkyl); [0056] R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or [0057] R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens; [0058] each R.sup.5 is independently hydrogen or C.sub.1-C.sub.6 alkyl; [0059] each R.sup.6 is independently hydrogen or C.sub.1-C.sub.6 alkyl; [0060] each R.sup.x is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, CN, and N(R.sup.6).sub.2; [0061] each R.sup.y is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, CN, and N(R.sup.6).sub.2; [0062] s is 0, 1, or 2; and [0063] t is 0, 1, 2, or 3.

    [0064] Disclosed herein, in certain embodiments, are compounds of formula (I):

    ##STR00006##

    or a pharmaceutically acceptable salt thereof, wherein: [0065] X is N or CH; [0066] R.sup.1 is selected from the group consisting of C(O)OR.sup.5, C(O)NR.sup.6R.sup.2, S(O).sub.2N(R.sup.6).sub.2, S(O).sub.m(C.sub.1-6alkyl), and S(O)N(R.sup.6).sub.2; [0067] R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with CN or OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.0-C.sub.4 alkylene)-phenyl, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7), (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2. 5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), (C.sub.0-C.sub.4 alkylene)-C.sub.3-C.sub.10cycloalkyl, and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned phenyl, 5-6 membered heteroaryl, C.sub.3-C.sub.10cycloalkyl, and 3-10 membered heterocyclyl are optionally substituted with one or more R; [0068] m is 1 or 2; [0069] n is 0, 1, or 2; [0070] R.sup.3 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 haloalkyl), O(C.sub.1-C.sub.6 alkyl), and O(C.sub.1-C.sub.6 haloalkyl); [0071] R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or [0072] R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens; [0073] each R.sup.5 is independently hydrogen or C.sub.1-C.sub.6 alkyl; [0074] each R.sup.6 is independently hydrogen or C.sub.1-C.sub.6 alkyl; [0075] R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C(O)(C.sub.1-6 alkyl), C(O)N(R.sup.6).sub.2, C(O).sub.2(C.sub.1-6 alkyl), S(O).sub.n(C.sub.1-C.sub.6 alkyl), and S(O).sub.nNR.sup.6(C.sub.1-C.sub.6 alkyl); [0076] each R is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, N(R.sup.6).sub.2, and oxo, wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with OH; [0077] each R.sup.x is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, and CN; [0078] each R.sup.y is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, halogen, OR.sup.5, and CN; [0079] s is 0, 1, or 2; and [0080] t is 0, 1, 2, or 3.

    [0081] In some embodiments, X is N. In some embodiments, X is CH.

    [0082] In some embodiments, R.sup.1 is C(O)NHR.sup.2. In some embodiments, R.sup.1 is S(O)R.sup.2. In some embodiments, R.sup.1 is C(O)OH. In some embodiments, R.sup.1 is S(O).sub.2R.sup.2. In some embodiments, R.sup.1 is S(O).sub.2NHR.sup.2. In some embodiments, R.sup.1 is S(O)CH.sub.3. In some embodiments, R.sup.1 is S(O).sub.2CH.sub.3. In some embodiments, R.sup.1 is S(O).sub.2NHCH.sub.3.

    [0083] In some embodiments, R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S).

    [0084] In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene)-5-6 membered heteroaryl.

    [0085] In some embodiments, R.sup.2 is CH(CH.sub.3)-5-6 membered heteroaryl.

    [0086] In some embodiments, R.sup.2 is CH.sub.2-5-6 membered heteroaryl.

    [0087] In some embodiments, the 5-6 membered heteroaryl is optionally substituted with C.sub.1-C.sub.6alkyl or N(R.sup.3).sub.2, wherein each R.sup.a is independently hydrogen or C.sub.1-C.sub.6alkyl.

    [0088] In some embodiments, the 5-6 membered heteroaryl is pyridyl. In some embodiments, the the 5-6 membered heteroaryl is

    ##STR00007##

    In some embodiments, the 5-6 membered heteroaryl is oxazolyl. In some embodiments, the 5-6 membered heteroaryl is

    ##STR00008##

    [0089] In some embodiments, R.sup.2 is C.sub.1-C.sub.6alkyl. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl)-OH. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl)-O(C.sub.1-C.sub.6 alkyl). In some embodiments, R.sup.2 is isopropyl. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OR.sup.5). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH and OCH.sub.3). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-CN. In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5. In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2.

    [0090] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00009##

    [0091] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00010##

    [0092] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00011##

    [0093] In some embodiments, m is 1. In some embodiments, m is 2.

    [0094] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

    [0095] In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2.

    [0096] In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3.

    [0097] In some embodiments, R.sup.3 is hydrogen. In some embodiments, R.sup.3 is C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.3 is methyl.

    [0098] In some embodiments, R.sup.3 is C.sub.1-C.sub.6 haloalkyl.

    [0099] In some embodiments, R.sup.3 is trifluoromethyl.

    [0100] In some embodiments, wherein R.sup.3 is halogen. In some embodiments, R.sup.3 is F.

    [0101] In some embodiments, R.sup.4 is hydrogen. In some embodiments, R.sup.4 is C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.4 is methyl. In some embodiments, R.sup.4 is halogen. In some embodiments, R.sup.4 is F.

    [0102] In some embodiments, R.sup.3 is C.sub.1-C.sub.6 haloalkyl and R.sup.4 is H. In some embodiments, R.sup.3 and R.sup.4 are both halogen. In some embodiments, R.sup.3 and R.sup.4 are both-C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.3 and R.sup.4 are both H.

    [0103] In some embodiments, R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens. In some embodiments, the halogen is F.

    [0104] In some embodiments, R.sup.3 and R.sup.4 are taken together to form cyclopropyl or cyclobutyl optionally substituted with one or more halogens. In some embodiments, R.sup.3 and R.sup.4 are taken together to form cyclopropyl or cyclobutyl optionally substituted with one or more fluoro. In some embodiments, R.sup.3 and R.sup.4 are taken together to form cyclopropyl. In some embodiments, R.sup.3 and R.sup.4 are taken together to form cyclobutyl optionally substituted with one or more fluoro.

    [0105] In some embodiments, R.sup.5 is hydrogen. In some embodiments, R.sup.5 is C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.5 is methyl.

    [0106] In some embodiments, R.sup.6 is hydrogen. In some embodiments, R.sup.6 is C.sub.1-C.sub.6 alkyl.

    [0107] In some embodiments, s and t are both 0.

    [0108] Disclosed herein, in certain embodiments, are compounds of formula (Ia):

    ##STR00012##

    or a pharmaceutically acceptable salt thereof, wherein: [0109] R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with CN or OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7), and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein the 5-6 membered heteroaryl is optionally substituted with one or more R.sup.w; [0110] n is 0, 1, or 2; [0111] R.sup.3 is selected from the group consisting of halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, and O(C.sub.1-C.sub.6 alkyl); [0112] R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or [0113] R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the 3-7 membered carbocyclic ring is optionally substituted with one or more halogens; [0114] each R.sup.5 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl; and [0115] each R.sup.6 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl [0116] R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C(O)(C.sub.1-6 alkyl), C(O)NR.sup.6, C(O).sub.2(C.sub.1-6 alkyl), and S(O).sub.2NR.sup.6(C.sub.1-C.sub.6 alkyl); [0117] each R.sup.w is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, N(R.sup.6).sub.2, and oxo, wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with OH.

    [0118] Disclosed herein, in certain embodiments, are compounds of formula (Ia):

    ##STR00013##

    or a pharmaceutically acceptable salt thereof, wherein: [0119] R.sup.2 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-CN, (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with CN or OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7), (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein the 5-6 membered heteroaryl is optionally substituted with one or more R.sup.w; [0120] n is 0, 1, or 2; [0121] R.sup.3 is selected from the group consisting of halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, and O(C.sub.1-C.sub.6 alkyl); [0122] R.sup.4 is selected from the group consisting of hydrogen, halogen, and C.sub.1-C.sub.6 alkyl; or [0123] R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the 3-7 membered carbocyclic ring is optionally substituted with one or more halogens; [0124] each R.sup.5 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl; and [0125] each R.sup.6 is independently for each occurrence, hydrogen or C.sub.1-C.sub.6 alkyl [0126] R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C(O)(C.sub.1-6 alkyl), C(O)N(R.sup.6).sub.2, C(O).sub.2(C.sub.1-6 alkyl), S(O).sub.n(C.sub.1-C.sub.6 alkyl), and S(O).sub.nNR.sup.6(C.sub.1-C.sub.6 alkyl); [0127] each R.sup.w is independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, N(R.sup.6).sub.2, and oxo, wherein the C.sub.1-C.sub.6 alkyl is optionally substituted with OH.

    [0128] In some embodiments, the compound is a compound of formula (Ib):

    ##STR00014##

    or a pharmaceutically acceptable salt thereof.

    [0129] In some embodiments, the compound is a compound of formula (Ic):

    ##STR00015##

    or a pharmaceutically acceptable salt thereof.

    [0130] In some embodiments, the compound is a compound of formula (Ib-1):

    ##STR00016##

    or a pharmaceutically acceptable salt thereof.

    [0131] In some embodiments, the compound is a compound of formula (Ib-2):

    ##STR00017##

    or a pharmaceutically acceptable salt thereof.

    [0132] In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene)-5-6 membered heteroaryl.

    [0133] In some embodiments, R.sup.2 is CH(CH.sub.3)-5-6 membered heteroaryl.

    [0134] In some embodiments, R.sup.2 is CH.sub.2-5-6 membered heteroaryl.

    [0135] In some embodiments, the 5-6 membered heteroaryl is optionally substituted with C.sub.1-C.sub.6alkyl or N(R.sup.a).sub.2, wherein each R.sup.a is independently hydrogen or C.sub.1-C.sub.6alkyl.

    [0136] In some embodiments, the 5-6 membered heteroaryl is pyridyl. In some embodiments, the 5-6 membered heteroaryl is

    ##STR00018##

    In some embodiments, the 5-6 membered heteroaryl is oxazolyl. In some embodiments, the 5-6 membered heteroaryl is

    ##STR00019##

    [0137] In some embodiments, R.sup.2 is C.sub.1-C.sub.6alkyl. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl)-OH. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl)-O(C.sub.1-C.sub.6 alkyl). In some embodiments, R.sup.2 is isopropyl. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OR.sup.5). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkyl substituted with OH and OCH.sub.3). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl). In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-CN. In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5. In some embodiments, R.sup.2 is (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2. In some embodiments, R.sup.2 is (C.sub.1-C.sub.6 alkylene)-N(R.sup.6).sub.2.

    [0138] In some embodiments, R.sup.2 is selected from the group consisting of (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-S(O).sub.n(C.sub.1-C.sub.6 alkyl), (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)OR.sup.5, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)C(O)N(R.sup.6).sub.2, (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7).sub.2, (C.sub.1-C.sub.6 alkylene)-OP(O)(OR.sup.5).sub.2, (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), and (C.sub.0-C.sub.4 alkylene)-(3-10 membered heterocyclyl having one, two, three, or four heteroatoms each independently selected from N, O, and S), wherein any aforementioned 5-6 membered heteroaryl and 3-10 membered heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of methyl, NH.sub.2, and oxo.

    [0139] In some embodiments, R.sup.2 is selected from the group consisting of (C.sub.1-C.sub.6 alkyl substituted with one or two OR.sup.5), (C.sub.1-C.sub.6 alkylene)-N(R.sup.6R.sup.7).sub.2, and (C.sub.1-C.sub.4 alkylene optionally substituted with OR.sup.5)-(5-6 membered heteroaryl having one, two, or three heteroatoms each independently selected from N, O, and S), wherein any aforementioned 5-6 membered heteroaryl and 3-10 membered heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of methyl, NH.sub.2, and oxo.

    [0140] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00020##

    [0141] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00021##

    [0142] In some embodiments, R.sup.2 is selected from the group consisting of methyl,

    ##STR00022##

    [0143] In some embodiments, R.sup.3 is C.sub.1-C.sub.6 haloalkyl.

    [0144] In some embodiments, R.sup.3 is trifluoromethyl.

    [0145] In some embodiments, R.sup.3 is halogen. In some embodiments, R.sup.3 is F.

    [0146] In some embodiments, R.sup.4 is hydrogen. In some embodiments, R.sup.4 is halogen. In some embodiments, R.sup.4 is F.

    [0147] In some embodiments, R.sup.3 and R.sup.4 are taken together to form a 3-7 membered carbocyclic ring with the carbon to which R.sup.3 and R.sup.4 are attached, wherein the carbocyclic ring is optionally substituted with one or more halogens. In some embodiments, the halogen is F.

    [0148] In some embodiments, the compound is selected from Table 1:

    TABLE-US-00001 TABLE 1 List of compounds. Compound No. Structure 1 [00023]embedded image 2 [00024]embedded image 3 [00025]embedded image 4 [00026]embedded image 5 [00027]embedded image 6 [00028]embedded image 7 [00029]embedded image 8 [00030]embedded image 9 [00031]embedded image 10 [00032]embedded image 11 [00033]embedded image 12 [00034]embedded image [00035]embedded image 13 [00036]embedded image [00037]embedded image 14 [00038]embedded image 15 [00039]embedded image 16 [00040]embedded image 17 [00041]embedded image 18 [00042]embedded image 19 [00043]embedded image [00044]embedded image [00045]embedded image [00046]embedded image 20 [00047]embedded image [00048]embedded image [00049]embedded image [00050]embedded image 21 [00051]embedded image [00052]embedded image [00053]embedded image [00054]embedded image 22 [00055]embedded image [00056]embedded image [00057]embedded image [00058]embedded image 23 [00059]embedded image 24 [00060]embedded image 25 [00061]embedded image 26 [00062]embedded image 27 [00063]embedded image 28 [00064]embedded image 29 [00065]embedded image 30 [00066]embedded image 31 [00067]embedded image 32 [00068]embedded image 33 [00069]embedded image 34 [00070]embedded image 35 [00071]embedded image 36 [00072]embedded image 37 [00073]embedded image 38 [00074]embedded image 39 [00075]embedded image 40 [00076]embedded image 41 [00077]embedded image 42 [00078]embedded image 43 [00079]embedded image 44 [00080]embedded image 45 [00081]embedded image 46 [00082]embedded image 47 [00083]embedded image 48 [00084]embedded image 49 [00085]embedded image 50 [00086]embedded image 51 [00087]embedded image 52 [00088]embedded image 53 [00089]embedded image 54 [00090]embedded image 55 [00091]embedded image 56 [00092]embedded image 57 [00093]embedded image 58 [00094]embedded image 59 [00095]embedded image 60 [00096]embedded image 61 [00097]embedded image 62 [00098]embedded image 63 [00099]embedded image 64 [00100]embedded image 65 [00101]embedded image 66 [00102]embedded image 67 [00103]embedded image 68 [00104]embedded image 69 [00105]embedded image 70 [00106]embedded image 71 [00107]embedded image [00108]embedded image 72 [00109]embedded image [00110]embedded image 73 [00111]embedded image 74 [00112]embedded image 75 [00113]embedded image 76 [00114]embedded image 77 [00115]embedded image 78 [00116]embedded image 79 [00117]embedded image 80 [00118]embedded image 81 [00119]embedded image [00120]embedded image 82 [00121]embedded image [00122]embedded image 83 [00123]embedded image 84 [00124]embedded image 85 [00125]embedded image 86 [00126]embedded image 87 [00127]embedded image 88 [00128]embedded image 89 [00129]embedded image 90 [00130]embedded image 91 [00131]embedded image 92 [00132]embedded image 93 [00133]embedded image 94 [00134]embedded image 95 [00135]embedded image 96 [00136]embedded image 97 [00137]embedded image 98 [00138]embedded image 99 [00139]embedded image 100 [00140]embedded image 101 [00141]embedded image 102 [00142]embedded image 103 [00143]embedded image [00144]embedded image 104 [00145]embedded image [00146]embedded image 105 [00147]embedded image 106 [00148]embedded image [00149]embedded image 107 [00150]embedded image [00151]embedded image 108 [00152]embedded image 109 [00153]embedded image 110 [00154]embedded image 111 [00155]embedded image 112 [00156]embedded image 113 [00157]embedded image 114 [00158]embedded image 115 [00159]embedded image 116 [00160]embedded image 117 [00161]embedded image 118 [00162]embedded image 119 [00163]embedded image 120 [00164]embedded image 121 [00165]embedded image 122 [00166]embedded image 123 [00167]embedded image 124 [00168]embedded image 125 [00169]embedded image 126 [00170]embedded image 127 [00171]embedded image 128 [00172]embedded image 129 [00173]embedded image 130 [00174]embedded image 131 [00175]embedded image 132 [00176]embedded image 133 [00177]embedded image 134 [00178]embedded image 135 [00179]embedded image 136 [00180]embedded image 137 [00181]embedded image 138 [00182]embedded image 139 [00183]embedded image 140 [00184]embedded image 141 [00185]embedded image 142 [00186]embedded image 143 [00187]embedded image 144 [00188]embedded image 145 [00189]embedded image 146 [00190]embedded image 147 [00191]embedded image 148 [00192]embedded image 149 [00193]embedded image 150 [00194]embedded image 151 [00195]embedded image 152 [00196]embedded image 153 [00197]embedded image 154 [00198]embedded image 155 [00199]embedded image 156 [00200]embedded image 157 [00201]embedded image 158 [00202]embedded image 159 [00203]embedded image 160 [00204]embedded image 161 [00205]embedded image 162 [00206]embedded image 163 [00207]embedded image 164 [00208]embedded image 165 [00209]embedded image 166 [00210]embedded image 167 [00211]embedded image 168 [00212]embedded image 169 [00213]embedded image 170 [00214]embedded image 171 [00215]embedded image 172 [00216]embedded image 173 [00217]embedded image 174 [00218]embedded image 175 [00219]embedded image 176 [00220]embedded image 177 [00221]embedded image

    Pharmaceutical Compositions and Routes of Administration

    [0149] Disclosed herein, in certain embodiments, are pharmaceutical compositions comprising a compound disclosed herein (e.g., a compound of Formula (I), Formula (I), Formula (Ia), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Ib-1), or Formula (Ib-2)) or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable excipient. In some embodiments, the excipient is selected from: inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. In some embodiments, the pharmaceutical compositions are administered alone or in combination with other therapeutic agents. Such compositions are prepared in a manner well known in the pharmaceutical art.

    [0150] In some embodiments, the pharmaceutical compositions are administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.

    [0151] One mode for administration is parenteral, particularly by injection. In some embodiments, the forms in which the novel compositions of the present disclosure are incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection, but less preferred in the context of the present disclosure. In some embodiments, ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils are employed. In some embodiments, the proper fluidity is maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In some embodiments, the prevention of the action of microorganisms is brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

    [0152] Sterile injectable solutions are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

    [0153] Oral administration is another route for administration of compounds in accordance with the disclosure. In some embodiments, administration is via capsule or enteric coated tablets, or the like. In some embodiments, in making the pharmaceutical compositions that include at least one compound described herein, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that is in the form of a capsule, sachet, paper or other container. In some embodiments, when the excipient serves as a diluent, it is in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient. Thus, in some embodiments, the compositions are e in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

    [0154] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. In some embodiments, the formulations additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.

    [0155] In some embodiments, the compositions of the disclosure are formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Another formulation for use in the methods of the present disclosure employs transdermal delivery devices (patches). In some embodiments, such transdermal patches are used to provide continuous or discontinuous infusion of the compounds of the present disclosure in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. In some embodiments, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

    [0156] The compositions are preferably formulated in a unit dosage form. The term unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule). The compounds are generally administered in a pharmaceutically effective amount. Preferably, for oral administration, each dosage unit contains from 1 mg to 2 g of a compound described herein, and for parenteral administration, preferably from 0.1 to 700 mg of a compound a compound described herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

    [0157] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present disclosure. In some embodiments, when referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition is readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

    [0158] In some embodiments, the tablets or pills of the present disclosure are coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, in some embodiments, the tablet or pill comprises an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. In some embodiments, the two components are separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. In some embodiments, a variety of materials are used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

    [0159] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. In some embodiments, the liquid or solid compositions contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In some embodiments, compositions in pharmaceutically acceptable solvents are nebulized by use of inert gases. In some embodiments, nebulized solutions are inhaled directly from the nebulizing device or the nebulizing device is attached to a facemask tent, or intermittent positive pressure breathing machine. In some embodiments, solution, suspension, or powder compositions are administered, orally or nasally, from devices that deliver the formulation in an appropriate manner.

    Methods of Treatment

    [0160] Disclosed herein, in certain embodiments, are methods of treating a disease or disorder modulated by abnormal activity of a TEAD isoform (e.g., TEAD1 and/or TEAD4) (e.g., hyperactivation of TEAD transcriptional complex) in an individual in need thereof, comprising administering to the individual a compound of formula (I), formula (I), formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2) or a pharmaceutically acceptable salt thereof (e.g., a therapeutically effective amount of a compound of formula (I), formula (I), formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2) or a pharmaceutically acceptable salt thereof).

    [0161] TEA domain transcription factors (TEADs) are downstream effectors of the Hippo signaling pathway. Currently, four isoforms of TEAD have been identified-TEAD1, TEAD2, TEAD3, and TEAD4. The TEAD isoforms share highly similar structures. The N-terminus of the four isoforms share a highly conserved 68-amino acid TEA/ATTS DNA-binding domain, which binds to the MCAT element (50-CATTCCA/T-30). The C-terminus contains the transactivation domain which recruits transcriptional coactivators YAP/TAZ.

    [0162] The expression of TEAD proteins is up-regulated in many cancer types including gastric, colorectal, breast, and prostate cancers. TEAD hyperactivation plays a role in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance and is correlated with poor survival in patients.

    [0163] Selective binding of TEAD1 and/or TEAD4 is beneficial for optimizing anti-tumor efficacy while minimizing undesired effects. Inhibition of TEAD3 has been associated with off-target toxicity (e.g., kidney toxicity), while inhibition of TEAD2 may be pro-proliferative.

    [0164] The TEAD isoform selectivity demonstrated by compounds disclosed herein is an advantage over TEAD inhibitors known in the art. For example, as demonstrated by Tang and Post using thermal shift assays, TEAD inhibitor VT3989 primarily interacts with TEAD1-3. The reported thermal shift data are provided in Table 2 below (Tang and Post, The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models, Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr. 8-13. Philadelphia (PA): AACR; Poster #5364). The data provided in Table 2 shows that VT3989 provides minimal selectivity over TEAD2 and 3, TEAD isoforms for which inhibition is undesirable. Furthermore, VT3989 shows lower levels of binding to TEAD4, a TEAD isoform for which inhibition is desirable. Each change in Tm ( C.) of 2.5 C. may be associated with an approximately 10-fold difference in binding affinity (Bhayani et al.; Determination of dissociation constants of protein ligands by thermal shift assay, Biochemical and Biophysical Research Communications, 2022, 560:1-6.)

    TABLE-US-00002 TABLE 2 Thermal shift assay of TEAD isoforms 1-4 treated with TEAD inhibitor VT3989 compared to inactive analog control. Isoform VT3989 Inactive Analog TEAD1 Tm ( C.) 11.6 0.2 TEAD2 Tm ( C.) 8.8 0.5 TEAD3 Tm ( C.) 8.5 0.2 TEAD4 Tm ( C.) 4.6 0.2

    [0165] In some embodiments, the compounds disclosed herein selectively bind one or more TEAD isoforms. In certain embodiments, the compounds disclosed herein selectively bind TEAD1. In certain embodiments, the compounds disclosed herein selectively bind TEAD4. In certain embodiments, the compounds disclosed herein selectively bind TEAD1 and TEAD4. In some embodiments, the binding selectivity for TEAD1 is 10-fold, 100-fold, 1,000-fold, or 10,000-fold over TEAD2 and/or TEAD3. In some embodiments, the binding selectivity for TEAD4 is 10-fold, 100-fold, 1,000-fold, or 10,000-fold over TEAD2 and/or TEAD3. Evidence of the TEAD isoform selectivity demonstrated by compounds disclosed herein is provided in Example 174 below.

    [0166] In some embodiments, the compounds disclosed herein are useful as a medical therapy for treating a disease, disorder or condition mediated by hyperactivation of YAP/TAZ-TEAD (e.g., TEAD1 and/or TEAD4) transcriptional co-activator complex. In some embodiments, the compounds disclosed herein are useful as a medical therapy for treating a disease, disorder or condition characterized by the hyperactivation of TEAD (e.g., TEAD1, TEAD2, TEAD3, and TEAD4 isoforms). In some embodiments, the disease, disorder or condition is characterized by the overexpression or genomic fusion or amplification of TEAD. TEAD1 and TEAD4 experience recurrent onco-fusions; for example, TEAD1-PARVA. These fusions drive higher expression of TEADs and may result in enhanced transcription of TEAD-target genes. Amplifications (genomic copy number gains) of TEAD4 occur in diverse cancers as part of the 12p13 locus in, e.g., ovarian and uterine carcinoma as well as testicular germ cell tumors. These genomic amplifications of TEAD4 are associated with strong increase in its mRNA expression and may drive high TEAD-YAP/TAZ transcriptional activity.

    [0167] In certain embodiments, the TEAD isoform is TEAD1. In certain embodiments, the TEAD isoform is TEAD4. In some embodiments, the disease, disorder or condition is a cancer characterized by abnormal TEAD transcriptional complex activity (e.g., hyperactivation). Such cancers include but are not limited to breast cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer including pancreatic adenocarcinoma, mesothelioma including malignant mesothelioma, hepatocellular cancer, prostate cancer, head and neck cancer, renal cell carcinoma, and medulloblastomas. In some embodiments, the cancer is selected from pancreatic adenocarcinoma, hepatocellular cancer, breast cancer, and malignant mesothelioma. In certain embodiments, the cancer is malignant mesothelioma.

    [0168] In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a colorectal cancer. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a head and neck cancer. In some embodiments, the cancer is a renal cell carcinoma. In some embodiments, the cancer is a medulloblastoma. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the cancer is medulloblastoma. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the cancer is a metastatic breast cancer. In some embodiments, the cancer is a metastatic lung cancer. In some embodiments, the cancer is a metastatic gastric cancer. In some embodiments, the cancer is a metastatic colorectal cancer. In some embodiments, the cancer is a metastatic prostate cancer. In some embodiments, the cancer is a metastatic head and neck cancer. In some embodiments, the cancer is a metastatic renal cell carcinoma. In some embodiments, the cancer is a metastatic mesothelioma. In some embodiments, the cancer is a metastatic pancreatic cancer. In some embodiments, the cancer is a metastatic hepatocellular cancer.

    [0169] In some embodiments, the disclosure provides for compounds of formula (I), formula (I), formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2) for modulating TEAD activity. In some embodiments, the disclosure provides for pharmaceutically acceptable salts of compounds of formula (I), formula (I), formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2) for modulating TEAD activity.

    [0170] In some embodiments, the disclosure provides for compounds of formula (I), formula (I), formula (Ia), formula (Ia), formula (Ib), formula (Ic), formula (Ib-1), or formula (Ib-2) or a pharmaceutically acceptable salts thereof for use in medical therapy.

    EXAMPLES

    [0171] The present disclosure will be further illustrated in the following Examples which are given for illustration purposes only and are not intended to limit the disclosure in any way.

    Abbreviations

    [0172] Boc for tert-butyloxycarbonyl [0173] DAST for diethylaminosulfur trifluoride [0174] DBU for 1,8-diazabicyclo(5.4.0)undec-7-ene [0175] DCC for dicyclohexylcarbodiimide [0176] DCE for 1,1-dichloroethane [0177] DCM for dichloromethane [0178] DEA for diethanolamine [0179] DEAD for diethyl azodicarboxylate [0180] DIAD for diisopropyl azodicarboxylate [0181] DIBAL for Diisobutylaluminium hydride [0182] DIPEA for N,N-diisopropylethylamine, Hnig's base [0183] DMA for N,N-dimethylacetamide [0184] DMAP for 4-(dimethylamino)pyridine [0185] DMF for N,N-dimethylformamide [0186] DMSO for dimethylsulfoxide. [0187] EDC for 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide [0188] EtOAc for ethyl acetate [0189] h for hours [0190] HATU for N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide [0191] HBTU for (1H-benzotriazol-1-yloxy) (dimethylamino)-N,N-dimethylmethaniminium hexafluorophosphate [0192] HOBT for N-hydroxybenzotriazole [0193] HPLC for High Pressure Liquid Chromatography. [0194] LAH for lithium aluminium hydride [0195] IPA for isopropyl alcohol [0196] LCMS for Liquid Chromatography-Mass Spectrometry [0197] LDA for Lithium diisopropylamide [0198] LiHMDS for Lithium bis(trimethylsilyl)amide [0199] mCPBA for meta-chloroperoxybenzoic acid [0200] MI for Molecular Ion [0201] Min for minutes [0202] MW for microwave [0203] NBS for N-bromosuccinamide [0204] NCS for N-chlorosuccinamide [0205] NFOBS for N-fluoro-o-benzenedisulfonimide [0206] NFSI for N-fluorobenzenesulfonimide [0207] NHS for N-hydroxysuccinimide [0208] NIS for N-iodosuccinamide [0209] NMM for N-methylmorpholine [0210] NMP for 1-methyl-2-pyrrolidinone [0211] NMR for Nuclear Magnetic Resonance. [0212] PdCl.sub.2(PPh.sub.3).sub.2 for Bis(triphenylphosphine)palladium chloride [0213] Pd(dppf).sub.2Cl.sub.2 for [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium (II) [0214] Pd(dppf).sub.2Cl.sub.2.Math.DCM for [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with DCM [0215] (Pd(dba).sub.2) for bis(dibenzylideneacetone)palladium [0216] Rbf for round bottomed flask [0217] RT for Retention Time. [0218] SCX-2 for a silica-based sorbent with a chemically bonded propylsulfonic acid functional group [0219] SFC for supercritical fluid chromatography [0220] TBAF for tetra-n-butylammonium fluoride [0221] TBDMS for tert-butyldimethylsilyl [0222] TFAA for trifluoroacetic anhydride [0223] TFA for trifluoroacetic acid [0224] THF for tetrahydrofuran [0225] TPP for tripotassium phosphate [0226] Ts for toluenesulfonyl [0227] XPhos-Pd-G1 for 2-Dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)[2-(2-aminoethyl)phenyl)]palladium (II) chloride [0228] XPhos-Pd-G2 for Chloro(2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)[2-(2-amino-1,1-biphenyl)]palladium (II)

    Analytical Methods

    [0229] Commercially available starting materials, reagents and dry solvents were used as supplied. Flash column chromatography or glass column chromatography was performed using Merck silica gel 230-400 mesh size. Flash chromatography was also performed on combi-flash RF Teledyne Isco machine. Preparative TLC was performed on Merck plates.

    Liquid Chromatography-Mass Spectrometry Methods

    Method-A

    [0230] Method Name: -UC02_FAR1, Machine Details: -Water Acquity UPLC-H Class equipped with PDA and Acquity SQ detector, Column: Waters X-bridge C18, 50*2.1 mm, 2.5 micron, Column temperature: 35 C., Auto sampler temperature: 15 C., Mobile Phase A: 0.1% Formic acid in Milli Q water (PH=2.70), Mobile Phase B: 0.1% Formic acid in Milli Q water:Acetonitrile (10:90); Mobile phase gradient details: T=0 min (97% A, 3% B) flow: 0.8 mL/min; T=0.75 min (97% A, 3% B) flow: 0.8 mL/min; gradient to T=2.7 min (2% A, 98% B) flow: 0.8 mL/min; gradient to T=3 min (0% A, 100% B) flow: 1 mL/min; T=3.5 min (0% A, 100% B) flow: 1 mL/min; gradient to T=3.51 min (97% A, 3% B) flow: 0.8 mL/min; end of run at T=4 min (97% A, 3% B), Flow rate: 0.8 mL/min, Flow rate: 0.8 mL/min, Run Time: 4 min, UV Detection Method: -PDA, Wavelength: 200-500 nm; Mass parameter: Probe: -ESI, Mode of Ionisation: -positive and negative, Cone voltage: 30V and 10 V, capillary voltage: 3.0 KV, Extractor Voltage: 1 V, Rf Lens: 0.1 V, Temperature of source: 120 C., Temperature of Desolvation: 400 C. Cone Gas Flow: 100 L/hour, Desolvation Gas flow: 800 L/hour.

    Method-B

    [0231] Method Name: -UC03_ABR2, Machine Details: -Waters Acquity Ultraperfomance LC connected with PDA and equipped with SQ detector, Column: Waters X-bridge C18, 50*4.6 mm, 3.5 micron, Column temperature: 35 C., Auto sampler temperature: 15 C., Mobile Phase A: 5 mM Ammonium Bicarbonate (pH=8.00) in Milli Q water, Mobile Phase B: Acetonitrile; Mobile phase gradient details: T=0 min (97% A, 3% B) Flow rate=1.0 ml/min, T=0.20 min (97% A, 3% B) Flow rate=1.0 ml/min; gradient to T=2.70 min (20% A, 80% B) Flow rate=1.0 ml/min; gradient to T=3.0 min (0% A, 100% B) Flow rate=1.2 ml/min; T=3.50 min (0% A, 100% B) Flow rate=1.2 ml/min; T=3.51 min (97% A, 3% B) Flow rate=1.0 ml/min; end of run at T=4.0 min (97% A, 3% B) Flow rate=1.0 ml/min, Run Time: 4 min, UV Detection Method: -PDA, Wavelength: 195 nm-500 nm; Mass parameter: Probe: -ESI, Mode of Ionisation: -Positive and Negative, Cone voltage: 30 and 10 V, capillary voltage: 3.0 KV, Extractor Voltage: 2 V, Rf Lens: 0.1 V, Temperature of source: 120 C., Temperature of Probe: 400 C., Cone Gas Flow: 100 L/Hr, Desolvation Gas flow: 800 L/Hr.

    High-Performance Liquid Chromatography Methods

    Method-A

    [0232] Method Name: -HP04_BR1 Machine Details: -Water alliance e2695 with 2998 PDA detector, Column temperature: 25 C., Auto sampler temperature: 25 C., Mobile Phase A: 0.1% ammonium hydroxide solution in HPLC water Mobile Phase B: 100% ACETONITRILE; Mobile phase gradient details: T=0 min (10% A, 90% B) flow: 1 mL/min; T=7 min (90% A, 10% B) flow: 1 mL/min; gradient to T=9 min (100% A, 0% B) flow: 1 mL/min; gradient to T=14 min (100% A, 0% B) flow: 1 mL/min; T=14.01 min (10% A, 90% B) flow: 1 mL/min; gradient to T=17 min (10% A, 90% B) flow: 1 mL/min; end of run at T=17 min (10% A, 90% B), Flow rate: 1 mL/min, Run Time: 17 min, UV Detection Method: -PDA.

    Method-B

    [0233] Method Name: -HP05_TFAR1.Machine Details: AGILENT TECHNOLOGY 1260 infinity series with PDA detector, Column temperature: 25 C., Auto sampler temperature: 25 C., Mobile Phase A: 0.05% Trifluoroacetic acid in HPLC water Mobile Phase B: 100% Acetonitrile; Mobile phase gradient details T=0 min (90% A, 10% B) flow: 1 mL/min; T=7 min (10% A, 90% B) flow: 1 mL/min; gradient to T=9 min (0% A, 100% B) flow: 1 mL/min; gradient to T=14 min (0% A, 100% B) flow: 1 mL/min; T=14.01 min (90% A, 10% B) flow: 1 mL/min; gradient to T=17 min (90% A, 10% B) flow: 1 mL/min; end of run at T=17 min (90% A, 10% B), Flow rate: 1 mL/min, Run Time: 17 min, UV Detection Method: -PDA.

    Method-C

    [0234] Method Name: -HP06_TFAR1 Machine Details: -AGILENT TECHNOLOGY 1100series with PDA detector, Column temperature: 25 C., Auto sampler temperature: 25 C., Mobile Phase A: 0.05% Trifluoroacetic acid in HPLC water Mobile Phase B: 100% Acetonitrile; Mobile phase gradient details T=0 min (90% A, 10% B) flow: 1 mL/min; T=7 min (10% A, 90% B) flow: 1 mL/min; gradient to T=9 min (0% A, 100% B) flow: 1 mL/min; gradient to T=14 min (0% A, 100% B) flow: 1 mL/min; T=14.01 min (90% A, 10% B) flow: 1 mL/min; gradient to T=17 min (90% A, 10% B) flow: 1 mL/min; end of run at T=17 min (90% A, 10% B), Flow rate: 1 mL/min, Run Time: 17 min, UV Detection Method: -PDA.

    NMR

    [0235] .sup.1H Nuclear magnetic resonance (NMR) spectroscopy was carried out using a Bruker Avance-400 instrument operating at 400 MHz using the stated solvent at room temperature unless otherwise stated. Samples were prepared as solutions in a suitable deuterated solvent and referenced to the appropriate internal non-deuterated solvent peak or tetramethylsilane. Chemical shifts were recorded in ppm () downfield of tetramethylsilane. In all cases, NMR data were consistent with the proposed structures. Characteristic chemical shifts () are given in parts-per-million using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; br, broad.

    Purification Methods

    Preparative Purification by Reverse Phase HPLC

    Preparatory HPLC Method-A

    [0236] Biotage-FC-01 with binary pump with UV/Visible wave-length detector, Column: YMC, 120 g, 50 m, column temperature: room temp., mobile phase A: 0.1% formic acid in water, mobile phase B: Acetonitrile: mobile phase gradient details: t=0.01 min (100% A, 0% B); t=3 min (85% A, 15% B); gradient to t=25 min (55% A, 45% B); t=35 min (0% A, 100% B); gradient to end of run at t=45 min (100% A, 0% B); flow rate: 80 mL/min, analysis time 45 min.

    Synthesis

    [0237] Several methods for the chemical synthesis of compounds of the present application are described herein. These and/or other well-known methods may be modified and/or adapted in various ways to facilitate the synthesis of additional compounds within the scope of the present application and claims. Such alternative Methods and modifications should be understood as being within the spirit and scope of this application and claims. Accordingly, Methods set forth in the following descriptions, Schemes and Examples are intended for illustrative purposes and are not to be construed as limiting the scope of the disclosure.

    [0238] In one approach (Scheme 1), compounds of formula [IIb] may be prepared by the reaction of a substituted Het-aromatic carboxylic acid of formula [II] with amide coupling reagent like HATU in DMF or DCM as solvent, with an amine of general formula [III] in the presence of a tertiary amine base such as DIPEA. The reaction is suitably conducted at RT. After reaction work up, typically by liquid-liquid extraction, the reaction product is purified by flash column chromatography, reverse phase preparative HPLC or re-crystallisation (Method A).

    ##STR00222##

    [0239] The following compounds were prepared according to the Methods described above using the indicated intermediates.

    Example 1Synthesis of N-isopropyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 1)

    ##STR00223##

    Step-1a:

    [0240] In 250 mL three neck RB flask, 4-(trifluoromethyl)cyclohexan-1-one CAS No: 75091-99-5, (0.5 g, 3.01 mmol, 1.0 eq.), in THF (31.5 mL) was added dropwise lithium bis(trimethylsilyl)amide (3.6 mL, 3.61 mmol, 1M solution in THF) over a period of 30 min with stirring at 78 C. then allowed stirring continue for another 1 h at 78 C., after 1 h solution of N-phenyltrifluoromethanesulfonimide (1.0 g, 3.01 mmol, 1.0 eq) in THF (4 mL) was added dropwise with stirring over a period of 30 min. Then the reaction mixture was stirred at 78 C. for another 2 h and slowly warmed to room temperature with stirring over a period of 6 h. The reaction was monitored on TLC (using EA:Hexane; 0.1:9.9 as mobile phase) which confirmed that the reaction got completed after 6 h of stirring at room temperature. The reaction mixture was extracted with EtOAc (310 mL). combined organic extracts were washed with water, dried over Na.sub.2SO.sub.4, and filtered. The filtrate was evaporated and the residue was purified by silica gel column chromatography (10% EtOAc in Hexane) yielded 4-(trifluoromethyl)Cyclohex-1-en-1-yl trifluoromethanesulfonate as a white solid (A1, 0.45 g, 1.509 mmol, Yield: 50.14%).

    [0241] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 5.80-5.81 (m, 1H), 2.51-2.47 (m, 2H), 2.43-2.30 (m, 2H), 2.20-2.15 (m, 1H), 1.84-1.73 (m, 1H), 0.83-0.90 (m, 1H). Note: aliphatic impurities with trace amount of PhN(OTf).sub.2.

    Step-1b:

    [0242] In 250 mL three neck RB flask, To a solution of 4-(trifluoromethyl)-cyclohex-1-enyl trifluoromethanesulfonate CAS: 73183-34-3, (A1, 0.1 g, 0.335 mmol, 1.0 eq) in dioxane (3.8 mL) was added bis(pinacolato)diboron, (0.102 g, 0.402 mmol, 1.2 eq), potassium acetate (0.109 g, 1.11 mmol, 3.0 eq), PdCl.sub.2 (dppf) (0.074 g, 0.100 mmol, 0.3 eq), under a nitrogen atmosphere. The reaction mixture was heated at 80 C. with stirring for 16 h, The reaction was monitored on TLC (using EA:Hexane; 1:9 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 80 C. and then cooled to room temperature, and filtered through celite bed. The filtrate was evaporated in vacuum and the residue was purified by silica gel column chromatography (10% EtOAc/hexane) yielded 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 0.027 g, 0.097 mmol, Yield: 29.16%).

    [0243] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 6.54-6.53 (m, 1H), 2.38-2.31 (m, 2H), 2.27-2.25 (m, 1H), 2.21-2.20 (m, 2H), 2.03-1.99 (m, 1H) 1.49-1.47 (m, 1H), 1.30 (s, 12H). Note: Minor aliphatic impurities observed

    Step-1:

    [0244] A solution of Methyl 8-bromoquinoline-3-carboxylate, (A13, 5.0 g, 18.791 mmol, 1.0 eq.) and NaOH (1.5 g, 37.581 mmol, 2.0 eq.) in methanol and water (50 mL, 9:1) was stirred for 2 h at room temperature. The reaction mixture was acidified with 1N HCl (40 mL; pH=3) and allowed to stir for 30 minutes at 0 C. to afford pale yellowish solid. The reaction was monitored by TLC (using EA:Hex; 3:7 as mobile phase) which confirmed the completion after 2 h of stirring at room temperature. The resulting solid was filtered with high vacuum and yielded 8-bromoquinoline-3-carboxylic acid (A3, 4.13 g, 16.38 mmol, Yield: 87.20%).

    [0245] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 7.64 (t, J=8.0 Hz, 1H), 8.25-8.31 (m, 2H), 9.05 (d, J=2.4 Hz, 1H), 9.40 (d, J=2.4 Hz, 1H)

    [0246] LCMS (Method A): 1.736 min, 100.0%, MS: ES+252.00 [M].sup.+

    Step-2:

    [0247] In 250 mL three neck RB flask, 8-bromoquinoline-3-carboxylic acid (A3, 4.0 g, 15.873 mmol, 1.0 eq.), Isopropyl amine CAS No: 75-31-0 (1.19 g, 15.873 mmol, 1.0 eq.), and DIPEA (6.2 g, 47.62 mmol, 3.0 eq.) were stirred with HATU (6.59 g, 17.46 mmol, 1.1 eq.) in DMF (40 mL, 10 v) for 16 h at room temperature. The reaction was monitored on TLC (using EA:Hexane; 1:1 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was diluted with ice-cold water (200 mL) and allowed to stirred for 1 h. The yellowish solid obtained was filtered through buchner funnel to yield 8-Bromo-N-isopropylquinoline-3-carboxamide (A4, 3.05 g, 10.41 mmol, Yield: 65.58%).

    [0248] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 9.34 (d, J=2.0 Hz, 1H), 8.87 (d, J=2.4 Hz, 1H), 8.67 (d, J=8.8 Hz, 1H), 8.26-8.24, (m, 1H), 8.16-8.13 (m, 1H), 7.62 (d, J=8.0 Hz, 1H), 4.22-4.13 (m, 1H), 1.23 (d, J=6.8 Hz, 6H),

    [0249] LCMS (Method A): 1.852 min, 100.0%, MS: ES+293.01 [M+H]

    Step-3:

    [0250] To a stirred solution of 8-bromo-N-isopropylquinoline-3-carboxamide (A4, 1.2 g, 4.093 mmol, 1.0 eq.), and 2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (A2, 1.24 g, 4.503 mmol, 1.1 eq.), in 1,4-dioxane and water (14.5 mL, 9:1), was added tripotassium phosphate (1.21 g, 12.28 mmol, 3.0 eq.) and purged with nitrogen for 30 minutes, followed by addition of Pd(dppf)Cl.sub.2 (0.94 g, 0.819 mmol, 0.2 eq.), the resulting reaction mixture heated up to 100 C. for 16 h at room temperature. The reaction was monitored on TLC (using EA:Hexane; 3:7 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was filtered through celite bed and the filtrate was concentrated under reduced pressure. The obtained crude residue (2.5 g) was purified by silica gel (60-120 mesh) as stationary phase (25% EtOAc in hexane) yielded N-isopropyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 1, 1.0 g, 2.759 mmol, Yield: 67.57%).

    [0251] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 8.58 (d, J=7.6 Hz, 1H), 8.01-7.98 (m, 1H), 7.63-7.62 (m, 2H), 5.87 (br s, 1H), 4.18-4.13 (m, 1H), 2.80-2.68 (m, 3H), 2.31-2.27 (m, 1H), 2.09-2.06 (m, 1H), 1.73-1.67 (m, 1H), 1.21 (d, J=8.0 Hz, 6H). Note: CF3-CH proton merged with DMSO solvent peak which is clearly observed in MeOD NMR.

    [0252] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.96 (dd, J=7.6, 2.0 Hz, 1H), 7.68-7.62 (m, 2H), 5.87 (br s, 1H), 4.33-4.26 (m, 1H), 2.79-2.64 (m, 3H), 2.55-2.49 (m, 1H), 2.41-2.36 (m, 1H), 2.18-2.14 (m, 1H), 1.92-1.83 (m, 1H), 1.33 (d, J=6.8 Hz, 6H). Note: CONH Proton exchanged in MeOD.

    [0253] LCMS (Method A): 2.239 min, 96.73%, MS: ES+363.10 [M+H]

    [0254] HPLC (Method B): 8.327 min, 97.65%, @254 nm.

    Example 2Synthesis of N((S)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 2)

    ##STR00224##

    Step-1:

    [0255] To a stirred solution of 8-bromoquinoline-3-carboxylic acid (A3, 0.3 g, 1.190 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 0.328 g, 1.190 mmol, 1.0 eq) and K.sub.3PO.sub.4 (1.2 g, 5.952 mmol, 5.0 eq) in 1,4 Dioxane:water (4 mL, 9:1) was added Pd(PPh.sub.3).sub.4 (0.137 g, 0.119 mmol, 0.1 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 2.5 h. The reaction was monitored on TLC (using EA:Hex; 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 2.5 h of stirring at 100 C. The resulting reaction mixture was diluted with water (20 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g (crude) 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.3 g, 0.934 mmol, Yield: Crude). Note: The crude compound used as such for next step without further purification.

    [0256] LCMS (Method A): 2.464 min, 86.69%, 254.0 nm, MS: ES+322.11 (M+1)

    Step-2:

    [0257] A solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.3 g, 0.9345 mmol, 1.0 eq), HATU (1.0 g, 2.803 mmol, 3.0 eq) and DIPEA (0.180 g, 1.401 mmol, 1.5 eq) in DCM (3 mL) at 0 C. under N.sub.2 atmosphere stirred for 20 min, then added CAS: 40154-78-7 (0.2 g, 1.027 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 5 h at room temperature. The reaction was monitored on TLC (using EA:Hex; 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 5 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (325 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.5 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mess) as stationary phase (45% EtOAc in hexane) yielding N((S)-1-(pyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 2, 0.065 g, 0.152 mmol, Yield: 12.84% (yield over 2 steps))

    [0258] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.29 (br s, 1H), 9.19 (d, J=7.6 Hz, 1H), 8.89 (br s, 1H), 8.54 (d, J=4.4 Hz, 1H), 8.02 (t, J=4.4 Hz, 1H), 7.78 (t, J=7.2 Hz, 1H), 7.65-7.62 (m, 2H), 7.48 (d, J=8.0 Hz, 1H), 7.28 (t, J=5.6 Hz, 1H), 5.87 (s, 1H), 5.28-5.23 (m, 1H), 2.81-2.69 (m, 3H), 2.46-2.42 (m, 1H), 2.32-2.29 (m, 1H), 2.1-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.55 (d, J=6.8 Hz, 3H).

    [0259] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.85 (d, J=2.4 Hz, 1H), 8.56 (d, J=1.6 Hz, 1H), 7.9 (dd, J=1.6 Hz, 1H), 7.86 (td, J=7.6 Hz, 1H), 7.70 (m, 2H), 7.54 (d, J=8.0 Hz, 1H), 7.35 (t, J=4.8 Hz, 1H), 5.87 (br s, 1H), 5.35 (q, J=7.1 Hz, 1H), 2.83-2.71 (m, 1H), 2.68-2.64 (m, 2H), 2.56-2.50 (m, 1H), 2.41-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.81-1.70 (m, 1H), 1.66 (d, J=2.0 Hz, 3H).

    [0260] LCMS (Method A): 2.295 min, 100%, 254.0 nm, MS: ES+426.23 (M+1)

    [0261] HPLC (Method B): 6.213 min, 99.75%, 254.0 nm

    [0262] Chiral HPLC: 2.28 min, 100%, 245.0 nm

    Example 3Synthesis of N((S)-1-(6-aminopyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide formate (Compound 3)

    ##STR00225##

    Step-1:

    [0263] A solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.3 g, 0.93 mmol, 1.0 eq), HATU (0.530 g, 1.39 mmol, 1.5 eq) and DIPEA (0.48 ml, 2.79 mmol, 3.0 eq) in DCM (5 mL) at 0 C. under nitrogen atmosphere stirred for 5 min, then CAS: 1415303-42-2 (0.265 g, 1.11 mmol, 1.2 eq), was added under nitrogen atmosphere. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EA:Hex; 8:2 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with water (10 mL) and extracted with DCM (325 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (50% Ethyl acetate in hexane as gradient) yielding N((S)-1-(6-bromopyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A6, 0.21 g, 0.416 mmol, Yield: 44%).

    [0264] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): 9.28-9.25 (m, 2H), 8.89 (d, J=2.4 Hz, 1H), 8.03-8.00 (m, 1H), 7.75 (t, J=7.6 Hz, 1H), 7.67-7.62 (m, 2H), 7.55-7.51 (m, 2H), 5.88 (br s, 1H), 5.22-5.15 (m 1H), 2.82-2.60 (m, 3H), 2.51-2.50 (m, 1H), 2.29-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.64 (m, 1H). 1.54 (d, J=7.2 Hz, 3H)

    [0265] LCMS (Method A): 2.817 min, 95.22%, 254.0 nm, MS: ES+506.04 (M+2)

    Step-2:

    [0266] A solution of N((S)-1-(6-bromopyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A6, 0.19 g, 0.37 mmol, 1.0 eq), Pd(OAc).sub.2 (0.012 g, 0.037 mmol, 0.1 eq), xantphos (0.021 g, 0.037 mmol, 0.1 eq) and Cs.sub.2CO.sub.3 (0.360 g, 1.11 mmol, 3.0 eq) in Dioxane (10 mL) was prepared at RT. The resulting mixture was purge with nitrogen for 5 min, then added CAS: 4248-19-5 (0.051 g, 0.44 mmol, 1.2 eq) under Nitrogen atmosphere. The resulting mixture was stirred for 16 h at 100 C. The reaction was monitored by TLC (using EA:Hex; 70:30 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with water (10 mL) and extracted with EtOAc (325 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.19 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase desired product was eluted in 30% Ethyl acetate in hexane as gradient afforded tert-butyl (6-((1S)-1-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) pyridin-2-yl) carbamate (A7, 0.15 g, 0.27 mmol, Yield: 73.89%).

    [0267] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.75 (s, 1H), 9.33 (d, J=1.6 Hz, 1H), 9.07 (d, J=7.6 Hz, 1H), 8.89 (d, J=2.4 Hz, 1H), 8.05-8.03 (m, 1H), 7.74-7.64 (m, 4H), 7.12 (d, J=7.2 Hz, 1H), 5.87 (br s, 1H), 5.15-5.12 (m, 1H), 2.80-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.08 (m, 1H), 1.73-1.68 (m, 1H), 1.5 (d, J=7.2 Hz, 3H) 1.48 (s, 9H)

    [0268] LCMS (Method A): 2.977 min, 96.51%, 254.0 nm, MS: ES+541.3 (M+1)

    Step-3:

    [0269] To a solution of tert-butyl (6-((1S)-1-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) pyridin-2-yl) carbamate (A7, 0.15 g, 0.277 mmol, 1.0 eq), in dioxane (10 mL) was added HCl in dioxane [4 M] (5 mL) at RT under nitrogen atmosphere. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored by TLC (using EA:Hex; 1:1 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was concentrated under reduced pressure to afford 0.15 g crude as HCl salt. The crude material was purified by reverse phase prep HPLC purification (Method-A 0.1% formic acid in water acetonitrile) to obtained the desired N((S)-1-(6-aminopyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide format (Compound 3, 0.043 g, 0.097 mmol, Yield: 35.24%).

    [0270] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.29 (br s, 1H), 9.13 (br s, 1H), 8.89 (br s, 1H), 8.04-8.01 (m, 1H), 7.66-7.63 (m, 2H), 7.42 (t, J=8.0 Hz, 1H), 6.60 (d, J=7.2 Hz, 1H), 6.41 (d, J=7.6 Hz, 1H), 5.87 (br s, 1H), 5.07-5.04 (br s, 1H), 2.80-2.67 (m, 3H), 2.51-2.50 (m, 1H), 2.29-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.64 (m, 1H), 1.51 (d, J=6.8 Hz, 3H) Note: NH.sub.2 protons aren't visible and compound in the form of format salt.

    [0271] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.4 Hz, 1H), 7.99 (dd, J=8.0, 1.6 Hz, 1H), 7.70-7.63 (m, 3H), 6.82 (d, J=7.2 Hz, 1H), 6.70 (d, J=8.4 Hz, 1H), 5.86 (br s, 1H), 5.21-5.15 (m, 1H 2.78-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.83 (m, 1H), 1.66 (d, J=7.2 Hz, 3H). Note: NH and NH.sub.2 protons aren't visible and compound in the form of format salt.

    [0272] LCMS (Method B): 2.98 min, 99.60%, 254.0 nm, MS: ES+441.07 (M+1),

    [0273] HPLC (Method A): 8.772 min, 99.60%, 254.0 nm

    [0274] Chiral HPLC: 3.76 min, 100%, 240.0 nm

    Example 4Synthesis of N((S)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 4)

    ##STR00226##

    Step-1:

    [0275] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.17 g, 0.529 mmol, 1.0 eq), HATU (0.30 g, 0.791 mmol, 1.5 eq) and DIPEA (0.20 g, 1.587 mmol, 3.0 eq) in DMF (1.7 mL) at 0 C. under nitrogen atmosphere stirred for 30 min, was added CAS: 2749 Nov. 3 (0.043 g, 0.582 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by TLC (using 100% Ethyl acetate as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.22 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (80% Ethyl acetate in hexane as gradient) yielding N((S)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 4, 0.123 g, 0.325 mmol, Yield: 61.43%).

    [0276] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.80 (d, J=2.4 Hz, 1H), 8.47 (d, J=8.0 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.87 (br s, 1H), 4.80 (t, J=6.0 Hz, 1H), 4.10-4.07 (m, 1H), 3.54-3.50 (m, 1H), 2.80-2.67 (m, 3H), 2.44-2.42 (m, 1H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.64 (m, 1H), 1.18 (d, J=6.8 Hz, 3H). Note: CF3-CH Proton merge with DMSO solvent peak which is clearly observed in MeOD NMR spectrum

    [0277] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 7.96 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.62 (m, 2H), 5.87 (br s, 1H), 4.32-4.26 (m, 1H), 3.67 (d, J=5.6 Hz, 2H), 2.81-2.75 (m, 1H), 2.68-2.64 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.32 (d, J=6.8 Hz, 3H). Note: OH and NH protons might exchange in MeOD.

    [0278] LCMS (Method A): 2.236 min, 99.62%, 254.0 nm, MS: ES+379.12 (M+1)

    [0279] HPLC (Method A): 7.941 min, 99.26%, 254.0 nm

    [0280] Chiral HPLC: 4.73 min, 50.10%, 240.0 nm; 5.10 min, 49.48%, 240.0 nm

    Example 5Synthesis of N-(pyridin-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 5)

    ##STR00227##

    Step-1:

    [0281] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.466 mmol, 1.0 eq), HATU (0.26 g, 0.700 mmol, 1.5 eq) and DIPEA (0.24 ml, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) was stirred for 15 min at 0 C. under nitrogen atmosphere, was added CAS: 3731-51-9 (0.055 g, 0.513 mmol, 1.1 eq). The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored by TLC (using 100% Ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.20 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (70% Ethyl acetate in hexane as gradient) yielding N-(pyridin-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 5, 0.057 g, 0.138 mmol, Yield: 29.67%).

    [0282] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 9.46 (t, J=6 Hz, 1H) 9.31 (d, J=2.4 Hz, 1H), 8.89 (d, J=2.0 Hz, 1H) 8.53 (d, J=4.0 Hz, 1H), 8.04-8.00 (m, 1H), 7.79 (dt J=7.6, 1.6 Hz, 1H), 7.67-7.62 (m, 2H), 7.41 (d J=7.6 Hz, 1H), 7.29 (t, J=5.2 Hz, 1H), 5.88 (br s, 1H), 4.65 (d, J=6.0 Hz, 2H), 2.81-2.78 (m, 1H), 2.72-2.67 (m, 2H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.72 (m, 1H)

    [0283] .sup.1H NMR (MeOD, 400 MHz): 9.28 (d, J=2.0 Hz, 1H), 8.82 (d, J=2.4 Hz, 1H), 8.51 (d, J=5.2 Hz, 1H), 7.95 (dd J=8.0, 2.0 Hz 1H), 7.84 (td J=7.6, 1.6 Hz, 1H), 7.67-7.60 (m, 2H), 7.49 (d, J=8.0 Hz, 1H), 7.34-7.31 (m, 1H), 5.84 (br s, 1H), 4.76 (s, 2H), 2.80-2.73 (m, 1H), 2.67-2.62 (m, 2H), 2.54-2.48 (m, 1H), 2.38-2.30 (m, 1H), 2.15-2.12 (m, 1H), 1.87-1.82 (m, 1H)

    [0284] LCMS (Method A): 2.145 min, 99.27%, 254.0 nm, MS: ES+412.17 (M+1)

    [0285] HPLC (Method A): 8.707 min, 98.45%, 254.0 nm

    Example 6Synthesis of N((S)-1-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 6)

    ##STR00228##

    Step-1:

    [0286] A solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.466 mmol, 1.0 eq), HATU (0.26 g, 0.700 mmol, 1.5 eq) and DIPEA (0.18 g, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) was stirred for 30 min at 0 C. under nitrogen atmosphere, then added CAS: 99636-32-5 (0.045 g, 0.513 mmol, 1.1 eq). The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by TLC (using 100% Ethyl acetate as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.22 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (70% Ethyl acetate in hexane as gradient) yielding N((S)-1-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 6, 0.063 g, 0.160 mmol, Yield: 34.38%).

    [0287] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 8.60 (d, J=8.0 Hz, 1H), 8.02-7.99 (m, 1H), 7.64-7.61 (m, 2H), 5.87 (s, 1H), 4.29-4.23 (m, 1H), 3.47-3.43 (m, 1H), 3.34-3.31 (m, 1H), 3.30 (s, 3H), 2.80-2.77 (m, 1H), 2.72-2.68 (m, 2H), 2.50-2.46 (m, 1H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.19 (d, J=6.8 Hz, 3H).

    [0288] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.6, 2.0 Hz, 1H), 7.70-7.63 (m, 2H), 5.87 (br s, 1H), 4.5-4.39 (m, 1H), 3.58-3.54 (m, 1H), 3.50-3.47 (m, 1H), 3.42 (s, 3H), 2.83-2.81 (m, 1H), 2.78-2.75 (m, 2H), 2.68-2.65 (m, 1H), 2.55-2.41 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.31 (d, J=6.8 Hz, 3H).

    [0289] LCMS (Method A): 2.505 min, 98.87%, 254.0 nm, MS: ES+393.17 (M+1)

    [0290] HPLC (Method A): 9.078 min, 98.54%, 254.0 nm

    [0291] Chiral HPLC: 5.31 min, 50.73%, 240.0 nm; 5.63 min, 49.26%, 240.0 nm.

    Example 7Synthesis of N((R)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 7)

    ##STR00229##

    Step-1:

    [0292] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.467 mmol, 1.0 eq), HATU (0.35 g, 0.934 mmol, 2.0 eq) and DIPEA (0.18 g, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 35320-23-1 (0.042 g, 0.560 mmol, 1.2 eq) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored on TLC (using EtOAc 100% as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (70% Ethyl acetate in hexane as gradient) yielding N((R)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 7, 0.097 g, 0.256 mmol, Yield: 54.91%).

    [0293] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.80 (d, J=2.4 Hz, 1H), 8.47 (d, J=8.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.79 (t, J=6.0 Hz, 1H), 4.12-4.01 (m, 1H), 3.54-3.48 (m, 1H), 3.42-3.38 (m, 1H), 2.89-2.77 (m, 1H), 2.73-2.68 (m, 2H), 2.50-2.46 (m, 1H), 2.33-2.25 (m, 1H), 2.09-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).

    [0294] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 7.97 (d, J=7.6 Hz, 1H), 7.69-7.62 (m, 2H), 5.86 (br s, 1H), 4.30-4.25 (m, 1H), 3.67 (d, J=5.6 Hz, 1H), 2.88-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.17-2.15 (m, 1H), 1.89-1.85 (m, 1H), 1.31 (d, J=6.8 Hz, 3H).

    [0295] LCMS (Method A): 2.237 min, 100%, 254.0 nm, MS: ES+379.1 (M+1)

    [0296] HPLC (Method A): 7.930 min, 100%, 254.0 nm

    [0297] Chiral HPLC: 6.17 min, 49.36%, 6.99 min, 50.32%, 240.0 nm

    Example 8Synthesis of N-((1-methyl-1H-imidazol-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 8)

    ##STR00230##

    Step-1:

    [0298] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.466 mmol, 1.0 eq), HATU (0.26 g, 0.700 mmol, 1.5 eq) and DIPEA (0.18 g, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added CAS: 53332-67-5 (0.094 g, 0.513 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by TLC (using MeOH:DCM; 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.223 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (5% Methanol in DCM) yielding N-((1-methyl-1H-imidazol-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 8, 0.058 g, 0.139 mmol, Yield: 29.97%)

    [0299] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.30-9.27 (m, 2H), 8.85 (s, 1H), 8.00-7.97 (m, 1H), 7.64-7.62 (m, 2H), 7.11 (s, 1H), 6.82 (s, 1H), 5.86 (br s, 1H), 4.60 (d, J=5.2 Hz, 2H), 3.69 (s, 3H), 2.71-2.67 (m, 3H), 2.50-2.45 (m, 1H), 2.25-2.22 (m, 1H), 2.09-2.06 (m, 1H), 1.71-1.65 (m, 1H)

    [0300] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.0 Hz, 1H), 7.96 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.62 (m, 2H), 7.09 (d, J=1.2 Hz, 1H), 6.93 (d, J=1.6 Hz, 1H), 5.86 (br s, 1H), 4.75 (s, 2H), 3.81 (s, 3H), 2.81-2.64 (m, 3H), 2.55-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.17-2.15 (m, 1H), 1.92-1.84 (m, 1H).

    [0301] LCMS (Method A): 1.892 min, 100.0%, 210.0 nm, MS: ES+415.1 (M+1)

    [0302] HPLC (Method A): 8.081 min, 98.59%, 210.0 nm

    Example 9Synthesis of N((R)-1-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 9)

    ##STR00231##

    Step-1:

    [0303] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.150 g, 0.466 mmol, 1.0 eq), HATU (0.26 g, 0.700 mmol, 1.5 eq) and DIPEA (0.18 g, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) at 0 C. under nitrogen atmosphere stirred for 15 min, was added CAS: 626220-76-6 (0.064 g, 0.513 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by TLC (using 100% EtOAc as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.180 g crude. The obtained crude material was purified by trituration with ACN yielding N((R)-1-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 9, 0.121 g, 0.308 mmol, Yield: 66.05%).

    [0304] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.79 (d, J=2.4 Hz, 1H), 8.60 (d, J=8.0 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.87 (br s, 1H), 4.29-4.23 (m, 1H), 3.47-3.43 (m, 1H), 3.35-3.31 (m, 1H) 3.29 (s, 3H), 2.80-2.77 (m, 1H), 2.72-2.68 (m, 2H), 2.47-2.46 (m, 1H), 2.32-2.24 (m, 1H), 2.09-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.19 (d, J=6.8 Hz, 3H).

    [0305] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.23 (d, J=2.4 Hz, 1H), 8.75 (d, J=2.0 Hz, 1H), 7.96 (dd, J=7.6, 2.0 Hz, 1H), 7.68-7.62 (m, 2H), 5.86 (br s, 1H), 4.43-4.39 (m, 1H), 3.57-3.50 (m, 1H), 3.49-3.46 (m, 1H), 3.42 (s, 3H), 2.80-2.71 (m, 1H), 2.67-2.55 (m, 2H), 2.52-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.18-2.14 (m, 1H), 1.92-1.81 (m, 1H), 1.31 (d, J=6.8 Hz, 3H).

    [0306] LCMS (Method A): 2.480 min, 100.0%, 254.0 nm, MS: ES+393.17 (M+1)

    [0307] HPLC (Method A): 9.068 min, 98.51, 210.0 nm

    [0308] Chiral HPLC: 4.64 min and 4.93 min, 49.45% and 50.54%, 240.0 nm

    Example 10Synthesis of N-((4-methyl-1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 10)

    ##STR00232##

    Step-1:

    [0309] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.466 mmol, 1.0 eq), HATU (0.26 g, 0.700 mmol, 1.5 eq) and DIPEA (0.18 g, 1.400 mmol, 3.0 eq) in DMF (1.5 mL) at 0 C. under nitrogen atmosphere stirred for 15 min, was added CAS: 2173991-88-1 (0.094 g, 0.513 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored by TLC (using MeOH:DCM; 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.194 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (70% Ethyl acetate in hexane as gradient) yielding N-((4-methyl-1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 10, 0.073 g, 0.176 mmol, Yield: 37.73%).

    [0310] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.54, 12.38 (s, 1H), 9.26 (d, J=2.4 Hz, 1H), 9.18-9.09 (m, 1H), 8.83 (d, J=2.4 Hz, 1H), 7.99-7.97 (m, 1H), 7.64-7.60 (m, 2H), 7.46 (br s, 1H), 5.86 (br s, 1H), 4.52 (d, J=4.8 Hz, 2H), 2.84-2.77 (m, 2H), 2.28-2.24 (m, 1H), 2.09-2.06 (m, 1H), 2.02 (s, 3H), 1.74-1.65 (m, 1H). Note: Aliphatic 2 proton merged with DMSO solvent peaks which is clearly visible in MeOD NMR.

    [0311] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 7.95 (d, J=7.6 Hz, 1H), 7.68-7.62 (m, 2H), 7.42 (br s, 1H), 5.86 (br s, 1H), 4.68 (s, 2H), 2.77-2.74 (m, 1H), 2.64 (d, J=2.8 Hz, 2H), 2.55-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.19-2.10 (m, 4H), 1.92-1.81 (m, 1H).

    [0312] LCMS (Method A): 2.331 min, 100.0%, 210.0 nm, MS: ES+415.1 (M+1)

    [0313] HPLC (Method A): 8.273 min, 98.67%, 210.0 nm

    Example 11Synthesis of N-(oxazol-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 11)

    ##STR00233##

    Step-1:

    [0314] To a solution 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.15 g, 0.466 mmol, 1.0 eq), HATU (0.35 g, 0.933 mmol, 2.0 eq) and DIPEA (0.24 g, 1.867 mmol, 4.0 eq) in DMF (1.5 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 1041053-44-4 (0.075 g, 0.560 mmol, 1.2 eq) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. The reaction was monitored by TLC (using EtOAc:Hexane; 8:2 as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.2 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (75% Ethyl acetate in hexane as gradient) yielding N-(oxazol-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 11, 0.090 g, 0.224 mmol, Yield: 48.03%).

    [0315] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.52 (t, J=5.6 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.0, Hz, 1H), 8.09 (d, J=0.8 Hz, 1H), 8.02 (dd, J=6.8, 2.8 Hz, 1H), 7.67-7.62 (m, 2H), 7.19 (d, J=0.8 Hz, 1H), 5.87 (br s, 1H), 4.67 (d, J=5.6 Hz, 2H), 2.85-2.78 (m, 1H), 2.71-2.67 (m, 2H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H). Note: CF3-CH proton merged with DMSO solvent peak which is clearly visible in MeOD NMR.

    [0316] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 8.82 (d, J=2.4 Hz, 1H), 7.98 (dd, J=8.0, 2.0 Hz, 1H), 7.93 (d, J=0.4 Hz, 1H), 7.71-7.64 (m, 2H), 7.18 (s, 1H), 5.87 (br s, 1H), 4.80 (s, 2H), 2.83-2.76 (m, 1H), 2.68-2.64 (m, 2H), 2.55-2.51 (m, 1H), 2.41-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.86 (m, 1H) Note: CONH proton exchanged in MeOD NMR.

    [0317] LCMS (Method A): 2.341 min, 99.58%, 220.0 nm, MS: ES+402.07 (M+1)

    [0318] HPLC (Method A): 8.385 min, 98.13%, 210.0 nm

    Example 12Chiral Separation of N-(oxazol-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compounds 12 and 13)

    ##STR00234##

    Procedure:

    [0319] Compound 11 (0.025 g) racemic was subjected to chiral SFC purification on (CHIRALPAK IG 25010 mm 5 m) column where 2 peaks were separated: Peak 1 (0.007 g Yield=28.00%) as Compound 12 and Peak 2 (0.004 g, Yield=16.00%) as Compound 13.

    [0320] COLUMN ID: CHIRALPAK IG, 25010 mm, 5 m

    [0321] MOBILE PHASE A: Liq.CO2

    [0322] MOBILE PHASE B: 0.1% Methanolic Ammonia in IPA-ACN (70-30)

    [0323] FLOW RATE (ML/MIN): 14

    [0324] INSTRUMENT ID: SFC INVESTIGATOR

    [0325] METHOD: TIME: FLOW: % A: % B (0:14:60:40), (7:14:60:40)

    Compound 12:

    [0326] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.53 (t, J=5.2 Hz, 1H), 9.28 (d, J=1.6 Hz, 1H), 8.86 (d, J=1.6 Hz, 1H), 8.09 (s, 1H), 8.02 (d, J=5.6 Hz, 1H), 7.66 (br s, 2H), 7.19 (s, 1H), 5.88 (s, 1H), 4.67 (d, J=5.2 Hz, 2H), 2.78-2.67 (m, 3H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.68 (m, 1H)

    [0327] LCMS (Method A): 2.368 min, 97.96%, 254.0 nm, MS: ES+402.2 (M+1)

    [0328] HPLC (Method A): 8.461 min, 98.53%, 254.0 nm

    Compound 13:

    [0329] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.53 (t, J=5.2 Hz, 1H), 9.28 (d, J=1.6 Hz, 1H), 8.86 (d, J=1.6 Hz, 1H), 8.09 (s, 1H), 8.02 (d, J=5.6 Hz, 1H), 7.66-7.63 (m, 2H), 7.20 (s, 1H), 5.88 (s, 1H), 4.67 (d, J=5.6 Hz, 2H), 2.81-2.68 (m, 3H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.67 (m, 1H)

    [0330] LCMS (Method A): 2.367 min, 98.83%, 254 nm, MS: ES+402.1 (M+1)

    [0331] HPLC (Method A): 8.481 min, 99.19%, 254.0 nm

    Example 13Synthesis of 3-(methylsulfinyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline (Compound 14)

    ##STR00235##

    Step-1:

    [0332] To a stirred solution of 8-bromoquinoline CAS: 16567-18-3 (5.0 g, 23.96 mmol, 1.0 eq) in Acetonitrile (50 mL) was added Iodine (12.16 g, 47.93 mmol, 2.0 eq) and TBHP (70% aqueous sol.) followed by addition of CAS: 75-91-2 (30.93 mL, 240.3 mmol, 10.0 eq). The resulting mixture was stirred at 80 C. for 16 h. The reaction was monitored on TLC (using EtOAc:Hexane; 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 80 C. The resulting reaction mixture was diluted with water (50 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 5.5 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (1% EtOAc in Hexane) yielding 8-bromo-3-iodoquinoline (A8, 4.1 g, 12.27 mmol, Yield: 51.09%).

    [0333] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): 9.16 (d, J=2.0 Hz, 1H), 8.97 (d, J=2.0 Hz, 1H), 8.18 (d, J=7.4 Hz, 1H), 7.98 (d, J=7.6 Hz, 1H), 7.56 (t, J=7.6 Hz, 8 Hz, 1H)

    [0334] LCMS (Method A): 2.516 min, 97.70%, 254.0 nm, MS: ES-336.0 (M+2)

    Step-2:

    [0335] To a stirred solution of 8-bromo-3-iodoquinoline (A8, 4.0 g, 11.98 mmol, 1.0 eq) in Toluene (40 mL) was added CAS: 5188-07-8 (1.17 g, 16.77 mmol, 1.4 eq) under N.sub.2. The resulting mixture was stirred at 80 C. for 3 h. The reaction was monitored on TLC (using EA:n-hexane; 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 3 h of stirring at 80 C. The resulting reaction mixture was quenched with cold water (40 mL) to precipetated out the crude which was filtered off and washed with 50 mL of water and dried under reduced pressure to afford 2.9 g crude. The obtained crude material was triturated by n-hexane yielding 8-bromo-3-(methylthio) quinoline (A9, 2.5 g, 9.84 mmol, Yield: 84.13%).

    [0336] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 8.90 (d, J=2.4 Hz, 1H), 8.24 (d, J=2.0 Hz, 1H), 8.04 (dd, J=7.6, 1.2 Hz, 1H), 7.95 (dd, J=8.2 Hz, 0.8 Hz, 1H), 7.52 (t, J=8.0 Hz, 1H), 2.66 (s, 3H).

    [0337] LCMS (Method A): 2.295 min, 95.98%, 254.0 nm, MS: ES+256.10 (M+2)

    Step-3:

    [0338] To a stirred solution of 8-bromo-3-(methylthio) quinoline (A9, 1.5 g, 5.90 mmol, 1.0 eq) in DCM (15 mL) was added m-CPBA (1.52 g, 8.85 mmol, 1.5 eq) at 0 C. under N.sub.2. The resulting mixture was stirred at room temperature for 2 h. The reaction was monitored on TLC (using EtOAc:Hex; 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at room temperature. The resulting reaction mixture was quenched with cold water (10 mL) and extracted with DCM (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.5 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (2% MeOH in DCM) yielding 8-bromo-3-(methylsulfinyl)quinoline (A10, 0.55 g, 2.04 mmol, Yield: 34.50%).

    [0339] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.23 (d, J=2.0 Hz, 1H), 8.80 (d, J=2.4 Hz, 1H), 8.29 (dd, J=7.6, 2.0 Hz, 1H), 8.23 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.65 (t, J=8.0 Hz, 1H), 2.97 (s, 3H).

    [0340] LCMS (Method A): 1.553 min, 96.36%, 254.0 nm, MS: ES+272.00 (M+2)

    Step-4:

    [0341] To a stirred solution of 8-bromo-3-(methylsulfinyl)quinoline (A10, 0.25 g, 0.925 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 0.38 g, 1.388 mmol, 1.5 eq) and Na.sub.2CO.sub.3 (0.29 g, 2.776 mmol, 3.0 eq) in Dioxane (2.0 mL) and water (0.5 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (0.075 g, 0.092 mmol, 0.1 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 3 h. The reaction was monitored by TLC (using EA:Hex; 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 3 h of stirring at 100 C. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.4 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (75% Ethyl acetate in n-hexane) yielding 3-(methylsulfinyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline (Compound 14, 0.07 g, 0.206 mmol, Yield: 22.78%).

    [0342] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.11 (d, J=2.0 Hz, 1H), 8.70 (d, J=2.0 Hz, 1H), 8.10-8.07 (m, 1H), 7.70-7.67 (m, 2H), 5.86 (br s, 1H), 2.94 (s, 3H), 2.77-2.67 (m, 3H), 2.33-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.67 (m, 1H). Note: CF3-CH merged with DMSO solvent peak which is clearly observed in MeOD NMR.

    [0343] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.10 (d, J=1.6 Hz, 1H), 8.69 (d, J=2.4 Hz, 1H), 8.01 (dd, J=7.6, 2.4 Hz, 1H), 7.74-7.68 (m, 2H), 5.87 (br s, 1H), 3.01 (s, 3H), 2.83-2.78 (m, 1H), 2.72-2.61 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.33 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.82 (m, 1H).

    [0344] Note: Minor aliphatic impurity observed.

    [0345] LCMS (Method A): 2.357 min, 97.92%, 254.0 nm, MS: ES+340.06 (M+1)

    [0346] HPLC (Method A): 8.493 min, 98.25%, 254.0 nm

    Example 14Synthesis of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic Acid (Compound 15)

    ##STR00236## ##STR00237##

    Step-1:

    [0347] To a solution of 2-amino-3-bromobenzoic acid (CAS: 20776-51-6) (5.0 g, 23.145 mmol, 1.0 eq) in THF (20 mL) was added BH.sub.3.THF (1M in THF, 81.0 mL, 81.007 mmol, 3.5 eq) at 0 C. The mixture was stirred at 70 C. for 12 h. The reaction was monitored on TLC (using EtOAc as mobile phase) which confirmed that the reaction got completed after 12 h of stirring at 70 C. Then the reaction mixture was quenched with MeOH, filtered and concentrated under reduced pressure to obtained a crude. The residue was stirred with water (100 mL) and filtered. The residue was dissolved in DCM and dried over Na.sub.2SO.sub.4 and evaporated under reduced pressure to give (2-Amino-3-bromo-phenyl) methanol (A11, 4.4 g, 21.78 mmol, 94.09% yield) as a pale brown solid.

    [0348] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm, 7.41 (dd, J=8.4, 1.6 Hz, 1H), 7.02 (d, J=7.6 Hz, 1H), 6.60 (t, J=8.0 Hz, 1H), 4.68 (s, 2H), 3.65 (br s, 3H). Note: Minor aliphatic impurities observed

    [0349] LCMS (Method A): 1.667 min, 98.41%, 254.0 nm, MS: ES+202.0 (M), 204.0 (M+2)

    Step-2:

    [0350] To a solution of (2-Amino-3-bromo-phenyl) methanol (A11, 4.4 g, 21.78 mmol, 1 eq) in DCM (40 mL) was added MnO.sub.2 (18.93 g, 232.40 mmol, 10 eq). The mixture was stirred at room temperature for 12 h. The reaction was monitored on TLC (using EA:Hex; 6.0:4.0 as mobile phase) which confirmed that the reaction got completed after 12 h of stirring at room temperature. The reaction mixture was filtered and concentrated under reduced pressure to give 2-amino-3-bromobenzaldehyde (A12, 3.5 g, 17.50 mmol, Yield: 78.75%).

    [0351] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm, 9.85 (s, 1H), 7.64 (dd, J=7.6, 1.6 Hz, 1H), 7.51 (dd, J=7.6, 1.6 Hz, 1H), 6.70 (t, J=7.6 Hz, 1H) Note: NH.sub.2 protons not observed.

    [0352] LCMS (Method A): 1.966 min, 98.98%, 254.0 nm, MS: ES+200.0 (M), 201.99 (M+2)

    Step-3:

    [0353] To a solution of (A12, 380 mg, 1.8996 mmol, 1 eq) in EtOH (4 mL) was added L-proline (109 mg, 0.9498 mmol, 0.5 eq) and CAS 922-67-80 (0.22 mL, 2.4695 mmol, 1.3 eq). The mixture was stirred at 80 C. for 16 h. The reaction was monitored on TLC (using EtOAc:Hex as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 80 C. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography using silica gel (60-120 mesh) as stationary phase (100% Ethyl acetate in hexane as gradient) to give Methyl 8-bromoquinoline-3-carboxylate (A13, 374 mg, 1.41 mmol, 73.99% yield).

    [0354] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm, 9.59 (d, J=2.0 Hz, 1H), 8.89 (d, J=2.0 Hz, 1H), 8.20 (dd, J=7.6, 1.6 Hz, 1H), 7.95 (dd, J=8.4, 1.2 Hz, 1H), 7.52 (t, J=8.0 Hz, 1H), 4.06 (s, 3H).

    [0355] LCMS (Method B): 2.61 min, 100%, 254.0 nm, MS: ES+268.02 (M+2)

    Step-4:

    [0356] To a stirred solution of 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 1.14 g, 4.133 mmol, 1.1 eq), methyl 8-bromoquinoline-3-carboxylate (A13, 1.0 g, 3.758 mmol, 1.0 eq) and K.sub.3PO.sub.4 (1.59 g, 7.516 mmol, 2.0 eq) in Dioxane (7 mL) and water (3 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (0.306 g, 0.375 mmol, 0.1 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 2 h. The reaction was monitored on TLC (using EtOAc:Hexane; 2.0:8.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 100 C. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.2 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (55% EtOAc in Hexane) yielding methyl 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylate (A14, 0.72 g, 2.147 mmol, Yield: 57.20%).

    [0357] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.0 Hz, 1H), 9.00 (d, J=2.0 Hz, 1H), 8.13 (dd, J=7.6, 1.6 Hz, 1H), 7.71-7.64 (m, 2H), 5.86 (br s, 1H), 3.95 (s, 3H), 2.80-2.77 (m, 1H), 2.69-2.66 (m, 3H), 2.31-2.27 (m, 1H), 2.09-2.06 (m, 1H), 1.72-1.66 (m, 1H).

    [0358] LCMS (Method A): 2.903 min, 100.0%, 210.0 nm, MS: ES+336.06 (M+1)

    Step-5:

    [0359] A solution of methyl 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylate (A14, 1.0 g, 2.982 mmol, 1.0 eq) and NaOH (0.59 g, 14.912 mmol, 5.0 eq) in MeOH:H.sub.2O (10 mL, 7:3) was prepared at 0 C. under nitrogen atmosphere. The resulting mixture was stirred for 4 h at room temperature. The reaction was monitored by TLC (using EtOAc:Hexane; 6.0:4.0 as mobile phase) which confirmed that the reaction got completed after 4 h. The resulting reaction mixture was concentrated under reduced pressure and obtained residue was poured onto ice-water then filtered off to afford the desired product 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.8 g, 2.489 mmol, Yield: 83.83%).

    [0360] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 13.54 (br s, 1H), 9.29 (d, J=2.4 Hz, 1H), 8.98 (d, J=2.4, Hz, 1H), 8.12 (dd, J=7.6, 2.0 Hz, 1H), 7.71-7.64 (m, 2H), 5.87 (br s, 1H), 2.84-2.67 (m, 3H), 2.47-2.42 (m, 1H), 2.33-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.65 (m, 1H).

    [0361] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.49 (d, J=2.0 Hz, 1H), 9.42 (d, J=2.0 Hz, 1H), 8.29 (dd, J=8.4, 1.2 Hz, 1H), 8.00 (dd, J=7.2, 1.2 Hz, 1H), 7.91 (t, J=8.0 Hz, 1H), 6.02 (br s, 1H), 2.78-2.71 (m, 2H), 2.68-2.57 (m, 2H), 2.47-2.40 (m, 1H), 2.25-2.21 (m, 1H), 1.98-1.88 (m, 1H).

    [0362] Note: COOH proton exchanged with MeOD.

    [0363] LCMS (Method A): 2.475 min, 100.0%, 254.0 nm, MS: ES+322.06 (M+1)

    [0364] HPLC (Method A): 4.280 min, 99.77%, 254.0 nm

    Example 15Synthesis of 3-(methylsulfonyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline (Compound 16)

    ##STR00238##

    Step-1:

    [0365] To a stirred solution of 5-bromo-3-(methylthio) quinoline (A9, 1.0 g, 3.934 mmol, 1.0 eq), in DCM (25 mL) was added m-chloroperbenzoic acid (2.10 g, 11.80 mmol, 3.0 eq) under N.sub.2. The resulting mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (using EA:Hex; 1.0:1.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was diluted with saturated aqueous sodium bicarbonate solution (200 mL) and extracted with DCM (2100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.65 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (55% Ethyl acetate in hexane as gradient) yielding 8-bromo-3-(methylsulfonyl)quinoline (A15, 0.50 g, 1.747 mmol, Yield: 44.41%).

    [0366] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.41 (d, J=2.4 Hz, 1H), 9.13 (d, J=2.4 Hz, 1H), 8.39 (dd, J=7.6, 1.2 Hz, 1H), 8.33 (dd, J=8.0, 1.2 Hz, 1H), 7.72 (t, J=8.0 Hz, 1H), 3.44 (s, 3H).

    [0367] LCMS (Method A): 1.807 min, 95.24%, 254.0 nm, MS: ES+286.01 (M), 288.01 (M+2)

    Step-2:

    [0368] To a stirred solution of 8-bromo-3-(methylsulfonyl)quinoline (A15, 0.3 g, 1.048 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 0.289 g, 1.048 mmol, 1.0 eq) and K.sub.3PO.sub.4 (0.666 g, 3.144 mmol, 3.0 eq) in dioxane (15 mL) was added Pd(PPh.sub.3).sub.4 (0.242 g, 0.209 mmol, 0.2 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 2 h. The reaction was monitored by TLC (using EA:Hexane; 1.0:1.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 100 C. The resulting reaction mixture was diluted with water (100 mL) and extracted with EtOAc (150 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.35 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (15% Ethyl acetate in hexane as gradient) yielding 3-(methylsulfonyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline (Compound 16, 0.113 g, 0.317 mmol, Yield: 30.37%).

    [0369] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 9.02 (d, J=2.4 Hz, 1H), 8.20 (dd, J=7.6, 2.0 Hz, 1H), 7.79-7.73 (m, 2H), 5.88 (br s, 1H), 3.40 (s, 3H), 2.79-2.76 (m, 1H), 2.76-2.70 (m, 1H), 2.29-2.26 (m, 1H), 2.11-2.08 (m, 1H), 1.75-1.65 (m, 1H). Note: 2H merged with DMSO solvent which is clearly visible in MeOD NMR.

    [0370] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.96 (d, J=2.4 Hz, 1H), 8.08 (dd, J=8.0, 1.6 Hz, 1H), 7.80 (dd, J=7.2, 1.6 Hz, 1H), 7.76-7.72 (m, 1H), 5.89 (br s, 1H), 3.30 (s, 3H), 2.83-2.78 (m, 1H), 2.72-2.68 (m, 1H), 2.68-2.61 (m, 1H), 2.57-2.52 (m, 1H), 2.41-2.34 (m, 1H), 2.20-2.15 (m, 1H), 1.90-1.80 (m, 1H).

    [0371] LCMS (Method A): 2.560 min, 95.70%, 254.0 nm, MS: ES+356.02 (M+1)

    [0372] HPLC (Method A): 9.069 min, 95.08%, 254.0 nm

    Example 16Synthesis of N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-sulfonamide (Compound 17)

    ##STR00239##

    Step-1a:

    [0373] To a stirred solution of phenylmethanethiol CAS: 100-53-8 (10.0 g, 80.645 mmol, 1.0 eq) in Diethyl Ether (100 mL) was added Na Metal (0.927 g, 40.257 mmol, 0.5 eq). The resulting mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using EtOAc:Hexane; 3.0:7.0 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was filtered using Buchner funnel, solid material was washed with diethyl ether and dried under vacuum yielding sodium phenylmethanethiolate as white solid (A16, 6.0 g, 41.04 mmol, Yield: 50.98%).

    [0374] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm, 7.25 (d, J=9.2 Hz, 2H), 7.16-7.11 (m, 2H), 7.01-6.98 (m, 1H), 3.50 (br s, 2H).

    Step-1:

    [0375] To a solution of 8-bromo-3-iodoquinoline (A8, 3.0 g, 8.983 mmol, 1.0 eq), in DMF (25 mL) was added sodium phenylmethanethiolate (A16, 1.83 g, 12.576 mmol, 1.4 eq) under Nitrogen. The resulting mixture was stirred for 6 h at 80 C. The reaction was monitored on TLC (using EA:Hexane; 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 6 h. The resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with EtOAc (350 mL). The combined organic layer were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 2.0 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (30% Ethyl acetate in hexane as gradient) yielding 3-(benzylthio)-8-bromoquinoline (A17, 1.5 g, 4.54 mmol, Yield: 50.56%).

    [0376] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 8.91 (d, J=2.4 Hz, 1H), 8.39 (d, J=2.4 Hz, 1H), 8.07 (dd, J=7.6, 1.2 Hz, 1H), 7.92 (dd, J=8.0, 1.2 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.41 (d, J=7.2 Hz, 2H), 7.32-7.28 (m, 2H), 7.25-7.21 (m, 1H), 4.45 (s, 2H).

    [0377] LCMS (Method-A): 2.780 min, 97.22%, 254.0 nm, MS: ES+332.01 (M+2)

    Step-2:

    [0378] To a stirred solution of 3-(benzylthio)-8-bromoquinoline (A17, 1.5 g, 4.542 mmol, 1.0 eq) in Acetonitrile, Acetic acid and water was added CAS: 118-52-5 (1.91 g, 9.084 mmol, 2 eq) at 0 C. and the resulting mixture was stirred at 0 C. for 2 h. The reaction was monitored by TLC (using EtOAc:Hexane; 3.0:7.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 0 C. The resulting reaction mixture was concentrated to dryness then diluted with DCM and cooled to 0 C., was added 5% aq. NaHCO.sub.3 and stirred reaction mixture for 15 minutes at 0 C., Organic layer washed with brine solution (50 ml). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.5 g crude 8-bromoquinoline-3-sulfonyl chloride (A18, 1.5 g, 4.893 mmol, Yield: Crude). Note: The crude obtained used as such for next step without further purification.

    [0379] LCMS (Method A): 2.455 min, 11.07%, 254.0 nm, MS: ES+, 308.0 (M+2)

    Step-3:

    [0380] To a solution of 8-bromoquinoline-3-sulfonyl chloride (A18, 1.5 g, 4.893 mmol, 1.0 eq) in DCM (20 mL) was added CAS: 74-89-5 (4.89 mL, 9.786 mmol, 2.0 eq) at 0 C. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 3.0:7.0 as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with DCM (350 mL). Combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.4 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (40% Ethyl acetate in hexane as gradient) yielding 8-bromo-N-methylquinoline-3-sulfonamide (A19, 1.1 g, 3.652 mmol, Yield: 80.42% (yield over 2 steps)).

    [0381] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.96 (d, J=2.0 Hz, 1H), 8.35-8.30 (m, 2H), 7.88 (q, J=4.8 Hz, 1H), 7.69 (t, J=8.0 Hz, 1H), 2.49 (s, 3H).

    [0382] LCMS (Method A): 1.859 min, 100%, 254.0 nm, MS: ES+302.96 (M+2)

    Step-4:

    [0383] To a stirred solution of 8-bromo-N-methylquinoline-3-sulfonamide (A19, 0.1 g, 0.332 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (A2, 0.11 g, 0.398 mmol, 1.2 eq) and Na.sub.2CO.sub.3 (0.088 g, 0.83 mmol, 2.5 eq) in dioxane (2 mL) and water (0.4 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (0.013 g, 0.016 mmol, 0.05 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 2 h. The reaction was monitored on TLC (using EA:Hexane; 1.0:1.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 100 C. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.120 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (30% EtOAc in Hexane) N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-sulfonamide (Compound 17, 0.079 g, 0.213 mmol, Yield: 64.23%).

    [0384] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm, 9.13 (d, J=2.4 Hz, 1H), 8.85 (d, J=2.4 Hz, 1H), 8.17 (dd, J=6.8, 2.8 Hz, 1H), 7.74-7.70 (m, 3H), 5.87 (br s, 1H), 2.80-2.66 (m, 4H), 2.49 (s, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H).

    [0385] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.17 (d, J=2.4 Hz, 1H), 8.80 (d, J=2.4 Hz, 1H), 8.04 (dd, J=8.0, 1.6 Hz, 1H), 7.77-7.69 (m, 2H), 5.88 (br s, 1H), 2.83-2.78 (m, 1H), 2.71-2.66 (m, 2H), 2.62 (s, 3H), 2.57-2.51 (m, 1H), 2.40-2.34 (m, 1H), 2.19-2.16 (m, 1H), 1.91-1.89 (m, 1H).

    [0386] Note: SO.sub.2NH proton exchanged in MeOD.

    [0387] LCMS (Method A): 2.599 min, 100%, 254.0 nm, MS: ES+371.12 (M+1)

    [0388] HPLC (Method A): 9.102 min, 100%, 254.0 nm

    Example 17Synthesis of N-(1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 18)

    ##STR00240##

    Step-1:

    [0389] To a stirred solution of oxazole CAS: 288-42-6 (0.2 g, 2.896 mmol, 1.0 eq), in THF (4 mL) was added n-BuLi (1.81 mL, 2.896 mmol, 1.5 M in Hexane, 1.0 eq) at 78 C. and continue stirred for 1 h at 78 C., then CAS: 3591-86-8 (0.327 g, 2.896 mmol, 1.0 eq) in THF (1 mL) was added under N.sub.2. The resulting mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using EA:Hexane; 1:1 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was quenched with 1N HCl (10 mL) and extracted with DCM (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude oxazole-2-carbaldehyde (A20, 0.25 g, 2.575 mmol, Yield: Crude). The obtained crude material was directly used for next step without further purification.

    [0390] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.72 (s, 1H), 7.95 (s, 1H), 7.66 (s, 1H).

    [0391] LCMS (Method A): 0.196 min, 38.56%, 210.0 nm, MS: ES+, 97.9 (M+1)

    Step-2:

    [0392] To a solution of oxazole-2-carbaldehyde (A20, 0.25 g, 2.57 mmol, 1.0 eq), in THF (3 mL) CAS: 146374-27-8 (0.374 g, 3.09 mmol, 1.2 eq) and CAS: 3087-36-3 (1.17 g, 5.15 mmol, 2.0 eq) were added. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 1:1 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with brine (50 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (40% Ethyl acetate in hexane as gradient) yielding (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A21, 0.15 g, 2.496 mmol, Yield: 25.87% (Yield over 2 steps)).

    [0393] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 8.45 (s, 1H), 8.29 (s, 1H), 7.63 (s, 1H), 1.19 (s, 9H).

    [0394] LCMS (Method A): 1.551 min, 98.61%, 254.0 nm, MS: ES+201.10 (M+1)

    Step-3:

    [0395] To a stirred solution of (E)-2-Methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A21, 0.150 g, 0.749 mmol, 1.0 eq), in DCM (3 mL) was added CH.sub.3MgBr (0.27 mL, 0.823 mmol, 1.1 eq) under N.sub.2 at 0 C. The resulting mixture was stirred at 0 C. for 1 h. The reaction was monitored on TLC (using EtOAc:Hexane; 1.0:1.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 0 C. The resulting reaction mixture was quenched with NH.sub.4Cl solution (5 mL) and extracted with DCM (310 mL). Then crude material was dissolved in MeOH (5 mL) was added 4 M HCl in Dioxane (0.347 mL, 1.388 mmol, 2.0 eq) and stirred reaction mixture for 1 h. The reaction was monitored on TLC (using EtOAc:Hexane; 4.0:1.0 as mobile phase) which confirmed that the reaction got completed after 1 h. Reaction mixture concentrated under reduced pressure to afford 0.15 g crude. The obtained crude material was purified by trituration yielding 1-(oxazol-2-yl)ethan-1-amine (A22, 0.08 g, 0.713 mmol, Yield: 71.88%)

    [0396] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.81 (s, 2H), 8.24 (d, J=0.8 Hz, 1H), 7.32 (d, J=0.8, 1H), 4.68-4.65 (m, 1H), 1.56 (d, J=6.8 Hz, 3H). (MeOH traces observed).

    Step-4:

    [0397] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A5, 0.2 g, 0.622 mmol, 1.0 eq), HATU (0.35 g, 0.933 mmol, 1.5 eq) and DIPEA (0.32 mL, 1.867 mmol, 3.0 eq) in DMF (5 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added 1-(oxazol-2-yl)ethan-1-amine (A22, 0.139 g, 0.933 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 12 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 7:3 as mobile phase) which confirmed that the reaction got completed after 12 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mess) as stationary phase (60% Ethyl acetate in hexane as gradient) yielding N-(1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 18, 0.141 g, 0.333 mmol, Yield: 54.53%).

    [0398] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.35 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.0 Hz, 1H), 8.85 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 8.02-8.00 (m, 1H), 7.66-7.62 (m, 2H), 7.19 (s, 1H), 5.87 (br s, 1H), 5.40-5.36 (m, 1H), 2.80-2.67 (m, 3H), 2.32-2.28 (m, 1H), 2.09-2.07 (m, 1H), 1.71-1.65 (m, 1H), 1.61 (d, J=7.6 Hz, 3H). Note: CF.sub.3CH Proton merged with DMSO Solvent peak which is clearly visible in MeOD NMR.

    [0399] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.4 Hz, 1H), 7.97 (dd, J=8.0, 2.0 Hz, 1H), 7.92 (d, J=0.4 Hz, 1H), 7.7-7.63 (m, 2H), 7.18 (d, J=0.4 Hz, 1H), 5.87 (br s, 1H), 5.52-5.46 (m, 1H), 2.75-2.68 (m, 1H), 2.68-2.65 (m, 2H), 2.56-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.14 (m, 1H), 1.92-1.83 (m, 1H), 1.73 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged with MeOD.

    [0400] LCMS (Method A): 2.466 min, 100%, 254.0 nm, MS: ES+416.18 (M+1) HPLC (Method A): 8.717 min, 99.37%, 254.0 nm

    Example 18Chiral separation of N-(1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compounds 19-22)

    ##STR00241##

    Procedure:

    [0401] Compound 18 (0.131 g) racemic was subjected to chiral SFC purification on (CHIRALPAK IG 25050 mm 5 m) column where 3 peaks were separated: Peak 1 (0.051 g, Yield=38.93%), Peak 2 (Compound 19, 0.0172 g Yield=13.13%), and Peak 3 (Compound 20 0.0142 g Yield=10.84%)

    [0402] COLUMN ID: CHIRALPAK IG 25050 mm 5 m

    [0403] MOBILE PHASE A: LIQ. CO.sub.2

    [0404] MOBILE PHASE B: 0.1% M.Math.NH.sub.3 IN MEOH-ACN (50-50)

    [0405] FLOW RATE (ML/MIN): 170

    [0406] INSTRUMENT ID: WATERS SFC 350 WITH 2489 UV Detector

    [0407] METHOD: TIME: FLOW: % A: % B (0.01:170:55:45), (17:170:55:45)

    Compound 19:

    [0408] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.35 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.4 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 8.03-8.00 (m, 1H), 7.67-7.63 (m, 2H), 7.19 (d, J=0.4 Hz, 1H), 5.88 (br s, 1H), 5.40-5.36 (m, 1H), 2.72-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.61 (d, J=6.8 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0409] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.98 (dd, J=7.6, 1.6 Hz, 1H), 7.92 (d, J=0.8 Hz, 1H), 7.71-7.64 (m, 2H), 7.18 (s, 1H), 5.87 (br s, 1H), 5.52-5.47 (m, 1H), 2.79-2.66 (m, 4H), 2.56-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.73 (d, J=7.2 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD)

    [0410] LCMS (Method A): 2.465 min, 100%, 254.0 nm, MS: ES+416.2 (M+1)

    [0411] HPLC (Method A): 8.775 min, 100%, 254.0 nm

    Compound 20:

    [0412] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.35 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.4 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 8.03-8.00 (m, 1H), 7.67-7.63 (m, 2H), 7.19 (d, J=0.4 Hz, 1H), 5.88 (br s, 1H), 5.40-5.36 (m, 1H), 2.72-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.61 (d, J=6.8 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0413] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.98 (dd, J=7.6, 1.6 Hz, 1H), 7.92 (d, J=0.8 Hz, 1H), 7.71-7.64 (m, 2H), 7.18 (s, 1H), 5.87 (br s, 1H), 5.52-5.47 (m, 1H), 2.79-2.66 (m, 4H), 2.56-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.73 (d, J=7.2 Hz, 3H) (Note: NH proton might exchange with deuterium from MeOD)

    [0414] LCMS (Method A): 2.466 min, 100%, 254.0 nm, MS: ES+416.2 (M+1)

    [0415] HPLC (Method A): 8.772 min, 99.71%, 254.0 nm

    [0416] Chiral Separation of Compound 21 & Compound 22:

    [0417] Procedure: Peak 1 (0.051 g) was further subjected for chiral SFC purification on (CHIRALPAK IG 25050 mm 5 um) column in order to obtain Peak 1 Isomer 1 (Compound 21, 0.0131 g, Yield=26.20%), and Peak 1 Isomer 2 (Compound 22, 0.0129 g, Yield=25.80%)

    [0418] COLUMN ID: CHIRALPAK IG 25050 mm 5 um

    [0419] MOBILE PHASE A: LIQ. CO2

    [0420] MOBILE PHASE B: 0.1% M.Math.NH3 in IPA-MEOH (70-30)

    [0421] FLOW RATE (ML/MIN): 150

    [0422] INSTRUMENT ID: WATERS SFC 350 WITH 2489 UV Detector

    [0423] METHOD: TIME: FLOW: % A: % B (0.01:150:70:30), (18:150:70:30)

    Compound 21:

    [0424] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.35 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.4 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 8.03-8.00 (m, 1H), 7.67-7.63 (m, 2H), 7.19 (d, J=0.4 Hz, 1H), 5.88 (br s, 1H), 5.40-5.36 (m, 1H), 2.72-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.61 (d, J=6.8 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0425] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.98 (dd, J=7.6, 1.6 Hz, 1H), 7.92 (d, J=0.8 Hz, 1H), 7.71-7.64 (m, 2H), 7.18 (s, 1H), 5.87 (bs, 1H), 5.52-5.47 (m, 1H), 2.79-2.66 (m, 4H), 2.56-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.73 (d, J=7.2 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD)

    [0426] LCMS (Method A): 2.427 min, 100%, 254.0 nm, MS: ES+416.2 (M+1)

    [0427] HPLC (Method A): 8.859 min, 100%, 254.0 nm

    Compound 22:

    [0428] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.35 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.4 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 8.03-8.00 (m, 1H), 7.67-7.63 (m, 2H), 7.19 (d, J=0.4 Hz, 1H), 5.88 (br s, 1H), 5.40-5.36 (m, 1H), 2.72-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.61 (d, J=6.8 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0429] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.98 (dd, J=7.6, 1.6 Hz, 1H), 7.92 (d, J=0.8 Hz, 1H), 7.71-7.64 (m, 2H), 7.18 (s, 1H), 5.87 (br s, 1H), 5.52-5.47 (m, 1H), 2.79-2.66 (m, 4H), 2.56-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.73 (d, J=7.2 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD)

    [0430] LCMS (Method A): 2.420 min, 100%, 254.0 nm, MS: ES+416.1 (M+1)

    [0431] HPLC (Method A): 8.851 min, 100%, 254.0 nm

    Example 19Synthesis of N-(2-(methylthio)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 23)

    ##STR00242##

    Step-1:

    [0432] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.1 g, 0.31 mmol, 1.0 eq), in DMF (1 mL) was prepared in 10 mL glass vial at room temperature. To this reaction solution, DIPEA (0.16 mL, 0.93 mmol, 3.0 eq) and HATU (0.17 g, 0.46 mmol, 1.5 eq) was added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (CAS: 18542-42-2) 2-(methylthio) ethan-1-amine (0.028 g, 0.31 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 16 h. The reaction was monitored by TLC (using EtOAc:Hexane; 4.0:6.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was diluted with water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.11 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as a stationary phase (elution gradient 20% EtOAc in Hexane) yielding as a N-(2-(methylthio)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 23, 0.055 g, 0.13 mmol, Yield: 45.08%)

    [0433] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.96 (t, J=5.6 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.02-7.99 (m, 1H), 7.65-7.61 (m, 2H), 5.86 (br s, 1H), 3.53 (q, J=6.4 Hz, 2H), 2.80-2.77 (m, 1H), 2.72-2.67 (m, 4H), 2.32-2.20 (m, 1H), 2.13-2.06 (m, 4H), 1.74-1.67 (m, 1H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0434] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.75 (d, J=2.0 Hz, 1H), 7.96 (d, J=8.0 Hz, 1H), 7.69-7.62 (m, 2H), 5.86 (br s, 1H), 3.68 (t, J=6.8 Hz, 2H), 2.80 (t, J=7.2 Hz, 3H), 2.68-2.60 (m, 2H), 2.55-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.19-2.15 (m, 4H), 1.92-1.81 (m, 1H) (Note: NH proton might exchange with deuterium from MeOD)

    [0435] LCMS (Method A): 2.614 min, 95.77%, 254 nm, MS: ES+395.12 (M+1)

    [0436] HPLC (Method B): 9.433 min, 95.17%, 254 nm

    Example 20Synthesis of N-(2-(methylsulfinyl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 24)

    ##STR00243##

    Step-1:

    [0437] A stirred solution of N-(2-(methylthio)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 23, 0.1 g, 0.25 mmol, 1.0 eq), in DCM (1 mL) was prepared in 10 mL glass vial at room temperature. To this resulting mixture m-CPBA (60% assay) (0.026 g, 0.25 mmol, 1.0 eq) in DCM (0.5 mL) was added dropwise at 0 C. under nitrogen atmosphere. Then the resulting reaction mixture was stirred from 0 C. to RT for 16 h. The reaction was monitored by TLC (using MeOH:DCM; 0.5:9.5 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was diluted with water (5 mL), basified with solution of sat NaHCO.sub.3 (5 mL) and extracted with DCM (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.11 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (elution gradient 3% MeOH in DCM) yielding as a N-(2-(methylsulfinyl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 24, 0.055 g, 0.13 mmol, Yield: 52.88%)

    [0438] 1H NMR (DMSO-d6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 9.13 (t, J=5.2 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 8.02-8.00 (m, 1H), 7.65-7.62 (m, 2H), 5.87 (br s, 1H), 3.77-3.64 (m, 2H), 3.15-3.08 (m, 1H), 2.97-2.91 (m, 1H), 2.79-2.71 (m, 2H), 2.62 (s, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR).

    [0439] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.96 (t, J=6.4 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.95-3.89 (m, 2H), 3.28-3.23 (m, 1H), 3.13-3.07 (s, 1H), 2.76 (s, 4H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.89-1.85 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0440] LCMS (Method A): 2.121 min, 100%, 254 nm, MS: ES+411.1 (M+1)

    [0441] HPLC (Method B): 7.334 min, 99.45%, 254 nm

    Example 21Synthesis of N-(2-(methyl sulfonyl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 25)

    ##STR00244##

    Step-1:

    [0442] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.1 g, 0.31 mmol, 1.0 eq), in DMF (1 mL) was prepared in 10 mL glass vial at room temperature. To this reaction solution, DIPEA (0.27 mL, 1.55 mmol, 5.0 eq) and HATU (0.17 g, 0.46 mmol, 1.5 eq) was added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., 2-(methyl sulfonyl)ethan-1-amine (CAS: 104458-24-4) (0.049 g, 0.31 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 16 h. The reaction was monitored by TLC (using Neat EtOAc as a mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was diluted with water (5 mL) and extracted with EtOAc (315 mL). The combined organic layers were washed with cold water (330 mL), dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.12 g crude. The obtained crude material was purified by trituration with diethyl ether yielding as a N-(2-(methyl sulfonyl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 25, 0.053 g, 0.12 mmol, Yield: 40.15%).

    [0443] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 9.09 (t, J=5.2 Hz, 1H), 8.79 (d, J=1.6 Hz, 1H), 8.02-8.00 (m, 1H), 7.65-7.62 (m, 2H), 5.87 (br s, 1H), 3.77 (q, J=6.4 Hz, 2H), 3.44 (t, J=6.8 Hz, 2H), 3.07 (s, 3H), 2.80-2.77 (m, 1H), 2.71-2.67 (m, 2H), 2.46-2.43 (m, 1H), 2.32-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0444] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.6, 3.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (s, 1H), 3.95 (t, J=6.4 Hz, 2H), 3.51 (t, J=6.8 Hz, 2H), 3.09 (s, 3H), 2.78-2.74 (m, 1H), 2.68-2.64 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.89-1.85 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0445] LCMS (Method A): 2.290 min, 98.55%, 254 nm, MS: ES+427.2 (M+1)

    [0446] HPLC (Method B): 8.152 min, 98.63%, 254 nm

    Example 22Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 26)

    ##STR00245##

    Step-1:

    [0447] A stirred solution of 8-bromoquinoline-3-carboxylic acid (A3, 0.50 g, 1.98 mmol, 1.0 eq) in DMF (5.0 mL) was prepared in 30 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.76 g, 5.95 mmol, 3.0 eq) and HATU (1.12 g, 2.97 mmol, 1.5 eq) were added at 0 C. under nitrogen atmosphere. After 10 min of stirring isopropyl amine (CAS: 75-31-0) (0.11 g, 1.98 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using EtOAc:Hexane; 1.0:1.0 as mobile phase) which confirmed that the reaction was completed after 16 h of stirring at RT. The resulting reaction mixture was extracted by EtOAc (50 mL) and H.sub.2O (50 mL), Organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtained crude product. The crude product was purified by combi-flash using 230-400 mesh size silica and product was eluting at 12% EtOAc:Hexane to yielding 8-bromo-N-isopropylquinoline-3-carboxamide (A23, 0.323 g, 1.101 mmol, Yield: 55.59%)

    [0448] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.33 (d, J=2.0 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.67 (d, J=4.8 Hz, 1H), 8.24 (d, J=6.8 Hz, 1H), 8.14 (d, J=8.0 Hz, 1H), 7.61 (t, J=8.0 Hz, 1H), 4.21-4.12 (m, 1H), 1.23 (d, J=6.4 Hz, 6H).

    [0449] LCMS (Method A): 1.866 min, 99.55%, 254 nm, MS: ES+294 (M+1)

    Step-2:

    [0450] A stirred solution of A23 (0.1 g, 0.34 mmol, 1 eq) in Dioxane:H.sub.2O (3:1) was prepared in 10 mL glass vial at room temperature. To this reaction solution, CAS: 1227068-84-9 (0.08 g, 0.33 mmol, 1 eq), Na.sub.2CO.sub.3 (0.10 g, 1.02 mmol, 3 eq) was added at same temperature. Purge by N.sub.2. After that Pd(dppf)Cl.sub.2 (0.02 g, 0.03 mmol, 0.1 eq) was added and stirred at 110 C. for 2 h. Then reaction was monitored by TLC (50% EtOAc:Hexane as a mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 110 C. The resulting reaction mixture was dilute with water (20 mL) and extracted with EtOAc (20 mL). The Organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtained crude product. The crude product was purified by combi-flash column chromatography using 230-400 mesh size silica and product was eluted at 10% EtOAc:Hexane to yielding as 8-(4,4-difluorocyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 26, 0.074 g, 0.223 mmol, Yield: 66.07%).

    [0451] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=1.6 Hz, 1H), 8.79 (d, J=1.6 Hz, 1H), 8.56 (d, J=7.2 Hz, 1H), 8.01 (t, J=5.6 Hz, 1H), 7.63 (t, J=7.2 Hz, 2H), 5.76 (br s, 1H), 4.18-4.13 (m, 1H), 2.90 (br s, 2H), 2.79 (t, J=14.8 Hz, 2H), 2.25-2.18 (m, 2H), 1.21 (d, J=6.4 Hz, 6H).

    [0452] LCMS (Method A): 2.313 min, 96.62%, 254.0 nm, MS: ES+331.2 (M+1)

    [0453] HPLC (Method B): 8.486 min, 99.62% at 254.0 nm.

    Example 23Synthesis of(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 27)

    ##STR00246##

    Step-1:

    [0454] A stirred solution of methyl 8-bromoquinoline-3-carboxylate (A13, 0.4 g, 1.50 mmol, 1.0 eq), 2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS: 1227068-84-9) (0.36 g, 1.50 mmol, 1.0 eq) and Na.sub.2CO.sub.3 (0.47 g, 4.50 mmol, 3.0 eq) in Dioxane:water (9:1) was prepared in 30 mL of glass vial at room temperature under N.sub.2 atmosphere. The reaction solution was degassed by N.sub.2 for 15 minutes at room temperature. To this reaction solution, PdCl.sub.2(dppf) (0.10 g, 0.15 mmol, 0.1 eq) was added at same temperature. The glass vial was sealed with cap and heated to 110 C. for 16 h. The reaction was monitored by TLC (using EtOAc:Hexane; 3.0:7.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 110 C. The resulting reaction mixture was cooled to room temperature, diluted with EtOAc (10 mL), filtered it through celite bed, washed it with EtOAc (30 mL) and filtrate was concentrated under reduced pressure to afford 0.7 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (10% EtOAc in hexane) yielding as a methyl 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylate (A24, 0.3 g, 0.98 mmol, Yield: 65.93%)

    [0455] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.31 (d, J=2.0 Hz, 1H), 9.02 (d, J=2.0 Hz, 1H), 8.16 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.73 (dd, J=6.8 Hz, 1.2 Hz, 1H), 7.68 (t, J=7.6 Hz, 1H), 5.76 (br s, 1H) 3.96 (s, 3H), 2.89 (br s, 2H), 2.83-2.75 (m, 2H), 2.27-2.17 (m, 2H).

    [0456] LCMS (Method A): 2.613 min, 98.28%, 254 nm, MS: ES+304.1 (M+1)

    Step-2:

    [0457] A stirred solution of methyl 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylate (A24, 0.3 g, 0.98 mmol, 1.0 eq) in MeOH:water (7:3) was prepared in 30 mL of glass vial at room temperature. To this reaction solution, NaOH (0.10 g, 2.630 mmol, 2.0 eq) was added at same temperature. The glass vial was sealed with cap and heated to 50 C. for 4 h. The reaction was monitored by TLC (using EtOAc:Hexane; 3.0:7.0 as mobile phase) which confirmed that the reaction got completed after 4 h of stirring at 110 C. The resulting reaction mixture was cooled to room temperature, diluted with MeOH (5 mL) and concentrated under reduced pressure. To this reaction mixture was added aq. solution of citric acid until pH become acidic to get precipitate. The obtain precipitates were filtered through Buckner funnel, washed with water (10 mL) and dried over reduce vacuum to yield 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25, 0.24 g, 0.82 mmol, Yield: 83.91%).

    [0458] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.30 (d, J=2.0 Hz, 1H), 8.97 (d, J=2.0 Hz, 1H), 8.13 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.72-7.64 (m, 2H), 5.76 (br s, 1H), 2.89 (br s, 2H), 2.79 (t, J=14.4 Hz, 2H), 2.27-2.17 (m, 2H). Note: COOH proton might exchange with DMSO moisture.

    [0459] LCMS (Method A): 2.164 min, 98.32%, 254 nm, MS: ES+290.1 (M+1)

    Step-3:

    [0460] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25, 0.1 g, 0.34 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.30 mL, 1.72 mmol, 5.0 eq) and HATU (0.19 g, 0.51 mmol, 1.5 eq) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (1S)-1-(Pyridin-2-yl)ethan-1-amine hydrochloride (CAS: 40154-78-7) (0.067 g, 0.34 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 1 h. The reaction was monitored by TLC (using neat EtOAc as a mobile phase) which confirmed that the reaction got completed after 1 h of stirring from 0 C. to RT. The resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.12 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (elution gradient 30% EtOAc in Hexane) yielding as a(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 27, 0.099 g, 0.25 mmol, Yield: 72.79%)

    [0461] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.31 (d, J=2.4 Hz, 1H), 9.20 (d, J=8.0 Hz, 1H), 8.90 (d, J=2.4 Hz, 1H), 8.54 (d, J=4.0 Hz, 1H), 8.04 (dd, J=7.2, 2.0 Hz, 1H), 7.78 (dt, J=8.0 Hz, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 7.48 (d, J=8.0 Hz, 1H), 7.29-7.26 (m, 1H), 5.77 (br s, 1H), 5.30-5.22 (m, 1H), 2.90-2.89 (m, 2H), 2.79 (t, J=15.6 Hz, 2H), 2.26-2.19 (m, 2H), 1.55 (d, J=6.8 Hz, 3H).

    [0462] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 8.85 (d, J=2.4 Hz, 1H), 8.55 (d, J=4.4 Hz, 1H), 8.00 (d, J=8.0 Hz, 1H), 7.87-7.83 (m, 1H), 7.70-7.63 (m, 2H), 7.54 (d, J=8.0 Hz, 1H), 7.36-7.32 (m, 1H), 5.75 (br s, 1H), 5.35 (q, J=7.2 Hz, 1H), 2.89-2.86 (m, 2H), 2.83-2.74 (m, 2H), 2.32-2.25 (m, 2H), 1.66 (d, J=7.2 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD)

    [0463] LCMS (Method A): 2.027 min, 95.17%, 210 nm, MS: ES+394.2 (M+1)

    [0464] HPLC (Method B): 8.283 min, 98.25%, 254 nm

    [0465] Chiral HPLC (Method C): 2.59 min, 98.10%, 240 nm

    Example 24Synthesis of(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 28)

    ##STR00247##

    Step-1:

    [0466] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25, 0.1 g, 0.34 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.18 mL, 1.03 mmol, 3.0 eq) and HATU (0.19 g, 0.51 mmol, 1.5 eq) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (S)-2-aminopropan-1-ol (CAS: 2749-11-3) (0.025 g, 0.34 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 1 h. The reaction was monitored by TLC (using neat EtOAc as a mobile phase) which confirmed that the reaction got completed after 1 h of stirring from 0 C. to RT. The resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.18 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (70% EtOAc in Hexane) yielding as a(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 28, 0.075 g, 0.21 mmol, Yield: 63.02%).

    [0467] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.0 Hz, 1H), 8.47 (d, J=7.6 Hz, 1H), 8.02 (dd, J=7.6, 2.4 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (br s, 1H), 4.79 (t, J=5.6 Hz, 1H), 4.10-4.06 (m, 1H), 3.53-3.48 (m, 1H), 3.42-3.37 (m, 1H), 2.89 (br s, 2H), 2.79 (t, J=14.8 Hz, 2H), 2.25-2.18 (m, 2H), 1.18 (d, J=6.4 Hz, 3H).

    [0468] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.0, 1.6 Hz, 1H), 7.69-7.59 (m, 2H), 5.75 (br s, 1H), 4.32-4.24 (m, 1H), 3.68 (dd, J=17.6 Hz, 11.6 Hz, 2H), 3.67 (s, 1H), 3.01 (br s, 2H), 2.89-2.74 (m, 2H), 2.34-2.24 (m, 2H), 1.39-1.28 (m, 3H). (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0469] LCMS (Method A): 1.970 min, 98.04%, 254 nm, MS: ES+347.2 (M+1)

    [0470] HPLC (Method B): 7.064 min, 97.63%, 254 nm

    [0471] Chiral HPLC (Method C): 2.79 min, 99.18%, 248 nm

    Example 25Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 29)

    ##STR00248##

    Step-1:

    [0472] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25, 0.1 g, 0.34 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.30 mL, 1.72 mmol, 5.0 eq) and HATU (0.19 g, 0.51 mmol, 1.5 eq) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., oxazol-2-ylmethanamine hydrochloride (0.046 g, 0.34 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 1 h. The reaction was monitored by TLC (using EtOAc; 10.0 as mobile phase) which confirmed that the reaction got completed after 1 h of stirring from 0 C. to RT. The resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.13 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (50% EtOAc in Hexane) yielding as an 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 29, 0.085 g, 0.23 mmol, Yield: 66.92%).

    [0473] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.53 (t, J=5.2 Hz, 1H), 9.28 (d, J=2.0 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.09 (s, 1H), 8.04 (dd, J=7.6 Hz, 1.6 Hz, 1H), 7.69-7.63 (m, 2H), 7.19 (s, 1H), 5.77 (br s, 1H), 4.67 (d, J=5.6 Hz, 2H), 2.90 (br s, 2H), 2.79 (t, J=14.4 Hz, 2H), 2.27-2.17 (m, 2H).

    [0474] LCMS (Method A): 2.111 min, 97.20%, 254 nm, MS: ES+370.1 (M+1)

    [0475] HPLC (Method B): 7.544 min, 98.69%, 254 nm

    Example 26Synthesis of 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 30)

    ##STR00249##

    Step-1:

    [0476] A stirred solution of A23 (0.1 g, 0.34 mmol, 1 eq) in Dioxane:H.sub.2O (3:1) were prepared in 10 mL glass vial at room temperature. To this reaction solution, CAS: 859217-67-7 (0.08 g, 0.33 mmol, 1 eq), Na.sub.2CO.sub.3 (0.10 g, 1.02 mmol, 3 eq) was added at same temperature. Purge by N.sub.2. After that Pd(dppf)Cl.sub.2 (0.02 g, 0.03 mmol, 0.1 eq) was added and stirred at 110 C. for 2 h. Then reaction was monitored by TLC (50% EtOAc:Hexane as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 110 C. The resulting reaction mixture was dilute with H.sub.2O (20 mL) and extracted with EtOAc (20 mL). The organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrate under high vacuum. The crude product was purification by combi-flash column chromatography using 230-400 mesh size silica. The product was eluted at 7% EtOAc:Hexane to yielding 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 30, 0.051 g, 0.158 mmol, Yield: 46.40%).

    [0477] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 8.56 (d, J=7.6 Hz, 1H), 7.98-7.96 (m, 1H), 7.63-7.59 (m, 2H), 5.73 (br s, 1H), 4.20-4.11 (m, 1H), 2.61 (br s, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.21 (d, J=6.4 Hz, 6H), 1.05 (s, 6H).

    [0478] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.22 (d, J=2 Hz, 1H), 8.71 (d, J=2.0 Hz, 1H), 7.93-7.90 (m, 1H), 7.62-7.59 (m, 2H), 5.78 (br s, 1H), 4.32-4.26 (m, 1H), 2.61 (s, 2H), 2.07-2.03 (m, 2H), 1.64 (t, J=6.4 Hz, 2H), 1.48 (d, J=6.8 Hz, 6H), 0.94 (s, 6H). (Note: NH proton might exchange with deuterium from MeOD)

    [0479] LCMS (Method A): 2.797 min, 100%, 254 nm, MS: ES+323.2 (M+1).

    [0480] HPLC (Method B): 10.612 min, 100% at 254 nm.

    Example 27Synthesis of(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 31)

    ##STR00250##

    Step-1:

    [0481] A stirred solution of commercially available 8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26, 0.1 g, 0.35 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.30 mL, 1.03 mmol, 5.0 eq) and HATU (0.20 g, 0.53 mmol, 1.5 eq) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (S)-1-(Pyridin-2-yl) Ethan amine hydrochloride (CAS: 40154-78-7) (0.069 g, 0.35 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 1 h. The reaction was monitored by TLC (using neat EtOAc as a mobile phase) which confirmed that the reaction got completed after 1 h of stirring from 0 C. to RT. The resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.14 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (40% EtOAc in Hexane) yielding as a(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 31, 0.078 g, 0.20 mmol, Yield: 56.93%)

    [0482] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.31 (d, J=2.0 Hz, 1H), 9.18 (d, J=7.6 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.54 (d, J=4.0 Hz, 1H), 8.00-7.98 (m, 1H), 7.77 (dt, J=7.6 Hz, 1.6 Hz, 1H), 7.64-7.61 (m, 2H), 7.47 (d, J=8.0 Hz, 1H), 7.29-7.26 (m, 1H), 5.74 (br s, 1H), 5.27-5.24 (m, 1H), 2.62 (br s, 2H), 2.01 (br s, 2H), 1.56-1.51 (m, 5H), 1.05 (s, 6H).

    [0483] LCMS (Method A): 2.560 min, 100%, 254 nm, MS: ES+386.2 (M+1)

    [0484] HPLC (Method B): 10.376 min, 100%, 254 nm

    [0485] Chiral HPLC (Method C): 9.687 min, 100%, 240 nm

    Example 28Synthesis of(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 32)

    ##STR00251##

    Step-1:

    [0486] A stirred solution of A26 (0.090 g, 0.310 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.124 g, 0.950 mmol, 3.0 eq) and HATU (0.18 g, 0.470 mmol, 1.5 eq) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, (S)-2-aminopropan-1-ol (CAS: 2749-11-3) (0.024 g, 0.310 mmol, 1.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using Neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was poured in cold water (40 mL) and extracted with ethyl acetate (502) organic dried over Na.sub.2SO.sub.4 and concentrated under reduce pressure to obtain crude product which was purified by prep TLC to yielding as a(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 32, 0.050 g, 0.147 mmol, Yield: 46.29%).

    [0487] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.26 (s, 1H), 8.78 (s, 1H), 8.45 (d, J=8.0 Hz, 1H), 7.97 (t, J=4.8 Hz, 1H), 7.63-7.60 (m, 2H), 5.74 (br s, 1H), 4.79 (t, J=5.6 Hz, 1H), 4.11-4.04 (m, 1H), 3.53-3.47 (m, 1H), 3.41-3.35 (m, 1H), 2.61 (br s, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.17 (d, J=6.8 Hz, 3H), 1.05 (s, 6H).

    [0488] LCMS (Method A): 2.411 min, 100%, 254.0 nm, MS: ES+339.11 (M+1)

    [0489] HPLC (Method B): 8.906 min, 100%, 254.0 nm

    [0490] Chiral HPLC (Method B): 4.01 min, 100%, 260.0 nm

    Example 29Synthesis of 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 33)

    ##STR00252##

    Step-1:

    [0491] A stirred solution of A26 (0.1 g, 0.35 mmol, 1 eq) in DMF (1 mL) were prepared in 10 mL glass vial at room temperature. To this reaction solution was added DIPEA (0.19 g, 1.053 mmol, 3 eq) and HATU (0.20 g, 0.53 mmol, 1.5 eq) at 0 C. and stirred for 10 min. Then oxazol-2-ylmethanamine (0.03 g, 0.30 mmol, 1 eq) was added and resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (EtOAc:Hexane 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was extracted by EtOAc (20 mL) and H.sub.2O (20 mL). The organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrate under high vacuum to obtained crude product. The crude product was purification by combi-flash column chromatography using 230-400 mesh size silica and product was eluted at 50% EtOAc:Hexane to yielding 8-(4-4-dimethylcyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 33, 0.026 g, 0.074 mmol, Yield: 20.27%).

    [0492] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.51 (br s, 1H), 9.27 (s, 1H), 8.84 (s, 1H), 8.08 (s, 1H), 7.98 (t, J=4.4 Hz 1H), 7.62 (d, J=4.4 Hz, 2H), 7.19 (s, 1H), 5.74 (br s, 1H), 4.66 (d, J=5.2 Hz, 2H), 2.67-2.33 (m, 2H), 2.01 (br s, 2H), 1.52 (t, J=5.6 Hz, 2H), 1.04 (s, 6H).

    [0493] .sup.1H NMR (MeOD, 400 MHz): ppm 9.28 (s, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.94 (t, J=4.4 Hz, 2H), 7.66-7.61 (m, 2H), 7.18 (s, 1H), 5.78 (br s, 1H), 4.66 (s, 2H), 2.62 (s, 2H), 2.04 (t, J=10.0 Hz, 2H), 1.64 (t, J=6.4 Hz, 2H), 1.10 (s, 6H). (Note: NH proton might exchange with deuterium from MeOD)

    [0494] LCMS (Method A): 2.569 min, 98.86% at 254 nm, MS: ES+362 (M+1)

    [0495] HPLC (Method B): 9.413 min, 100% at 254 nm.

    Example 30Synthesis of 8-(cyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 34)

    ##STR00253##

    Step-1:

    [0496] A stirred solution of A13 (1.0 g, 3.750 mmol, 1.0 eq), and CAS: 141091-37-4 (0.78 g, 3.750 mmol, 1.0 eq) in Dioxane:water (4:1) were prepared in 35 mL glass vial at room temperature. To this reaction solution, Na.sub.2CO.sub.3 (1.19 g, 11.20 mmol, 3.0 eq) was added at same temperature. Then the resulting reaction mixture was stirred at RT and nitrogen purging for 15 min. After purging nitrogen gas added PdCl.sub.2 (dppf) at RT then the reaction was stirred at 110 C. for 16 h. The reaction was monitored by TLC (20% ethyl acetate in hexane as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 110 C. Then resulting reaction mixture was cooled at RT and poured in cold water (200 mL). Then again extracted with ethyl acetate (2200 mL) organic dried over Na.sub.2SO.sub.4, filtered and concentrated under reduce pressure to obtain crude material which was purified by column chromatography using hexane and ethyl acetate. Product was eluted at 7% ethyl acetate in hexane to afford methyl 8-(cyclohex-1-en-1-yl)quinoline-3-carboxylate (A27, 0.6 g, 2.244 mmol, Yield: 59.72%).

    [0497] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.30 (d, J=2.0 Hz, 1H), 8.99 (d, J=2.0 Hz, 1H), 8.10 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.83 (br s, 1H), 3.95 (s, 3H), 2.57 (br s, 2H), 2.22 (br s, 2H), 1.78-1.70 (m, 4H).

    [0498] LCMS (Method A): 2.821 min, 96.51%, 254.0 nm, MS: ES+268.10 (M+1)

    Step-2:

    [0499] A stirred solution of A27 (0.6 g, 2.240 mmol, 1.0 eq) in MeOH:H.sub.2O (4.2:1.8 mL) was prepared in 35 mL glass vial at room temperature. To this reaction solution, NaOH (0.179 g, 4.480 mmol, 2.0 eq), were added at same temperature. Then, the resulting reaction mixture was stirred at 50 C. for 3 h. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 3 h of stirring at RT. The resulting reaction mixture was directly concentrated under reduce pressure then added water (15 mL) after acidify with citric acid to obtain white solid. The precipitate was filtered through buckler funnel and washed with water (20 mL) and dried over high vacuum to yielding 8-(cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A28, 0.45 g, 1.776 mmol, Yield: 79.22%).

    [0500] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.54 (br s, 1H), 9.29 (d, J=2.0 Hz, 1H), 8.93 (d, J=2.0 Hz, 1H), 8.07 (dd, J=7.6 Hz, J=2.0 Hz, 1H), 7.66-7.13 (m, 2H), 5.83 (br s, 1H), 2.58 (br s, 2H), 2.22 (br s, 2H), 1.77-1.70 (m, 4H).

    [0501] LCMS (Method A): 2.220 min, 99.73%, 254.0 nm, MS: ES+254.10 (M+1)

    Step-3:

    [0502] A stirred solution of A28 (0.1 g, 0.390 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.153 g, 1.180 mmol, 3.0 eq) and HATU (0.225 g, 0.590 mmol, 1.5 eq) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, propan-2-amine (CAS: 75-31-0) (0.023 g, 0.390 mmol, 1.0 eq) was added at 0 C. Then the resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using 50% ethyl acetate in hexane as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was poured in cold water (40 mL) and extracted with ethyl acetate (240 mL) organic dried over Na.sub.2SO.sub.4 and concentrated under reduce pressure to obtain crude product which was purified by normal column chromatography using hexane and ethyl acetate product was eluted at 30% ethyl acetate in hexane to yielding as a 8-(cyclohex-1-en-1-yl)-N-isopropylquinoline-3-carboxamide (Compound 34, 0.065 g, 0.220 mmol, Yield: 56.03%).

    [0503] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.23 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 8.56 (d, J=7.6 Hz, 1H), 7.96 (t, J=4.8 Hz, 1H), 7.63-7.60 (m, 2H), 5.83 (br s, 1H), 4.18-4.11 (m, 1H), 2.67 (br s, 2H), 2.22 (br s, 2H), 1.77-1.70 (m, 4H), 1.21 (d, J=6.8 Hz, 6H).

    [0504] LCMS (Method A): 2.397 min, 100%, 254.0 nm, MS: ES+295.16 (M+1)

    [0505] HPLC (Method B): 9.316 min, 99.74%, 254.0 nm

    Example 31Synthesis of(S)-8-(cyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 35)

    ##STR00254##

    Step-1:

    [0506] A stirred solution of A28 (0.1 g, 0.390 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.255 g, 1.900 mmol, 5.0 eq) and HATU (0.225 g, 0.590 mmol, 1.5 eq) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, CAS: 40154-78-7 (0.077 g, 0.390 mmol, 1.0 eq) was added at 0 C. Then the resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was poured in cold water (40 mL) and extracted with ethyl acetate (240 mL) organic dried over Na.sub.2SO.sub.4 and concentrated under reduce pressure to obtain crude product which was purified by normal column chromatography using hexane and ethyl acetate product was eluted at 35% ethyl acetate in hexane further purified by prep TLC to yielding as a(S)-8-(cyclohex-1-en-1-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 35, 0.031 g, 0.086 mmol, Yield: 21.98%).

    [0507] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.28 (d, J=2.0 Hz, 1H), 9.19 (d, J=7.6 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.54 (d, J=4.4 Hz, 1H) 7.98 (t, J=4.8 Hz, 1H), 7.78 (dt, J=7.6 Hz, 1.6 Hz, 1H), 7.62 (d, J=4.8 Hz, 2H), 7.47 (d, J=8.0 Hz, 1H), 7.29-7.26 (m, 1H), 5.84 (br s, 1H), 5.29-5.22 (m, 1H), 2.59 (br s, 2H), 2.33 (br s, 2H), 1.77-1.70 (m, 4H), 1.55 (d, J=7.2 Hz, 3H).

    [0508] LCMS (Method A): 2.131 min, 100%, 210 nm, MS: ES+358.12 (M+1)

    [0509] HPLC (Method B): 9.162 min, 99.49%, 254.0 nm

    [0510] Chiral HPLC (Method C): 2.88 min, 98.97%, 241.0 nm

    Example 32Synthesis of(S)-8-(cyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 36)

    ##STR00255##

    Step-1:

    Procedure:

    [0511] A stirred solution of A28 (0.1 g, 0.390 mmol, 1.0 eq) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.153 g, 1.110 mmol, 3.0 eq) and HATU (0.225 g, 0.590 mmol, 1.5 eq) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, (S)-2-aminopropan-1-ol (CAS: 2749-11-3) (0.030 g, 0.390 mmol, 1.0 eq) was added at 0 C. Then the resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was poured in cold water (35 mL) and extracted with ethyl acetate (250 mL) organic dried over Na.sub.2SO.sub.4 and concentrated under reduce pressure to obtain crude product which was purified by normal column chromatography using hexane and ethyl acetate product was eluted at 50% ethyl acetate in hexane to yielding as a(S)-8-(cyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 36, 0.055 g, 0.177 mmol, Yield: 45.08%).

    [0512] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.46 (d, J=8.0 Hz, 1H), 7.96 (t, J=4.8 Hz, 1H), 7.63-7.60 (m, 2H), 5.83 (br s, 1H), 4.79 (t, J=6.0 Hz, 1H), 4.11-4.04 (m, 1H), 3.53-3.48 (m, 1H), 3.41-3.37 (m, 1H), 2.59 (br s, 2H), 2.22 (br s, 2H), 1.77-1.70 (m, 4H), 1.17 (d, J=6.4 Hz, 3H).

    [0513] LCMS (Method A): 2.006 min, 95.61%, 254 nm, MS: ES+311.11 (M+1)

    [0514] HPLC (Method B): 7.558 min, 97.76%, 254.0 nm

    [0515] Chiral HPLC (Method C): 2.85 min, 100%, 241.0 nm

    Example 33Synthesis of 8-(cyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 37)

    ##STR00256##

    Step-1:

    [0516] A stirred solution of A28 (0.1 g, 0.39 mmol, 1 eq) in DMF (1 mL) were prepared in 10 mL glass vial at room temperature. To this reaction solution was added DIPEA (0.15 g, 1.8 mmol, 3 eq), HATU (0.22 g, 0.58 mmol, 1.5 eq) at 0 C. and stirred for 10 min. Then oxazol-2-ylmethanamine (0.03 g, 0.39 mmol, 1 eq) was added and resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (MeOH:DCM, 1.0:9.0 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at RT. The resulting reaction mixture was extracted by EtOAc (20 mL) and H.sub.2O (20 mL). The organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtained crude product. The crude product was purification by combi-flash column chromatography using 230-400 mesh size silica and product was eluted at 12% EtOAc:Hexane yielding as an 8-(cyclohex-1-en-1-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide. (Compound 37, 0.042 g, 0.125 mmol, Yield: 32.06%).

    [0517] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.52 (t, J=5.2 Hz, 1H), 9.27 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.09 (s, 1H), 7.99-7.97 (m, 1H), 7.62 (d, J=4.0 Hz, 2H), 7.19 (s, 1H), 5.84 (br s, 1H), 4.67 (d, J=5.2 Hz, 2H), 2.58 (br s, 2H), 2.22 (br s, 2H), 1.77-1.70 (m, 4H).

    [0518] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 7.95 (t, J=6.0 Hz, 2H), 7.67-7.62 (m, 2H), 7.18 (s, 1H), 5.86 (br s, 1H), 4.79 (s, 2H), 2.56 (d, J=1.6 Hz, 2H), 2.31-2.29 (m, 2H), 1.89-1.86 (m, 2H), 1.83-1.80 (m, 2H). (Note: NH proton might exchange with deuterium from MeOD)

    [0519] LCMS (Method A): 2.209 min, 95.17%, 254 nm, MS: ES+334.1 (M+1)

    [0520] HPLC (Method B): 8.202 min, 96.41%, 254 nm

    Example 34Synthesis of N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 38)

    ##STR00257##

    Step-1:

    [0521] To a solution 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.159 g, 0.420 mmol, 1.5 eq) and DIPEA (0.14 ml, 0.840 mmol, 3.0 eq) in DMF (1 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added CAS: 74-89-5 (0.021 g, 0.420 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hex; 8:2 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.15 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (50% Ethyl acetate in hexane) yielding N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 38, 0.035 g, 0.104 mmol, Yield: 37.38%).

    [0522] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.80-8.74 (m, 2H), 8.01-7.99 (dd, J=6.0 Hz, =4.0 Hz, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 2.87 (d, J=4.8 Hz, 3H), 2.87-2.59 (m, 1H), 2.80-2.50 (m, 2H), 2.33-2.24 (m, 2H), 2.33-2.07 (m, 1H), 1.74-1.64 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0523] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.74 (t, J=2.4 Hz, 1H), 7.96 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.02 (s, 3H), 2.76-2.64 (m, 1H), 2.55-2.33 (m, 2H), 2.51 (s, 1H), 2.18-2.03 (m, 1H), 1.92-1.82 (br s, 1H), 1.92-1.82 (m, 1H) (Note: NH proton might exchange with deuterium from MeOD)

    [0524] LCMS (Method A): 2.327 min, 98.92%, 254.0 nm, MS: ES+429.3 (M+1)

    [0525] HPLC (Method A): 8.561 min, 97.93%, 210.0 nm

    [0526] CHIRAL HPLC (Method A): Peak-1 3.73 min, 49.03%, 240.0 nm; Peak-2 4.02 min, 50.02%, 240.0 nm

    Example 35Synthesis of N-(2-hydroxyethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 39)

    ##STR00258##

    Step-1:

    [0527] To a solution 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.159 g, 0.420 mmol, 1.5 eq) and DIPEA (0.14 ml, 0.840 mmol, 3.0 eq) in DMF (1 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added CAS: 141-43-5 (0.025 g, 0.420 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hex; 8:2 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.15 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (80% Ethyl acetate in hexane as elution gradient) yielding N-(2-hydroxyethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 39, 0.034 g, 0.093 mmol, Yield: 33.32%).

    [0528] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.81-8.80 (m, 2H), 8.00 (J=5.6, 4.7 Hz, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.80 (t, J=5.6 Hz, 1H), 3.59-3.54 (q, J=6.0 Hz, 2H), 3.42-3.34 (q, J=6.0 Hz, 2H), 2.80-2.77 (m, 1H), 2.72-2.67 (m, 2H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.64 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0529] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.97 (dd, J=7.6, 2 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (s, 1H), 3.78 (t, J=5.6 Hz, 2H), 3.59 (t, J=5.6 Hz, 2H), 2.78-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.85 (m, 1H). (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0530] LCMS (Method A): 2.154 min, 100%, 254.0 nm, MS: ES+365 (M+1)

    [0531] HPLC (Method A): 7.651 min, 99.49%, 210.0 nm

    [0532] CHIRAL HPLC (Method A): Peak-1 4.25 min, 49.65%, 240.0 nm; 4.69 min, 49.98%, 240.0 nm

    Example 36Synthesis of N-(2-methoxyethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 40)

    ##STR00259##

    Step-1

    [0533] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 109-85-3 (0.0315 g, 0.420 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 7.0:3.0 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.08 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (elution gradient 50% Ethyl acetate in hexane) yielding N-(2-methoxyethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 40, 0.047 g, 0.124 mmol, Yield: 44.34%)

    [0534] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.90 (br s, 1H), 8.81 (d, J=2.0 Hz, 1H), 8.02-7.99 (m, 1H), 7.65-7.62 (m, 2H), 5.87 (br s, 1H), 3.51 (s, 4H), 3.30 (s, 3H), 2.81-2.69 (m, 3H), 2.29-2.25 (m, 1H), 2.09-2.07 (m, 1H), 1.74-1.64 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0535] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.77 (d, J=2.4 Hz, 1H), 7.97 (dd, J=1.6, 7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 3.67 (s, 4H), 3.42 (s, 3H), 2.83-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H) (Note: NH proton might exchange with deuterium from MeOD)

    [0536] LCMS (Method A): 2.393 min, 98.83%, 254.0 nm, MS: ES+379.1 (M+1)

    [0537] HPLC (Method A): 8.672 min, 97.52%, 254.0 nm

    [0538] Chiral HPLC: Peak-1: 5.14 min, 49.67%, 240 nm; Peak-2: 5.57 min, 50.32%, 240 nm

    Example 37Synthesis of N-isopropyl-N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 41)

    ##STR00260##

    Step-1:

    [0539] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 1.2 mmol, 1.0 eq), CAS: 4747-21-1 (0.024 g, 0.336 mmol, 1.2 eq) and DIPEA (0.10 g, 0.84 mmol, 3.0 eq) in DMF (2 mL) under inert condition N.sub.2 (g) was added HATU (0.159 g, 0.42 mmol, 1.5 eq). The reaction was monitored by TLC (using ethyl acetate in hexane (3:7) as mobile phase) which confirmed that the reaction got completed after 3 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.07 g crude. The crude was purified by reverse phase HPLC yielding N-Isopropyl-N-methyl-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 41, 0.023 g, 0.061 mmol, Yield 19.16%)

    [0540] .sup.1H VT-NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.86 (br s, 1H), 8.36 (br s, 1H), 7.95 (br s, 1H), 7.61 (br s, 1H), 5.89 (br s, 2H), 4.28 (br s, 1H), 2.89-2.70 (m, 6H), 2.34-2.31 (m, 1H), 2.12-2.10 (m, 1H), 1.75-1.73 (m, 1H), 1.26-1.19 (br s, 6H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0541] .sup.1H-NMR (MeOD, 400 MHz): ppm, 8.87 (d, J=12.4 Hz, 1H), 8.40 (d, J=17.2 Hz, 1H), 7.94 (dd, J=6.8, 7.2 Hz, 1H), 7.67-7.62 (m, 2H), 5.86 (br s, 1H), 4.04-3.95 (m, 1H), 3.36-2.95 (s, 3H), 2.79-2.62 (m, 3H) 2.55-2.50 (m, 1H), 2.40-2.36 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.86 (m, 1H), 1.32 (d, J=6.8 Hz, 3H) 1.27 (d, J=6.8 Hz, 3H)

    [0542] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.87 (d, J=12.4 Hz, 1H), 8.46 (br s, 1H), 8.40 (br s, 1H), 7.98-7.96 (m, 1H), 7.64-7.61 (m, 3H), 5.85 (s, 2H), 4.78 (br s, 1H), 3.86 (br s, 1H), 2.90-2.60 (m, 9H), 2.33-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.74-1.63 (m, 1H), 1.23-1.14 (m, 6H) (Note: Due to rotamers peaks observed broad)

    [0543] LCMS (Method-A): 2.512 min, (100%), 254 nm, m/z=377.17 (M+H).sup.+

    [0544] HPLC (Method-A): 9.81 min, (100%), 210 nm

    Example 38Synthesis of N-(pyrimidin-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 42)

    ##STR00261##

    Step-1:

    [0545] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.01 g, 0.31 mmol, 1.0 eq), CAS: 372118-67-7 (0.045 g, 0.31 mmol, 1.0 eq) and DIPEA (0.12 g, 0.93 mmol, 3.0 eq) in DMF (2 mL) under inert condition N.sub.2(g) was added HATU (0.178 g, 0.46 mmol, 1.5 eq). The reaction was monitored by TLC (using MeOH in DCM (0.5:9.5) as mobile phase) which confirmed that the reaction got completed after 3 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL). dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.06 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 50% methanol in DCM) yielding Compound 42 (0.039 g, 0.094 mmol, Yield 32.88%)

    [0546] .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): ppm 9.45 (t, J=6.0 Hz, 1H), 9.31 (d, J=2.4 Hz, 1H), 8.88 (d, J=2.4 Hz, 1H), 8.79 (d, J=4.8 Hz, 2H), 8.04-8.01 (m, 1H), 7.66-7.63 (m, 2H), 7.43 (t, J=4.8 Hz, 1H), 5.88 (br s, 1H), 4.74 (d, J=6.0 Hz, 2H), 2.82-2.80 (m, 1H), 2.79-2.67 (m, 2H), 2.40-2.25 (m, 2H), 2.10-2.07 (m, 1H), 1.73-1.66 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0547] .sup.1H-NMR (MeOD, 400 MHz): ppm, 9.32 (d, J=2.0 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.80 (d, J=5.2 Hz, 2H), 8.00 (dd, J=8.0, 7.6 Hz, 1H), 7.71-7.64 (m, 2H), 7.43 (t, J=4.8 Hz, 1H), 5.88 (br s, 1H), 2.79-2.76 (m, 1H), 2.69-2.66 (m, 2H), 2.56-2.51 (m, 1H), 2.39-2.33 (m, 1H), 2.18-2.16 (m, 1H) 1.93-1.83 (m, 1H), (Note: NH proton might exchange with deuterium from MeOD; 2H merged with MeOD moisture peak)

    [0548] LCMS (Method-A): 2.28 min, (98.45%), 254 nm; MS: ES+413 (M+1)

    [0549] HPLC (Method-A): 8.20 min, (97.7%), 210 nm

    Example 39Synthesis of N-(pyridazin-3-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 43)

    ##STR00262##

    Step-1:

    [0550] To a solution 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.159 g, 0.420 mmol, 1.5 eq) and DIPEA (0.14 ml, 0.840 mmol, 3.0 eq) in DMF (1 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added CAS: 93319-65-4 (0.036 g, 0.336 mmol, 1.2 eq) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using MDC:MeOH; 9:1 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.15 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (5% MeOH in DCM) yielding N-(2-hydroxyethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 43, 0.076 g, 0.184 mmol, Yield: 65.79%).

    [0551] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.60 (t, J=5.2 Hz, 1H), 9.31 (d, J=2.0 Hz, 1H), 9.16 (d, J=2.4 Hz, 1H), 8.88 (d, J=2.0 Hz, 1H), 8.03-8.01 (m, 1H), 7.73-7.63 (m, 4H), 5.87 (br s, 1H), 4.85 (d, J=5.6 Hz, 2H), 2.85-2.71 (m, 2H), 2.28-2.25 (m, 1H), 2.09-2.07 (m, 1H), 1.74-1.67 (m, 1H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0552] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.31 (d, J=2.4 Hz, 1H), 9.14 (d, J=4.0 Hz, 1H), 8.85 (d, J=2.4 Hz, 1H), 7.98 (dd, J=1.2 Hz, 1H), 7.85 (d, J=7.6 Hz, 1H), 7.77-7.74 (m, 1H), 7.69-7.64 (m, 2H), 5.87 (br s, 1H), 4.95 (s, 2H), 2.79-2.76 (m, 1H), 2.69-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.41-2.33 (m, 1H), 2.18-2.15 (m, 1H), 1.88-1.82 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0553] LCMS (Method A): 2.243 min, 98.55%, 254.0 nm, MS: ES+413 (M+1)

    [0554] HPLC (Method A): 7.95 min, 98.09%, 254.0 nm

    [0555] CHIRAL HPLC (Method A): Peak-1 4.25 min, 49.65%, 240.0 nm;

    [0556] Peak-2 4.69 min, 49.98%, 240.0 nm

    Example 40Synthesis of N-(pyrazin-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 44)

    ##STR00263##

    Step-1

    [0557] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 20010-99-5 (0.046 g, 0.420 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using 100% EtOAc as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.072 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (eluent gradient 95% ethyl acetate in hexane) yielding N-(pyrazin-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 44, 0.072 g, 0.174 mmol, Yield: 62.33%).

    [0558] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.54 (t, J=5.6 Hz, 1H), 9.30 (d, J=2.0 Hz, 1H), 8.88 (d, J=1.6 Hz, 1H), 8.73 (s, 1H), 8.62 (s, 1H), 8.57 (d, J=2.0 Hz, 1H), 8.03-8.01 (m, 1H), 7.66-7.63 (m, 2H), 5.87 (br s, 1H), 4.71 (d, J=5.6 Hz, 2H), 2.81-2.68 (m, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.67 (m, 1H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0559] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.30 (d, J=2.0 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 8.75 (s, 1H), 8.62 (s, 1H), 8.55 (d, J=2.0 Hz, 1H), 7.98 (dd, J=1.6, 8.0 Hz, 1H), 7.70-7.64 (m, 2H), 5.87 (br s, 1H), 4.87 (s, 2H), 2.79-2.79-2.77 (m, 1H), 2.69-2.66 (m, 2H), 2.56-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.85 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0560] LCMS (Method-A): 2.305 min, 98.22%, 254.0 nm, MS: ES+413.2 (M+1)

    [0561] HPLC (Method-A): 8.360 min, 97.65%, 254.0 nm

    Example 41Synthesis of N-((5-methyloxazol-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 45)

    ##STR00264##

    Step-1

    [0562] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 2173992-46-4 (0.0457 g, 0.420 mmol, 1.5 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using 5% MeOH:DCM as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.08 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (5% MeOH in DCM) yielding N-((5-methyloxazol-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 45, 0.038 g, 0.0914 mmol, Yield: 32.66%)

    [0563] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.49 (br s, 1H), 9.27 (s, 1H), 8.86 (s, 1H), 8.02 (d, J=3.6 Hz, 1H), 7.66 (s, 2H), 6.79 (s, 1H), 5.87 (br s, 1H), 4.60 (d, J=4.8 Hz, 2H), 2.81-2.68 (m, 3H), 2.32-2.28 (m, 4H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H) (Note: CF.sub.3CH proton merge with DMSO solvent peak which is clearly observed in MeOD NMR)

    [0564] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.29 (s, 1H), 8.83 (s, 1H), 7.98 (d, J=7.2 Hz, 1H), 7.70-7.64 (m, 2H), 6.78 (s, 1H), 5.87 (br s, 1H), 4.73 (s, 2H), 2.79-2.66 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.34 (m, 4H), 2.18-2.15 (m, 1H), 1.91-1.85 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0565] LCMS (Method-A): 2.433 min, 97.16%, 254.0 nm, MS: ES+416.1 (M+1)

    [0566] HPLC (Method-A): 8.81 min, 97.37%, 254.0 nm

    Example 42Synthesis of N-(2-hydroxy-1-(pyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 46)

    ##STR00265##

    Step-1

    [0567] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 1187930-63-7 (0.065 g, 0.308 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using MeOH:DCM; 0.5:9.5 as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.08 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (elution gradient 95% Ethyl acetate in hexane) yielding N-(2-hydroxy-1-(pyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 46, 0.058 g, 0.131 mmol, Yield: 46.90%)

    [0568] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.30 (s, 1H), 9.09 (d, J=7.6 Hz, 1H), 8.92 (s, 1H), 8.55 (d, J=4.0 Hz, 1H), 8.03 (t, J=4.8 Hz, 1H), 7.78 (t, J=6.8 Hz, 1H), 7.66 (d, J=4.4 Hz, 2H), 7.49 (d, J=8.0 Hz, 1H), 7.29 (t, J=5.6 Hz, 1H), 5.88 (br s, 1H), 3.90-3.82 (m, 2H), 2.81-2.68 (m, 4H), 2.33-2.26 (m, 1H), 2.10-2.08 (m, 1H), 1.72-1.68 (m, 1H). (Note: CF.sub.3CH proton merge with DMSO solvent peak which is clearly observed in MeOD NMR)

    [0569] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.30 (d, J=2.0 Hz, 1H), 8.89 (d, J=2.4 Hz, 1H), 8.59 (d, J=4.4 Hz, 1H), 8.00 (dd, J=2.0, 8.0 Hz, 1H), 7.86 (dt, J=1.6, 8.0 Hz, 1H), 7.70-7.65 (m, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.38-7.35 (m, 1H), 5.88 (br s, 1H), 5.39 (t, J=6.4 Hz, 1H), 4.09-3.99 (m, 2H), 2.83-2.66 (m, 3H), 2.56-2.52 (m, 1H), 2.41-2.34 (m, 1H), 2.19-2.16 (m, 1H), 1.93-1.86 (m, 1H). (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0570] LCMS (Method-A): 2.171 min, 100%, 210.0 nm, MS: ES+442.2 (M+1)

    [0571] HPLC (Method-A): 8.19 min, 99.16%, 254.0 nm

    Example 43Synthesis of N-((1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 47)

    ##STR00266##

    Step-1

    [0572] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 1196153-72-6 (0.041 g, 0.308 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using MeOH:DCM; 0.5:9.5 as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.08 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (elution gradient 5% MeOH in DCM) yielding N-((1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 47, 0.038 g, 0.0949 mmol, Yield: 33.88%)

    [0573] .sup.1H NMR (DMSO-d.sub.6, 400 MHz) VT NMR: ppm, 12.47 (s, 1H), 9.29 (s, 1H), 8.99 (s, 1H), 8.81 (s, 1H), 7.97 (d, J=6.8 Hz, 1H), 7.64-7.61 (m, 3H), 6.24 (s, 1H), 5.89 (br s, 1H), 4.58 (d, J=4.8 Hz, 2H), 2.82-2.70 (m, 3H), 2.35-2.28 (m, 1H), 2.13-2.10 (m, 1H), 1.80-1.71 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0574] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 7.97 (dd, J=1.6, 8.0 Hz, 1H), 7.69-7.63 (m, 3H), 6.38 (s, 1H), 5.87 (br s, 1H), 4.71 (s, 2H), 2.78-2.65 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.33 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0575] LCMS (Method-A): 2.257 min, 98.28%, 254.0 nm, MS: ES+401.2 (M+1)

    [0576] HPLC (Method-A): 8.02 min, 95.17%, 254.0 nm

    Example 44Synthesis of N-((1H-1,2,4-triazol-3-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 48)

    ##STR00267##

    Step-1

    [0577] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.09 g, 0.280 mmol, 1.0 eq), HATU (0.160 g, 0.420 mmol, 1.5 eq) and DIPEA (0.15 mL, 0.840 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 1197157-75-7 (0.041 g, 0.308 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 2 h at room temperature. The reaction was monitored on TLC (using MeOH:DCM; 0.5:9.5 as mobile phase) which confirmed that the reaction got completed after 2 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.07 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (elution gradient 5% MeOH in DCM) yielding N-((1H-1,2,4-triazol-3-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 48, 0.040 g, 0.0996 mmol, Yield: 35.58%)

    [0578] .sup.1H NMR (DMSO-d.sub.6, 400 MHz) VT NMR: ppm, 13.70 (s, 1H), 9.29 (d, J=1.6 Hz, 1H), 9.13 (bs, 1H), 8.83 (d, J=1.6 Hz, 1H), 8.44 (br s, 1H), 7.98 (d, J=6.4 Hz, 1H), 7.67-7.61 (m, 2H), 5.91 (br s, 1H), 4.66 (s, 2H), 3.54-3.46 (m, 1H), 2.83-2.68 (m, 4H), 2.35-2.28 (m, 1H), 2.13-2.11 (m, 1H), 1.80-1.71 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0579] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.30 (s, 1H), 8.84 (s, 1H), 8.48 (br s, 1H), 7.98 (d, J=7.6 Hz, 1H), 7.70-7.63 (m, 2H), 5.87 (br s, 1H), 4.81 (s, 2H), 2.79-2.65 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.33 (m, 1H), 2.18-2.16 (m, 1H), 1.93-1.83 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0580] LCMS (Method-A): 2.069 min, 99.06%, 254.0 nm, MS: ES+402.2 (M+1)

    [0581] HPLC (Method-A): 6.22 min, 98.60%, 254.0 nm

    Example 45Synthesis of N-(cyanomethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 49)

    ##STR00268##

    Step-1:

    [0582] To a solution of 8-(4-(triflouromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.1 g, 0.3112 mmol, 1.0 eq), HATU (0.177 g, 0.466 mmol, 1.5 eq) and DIPEA (0.161 g, 1.244 mmol, 4.0 eq) in DMF (1 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 6011-14-9 (0.03168 g, 0.342 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 30 min at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 1:1 as mobile phase) which confirmed that the reaction got completed after 30 min. The resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.15 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh size) as stationary phase (30% Ethyl acetate in hexane) yielding N-(Cyanomethyl)-8-(4-(triflouromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 49, 0.1 g, 0.278 mmol, Yield: 89.41%)

    [0583] .sup.1H NMR (DMSO d.sup.6, 400 MHz): ppm, 9.58 (t, J=5.2 Hz, 1H), 9.25 (d, J=2.0 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.04 (dd, J=7.2 Hz, 2.8 Hz, 7.2 Hz, 1H), 7.69-7.64 (m, 2H), 5.88 (s, 1H), 4.43 (d, J=5.6 Hz, 2H), 2.81-2.567 (m, 3H), 2.33-2.25 (m, 1H), 2.09 (d, J=11.6, 1H), 1.75-1.64 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0584] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 7.99 (dd, J=8.0 Hz, 1H), 7.72-7.65 (m, 2H), 5.87 (s, 1H), 4.45 (s, 2H), 2.79-2.66 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.17 (d, J=12.8 Hz, 1H), 1.93-1.85 (m, 1H). (Note: NH proton might exchange with deuterium from MeOD)

    [0585] LCMS (Method A): 2.438 min, 100%, 254.0 nm, MS: ES+360.07 (M+1)

    [0586] HPLC (Method A): 8.764 min, 100%, 254.0 nm

    [0587] Chiral HPLC: Peak 1=3.87 min, 49.62%, 240.0 nm; Peak 2=4.46 min, 50.38%, 240.0 nm

    Example 46Synthesis of (8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-alanine (Compound 50)

    ##STR00269##

    Step-1:

    [0588] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.5 g, 1.5 mmol, 1.0 eq), CAS: 14316-06-4 (0.21 g, 1.54 mmol, 1.0 eq) and DIPEA (0.8 ml, 4.6 mmol, 3.0 eq) in DMF (5 mL) under inert condition N.sub.2(g) was added HATU (0.88 g, 2.3 mmol, 1.5 eq). The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 4 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.45 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 20% Ethyl acetate in hexane) yielding methyl (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A29, 0.3 g, 0.738 mmol, Yield 47.44%).

    [0589] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.26 (d, J=2.0 Hz, 1H), 9.17 (d, J=6.8 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.02 (dd, J=6.0, 3.6 Hz, 1H), 7.66-7.63 (m, 2H), 5.87 (br s, 1H), 4.59-4.52 (m, 1H), 3.67 (s, 3H), 2.80-2.67 (m, 3H), 2.50-2.46 (m, 1H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.64 (m, 1H), 1.45 (d, J=7.6 Hz, 3H)

    [0590] LCMS: 2.51 min, 100%, 215 nm

    Step-2:

    [0591] To a stirred solution of A29 (0.15 g, 0.36 mmol, 1.0 eq), LiOH (0.018 g, 0.44 mmol, 1.2 eq) in MeOH:H.sub.2O (8:2) was added at 0 C., then the reaction is allowed to run at room temperature. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at room temperature. The resulting reaction mixture was concentrated then acidified using IN HCl, then filtered using Buchner filtration to yield (8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-alanine (Compound 50, 0.056 g, 0.143 mmol, Yield 38.67%)

    [0592] .sup.1H NMR (DMSO, 400 MHz): ppm 9.32 (d, J=2.0 Hz, 1H), 9.21 (d, J=6.8 Hz, 1H), 9.04 (s, 1H), 8.08-8.07 (m, 1H), 7.72-7.68 (m, 2H), 5.89 (br s, 1H), 4.53-4.46 (m, 1H), 2.77-2.69 (br s, 2H), 2.65-2.51 (m, 1H), 2.47-2.42 (m, 1H), 2.33-2.26 (m, 1H), 2.10-2.07 (m, 1H), 1.77-1.68 (m, 1H), 1.46 (d, J=7.2 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0593] .sup.1H NMR (MeOD, 400 MHz): ppm 9.68 (d, J=1.6 Hz, 1H), 9.49 (d, J=1.6 Hz, 1H), 8.38 (d, J=8.0 Hz, 1H), 8.13 (dd, J=6.8 Hz, 1H), 8.05 (t, J=8.0 Hz, 1H), 6.10 (br s, 1H), 4.75-4.70 (m, 1H), 3.42-2.25 (s, 6H), 2.03-1.91 (m, 1H), 1.63 (d, J=7.6 Hz, 3H). (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0594] LCMS: 2.28 min, 100%, 210 nm

    [0595] HPLC: 4.49 min, 99.17%, 254 nm

    [0596] CHIRAL HPLC: Peak-1 3.58 min, 48.54%, 240 nm; Peak-2: 3.90 min, 49.73%, 240 nm

    Example 47Synthesis of O-methyl-N-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-serine (Compound 51)

    ##STR00270##

    Step-1:

    [0597] In 250 mL three neck RB flask, as a white amorphous 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.250 g, 0.775 mmol)., methyl O-Methyl-D-serinate hydrochloride CAS 1800300-79-1 (0.315 g, 0.934 mmol, 1.2 eq.), and DIPEA (1.12 ml, 2.35 mmol, 3.0 eq.) were stirred with HATU (0.89 g, 1.16 mmol, 1.5 eq.) in DMF (2 mL, 10 v) for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 3:7 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was diluted with ice-cold water (10 mL) and was extracted with DCM. The combined layer was evaporated under vacuum and crude residue was purified on silica column chromatography (60-120 mesh; 30% of EtOAc and hexane) and yielded methyl O-Methyl-N-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-serinate (A30, 0.185 g, 0.424 mmol, Yield: 54.48%).

    [0598] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.25 (d, J=2.0 Hz, 1H), 9.21 (d, J=7.2 Hz, 1H), 8.88 (d, J=4.0 Hz, 1H), 8.03 (dd, J=6.4, 4.8 Hz, 1H), 7.67-7.63 (m, 2H), 5.88 (br s, 1H), 4.82-4.77 (m, 1H), 3.87-3.50 (m, 5H), 3.26 (s, 3H), 2.81-2.68 (m, 4H), 2.33-2.25 (m, 1H), 2.30-2.20 (m, 1H), 2.10-2.1 (m, 1H), 1.74-1.64 (m, 1H).

    [0599] LCMS (Method A): 2.513 min, 100.0%, MS: ES+437.18 [M+H]

    Step-2:

    [0600] A suspension of methyl O-Methyl-N-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-serinate (A30, 0.170 g, 0.3895 mmol 1.0 eq) in THF/water (3 mL/1 mL) was cooled to 0 C., then treated with LiOH (0.033 g, 0.824 mmol 2.0 eq), and the reaction solution stirred at this temperature for 12 hours. The solution was acidified with 1N HCl. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), washed dried to give as gray solid O-methyl-N-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl)-D-serine (Compound 51, 0.052 g, 0.123 mmol 31.06% yield).

    [0601] .sup.1H NMR (400 MHz, DMSO-d.sub.6) ppm: 9.27 (d, J=2.0 Hz, 1H), 9.11 (d, J=7.6 Hz, 1H,) 8.93 (s, 1H), 8.03 (dd, J=6.4, 4.8 Hz, 1H), 7.67-7.64 (m, 2H), 5.88 (br s, 1H), 4.72 (q, J=10.0 Hz, 1H), 3.83-3.68 (m, 1H), 3.32 (s, 3H), 2.81-2.67 (m, 3H), 2.58-2.51 (m, 1H), 2.33-2.26 (m, 1H), 2.10-2.07 (m, 1H), 1.76-1.66 (m, 1H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0602] .sup.1H NMR (400 MHz, MeOD) (ppm): 9.48 (s, 1H), 9.42 (d, J=2.0 Hz, 1H), 8.29 (d, J=4.0 Hz, 1H), 8.02 (d, J=4.0 Hz, 1H), 7.96 (t, J=8.0 Hz, 1H), 6.04 (br s, 1H), 4.00-3.97 (m, 1H), 3.89-3.82 (m, 1H), 3.45 (s, 3H) 3.74 (br s, 2H), 2.65-2.56 (m, 2H), 2.48-2.41 (m, 1H), 2.61-2.24 (m, 1H), 2.01-1.90 (m, 1H) (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0603] LCMS (Method A): 2.31 min, 95.47%, 254 nm

    [0604] HPLC (Method A): 4.34 min, 96.33%, 254 nm

    [0605] CHIRAL HPLC: Peak-1 6.26 min, 36.05%, 240 nm: Peak-2 6.71 min, 43.16%, 240 nm

    Example 48Synthesis of N((R)-1-(methylamino)-1-oxopropan-2-yl)-8-(4 (trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 52)

    ##STR00271##

    Step-1:

    [0606] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 50, 0.16 g, 0.40 mmol, 1.0 eq), CAS: 61302-99-6 (0.027 g, 0.40 mmol, 1.0 eq) and DIPEA (0.2 ml, 1.2 mmol, 3.0 eq) in DMF (2 mL) was prepared under inert condition N.sub.2(g) then HATU (0.232 g, 0.612 mmol, 1.5 eq) was added. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.45 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 20% Ethyl acetate in hexane) then purified by prep HPLC purification (Method-A) yielding N((R)-1-(methylamino)-1-oxopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 52, 0.023 g, 0.057 mmol, Yield 13.91%).

    [0607] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.28 (d, J=2.0 Hz, 1H), 8.91-8.88 (m, 2H), 8.02-7.80 (m, 2H), 7.95 (m, J=4.4 Hz, 2H), 7.65-7.64 (m, 1H), 5.88 (br s, 1H), 4.51-4.48 (m, 1H), 2.79 (br s, 1H), 2.72-2.68 (m, 2H), 2.62-2.57 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.68 (m, 1H), 1.37 (d, J=7.2 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0608] .sup.1H NMR (MeOD, 400 MHz): ppm 9.28 (d, J=2.0 Hz, 1H), 8.85 (d, J=2.0 Hz, 1H), 7.98 (dd, J=7.8, 1.6 Hz, 1H), 7.70-7.64 (m, 2H), 5.87 (br s, 1H), 4.61 (q, J=7.2 Hz, 1H), 2.80 (s, 3H), 2.79-2.75 (m, 2H), 2.68-2.65 (m, 1H), 2.56-2.51 (m, 1H), 2.41-2.38 (m, 1H), 2.18-2.15 (m, 1H), 1.53 (d, J=7.2 Hz, 3H) (Note: NH proton might exchange with deuterium from MeOD)

    [0609] LCMS (Method A): 2.20 min, 100%, 254.0 nm, m/z=406.12 (M+H)+

    [0610] HPLC (Method A): 7.75 min, 99.61%, 210 nm

    [0611] CHIRAL HPLC: Peak-1: 3.55 min, 42.28%, 245 nm: Peak-2: 4.07 min, 43.73%, 245 nm

    Example 49Synthesis of N((R)-1-aminopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 53)

    ##STR00272##

    Step-1:

    [0612] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.2 g, 0.62 mmol, 1.0 eq), CAS: 333743-54-7 (0.10 g, 0.62 mmol, 1.0 eq) and DIPEA (0.3 ml, 1.8 mmol, 3.0 eq) in DMF (2 mL) under inert condition N.sub.2(g) was added HATU (0.35 g, 0.93 mmol, 1.5 eq). The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 4 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.3 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 20% Ethyl acetate in hexane) yielding tert-butyl ((2R)-2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (A31, 0.22 g, 0.461 mmol, Yield 67.28%).

    [0613] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=1.6 Hz, 1H), 8.77 (d, J=1.6 Hz, 1H), 8.48 (d, J=8.4 Hz, 1H), 7.98 (t, J=4.8 Hz, 1H), 7.64-7.61 (m, 2H), 7.01 (t, J=5.6 Hz, 1H), 5.87 (br s, 1H), 4.15-4.08 (m, 1H), 3.43-3.07 (m, 2H), 2.79-2.68 (m, 4H), 2.31-2.25 (m, 1H), 2.01-2.07 (m, 1H), 1.74-1.63 (m, 1H), 1.35 (s, 9H), 1.14 (d, J=6.8 Hz, 3H)

    [0614] LCMS (Method-A): RT=2.72 min, 100%, 254 nm, m/z=478.24 (M+H)+

    Step-2:

    [0615] To a stirred solution of A31 (0.1 g, 0.20 mmol, 1.0 eq), in DCM (1 ml) was added 4M HCl in Dioxane at 0 C., then the reaction is allowed to run at room temperature. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was concentrated then triturated using pentane and diethyl ether to yield N((R)-1-aminopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 53, 0.070 g, 0.18 mmol, Yield 88.57%)

    [0616] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.33 (s, 1H), 8.96 (s, 1H), 8.90 (d, J=8.0 Hz, 1H), 8.09 (br s, 2H), 8.04-8.02 (m, 1H), 7.68-7.66 (m, 2H), 5.88 (br s, 1H), 4.35 (t, J=6.8 Hz, 1H), 3.01 (br s, 2H), 2.76-2.67 (m, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.68 (m, 1H), 1.23 (d, J=6.4 Hz, 3H). (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0617] .sup.1H NMR (MeOD, 400 MHz): ppm 9.60 (s, 1H), 9.49 (s, 1H), 8.34 (d, J=8.0 Hz, 1H), 8.08 (d, J=6.4 Hz, 1H), 8.01 (t, J=7.6 Hz, 1H), 6.07 (br s, 1H), 4.56-4.52 (m, 1H), 3.33-3.16 (m, 2H), 2.75-2.61 (m, 4H), 2.49-2.42 (m, 1H), 2.28-2.25 (m, 1H), 2.0-1.90 (m, 1H), 1.46 (d, J=6.8 Hz, 3H) (Note: NH proton might exchange with deuterium from MeOD)

    [0618] LCMS (Method-A): 1.86 min, 100%, 210.0 nm, m/z=378.1

    [0619] HPLC (Method-A): 8.34 min, 100%, 210 nm

    [0620] CHIRAL HPLC: Peak-1: 5.27 min, 47.54%, 240 nm; Peak-2: 5.75 min, 52.45%, 240 nm

    Example 50Synthesis of N((R)-4-hydroxybutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 54)

    ##STR00273##

    Step-1:

    [0621] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.2 g, 0.62 mmol, 1.0 eq), CAS: 61477-40-5 (0.055 g, 062 mmol, 1.0 eq) and DIPEA (0.3 ml, 1.8 mmol, 3.0 eq) in DMF (2 mL) under inert condition N.sub.2(g) was added HATU (0.355 g, 0.934 mmol, 1.5 eq). The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 4 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.45 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh size) as stationary phase (gradient elution 20% Ethyl acetate in hexane) yielding N((R)-4-hydroxybutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 54, 0.063 g, 0.161 mmol, Yield 25.79%).

    [0622] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=1.6 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.55 (d, J=8.4 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.64 (d, J=4.4 Hz, 2H), 5.87 (br s, 1H), 4.47 (t, J=4.8 Hz, 1H), 4.21-4.14 (m, 1H), 3.49-3.46 (m, 2H), 2.80-2.07 (m, 5H), 1.80-1.42 (m, 3H), 1.20 (d, J=6.4 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0623] .sup.1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.75 (d, J=2.0 Hz, 1H), 7.97 (d, J=6.4 Hz, 1H), 7.69-7.63 (m, 2H), 6.87 (br s, 1H), 4.39-4.34 (m, 1H), 3.75-3.66 (m, 2H), 2.88-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.82 (m, 3H), 1.35 (d, J=6.8 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD)

    [0624] LCMS (Method-A): 2.27 min, 98.91%, 254.0 nm, m/z=393.17 (m+H).sup.+

    [0625] HPLC (Method-A): 8.25 min, 100%, 210 nm

    [0626] CHIRAL HPLC: Peak-1: 4.22 min, 50.06%, 240 nm; Peak-2: 4.53 min, 49.93%, 240 nm

    Example 51Synthesis of (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic Acid (Compound 55)

    ##STR00274##

    Step-1

    [0627] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15, 0.45 g, 1.4 mmol, 1.0 eq), CAS: 139243-54-2 (0.23 g, 1.54 mmol, 1.1 eq) and DIPEA (0.542 g, 4.2 mmol, 3.0 eq) in DMF (2 mL) under inert condition N.sub.2(g) was added HATU (0.798 g, 2.1 mmol, 1.5 eq). The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 4 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.45 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 20% Ethyl acetate in hexane) yielding methyl (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A32, 0.41 g, 0.975 mmol, Yield 69.72%)

    [0628] .sup.1H NMR (MeOD, 400 MHz): ppm 9.22 (d, J=2.4 Hz, 1H), 8.73 (d, J=2.0 Hz, 1H), 7.96 (dd, J=7.6, 1.6 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 4.62-4.57 (m, 1H), 3.70 (s, 3H), 2.77-2.72 (m, 2H), 2.68-2.63 (m, 3H), 2.55-2.51 (m, 1H), 2.41-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.90-1.85 (m, 1H), 1.37 (d, J=6.8 Hz, 3H). (Note: NH proton might exchange with deuterium from MeOD; EA solvent Traces observed)

    [0629] LCMS (Method A): 2.523 min, 100%, 254 nm, (M+H).sup.+=421.12

    [0630] CHIRAL HPLC: Peak-1 3.31 min, 49.60%, 240 nm Peak-2 3.52 min, 50.39%, 240 nm

    Step-2

    [0631] To a stirred solution of (A32, 0.38 g, 0.90 mmol, 1.0 eq), LiOH.Math.H.sub.2O (0.094 g, 1.80 mmol, 2.0 eq) in MeOH:H.sub.2O (8:2) was added at 0 C., then the reaction is allowed to run at room temperature. The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at room temperature. The resulting reaction mixture was concentrated then acidified using 1N HCl, then filtered using Buchner filtration to yield (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoic acid (Compound 55, 0.18 g, 0.44 mmol, Yield 49%)

    [0632] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.84 (s, 1H), 8.75 (d, J=7.6 Hz, 1H), 8.04-8.02 (m, 1H), 7.68-7.66 (m, 3H), 5.87 (br s, 1H), 4.43-4.35 (m, 1H), 2.79-2.61 (m, 4H), 2.47-2.43 (m, 1H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.68 (m, 1H), 1.24 (d, J=8.0 Hz, 3H) (Note: -one CF.sub.3CH proton merge with DMSO solvent peak and clearly visible in MeOD NMR)

    [0633] .sup.1H NMR (MeOD, 400 MHz): ppm 9.52 (d, J=1.6 Hz, 1H), 9.41 (d, J=1.6 Hz, 1H), 8.32 (d, J=7.6 Hz, 1H), 8.08 (d, J=6.0 Hz, 1H), 8.01 (t, J=8.0 Hz, 1H), 6.07 (br s, 1H), 4.64-4.59 (m, 1H), 2.80-2.74 (m, 4H), 2.66-2.63 (m, 2H), 2.49-2.46 (m, 1H), 2.28-2.25 (m, 1H), 1.97-1.93 (m, 1H), 1.41 (d, J=6.8 Hz, 3H) (Note: NH and OH proton might exchange with deuterium from MeOD)

    [0634] LCMS (Method A): 2.28 min, 100%, 242.0 nm, (M+H).sup.+=407.12

    [0635] HPLC (Method A): 4.51 min, 99.47%, 254 nm

    [0636] CHIRAL HPLC: Peak-1 4.97 min, 47.33%, 240 nm; Peak-2 5.52 min, 44.05%, 240 nm

    Example 52Synthesis of N((R)-4-(methylamino)-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 56)

    ##STR00275##

    Step-1

    [0637] To a stirred solution of (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (Compound 55, 0.107 g, 0.263 mmol, 1.0 eq), CAS: 593-51-1 (0.0195 g, 0.289 mmol, 1.1 eq) and DIPEA (0.102 g, 0.789 mmol, 3.2 eq) in DCM (2 mL) under inert condition N.sub.2 (g) were added EDCl.Math.HCl (0.0757 g, 0.395 mmol, 1.5 eq) and HOBt (0.0534 g, 0.39 mmol, 1.5 eq). The reaction was monitored by TLC (using neat ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.07 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution in neat ethyl acetate) yielding N((R)-4-(methylamino)-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 56, 0.045 g, 0.107 mmol, Yield 40.75%)

    [0638] .sup.1H NMR (MeOD, 400 MHz): ppm 9.22 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.4, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.59-4.54 (m, 1H), 2.89-2.75 (m, 4H), 2.68-2.65 (m, 1H), 2.62-2.61 (m, 1H), 2.59-2.46 (m, 3H), 2.41-2.34 (m, 1H), 2.41-2.34 (m, 1H), 1.93-1.83 (m, 1H), 1.38 (d, (d, J=6.8 Hz, 3H)

    [0639] .sup.1H NMR (CD.sub.3CN, 400 MHz): ppm 9.20 (d, J=2.0 Hz, 1H), 8.63 (d, J=2.0 Hz, 1H), 7.94 (dd, J=7.6, 1.6 Hz, 1H), 7.71 (d, J=7.6 Hz, 1H), 7.66-7.60 (m, 2H), 6.51 (br s, 1H), 5.89 (br s, 1H), 4.51-4.45 (m, 1H), 2.83-2.48 (m, 2H), 2.43 (d, J=6.4 Hz, 3H), 2.40-2.32 (m, 4H), 1.83-1.77 (m, 2H), 1.96-1.78 (m, 1H), 1.29 (d, J=6.8 Hz, 3H)

    [0640] LCMS (Method A): 2.22 min, 99.89%, 254 nm, (M+H).sup.+=420.18

    [0641] HPLC (Method A): 7.69 min, 99.53%, 210 nm

    [0642] CHIRAL HPLC: Peak-1 11.21 min, 52.16%, 225 nm; Peak-2 11.81 min, 47.84%, 225 nm

    Example 53Synthesis of 5-(4,4-difluorocyclohex-1-en-1-yl)-N-isopropyl-2-naphthamide (Compound 57)

    ##STR00276##

    Step-1

    [0643] To a solution of 5-bromo-2-naphthoic acid CAS: 1013-83-8 (1.0 g, 3.982 mmol, 1.0 eq), HATU (2.27 g, 5.974 mmol, 1.5 eq) and DIPEA (1.36 mL, 7.965 mmol, 2.0 eq) in DCM (10 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added propan-2-amine CAS: 75-31-0 (0.258 g, 4.389 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 3:7 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with ice-cold water (20 mL) and extracted with DCM (325 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.3 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (0-20% Ethyl acetate in hexane) yielding 5-bromo-N-isopropyl-2-naphthamide (A33) (0.95 g, 3.251 mmol, Yield: 81.64%).

    [0644] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm, 8.51-8.48 (m, 2H), 8.17 (d, J=8.8 Hz, 1H), 8.09 (dd, J=8.8, 1.6 Hz, 2H), 7.98 (d, J=7.6 Hz, 1H), 7.52 (t, J=8.0 Hz, 1H), 4.19-4.14 (m, 1H), 1.27-1.17 (m, 6H). Note: Some aliphatic impurities present that related to SM.

    [0645] LCMS (Method A): 2.286 min, 97.67%, 254.0 nm, MS: ES+292.1 (M), 294.1 (M+2)

    Step-2

    [0646] A stirred solution of 5-bromo-N-isopropyl-2-naphthamide (A33) (0.3 g, 1.229 mmol, 1.0 eq.), 2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, CAS: 1227068-84-9 (Purchased from commercial source combi block) (0.32 g, 1.106 mmol, 0.9 eq), and Tripotassium phosphate (0.78 g, 3.687 mmol, 3.0 eq) in 1,4-dioxane (3 mL) was purged with nitrogen for 30 minutes then Pd(PPh.sub.3).sub.4 (0.143 g, 0.123 mmol, 1.3 eq.) was added and the resulting reaction mixture was heated up to 100 C. for 16 h. The reaction was monitored by TLC (using EA:Hex; 3:7 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 100 C. The resulting reaction mixture was filtered through celite bed and the filtrate was concentrated under reduced pressure to obtained the crude residue (0.4 g) which was purified by silica gel (60-120 mesh) as stationary phase (25% EtOAc in Hex) yielded 5-(4,4-difluorocyclohex-1-en-1-yl)-N-isopropyl-2-naphthamide (Compound 57) (0.14 g, 0.425 mmol, Yield: 34.65%).

    [0647] .sup.1H NMR (DMSO-d6, 400 MHz): ppm 8.45 (s, 1H), 8.39 (d, J=7.6 Hz, 1H), 7.97-7.91 (m, 3H), 7.55 (t, J=8.0 Hz, 1H), 7.40 (d, J=6.8 Hz, 1H), 5.64 (br s, 1H), 4.18-4.13 (m, 1H), 2.82 (t, J=14.8 Hz, 2H), 2.65-2.55 (m, 2H), 2.34-2.24 (m, 2H), 1.21 (d, J=6.4 Hz, 6H).

    [0648] LCMS (Method A): 2.398 min, 98.32%, MS: ES+330.16 [M+H]

    [0649] HPLC (Method C): 8.357 min, 96.83%, 210 nm

    Example 54Synthesis of N((S)-1-(pyridin-2-yl)ethyl)-5-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-2-naphthamide (Compound 58)

    ##STR00277##

    Step-1

    [0650] A solution of 2-naphthoic acid CAS: 93-09-4 (24.0 g, 139.4 mmol, 1.0 eq), Br.sub.2 (22.2 g, 139.4 mmol, 1.0 eq) and I.sub.2 (0.706 g, 2.788 mmol, 0.02 eq) in AcOH (240 mL) was stirred at 120 C. for 5 h. The reaction was monitored on TLC (using EA:Hex; 2.0:8.0 as mobile phase) which confirmed the completion of reaction after 5 h of stirring at 120 C. The resulting reaction mixture was cool down to RT. The solid obtained was filtered off and washed with AcOH (50 mL) and water (200 mL) to afford 20.0 g crude product. Then the crude material was triturated by using MeOH (250 mL) to afford 5-bromo-2-naphthoic acid (A34) (15.0 g, 59.74 mmol, Yield: 42.86%)

    [0651] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.31 (br s, 1H), 8.68 (d, J=1.6 Hz, 1H), 8.21 (t, J=8.4 Hz, 2H), 8.14 (dd, J=8.8, 1.6 Hz, 1H), 8.03 (dd, J=7.6, 1.2 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H).

    Step-2

    [0652] To a stirred solution of 5-bromo-2-naphthoic acid (A34) (0.25 g, 0.996 mmol, 1.0 eq), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (CAS: 683242-93-5) (0.41 g, 1.195 mmol, 1.2 eq) and K.sub.3PO.sub.4 (1.05 g, 4.980 mmol, 5.0 eq) in Dioxane (2 mL) and water (1 mL) was added Pd(dppf)Cl.sub.2: DCM (0.081 g, 0.099 mmol, 0.1 eq) under N.sub.2. The resulting mixture was stirred at 100 C. for 2 h. The reaction was monitored by TLC (using EA:Hex; 8.0:2.0 as mobile phase) which confirmed that the reaction got completed after 2 h of stirring at 100 C. The resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.320 g crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (69% EA in Hexane) to afford 5-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-2-naphthoic acid (A35) (0.30 g, 0.936 mmol, Yield: 94.06%).

    [0653] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 13.11 (br s, 1H), 8.60 (d, J=1.6 Hz, 1H), 8.06 (t, J=11.2 Hz, 2H), 7.96 (dd, J=8.8, 2.0 Hz, 1H), 7.57 (t, J=8.0 Hz, 1H), 7.42 (dd, J=7.2, 1.2 Hz, 1H), 5.73 (br s, 1H), 3.94 (br s, 1H), 2.80-2.77 (m, 1H), 2.56-2.54 (m, 1H), 2.49-2.27 (m, 2H), 2.10-2.07 (m, 1H), 1.77-1.73 (m, 1H). Note: Minor aliphatic impurity peaks were observed.

    [0654] LCMS (Method A): 2.732 min, 92.64%, 280.0 nm, MS: ES-319.4 (M1)

    Step-3

    [0655] To a solution of 5-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-2-naphthoic acid (A35) (0.15 g, 0.468 mmol, 1.0 eq), HATU (0.26 g, 0.703 mmol, 1.5 eq) and DIPEA (0.17 g, 1.370 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 15 min, was added CAS: 40154-78-7 (0.068 g, 0.562 mmol, 1.2 eq) under N.sub.2 atmosphere. The resulting mixture was stirred for 4 h at room temperature. The reaction was monitored by TLC (using EA:Hexane; 5.0:5.0 as mobile phase) which confirmed that the reaction got completed after 4 h. The resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.250 g crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mess) as stationary phase (35% Ethyl acetate in hexane) to afford N((S)-1-(pyridin-2-yl)ethyl)-5-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-2 naphthamide (Compound 58) (0.063 g, 0.148 mmol, Yield: 15.85%)

    [0656] .sup.1H NMR (DMSO, 400 MHz): ppm, 9.01 (d, J=8.0 Hz, 1H), 8.56-8.53 (m, 2H), 8.04 (d, J=9.2 Hz, 1H), 7.96-7.94 (m, 2H), 7.76 (td, J=8.0, 1.6 Hz, 1H), 7.56 (t, J=8.0 Hz, 1H), 7.46-7.38 (m, 2H), 7.28-7.25 (m, 1H), 5.74 (br s, 1H), 5.28-5.24 (m, 1H), 2.79 (br s, 1H), 2.52-2.51 (m, 1H), 2.45-2.33 (m, 3H), 2.11-2.08 (m, 1H), 1.83-1.73 (m, 1H), 1.55 (d, J=7.2 Hz, 3H).

    [0657] .sup.1H NMR (MeOD, 400 MHz): ppm, 8.56-8.54 (m, 1H), 8.47 (d, J=1.6 Hz, 1H), 8.06 (d, J=8.8 Hz, 1H), 7.94-7.92 (m, 2H), 7.85 (td, J=7.6, 2.0 Hz, 1H), 7.56-7.52 (m, 2H), 7.40 (dd, J=6.8, 1.2 Hz, 1H), 7.35-7.31 (m, 1H), 5.79 (br s, 1H), 5.35 (q, J=7.2 Hz, 1H), 2.67-2.38 (m, 5H), 2.22-2.18 (m, 1H), 1.89-1.85 (m, 1H) 1.65 (d, J=7.2 Hz, 3H). Note: Amidic-NH not observed.

    [0658] LCMS (Method A): 2.572 min, 97.37%, 210.0 nm, MS: ES+425.23 (M+1)

    [0659] HPLC (Method B): 6.907 min, 95.34%, 210.0 nm

    [0660] Chiral HPLC (Method A): 2.51 min, 95.16%, 230.0 nm

    Example 55Synthesis of N-isopropyl-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 59)

    ##STR00278##

    Step-1

    [0661] To a stirred solution of 1,4-dioxaspiro[4.5]decan-8-one (CAS: 4746-97-8) (25 g, 160.07 mmol, 1.0 eq), CAS: 1779-49-3 (57.1 g, 160.07 mmol, 1.0 eq) in toluene (200 mL) was added KO.sup.tBu (21.5 g, 192.08 mmol, 1.2 eq) to the reaction mixture under N.sub.2 atmosphere. Then the resulting mixture was stirred at room temperature 110 C. for 16 h. The reaction was monitored by TLC (using EA:Hexane 1:9 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was quenched using NH.sub.4Cl extracted with ethyl acetate (230 mL). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 25 g crude. The crude was purified by manual column chromatography using silica (60-120 mesh) as stationary phase (gradient elution 4% EA in hexane) to afford 8-methylene-1,4-dioxaspiro[4.5]decane (A36) (18 g, 116.88 mmol, Yield 72.92%)

    [0662] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 4.69 (s, 2H), 3.98 (s, 4H), 2.30 (t, J=6.4 Hz, 4H), 1.72 (t, J=6.8 Hz, 4H).

    Step-2

    [0663] To a stirred solution of A36 (5.2 g, 34 mmol, 1.0 eq), Diethylzinc (87.9 mL, 87.9 mmol, 2.56 eq) in toluene (52 mL) was added to the reaction mixture under N.sub.2 atmosphere at 40 C. Then the resulting mixture was stirred at 40 C. for 20 min. The CH.sub.2I.sub.2 (46.06 g, 172 mmol, 5.2 eq), was added at 40 C. and reaction mixture was allowed to run overnight. The reaction was monitored by TLC (EA:Hexane 1:9 as mobile phase) which confirmed that the reaction got completed after 18 h of stirring at room temperature. The resulting reaction mixture was quenched using NH.sub.4Cl extracted with diethyl ether (430 mL). The combined organic layers were washed with sodium thiosulfate (340 ml) and dried over Na.sub.2SO.sub.4 then concentrated under reduced pressure to afford 5.3 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 3% Ethyl acetate in hexane) yielding 7,10-dioxadispiro[2.2.4.2]dodecane (A37) (3 g, 17.85 mmol, Yield 52%)

    [0664] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 3.98 (s, 4H), 1.71 (t, J=6.0 Hz, 4H), 1.45-1.42 (m, 4H), 0.30 (s, 4H).

    Step 3

    [0665] To a stirred solution of A37 (1.1 g, 6.54 mmol, 1.0 eq) in THF:H.sub.2O (8.33 mL, 3:2) was added TFA (1.67 mL, 21.58 mmol, 3.3 eq) to the reaction mixture under N.sub.2 atmosphere at 0 C. The resulting mixture was stirred at 0 C. for 18 h. The reaction was monitored by TLC (using Diethyl ether:pentane 1:9 as mobile phase) which confirmed that the reaction got completed after 18 h of stirring at room temperature. After completion the reaction mixture was quenched using aq. Na.sub.2CO.sub.3 extracted with diethyl ether (430 mL). The combined organic layers were washed with Na.sub.2SO.sub.3 (340 ml) and dried over Na.sub.2SO.sub.4, concentrated under reduced pressure to afford 5.3 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (2% Ethyl acetate in hexane) yielding spiro[2.5]octan-6-one (A38) (0.2 g, 1.61 mmol, Yield 24.63%)

    [0666] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 2.54-2.42 (m, 4H), 1.70 (t, J=6.8 Hz, 4H), 0.51 (s, 4H).

    Step 4

    [0667] To a stirred solution of A38 (0.2 g, 1.61 mmol, 1.0 eq) in THF (4 mL) was added LiHMDS (1.7 mL, 1.77 mmol, 1.1 eq, 1.0 M in THF) dropwise under N.sub.2 atmosphere at 78 C. Then the resulting mixture was stirred at 78 C. for 1 h. After 1 h. N-Phenyl-bis(trifluoromethanesulfonimide) CAS: 37595-74-7 (0.68 g, 1.93 mmol, 1.2 eq) was added to the reaction mixture and the reaction was allowed to run overnight. The reaction was monitored by TLC (ethyl acetate:hexane 1:9 as mobile phase) which confirmed that the reaction got completed after 18 h of stirring at room temperature. The resulting reaction mixture was quenched using H.sub.2O and extracted with ethyl acetate (430 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.25 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 5% Ethyl acetate in hexane) to afford spiro[2.5]oct-5-en-6-yl trifluoromethanesulfonate (A39) (0.19 g, 0.74 mmol, Yield 46.04%)

    [0668] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 8.81-5.79 (m, 1H), 2.45-2.40 (m, 2H), 2.07-2.04 (m, 2H), 1.57 (t, J=6.4 Hz, 2H), 0.41 (s, 4H).

    Step 5

    [0669] To a stirred solution of A39 (1.4 g, 5.46 mmol, 1.0 eq) in Dioxane (14 MI) was added B.sub.2Pin.sub.2 (CAS: 73183-34-3) (1.52 g, 6.0 mmol, 1.1 eq) followed by addition of KOAc (1.62 g, 16.54 mmol, 3.03 eq), PdCl.sub.2 (dppf) (0.39 g, 0.54 mmol, 0.1 eq) and reaction mixture was purged with N.sub.2 for 10 min then stirred overnight at 100 C. TLC (ethyl acetate:hexane 1:9 as mobile phase) confirmed the completion of reaction. The resulting reaction mixture was filtered using celite and extracted with ethyl acetate (430 Ml). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.41 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (10% Ethyl acetate in hexane) yielding 4,4,5,5-tetramethyl-2-(spiro[2.5]oct-5-en-6-yl)-1,3,2-dioxaborolane (A40) (0.6 g, 2.56 mmol, Yield 46.90%)

    [0670] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 6.61-6.60 (m, 1H), 2.25-2.21 (m, 2H), 2.01-1.99 (m, 2H), 1.39-1.36 (m, 2H), 1.29 (s, 1H), 0.32-0.28 (m, 4H).

    Step 6

    [0671] To a stirred solution of A40 (0.07 g, 0.29 mmol, 1.1 eq) and A23 (0.08 g, 0.27 mmol, 1.0 eq) in Dioxane:H.sub.2O (8:2) was added K.sub.3PO.sub.4 (0.173 g, 0.81 mmol, 3.0 eq), PdCl.sub.2 (dppf).Math.DCM (0.11 g, 0.31 mmol, 0.5 eq) and the reaction mixture was allowed to run overnight at 110 C. The reaction was monitored by TLC (ethyl acetate:hexane 5:5 as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at 110 C. The resulting reaction mixture was filtered using celite and the filtrate was extracted with ethyl acetate (430 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.078 g crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 35% Ethyl acetate in hexane) yielding N-isopropyl-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 59) (0.03 g, 0.09 mmol, Yield 31.32%) 1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.4 Hz, 1H), 8.72 (d, J=2.4 Hz, 1H), 7.93 (dd, J=8.0, 1.6 Hz, 1H), 7.68-7.61 (m, 2H), 5.90-5.88 (m, 1H), 4.33-4.26 (m, 1H), 2.69-2.65 (m, 2H), 2.20-2.18 (m, 2H), 1.68-1.65 (m, 2H), 1.33-1.30 (m, 6H), 0.44 (s, 4H). Note: CONH proton exchanged in MeOD NMR.

    [0672] LCMS (Method A)-2.57 min, 100%, 254.0 nm MS; ES+321.2 (M+H)

    [0673] HPLC (Method A)-9.81 min, 95.41%, 210 nm

    Example 56Synthesis of(S)N-(1-(pyridin-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 60)

    ##STR00279##

    Step-1

    [0674] To a stirred solution of methyl 8-bromoquinoline-3-carboxylate (A13) (1.8 g, 6.76 mmol, 1.0 eq), A40 (1.74 g, 7.44 mmol, 1.1 eq) in Dioxane:H.sub.2O (8:2) was added K.sub.3PO.sub.4 (4.28 g, 20.2 mmol, 3.0 eq) and purged with N.sub.2 for 15 min. Then PdCl.sub.2(dppf) (0.24 g, 0.338 mmol, 0.05 eq), was added to the reaction mixture then stirred at 110 C. for 16 h. TLC (EA:Hexane 1:1 as mobile phase) indicated completion of reaction. The resulting reaction mixture was filtered using celite then filtrate was extracted with ethyl acetate (230 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 1.75 g crude. The crude was purified by manual column chromatography using silica (60-120 mesh) as stationary phase (gradient elution 30% Ethyl acetate in hexane) to afford methyl 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylate (A41) (1.15 g, 3.91 mmol, Yield 57.95%)

    [0675] .sup.1H NMR (MeOD, 400 MHz): ppm 9.36 (d, J=2.0 Hz, 1H), 8.96 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.0 Hz, 1.6 Hz, 1H), 7.72 (dd, J=6.8 Hz, 1.2 Hz, 1H), 7.65 (t, J=8.0 Hz, 1H), 5.90-5.88 (m, 1H), 4.03 (s, 3H), 2.68-2.67 (m, 2H), 2.20-2.18 (m, 2H), 1.67 (t, J=6.0 Hz, 2H), 0.45 (s, 4H).

    [0676] LCMS (Method A): 2.982 min, 99.11%, 254.0 nm, MS: ES+294.2 (M+1)

    Step 2

    [0677] To a stirred solution of A41 (1.1 g, 3.74 mmol, 1.0 eq) in MeOH:H.sub.2O (8:1) (11 ml) was added NaOH (0.74 g, 18.74 mmol, 5.0 eq) at RT. Then the resulting mixture was stirred at room temperature for 16 h. The reaction was monitored by TLC (using 100% ethyl acetate as mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was concentrated under vacuum then residue was acidified (PH=3) with dil. HCl. The solid obtained was filtered and dried under vacuum to afford 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.73 g, 2.61 mmol, Yield 69.70%)

    [0678] .sup.1H NMR (DMSO, 400 MHz): ppm 9.36 (d, J=2.0 Hz, 1H), 8.94 (d, J=2.0 Hz, 1H), 7.97 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.70 (dd, J=6.8 Hz, 1.2 Hz, 1H), 7.63 (t, J=7.6 Hz, 1H), 5.90-5.88 (m, 1H), 2.68-2.65 (m, 2H), 2.20-2.18 (m, 2H), 1.66 (t, J=6.0 Hz, 2H), 0.44 (s, 4H). Note: COOH proton might be exchanged in MeOD NMR.

    [0679] LCMS (Method A): 2.510 min, 99.38%, 254.0 nm, MS: ES+280.11 (M+1)

    Step 3

    [0680] To a stirred solution of A42 (0.09 g, 0.322 mmol, 1.0 eq) in DCM (1 mL) was added HATU (0.18 g, 0.48 mmol, 1.5 eq) followed by addition of DIPEA (0.12 g, 0.96 mmol, 3.0 eq) under N.sub.2 atmosphere. Then after 10 min CAS: 40154-78-7 (S)-1-(pyridin-2-yl)ethanamine dihydrochloride (0.037 g, 0.35 mmol, 1.1 eq) was added and the resulting mixture was stirred at RT for 18 h. The reaction was monitored by TLC (100% EA mobile phase) which indicated completion of reaction. The resulting reaction mixture was poured into water (10 mL) and extracted with ethyl acetate (230 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford the crude product. The crude was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (gradient elution 100% Ethyl acetate) to afford (S)N-(1-(pyridin-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 60) (0.034 g, 0.088 mmol, Yield 27.52%)

    [0681] .sup.1H NMR (MeOD, 400 MHz): ppm 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.4 Hz, 1H), 8.55 (d, J=4.0 Hz, 1H), 7.95 (d, J=8.0 Hz, 2.0 Hz, 1H), 7.85 (dt, J=7.6 Hz, 1.6 Hz, 1H), 7.69-7.64 (m, 2H), 7.54 (d, J=7.6 Hz, 1H), 7.35-7.32 (m, 1H), 5.90-5.88 (m, 1H), 5.35 (q, J=7.2 Hz, 1H), 2.69-2.65 (m, 2H), 2.20-2.18 (m, 2H), 1.68-1.65 (m, 5H), 0.44 (s, 4H). Note: CONH proton exchanged in MeOD NMR.

    [0682] LCMS (Method A): 2.273 min, 100%, 254.0 nm, MS: ES+384.2 (M+1)

    [0683] HPLC (Method A): 9.67 min, 99.33%, 254.0 nm.

    [0684] Chiral HPLC (Method A): 7.82 min, 94.27%, 300 nm.

    Example 57Synthesis of N-(oxazol-2-ylmethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 61)

    ##STR00280##

    Step-1

    [0685] To a stirred solution of oxazole-2-carbaldehyde (5.0 g, 51.5 mmol, 1.0 eq) in DMF (10 mL) was added 2-Methylpropane-2-sulfinamide CAS: 146374-27-8 (7.4 g, 61.8 mmol, 1.2 eq), and Piperidine-1-carbaldehyde CAS: 3087-36-3 (25.5 ml, 10.3 mmol, 2.0 eq) at 0 C. under Nitrogen atmosphere. Then reaction mixture was stirred at RT for 16 h. The TLC (50% EtOAc in Hexane as a mobile phase) indicated the completion of reaction. The resulting reaction mixture was poured onto water (100 mL) and extracted with EtOAc (3200 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude. The resulting crude product was purified by column chromatography using silica gel 230-400 mesh size and desired product eluted in 40% EtOAc in hexane to afford (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A43) (4.9 g, 24.46 mmol, Yield: 47.50%).

    [0686] .sup.1H NMR (DMSO, 400 MHz): ppm 8.45 (s, 1H), 8.28 (s, 1H), 7.62 (s, 1H), 1.27 (s, 9H).

    [0687] LCMS (Method A): LCMS does not support the desired product mass.

    Step-2

    [0688] To a stirred solution of (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A43) (4.9 g, 29.9 mmol, 1.0 eq) in MeOH (20 mL) was added NaBH.sub.4 (1.7 g, 44.9 mmol, 2.0 eq) at 0 C. The reaction mixture was stirred at RT for 30 min and monitored on TLC (5% DCM:MeOH as mobile phase). The resulting reaction mixture was poured into water (400 mL) and extracted with EtOAc (3200 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude. The resulting crude product was purified by column chromatography (desired product eluted in 2% MeOH in DCM) to afford 2-methyl-N-(oxazol-2-ylmethyl) propane-2-sulfinamide (A44) (4.1 g, 20.26 mmol, Yield: 82.84%).

    [0689] LCMS (Method A): 1.303 min, 100.0%, 210.0 nm MS: ES+203.0 (M+1).

    [0690] .sup.1H NMR (DMSO, 400 MHz): ppm 7.64 (s, 1H), 7.09 (s, 1H), 4.49-4.37 (m, 2H), 3.94 (t, J=8.8 Hz 1H), 1.24 (s, 9H).

    Step-3

    [0691] To a stirred solution of 2-methyl-N-(oxazol-2-ylmethyl) propane-2-sulfinamide (A44) (9.0 g, 44.4 mmol, 1.0 eq) in MeOH (90 mL) was added 4M HCl in Dioxane (11.68 g, 31.1 mmol, 7.0 v) at 0 C. and reaction mixture was stirred at RT for 1 h. The reaction was monitored on TLC (using; 5% DCM:MeOH as mobile phase). After completion, the resulting reaction mixture was directly concentrated under reduced pressure to obtain the crude material which was triturated using pentane to afford oxazol-2-ylmethanamine hydrochloride (A45) (7.0 g, 52.02 mmol, Yield: 87.88%).

    [0692] LCMS (Method A): LCMS does not support the desired product mass

    [0693] .sup.1H NMR (DMSO, 400 MHz): ppm 8.94 (s, 3H), 8.23 (s, 1H), 7.30 (s, 1H), 4.22 (s, 2H).

    Step-4

    [0694] To a stirred solution of A42 (0.2 g, 0.71 mmol, 1.0 eq) in DCM (2 mL) was added HATU (0.40 g, 1.07 mmol, 1.5 eq) and DIPEA (0.27 g, 2.1 mmol, 3.0 eq) at 0 C. then after 10 min (A45) (0.12 g, 0.93 mmol, 1.3 eq) was added to the reaction mixture under N.sub.2 atmosphere. The resulting reaction mixture was stirred at room temperature for 16 h. The TLC (100% EA as mobile phase) indicates completion of reaction. The resulting reaction mixture was poured onto ice water (10 mL) and extracted with ethyl acetate (220 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.21 g crude. The crude was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (gradient elution 100% Ethyl acetate) yielding N-(oxazol-2-ylmethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 61) (0.09 g, 0.25 mmol, Yield 34.97%)

    [0695] .sup.1H NMR (MeOD, 400 MHz): ppm 9.29 (d, J=2.4 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 7.96-7.93 (m, 2H), 7.70-7.62 (m, 2H), 7.18 (s, 1H), 5.89 (br s, 1H), 4.80 (s, 2H), 2.68-2.67 (m, 2H), 2.19 (d, J=3.2 Hz, 2H), 1.67 (t, J=6.0 Hz, 2H), 0.44 (s, 4H). Note: CONH proton exchanged in MeOD NMR.

    [0696] .sup.1H NMR (DMSO, 400 MHz): ppm 9.51 (t, J=5.6 Hz, 1H), 9.28 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.09 (s, 1H), 8.00-7.98 (m, 1H), 7.67-7.61 (m, 2H), 7.19 (s, 1H), 5.89 (br s, 1H), 4.67 (d, J=5.6 Hz, 2H), 2.69 (br s, 2H), 2.13 (br s, 2H), 1.55 (t, J=6.0 Hz, 2H), 0.40 (s, 4H).

    [0697] LCMS (Method A)-2.38 min, 100%, 254.0 nm, MS: ES+360.3 (M+1)

    [0698] HPLC (Method A)-8.76 min, 97.68%, 210 nm

    Example 58N((S)-1-hydroxy-3-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 62)

    ##STR00281##

    Step-1

    [0699] A solution of benzonitrile CAS 100-47-0 (15 g, 145.63 mmol, 1.0 eq) and acetyl chloride (83 ml, 1165.04 mmol, 8.0 eq), in EtOH (75 mL) was stirred at RT for 16 h. The reaction was monitored on TLC (using EtOAc:Hex; 3:7 as mobile phase) which confirmed that the reaction got completed after 16 h. The resulting reaction mixture was quenched with Sat. NaHCO.sub.3 (30 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 20.0 g crude. The obtained crude material was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (gradient elution 10% EA in Hex) to afford ethyl benzimidate (A46) (14 g, 93.95 mmol, Yield: 64.52%).

    [0700] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 8.89 (s, 1H), 7.83-7.81 (m, 2H), 7.51-7.42 (m, 3H), 4.24 (q, J=7.2 Hz, 2H), 1.31 (t, J=7.2 Hz, 3H)

    [0701] LCMS (Method A): 1.081 min, 91%, 254.0 nm, MS: ES+149 (M+1)

    Step-2

    [0702] A solution of ethyl benzimidate (A46) (14 g, 93.95 mmol, 1.0 eq) and methyl L-serinate hydrochloride CAS 5680-80-8 (16 g, 103.35 mmol, 1.1 eq) in 1,2 DCE (140 mL) was stirred at 80 C. for 20 h. TLC (EA:Hex; 1:1 as mobile phase) indicated completion of reaction then resulting reaction mixture was filtered through celite bed and filtrate was concentrate under reduce pressure to obtained the residue. The obtained crude residue was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (gradient elution 30% EA in Hex) to afford(S)-2-phenyl-4,5-dihydrooxazole-4-carboxylate (A47) (14 g, 68.292 mmol, Yield: 72%).

    [0703] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 7.9-7.86 (m, 2H), 7.61-7.57 (m, 1H), 7.52-7.48 (m, 2H), 4.99-4.95 (dd, J=10 Hz, 8 Hz, 1H), 4.64-4.56 (m, 2H), 3.71 (s, 3H),

    [0704] LCMS (Method A): 1.799 min, 99.47%, 254.0 nm, MS: ES+206 (M+1)

    Step-3

    [0705] To a stirred solution of(S)-2-phenyl-4,5-dihydrooxazole-4-carboxylate (A47) (14 g, 68.292 mmol, 1.0 eq) in THF (1.8 mL) was added DIBAL-H (204 ml, 204.87 mmol, 3.0 eq) at 0 C., The resulting reaction mixture was stirred for 3 h at room temperature. The reaction was monitored on TLC (EA:Hex; 7:2 as mobile phase) which confirmed that the reaction got completed after 3 h. The resulting reaction mixture was quenched with Sat. NH.sub.4Cl (50 mL) and extracted with EtOAc (3100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 15 g crude. The obtained crude material was purified by Manual column using silica (100-200 mesh) as stationary phase (70% EA in Hex) to afford (R)-(2-phenyl-4,5-dihydrooxazol-4-yl) methanol (A48) (8.0 g, 45.197 mmol, Yield: 66%).

    [0706] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 7.86 (d, J=7.2 Hz, 2H), 7.56-7.45 (m, 3H), 4.9 (t, J=5.6 Hz, 1H), 4.32-4.24 (s, 3H), 3.62-3.44 (m, 2H).

    [0707] LCMS (Method A): 1.006 min, 94%, 254.0 nm, MS: ES+178 (M+1)

    Step-4

    [0708] To a stirred solution of (R)-(2-phenyl-4,5-dihydrooxazol-4-yl) methanol (A48) (8.0 g, 45.197 mmol, 1.0 eq) in THF (1 ml) was added NaH (3.6 g, 90.39 mmol, 2.0 eq) and Mel (16.04 g, 112.9 mmol, 2.5 eq) at 0 C. then reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (EA:HEX; 1:1 as mobile phase) which indicated the completion of reaction. The resulting reaction mixture was poured onto ice cold water (50 mL) and extracted with EtOAc (3100 mL) dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford the crude. The obtained crude material was purified by manual column using silica (100-200 mesh) as stationary phase (gradient elution 50% EA in Hex) yielding (R)-4-(methoxymethyl)-2-phenyl-4,5-dihydrooxazole (A49) (3.5 g, 18.324 mmol, Yield: 40%).

    [0709] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm, 7.87-7.85 (m, 2H), 7.57-7.46 (m, 3H), 4.49-4.39 (m, 2H), 4.21 (t, J=7.2 Hz, 1H), 3.52 (dd, J=9.6, 4 Hz, 1H), 3.42 (dd, J=9.6, 4 Hz, 1H), 3.29 (s, 3H).

    [0710] LCMS (Method A): 1.345 min, 88%, 254.0 nm, MS: ES+192 (M+1)

    Step-5

    [0711] A solution of (R)-4-(methoxymethyl)-2-phenyl-4,5-dihydrooxazole (A49) (14.0 g, 73.210 mmol, 1.0 eq) in 4.0 M aq. HCl (420 mL) was stirred at RT for 5 min then resulting reaction mixture was heated at 110 C. for 20 h. TLC (5% MeOH in DCM as mobile phase) indicated the completion of reaction. The resulting reaction mixture was cooled to RT then filtered through Buchner funnel. Obtained filtrate was extracted with ether (4100 mL) to remove the impurities then combined aqueous layer was concentrated under reduced pressure to afford 12.0 g (S)-2-amino-3-methoxypropan-1-ol hydrochloride (A50) (12.0 g, 114.12 mmol, Yield: Quantative).

    [0712] .sup.1H NMR (DMSO-d.sup.6, 400 MHz): ppm 8.31 (br s, 3H), 3.57-3.47 (m, 5H), 3.27 (s, 3H), 3.21-3.20 (m, 1H),

    [0713] LCMS (Method A): 0.197 min, 70.29%, 210.0 nm, MS: ES+106.0 (M+1)

    Step-6

    [0714] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.5 g, 1.557 mmol, 1.0 eq.), HATU (0.887 g, 2.334 mmol, 1.5 eq.) and DIPEA (0.8 mL, 4.669 mmol, 3.0 eq.) in DMF (5 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added (S)-2-amino-3-methoxypropan-1-ol (A50) (0.327 g, 3.115 mmol, 2.0 eq.) under nitrogen atmosphere. The resulting mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (330 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (70% Ethyl acetate in hexane) to afford N((S)-1-hydroxy-3-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 62) (0.15 g, 0.367 mmol, Yield: 23.60%).

    [0715] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (m, 1H), 8.28 (m, 1H), 8.53 (d, J=8.0 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.87 (br s, 1H), 4.83 (t, J=5.6 Hz, 1H), 4.21-4.18 (m, 1H), 3.55-3.50 (m, 1H), 3.31 (s, 3H), 2.72-2.68 (m, 3H), 2.32-2.07 (m, 3H), 1.71-1.67 (m, 1H). Note: CF3 CH proton merged in DMSO Solvent peak.

    [0716] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (m, 1H), 8.79 (m, 1H), 7.97 (dd, J=7.6 Hz, J=8.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.39 (t, J=5.6 Hz, 1H), 3.80-3.76 (m, 2H), 3.67-3.64 (m, 2H), 3.63 (s, 3H), 2.78-2.15 (m, 6H), 1.91-1.85 (m, 1H). Note: CONH and OH proton exchanged in MeOD NMR.

    [0717] LCMS (Method A): 2.215 min, 100%, 254.0 nm, MS: ES+409.42 (M+1)

    [0718] HPLC (Method A): 7.84 min, 100%, 254.0 nm

    Example 59Synthesis of N(R)-4aminobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 63)

    ##STR00282##

    Step-1:

    [0719] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.2 g, 0.62 mmol, 1.0 eq), HATU (0.35 g, 0.93 mmol, 1.5 eq) and DIPEA (0.24 g, 1.86 mmol, 3.0 eq) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 15 min, was added CAS: 1187927-71-4 (0.12 g, 0.68 mmol, 1.1 eq) under Nitrogen. The resulting mixture was stirred for 30 min at room temperature. The reaction was monitored on TLC (using EtOAc:Hexane; 7:3 as mobile phase) which confirmed that the reaction got completed after 30 min. The resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with EtOAc (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (40% Ethyl acetate in hexane) yielding tert-butyl ((3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butyl) carbamate (A51) (0.2 g, 0.40 mmol, Yield: 65.38%).

    [0720] .sup.1H NMR (DMSO d.sup.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.56 (d, J=8.4 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.64-7.61 (m, 2H), 6.82-6.79 (m, 1H), 5.86 (br s, 1H), 4.13-4.06 (m, 1H), 3.04-2.95 (m, 2H), 2.80-2.67 (m, 3H), 2.31-2.24 (m, 1H), 2.09-2.06 (m, 1H), 1.74-1.61 (m, 3H), 1.36 (s, 9H), 1.19 (d, J=6.4 Hz, 4H).

    [0721] LCMS (Method A): 2.781 min, 100%, 254.0 nm, MS: ES+492.2 (M+1)

    Step-2

    [0722] To a solution of tert-butyl ((3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butyl) carbamate (A51) (0.19 g, 0.387 mmol, 1.0 eq) in DCM (1.9 ml) was added dropwise 4M HCl in Dioxane (1 ml) at 0 C. under nitrogen atmosphere and stirred for 4 h at room temperature. The reaction was monitored on TLC (using MeOH:DCM; 0.5:9.5 as mobile phase) which confirmed that the reaction got completed after 4 h. The resulting reaction mixture was evaporated to obtain the crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (15% MeOH:DCM) yielding N(R)-4 aminobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 63) (0.062 g, 0.15 mmol, Yield: 41.11%).

    [0723] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.45 (m, 2H), 9.05 (d, J=7.6 Hz, 1H), 8.28 (d, J=8.0 Hz, 1H), 8.03 (d, J=6.8 Hz, 1H), 7.98-7.94 (m, 2H), 6.04 (br s, 1H), 4.37-4.34 (m, 1H), 3.15-3.06 (m, 2H), 2.75-2.64 (m, 3H), 2.63-2.60 (m, 1H), 2.48-2.45 (m, 1H), 2.26-2.23 (m, 1H), 2.04-1.92 (m, 3H), 1.44 (d, J=6.8 Hz, 3H).

    [0724] .sup.1H NMR (DMSO d.sub.6, 400 MHz): ppm, 9.28 (d, J=1.6 Hz, 1H), 8.88 (s, 1H), 8.79 (d, J=8.0 Hz, 1H), 8.03 (t, J=5.6 Hz, 1H), 7.89 (s, 3H), 7.67-7.66 (m, 2H), 5.875 (br s, 1H), 4.19-4.16 (m, 1H), 2.87-2.84 (m, 2H), 2.79-2.68 (m, 3H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.86-1.82 (m, 2H), 1.72-1.68 (m, 1H), 1.25 (d, J=6.4 Hz, 3H).

    [0725] LCMS (Method A): 1.886 min, 100%, 254.0 nm, MS: ES+392.2 (M+1)

    [0726] HPLC (Method A): RT=5.51 min, 100%, 270 nm.

    [0727] Chiral HPLC: Peak 1 RT=8.56 min, 39.00%, 241 nm; Peak 2=RT: 9.92 min, 60.09%, 241 nm

    Example 60Synthesis of N((S)-1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 64)

    ##STR00283##

    Step-1

    [0728] To a stirred solution of ((benzyloxy) carbonyl)-L-serine (CAS: 1145-80-8) (2.00 g, 8.36 mmol, 1.0 eq) in DCM (20 ml), was added 1.0 M dimethylamine CAS: 124-40-3 (0.843 ml, 12.54 mmol, 1.5 eq), followed by addition of DIPEA (4.36 ml, 25.08 mmol, 3.0 eq) and HATU (4.765 g, 12.54 mmol, 1.5 eq). The resulting mixture was stirred at room temperature for 16 h. TLC indicate the completion of reaction; the resulting reaction mixture was concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 3% MeOH in DCM) to afford benzyl(S)-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl) carbamate (A52) (0.358 g, 1.34 mmol, Yield 16%)

    [0729] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 7.38-7.29 (m, 6H), 5.01 (s, 2H), 4.87 (t, J=6.0 Hz, 1H), 4.54 (m, 1H), 3.57-3.53 (m, 1H), 3.46-3.42 (m, 1H), 3.05 (s, 3H), 2.82 (s, 3H).

    [0730] LCMS (Method A): 1.495 min, 95.91%, 220.0 nm, MS: ES+267.15

    Step-2

    [0731] To a solution of benzyl(S)-(1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl) carbamate (A52) (0.15 g, 0.56 mmol, 1.0 eq) in MeOH (5 mL) at room temperature under nitrogen atmosphere, was added Pd/C (0.075 g, 50% by wt) and stirred at room temperature under H.sub.2 atmosphere for 5 h. TLC indicated the completion of reaction. The resulting reaction mixture was filtered through celite bed and concentrated under reduced pressure to afford the desired product A53 (S)-2-amino-3-hydroxy-N,N-dimethylpropanamide (0.078 g, 0.59 mmol, Yield: 7.44%).

    [0732] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 4.77-4.68 (bs, 1H), 3.67 (t, J=7.6 Hz, 1H), 3.42-3.36 (m, 1H), 3.26-3.2 (m, 1H), 3.03 (s, 3H), 2.85 (s, 3H), 1.81-1.76 (bs, 2H),

    [0733] LCMS (Method B): 0.70 min, 100%, 220.0 nm, MS: ES+133.1

    Step-3

    [0734] To a stirred solution of 8-bromo-6-methoxyquinoline-3-carboxylic acid (Compound 15) (0.606 g, 1.89 mmol, 1.0 eq) in DMF (10 ml), was added(S)-2-amino-3-hydroxy-N,N-dimethylpropanamide (A53) (0.150 mg, 1.89 mmol, 1.0 eq), DIPEA (0.736 g, 5.66 mmol, 3.0 eq) and HATU (1.07 g, 2.83 mmol, 1.5 eq). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (100 ml) and extracted with EtOAc (2125 ml). Combined organic phases were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by prep HPLC (Method-A) to afford N((S)-1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 64) (0.055 g, 0.694 mmol, 6.69%).

    [0735] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.88 (m, 2H), 8.01-7.98 (m, 1H), 7.64 (m, 2H), 5.87 (br s, 1H), 5.08-5.03 (m, 1H), 4.98 (t, J=6.0 Hz, 1H), 3.79-3.73 (m, 1H), 3.67-3.62 (m, 1H), 3.15 (s, 3H), 2.97-2.87 (m, 4H), 2.87-2.80 (1H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H), (Note: 2 proton merged with DMSO solvent peak)

    [0736] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 2H), 7.98 (dd, J=6.0, 1.6, Hz 1H), 7.70-7.63 (m, 2H), 5.87 (bs, 1H), 5.26 (t, J=4.0 Hz, 1H), 3.97-3.86 (m, 2H), 3.29 (s, 3H), 3.03 (s, 3H), 2.78-2.65 (m, 2H), 2.55-2.51 (1H), 2.40-2.22 (m, 1H), 1.92-1.89 (m, 1H), 1.88-1.86 (m, 1H).

    [0737] HPLC (Method A): 7.419 min, 100%, 254.0 nm.

    [0738] LCMS (Method A): 2.164 min, 100%, 254.0 nm, MS: ES+436.2

    [0739] Chiral HPLC: Peak-1: 3.96, 49.9%; Peak-2: 4.90, 50% 250 nm

    Example 61Synthesis of N-(2-hydroxy-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 65)

    ##STR00284##

    Step-1

    [0740] A stirred solution of DMSO (2.1 g, 27.21 mmol, 2.4 eq.) in DCM (40 mL) was prepared in 100 mL 3 neck RBF at 78 C. To this solution was added oxalyl chloride (1.43 g, 11.34 mmol, 1.0 eq.) at same temperature and stirred for 30 min, followed by addition of 2-((tert-butyldimethylsilyl)oxy) ethan-1-ol (CAS: 102229-10-7) (2.0 g, 11.34 mmol, 1.0 eq.) and again stirred at same temperature for another 30 min. After 30 min Et.sub.3N (5.7 g, 56.71 mmol, 5.0 eq.) was added at 78 C. and resulting reaction mixture was stirred at room temperature for 3 h. TLC indicated completion of reaction, the resulting reaction mixture was diluted with water (100 mL) and extracted with EtOAc (350 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained crude 2-((tert-butyldimethylsilyl)oxy) acetaldehyde (A54) (2.2 g, 0.126 mmol, Yield: Quantitative). (The crude obtained was directly used as such for the next step without any further purification due to volatile nature of the product.)

    Step-2

    [0741] A stirred solution of 2-((tert-butyldimethylsilyl)oxy) acetaldehyde (A54) (2.0 g, 11.47 mmol, 1.0 eq.), 2-methylpropane-2-sulfinamide (CAS: 146374-27-8) (1.6 g, 13.76 mmol, 1.2 eq.) in THF (50 mL) was prepared in 100 mL 3 neck RBF at 0 C. To this solution was added Ti(OC.sub.2H.sub.5).sub.4 (CAS: 3087-36-3) (5.2 g, 22.94 mmol, 2.0 eq.) at 0 C. and reaction mixture allowed to stirred at room temperature for 16 h, TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (100 mL) and extracted with EtOAc (200 mL). Then filtered through Buchner funnel and two layers were separated. The organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtain crude product. The obtained crude was purified by flash column chromatography using silica gel (100-200 mesh) (50% EtOAc in Hexanes as a mobile phase) to afford N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide (A55) (0.6 g, 2.162 mmol, Yield: 18.86%).

    [0742] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 7.90 (s, 1H), 4.60 (d, J=2.8 Hz, 2H), 1.12 (s, 9H), 0.89 (s, 9H), 0.07 (s, 6H).

    [0743] LCMS (Method A): 2.853 min, 99.01%, 254.0 nm, MS: ES+278.15 (M+1)

    Step-3

    [0744] A stirred solution of oxazole (CAS: 288-42-6) (0.024 g, 0.360 mmol, 1.0 eq.) in THF (2 mL) was prepared in 30 mL glass vial at 78 C. To this solution was added n-BuLi (2.5 M in Hexane) (0.14 mL, 0.360 mmol, 1.0 eq.) at 78 C. and stirred for 1 h. Followed by addition of N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide (A55) (0.1 g, 0.360 mmol, 1.0 eq.) and reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with aq. NH.sub.4Cl (1 mL) and diluted with water (10 mL) and further extracted with EtOAc (310 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained crude product. The crude obtained product was purified by Flash Column Chromatography using silica gel (100-200 mesh) (60% EtOAc in Hexanes as a mobile phase) to afford N-(2-((tert-butyldimethylsilyl)oxy)-1-(oxazol-2-yl)ethyl)-2-methylpropane-2-sulfinamide (A56) (0.03 g, 0.086 mmol, Yield: 24.19%).

    [0745] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.34 (s, 1H), 7.96 (s, 1H), 5.38 (d, J=8.0 Hz, 1H), 4.23-4.21 (m, 1H), 3.87-3.83 (m, 1H), 3.77-3.72 (m, 1H), 1.08 (s, 9H), 0.85 (s, 9H), 0.01 (s, 6H).

    [0746] LCMS (Method A): 2.550 min, 97.60%, 220.0 nm, MS: ES+347.11 (M+1)

    Step-4

    [0747] A stirred solution of N-(2-((tert-butyldimethylsilyl)oxy)-1-(oxazol-2-yl)ethyl)-2-methylpropane-2-sulfinamide (A56) (0.03 g, 0.086 mmol, 1.0 eq.) in MeOH (0.3 mL) was prepared in 5 mL single neck RBF at room temperature. To this solution was added 4M HCl in Dioxane (0.3 mL) at room temperature and resulting reaction mixture was stirred for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was directly concentrated under reduced pressure to afford 2-amino-2-(oxazol-2-yl)ethan-1-ol hydrochloride (A57) (0.02 g, Yield: Quantitative). (The crude obtained was directly used as such for the next step without any further purification).

    [0748] LCMS (Method B): 0.70 min, 100.00%, 210.0 nm, MS: ES+129.1 (M+1)

    Step-5

    [0749] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.175 g, 0.547 mmol, 1.0 eq.) in DMF (2 mL) was prepared in 10 mL of glass vial at room temperature. To this solution was added HATU (0.311 g, 0.820 mmol, 1.5 eq.) and DIPEA (0.212 g, 1.641 mmol, 3.0 eq.) at 0 C. and stirred reaction mixture for 10-15 min, followed by addition of A57 (0.090 g, 0.547 mmol, 1.0 eq.) at room temperature and stirred for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL) and EtOAc (230 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtain the crude. The crude obtained product was purified by Flash column chromatography using silica gel (230:400 mesh) (5% MeOH in DCM as a mobile phase) to afford N-(2-hydroxy-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 65) (0.019 g, 0.044 mmol, Yield: 15.83%).

    [0750] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.28 (d, J=1.6 Hz, 1H), 8.96 (d, J=8.4 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.35 (s, 1H), 8.05 (s, 1H), 8.00 (t, J=5.6 Hz, 1H), 7.65-7.62 (m, 2H), 5.87 (br s, 1H), 5.19-5.14 (m, 1H), 5.01 (t, J=5.6 Hz, 1H), 3.84-3.73 (m, 2H), 2.81-2.67 (m, 3H), 2.29-2.25 (m, 1H), 2.09 (m, 1H), 1.74-1.64 (m, 1H). (Note: CF.sub.3CH-proton merged with DMSO solvent peak)

    [0751] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (d, J=2.4 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 8.22 (s, 1H), 7.98-7.96 (m, 2H), 7.70-7.63 (m, 2H), 5.86 (br s, 1H), 5.36 (t, J=6.0 Hz, 1H), 4.02-3.99 (m, 2H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.14 (m, 1H), 1.89-1.85 (m, 1H). Note: NH and OH proton exchanged with MeOD.

    [0752] LCMS (Method A): 2.196 min, 97.78%, 254.0 nm, MS: ES+432.23 (M+1)

    [0753] HPLC (Method A): 7.61 min, 96.07%, 254.0 nm

    Example 62Synthesis of N-((5-oxopyrrolidin-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 66)

    ##STR00285##

    Step-1

    [0754] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.05 g, 0.15 mmol, 1.0 eq.) in DMF (0.5 mL) was prepared in 10 mL of glass vial and cooled to 0 C. To this reaction solution, HATU (0.088 g, 0.23 mmol, 1.5 eq.) was added at 0 C. under nitrogen atmosphere. After 30 min of stirring, DIPEA (0.06 g, 0.46 mmol, 3.0 eq.) and 5-(aminomethyl) pyrrolidin-2-one hydrochloride (CAS: 115307-13-6) (0.02 g, 0.15 mmol, 1.0 eq.) were added. The resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction, the resulting reaction mixture was poured on to cold water (20 mL) and precipitated out which were filtered and washed with water (50 mL) and dried under reduced pressure to obtain crude which was purified by normal phase column chromatography (desired product eluted at 7% MeOH in DCM) to afford N-((5-oxopyrrolidin-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 66) (0.046 g, 0.11 mmol, Yield: 70.81%).

    [0755] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.87 (t, J=5.6 Hz, 1H), 8.82 (d, J=2.4 Hz, 1H), 8.02-7.99 (m, 1H), 7.84 (s, 1H), 7.65-7.64 (m, 2H), 5.87 (br s, 1H), 3.78-3.75 (m, 1H), 3.42-3.38 (m, 2H), 2.80-2.67 (m, 2H), 2.42-2.39 (m, 2H), 2.33-2.21 (m, 2H), 2.19-2.07 (m, 2H), 1.82-1.79 (m, 1H), 1.72-1.67 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in MeOD.

    [0756] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.6 Hz, 1.6 Hz, 1H), 7.70-7.64 (m, 2H), 5.87 (br s, 1H), 4.03-4.00 (m, 1H), 3.65-3.58 (m, 2H), 3.55-3.50 (m, 1H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.46-2.34 (m, 3H), 2.18-2.15 (m, 1H), 2.00-1.85 (m, 2H). Note: CONH proton exchange in MeOD Solvent.

    [0757] LCMS (Method A): 2.156 min, 99.55%, 254.0 nm, MS: ES+418.2 (M+1)

    [0758] HPLC (Method A): 7.39 min, 99.49%, 254.0 nm

    [0759] Chiral HPLC: Peak-1: 3.57 min, 21.70%, 240.0 nm; Peak-2: 3.81 min, 27.86%, 240.0 nm; Peak-3: 5.05 min, 25.38%, 240.0 nm; Peak-4: 6.30 min, 25.0414%, 240.0 nm

    Example 63Synthesis of N-((6-oxo-1,6-dihydropyridin-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 67)

    ##STR00286##

    Step-1

    [0760] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.05 g, 0.155 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.088 g, 0.233 mmol, 1.5 eq.) at 0 C. and stirred for 10 minutes. Followed by addition of DIPEA (0.07 mL, 0.466 mmol, 3.0 eq.) and 6-(aminomethyl)pyridin-2 (1H)-one hydrochloride (CAS: 95878-02-7) (0.027 g, 0.171 mmol, 1.1 eq.) at 0 C. Then the resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (5 mL) to obtain the precipitate. The obtained precipitate was filtered through buchner funnel and washed with water (20 mL) then dried under reduced pressure and crude was purified by column chromatography (desired product eluted in 0-2% MeOH in DCM) to afford N-((6-oxo-1,6-dihydropyridin-2-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 67) (0.021 g, 0.049 mmol, Yield: 31.57%).

    [0761] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 11.62 (br s, 1H), 9.32 (t, J=6.0 Hz, 1H), 9.29 (d, J=2.0 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.04-8.01 (m, 1H), 7.66-7.63 (m, 2H), 7.39 (t, J=7.6 Hz, 1H), 6.23-6.14 (m, 2H), 5.87 (br s, 1H), 4.39 (d, J=5.2 Hz, 2H), 2.81-2.67 (m, 4H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.67 (m, 1H).

    [0762] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.29 (d, J=2.0 Hz, 1H), 8.83 (d, J=2.4 Hz, 1H), 7.98 (dd, J=7.6, 1.2 Hz, 1H), 7.71-7.64 (m, 2H), 7.58 (t, J=8.8 Hz, 1H), 6.48-6.41 (m, 2H), 5.87 (br s, 1H), 4.56 (s, 2H), 2.85-2.75 (m, 1H), 2.69-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.33 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.85 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [0763] LCMS (Method A): 2.189 min, 100.00%, 254 nm, MS: ES+428.23 (M+1)

    [0764] HPLC (Method A): 7.37 min, 99.08%, 254 nm

    [0765] Chiral HPLC: Peak-1 6.07 min, 49.36%, 242 nm; Peak-2 6.53 min, 49.55%, 242 nm

    Example 64Synthesis of N-((2-oxo-1,2-dihydropyridin-3-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 68)

    ##STR00287##

    Step-1

    [0766] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.05 g, 0.15 mmol, 1.0 eq.) in DMF (0.5 mL) was prepared in 10 mL of glass vial and cooled to 0 C. To this reaction solution, HATU (0.09 g, 0.23 mmol, 1.5 eq.) was added at 0 C. under nitrogen atmosphere. After 30 min of stirring, DIPEA (0.06 g, 0.46 mmol, 3.0 eq.) and 3-(aminomethyl) 173yridine-2 (1H)-one hydrochloride (CAS: 85468-38-8) (0.02 g, 0.15 mmol, 1.0 eq.) were added. The resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction, the resulting reaction mixture was poured onto cold water (20 mL) and precipitated out which were filtered and washed with water (50 mL) and dried under reduced pressure to obtain the crude and purified by reverse phase column chromatography, desired product eluted at 50% water in acetonitrile to afford N-((2-oxo-1,2-dihydropyridin-3-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 68) (0.037 g, 0.09 mmol, Yield: 55.63%).

    [0767] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 11.69 (s, 1H), 9.29 (d, J=1.6 Hz, 1H), 9.16 (t, J=5.6 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.02-8.00 (m, 1H), 7.65-7.64 (m, 2H), 7.35 (dd, J=6.4, 24.0 Hz, 2H), 6.18 (t, J=6.4, 1H), 5.87 (br s, 1H), 4.31 (d, J=5.6 Hz, 2H), 2.81-2.67 (m, 3H), 2.33-2.25 (m, 1H), 2.10-2.08 (m, 1H), 1.75-1.66 (m, 1H). Note: CF.sub.3CH-proton merged with DMSO solvent peak.

    [0768] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.29 (s, 1H), 8.81 (s, 1H), 7.97 (d, J=7.6 Hz, 1H), 7.69-7.63 (m, 3H), 7.41 (d, J=6.4 Hz, 1H), 6.43 (t, J=6.8 Hz, 1H), 5.87 (br s, 1H), 4.52 (s, 2H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.85 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [0769] LCMS (Method A): 2.266 min, 95.77%, 254.0 nm, MS: ES+428.2 (M+1)

    [0770] HPLC (Method A): 7.56 min, 100%, 254.0 nm

    [0771] Chiral HPLC: Peak-1: 7.75 min, 49.18%, 240.0 nm; Peak-2: 8.57 min, 50.81%, 240.0 nm

    Example 65Synthesis of N-(1-(hydroxymethyl)cyclopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 69)

    ##STR00288##

    Step-1

    [0772] A stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.31 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial and cooled to 0 C. To this reaction solution, was added DIPEA (0.12 g, 0.93 mmol, 3.0 eq.) stirred for 5 min then added HATU (0.17 g, 0.46 mmol, 1.5 eq.) at 0 C. under nitrogen atmosphere. After 30 min of stirring CAS: 115652-52-3 1-Amino-cyclopropanemethanol hydrochloride (0.04 g, 0.37 mmol, 1.2 eq.) was added and resulting reaction mixture was stirred at RT for 3 h. TLC indicate the completion of reaction, the resulting reaction mixture was poured onto cold water (20 mL) and extracted with ethyl acetate. Organic layer was dried over N.sub.2SO.sub.4 and concentrate under reduced pressure to obtain crude which was purified by normal phase flash column chromatography on silica gel (230-400 mesh) (desired product eluted at 40% Ethyl acetate in Hexane) to afford, N-(1-(hydroxymethyl)cyclopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 69) (0.047 g, 0.12 mmol, Yield: 38.84%)

    [0773] .sup.1H NMR (MeOD 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 9.96 (dd, J=7.6, 1.6 Hz, 1H), 7.69-7.62 (m, 2H), 5.86 (br s, 1H), 3.74 (s, 2H), 2.77-2.74 (m, 1H), 2.67-2.64 (m, 2H), 2.55-2.50 (m, 1H), 2.33-2.15 (m, 1H), 2.17-2.15 (m, 1H), 1.89-1.85 (m, 1H), 0.95 (s, 4H). Note: CONH and OH proton exchanged in MeOD NMR.

    [0774] .sup.1H NMR (DMSO-d.sub.6 400 MHz): ppm, 9.23 (d, J=2.0 Hz, 1H), 9.01 (s, 1H), 8.80 (d, J=1.6 Hz, 1H) 7.98-7.96 (m, 1H), 7.63-7.60 (m, 2H), 5.87 (br s, 1H), 4.82 (t, J=5.6 Hz, 1H), 3.57 (d, J=5.6 Hz, 2H), 2.80-2.67 (m, 3H), 2.32-2.25 (m, 2H), 2.09-2.06 (m, 1H), 1.74-1.65 (m, 1H) 0.82-0.74 (m, 4H).

    [0775] LCMS (Method A): 2.244 min, 100%, 254.0 nm, MS: ES+391.17 (M+1)

    [0776] HPLC (Method A): 7.99 min, 99.74%, 254.0 nm

    [0777] Chiral HPLC: Peak-1: 3.06 min, 49.18%, 240.0 nm; Peak-2: 3.50 min, 49.9%, 240.0 nm

    Example 66Synthesis of N((R)-1-acetamidopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 70)

    ##STR00289##

    Step-1

    [0778] To a stirred solution of N((R)-1-aminopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 53) (0.115 g, 0.30 mmol, 1.0 eq.) in DCM (2 mL) was added acetyl chloride (0.040 g, 0.36 mmol, 1.2 eq.) under N.sub.2 atmosphere. Followed by addition of TEA (0.08 mL, 0.61 mmol, 2.0 eq.) and reaction mixture was stirred at RT for 1 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with DCM (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica gel (230-400 mesh) as stationary phase (gradient elution 20% Ethyl acetate in hexane) to afford N((R)-1-acetamidopropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 70) (0.053 g, 0.128 mmol, Yield 41.47%).

    [0779] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.56 (d, J=8.0 Hz, 1H), 8.02-7.99 (m, 2H), 7.64-7.63 (m, 2H), 5.87 (br s, 1H), 4.15-4.11 (m, 1H), 3.30-3.17 (m, 2H), 2.79-2.60 (m, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.82 (s, 3H), 1.73-1.67 (m, 1H), 1.15 (d, J=6.8 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [0780] .sup.1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 7.98 (dd, J=5.6, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 4.35-4.30 (m, 1H), 3.47-3.32 (m, 2H), 2.78-2.68 (m, 3H), 2.65-2.55 (m, 1H), 2.51-2.40 (m, 1H), 2.17-2.09 (m, 1H), 1.97 (s, 3H), 1.39-1.29 (m, 1H), 0.93 (d, J=6.8 Hz, 3H). Note: CONH protons exchanged in MeOD NMR.

    [0781] LCMS (Method A): 2.22 min, 100%, 220 nm, MS: ES+420.13 (M+1)

    [0782] HPLC (Method A): 7.75 min, 99.80%, 210 nm

    [0783] Chiral HPLC: 6.74 min, 7.06 min, 48.93%, 51.06%, 240 nm

    Example 67Chiral Separation of N((S)-1-(pyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 71 and Compound 72)

    ##STR00290##

    [0784] COLUMN ID: CHIRALCEL ODH (2504.6 mm 5 um)

    [0785] MOBILE PHASE A: Liq. CO.sub.2

    [0786] MOBILE PHASE B: M.Math.NH3-MEOH-ACN (50-50)

    [0787] FLOW RATE (ML/MIN): 3

    [0788] INSTRUMENT ID: SFC INVESTIGATOR

    [0789] METHOD: TIME: FLOW: % A: % B (0:14:60:40), (7:14:60:40)

    [0790] Input Quantity: 0.060 g.

    [0791] Output Quantity: Compound 71=0.015 g (% Yield=33.33%) and Compound 72=0.013 g (% Yield=25%)

    Compound 71:

    [0792] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2 Hz, 1H), 8.56 (d, J=4.8 Hz, 1H), 7.99 (dd, J=7.6, 1.6 Hz, 1H), 7.86 (td, J=7.6, 1.6 Hz, 1H), 7.70-7.64 (m, 2H), 7.55 (d, J=8 Hz, 1H), 7.36-7.33 (m, 1H), 5.87 (s, 1H), 5.36-5.32 (m, 1H), 2.78-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.85 (m, 1H), 1.66 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [0793] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 9.21 (d, J=7.6 Hz, 1H), 8.89 (d, J=2.0 Hz, 1H), 8.54 (d, J=4.4 Hz, 1H), 8.02 (dd, J=5.2, 4.0 Hz, 1H), 7.80-7.75 (m, 1H), 7.65-7.62 (m, 2H), 7.48 (d, J=8.0 Hz, 1H), 7.29 (dd, J=7.2, 5.2 Hz, 1H), 5.87 (br s, 1H), 5.29-5.22 (m, 1H), 2.81-2.67 (m, 3H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.65 (m, 1H), 1.55 (d, J=7.2 Hz, 3H).

    [0794] LCMS (Method A): 2.321 min, 100%, 254.0 nm, MS: ES+426.3 (M+1)

    [0795] HPLC (Method A): 9.18 min, 100%, 254.0 nm

    [0796] Chiral HPLC: 2.29 min, 100%, 246 nm

    Compound 72:

    [0797] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.86 (d, J=2 Hz, 1H), 8.56 (d, J=4.8 Hz, 1H), 7.99 (dd, J=7.6, 1.6 Hz, 1H), 7.86 (td, J=7.6, 1.6 Hz, 1H), 7.70-7.64 (m, 2H), 7.55 (d, J=8 Hz, 1H), 7.36-7.33 (m, 1H), 5.87 (s, 1H), 5.36-5.32 (m, 1H), 2.78-2.65 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.85 (m, 1H), 1.66 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [0798] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 9.21 (d, J=7.6 Hz, 1H), 8.89 (d, J=2.0 Hz, 1H), 8.54 (d, J=4.4 Hz, 1H), 8.02 (dd, J=5.2, 4.0 Hz, 1H), 7.80-7.75 (m, 1H), 7.65-7.62 (m, 2H), 7.48 (d, J=8.0 Hz, 1H), 7.29 (dd, J=7.2, 5.2 Hz, 1H), 5.87 (br s, 1H), 5.29-5.22 (m, 1H), 2.81-2.67 (m, 3H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.65 (m, 1H), 1.55 (d, J=7.2 Hz, 3H).

    [0799] LCMS (Method A): 2.321 min, 100%, 254.0 nm, MS: ES+426.3 (M+1)

    [0800] HPLC (Method A): 9.20 min, 100%, 254.0 nm

    [0801] Chiral HPLC (Method A): 2.32 min, 100%, 246 nm

    Example 68Synthesis of N((R)-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 73)

    ##STR00291## ##STR00292##

    Step-1

    [0802] To a stirred solution of oxazole CAS: 288-42-6 (10.0 g, 144.80 mmol, 1.0 eq.) in dry THF (50 mL) was added n-BuLi (90.50 mL, 144.80 mmol, 1.0 eq.) at 78 C. and stirred for 1 h. Followed by addition of CAS: 2591-86-8 (16.36 g, 144.80 mmol, 1.0 eq.) under N.sub.2 atmosphere. The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with 1N HCl (200 mL) and extracted with DCM (3300 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude oxazole-2-carbaldehyde (A58) (12.8 g, 131.86 mmol, Yield: 91.07%). The obtained crude material was directly used for next reaction (Note: organic layer was concentrated at lower temperature 25 C. on rotavapor due to volatile nature of the compound, also did not removed solvent completely)

    [0803] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.73 (s, 1H), 8.50 (s, 1H), 7.66 (s, 1H).

    Step-2

    [0804] To a solution of oxazole-2-carbaldehyde (A58) (5.0 g, 51.509 mmol, 1.0 eq.) in THF (50 mL), CAS: 343338-28-3 (7.49 g, 61.811 mmol, 1.2 eq.) and Ti(OC.sub.2H.sub.4).sub.4 CAS: 3087-36-3 (22.988 g, 103.06 mmol, 2.0 eq.) were added and allowed reaction mixture to stirred at RT for 16 h. TLC indicate the completion of reaction, the resulting reaction mixture was quenched with saturated brine (100 mL) and extracted with EtOAc (3300 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (100-200 mesh) as stationary phase (desired product was eluted in 40% Ethyl acetate in hexane) to afford (S,E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A59) (4.0 g, 19.974 mmol, Yield: 38.78%).

    [0805] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.46 (s, 1H), 8.29 (s, 1H), 7.64 (s, 1H), 1.19 (s, 9H).

    [0806] LCMS (Method A): 1.547 min, 100%, 285.0 nm, MS: ES+201.0 (M+1)

    Step-3

    [0807] To a stirred solution of (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A59) (4.0 g, 19.974 mmol, 1.0 eq.), in DCM (40 mL) was added CH.sub.3MgBr (3M in Et.sub.2O) (7.989 mL, 23.969 mmol, 1.2 eq.) under N.sub.2 at 78 C. The resulting mixture was stirred at 78 C. for 1.5 h, then allowed to warm up to room temperature for 1.5 h. The second portion of CH.sub.3MgBr (3M in Et.sub.2O) (7.989 mL, 23.969 mmol, 1.2 eq.) was added and again stirred reaction mixture at 78 C. for 1 h. After 1 h allowed to warm up to room temperature for 3 h. The third portion of CH.sub.3MgBr (3M in Et.sub.2O) (3.99 mL, 11.984 mmol, 0.6 eq.) was added at 78 C., then allowed reaction mixture to warm up to room temperature for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was poured into aq. NH.sub.4Cl (100 mL) slowly and extracted with EtOAc (3100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by trituration with pentane to afford (S)-2-methyl-N((R)-1-(oxazol-2-yl)ethyl) propane-2-sulfinamide (A60) (3.0 g, 13.868 mmol, Yield: 69.44%).

    [0808] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): 8.07 (s, 1H), 7.16 (s, 1H), 5.93 (d, J=7.6 Hz, 1H), 4.56-4.48 (m, 1H), 1.50 (d, J=6.8 Hz, 3H), 1.09 (s, 9H).

    [0809] LCMS (Method A): 1.404 min, 100%, 220.0 nm, MS: ES+217.1 (M+1).

    [0810] Chiral HPLC: 4.14 min, 100%, 216.0 nm.

    Step-4

    [0811] To a solution of(S)-2-methyl-N((R)-1-(oxazol-2-yl)ethyl) propane-2-sulfinamide (A60) (3.0 g, 13.870 mmol, 1.0 eq.) in MeOH (30 mL) was added 4M HCl in Dioxane (7.28 mL, 29.126 mmol, 2.1 eq.) and stirred for 1 h at RT. TLC indicated the completion of reaction then concentrated under reduced pressure to afford (R)-1-(oxazol-2-yl)ethan-1-amine hydrochloride (A61) (2.77 g, 18.642 mmol, Yield: Quantitative)

    [0812] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 8.78 (br s, 2H), 8.25 (s, 1H), 7.33 (s, 1H), 4.70-4.64 (m, 1H), 1.56 (d, J=6.8 Hz, 3H).

    [0813] LCMS (Method A): 0.196 min, 94.57%, 210.0 nm, MS: ES+112.9 (M+1)

    Step-5

    [0814] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid Compound 15 (5.0 g, 15.562 mmol, 1.0 eq.), HATU (8.876 g, 23.343 mmol, 1.5 eq.) and DIPEA (8.045 MI, 46.685 mmol, 3.0 eq.) in DMF (50 Ml) at 0 C. under nitrogen atmosphere stirred for 20 min, was added A61 (2.77 g, 18.674 mmol, 1.2 eq.) and reaction mixture was stirred for 3 h at room temperature. TLC indicated the completion of reaction, then water (100 mL) was added and extracted with EtOAc (3100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 60% Ethyl acetate in hexane) to afford N((R)-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 73) (4.6 g, 11.073 mmol, Yield: 71.16%).

    [0815] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.36 (d, J=7.6 Hz, 1H), 9.27 (d, J=2.0 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 8.03-8.00 (m, 1H), 7.66-7.63 (m, 2H), 7.19 (s, 1H), 5.88 (br s, 1H), 5.40-5.36 (m, 1H), 2.80-2.67 (m, 4H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.65 (m, 1H), 1.61 (d, J=6.8 Hz, 3H).

    [0816] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.99-7.92 (m, 2H), 7.70-7.63 (m, 2H), 7.18 (s, 1H), 5.88 (br s, 1H), 5.52-5.46 (m, 1H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.85 (m, 1H), 1.73 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [0817] LCMS (Method A): 2.460 min, 98.73%, 254.0 nm, MS: ES+416.2 (M+1)

    [0818] HPLC (Method A): 8.77 min, 99.01%, 254.0 nm.

    [0819] Chiral HPLC: Peak-1 (5.02 min, 47.83%, 245.0 nm); Peak-2 (6.08 min, 49.16%, 245.0 nm)

    Example 69Synthesis of N((R)-4-(dimethylamino)-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 74)

    ##STR00293##

    Step-1

    [0820] To a solution of (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (Compound 55) (0.15 g, 0.36 mmol, 1.0 eq.), EDCl.Math.HCl (0.106 g, 0.553 mmol, 1.5 eq.), HOBt (0.075 g, 0.553 mmol, 1.5 eq.) and DIPEA (0.143 g, 1.107 mmol, 3.0 eq.) in DCM (20 v) at 0 C. under nitrogen atmosphere stirred for 15 min, was added Dimethyl amine (2 M in THF) CAS: 124-40-3 (0.067 g, 1.476 mmol, 4.0 eq.) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with DCM (315 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by trituration with n-pentane to afford N((R)-4-(dimethylamino)-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 74) (0.04 g, 0.0922 mmol, Yield: 25%).

    [0821] .sup.1H NMR (MeOD, 400 MHz) ppm 9.22 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.95 (dd, J=7.6, 2.0 Hz, 1H), 7.68-7.65 (m, 2H), 5.87 (br s, 1H), 4.62-4.57 (m, 1H), 3.17 (s, 3H), 2.96 (s, 3H), 2.88-2.83 (m, 1H), 2.77-2.75 (m, 1H), 2.69-2.64 (m, 3H), 2.55-2.51 (m, 1H), 2.40-2.38 (m, 1H), 2.18-2.15 (m, 1H), 1.92-1.85 (m, 1H), 1.41 (d, J=5.4 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [0822] .sup.1H NMR (DMSO-d6, 400 MHz) ppm 9.23 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.4 Hz, 1H), 8.64 (d, J=7.6 Hz, 1H), 8.02-7.99 (m, 1H), 7.65-7.63 (m, 2H), 5.88 (br s, 1H), 4.42-4.39 (m, 1H), 3.02 (s, 3H), 2.83 (s, 3H), 2.76-2.71 (m, 2H), 2.69-2.61 (m, 2H), 2.57-2.53 (m, 1H), 2.51-2.43 (m, 1H), 2.35-2.32 (m, 1H), 2.07 (m, 1H), 1.75-1.67 (m, 1H), 1.25 (d, J=6.4 Hz, 3H).

    [0823] LCMS (Method A): 2.290 min, 100%, 210.0 nm, MS: ES+434.3 (M+1)

    [0824] HPLC (Method A): 8.26 min, 98.29%, 210.0 nm.

    [0825] Chiral HPLC (Method A): Peak 1: 8.12 min, 45.66%, 240 nm; Peak 2: 8.49 min, 53.04%, 240 nm.

    Example 70Synthesis of N-(3-(dimethylamino)-3-oxopropyl)-8-(4-(trifluoro methyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 75)

    ##STR00294##

    Step-1

    [0826] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.5 g, 1.55 mmol, 1.0 eq.) in DMF (5.0 mL) was added HATU (0.88 g, 2.33 mmol, 1.5 eq.) at 0 C. Followed by addition of DIPEA (0.8 mL, 4.67 mmol, 3.0 eq.) and stirred at 0 C. After 10 min of stirring, CAS: 3196-73-4 B-Alanine methyl ester hydrochloride (0.239 g, 1.71 mmol, 1.1 eq.) was added at 0 C. The resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice-cold water (10 mL) and was extracted with EtOAc (20 mL). The combined organic layer was evaporated under vacuum and crude residue was purified with silica column chromatography (60-120 mesh; 50% of EtOAc and hexane) and yielded methyl 3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A62) (0.34 g, 0.862 mmol, Yield: 55.34%).

    [0827] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.92 (t, J=6.8 Hz, 1H), 8.78 (d, J=1.6 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 3.62 (s, 3H), 3.57 (q, J=5.6 Hz, 2H), 2.80-2.64 (m, 5H), 2.45-2.40 (m, 1H), 2.31-2.24 (m, 1H), 2.09-2.06 (m, 1H), 1.74-1.63 (m, 1H).

    [0828] LCMS (Method A): 2.418 min, 99.31%, MS: ES+407.22 [M+H].

    Step-2

    [0829] To a solution of methyl 3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A62) (0.340 g, 0.832 mmol) in MeOH:H.sub.2O (3:1 mL) was added LiOH.Math.H.sub.2O (0.068 g, 1.67 mmol, 2 eq.) at 0 C. The reaction mixture was stirred for 3 h at room temperature, TLC indicate the completion of reaction, the resulting reaction mixture was acidified with 1N HCl and extracted with Ethyl Acetate (15 mL3). The combined organic layer was concentrated under reduced pressure to afford 3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid as a white amorphous solid (A63) (0.32 g, 0.765 mmol, Yield: 32.82%).

    [0830] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.92 (t, J=5.2 Hz, 1H), 8.81 (d, J=2.0 Hz, 1H), 8.02-7.99 (m, 1H), 7.65-7.62 (m, 2H), 5.87 (br s, 1H), 3.53 (q, J=6.8 Hz, 2H), 2.80-2.67 (m, 3H), 2.59-2.56 (m, 2H), 2.50-2.46 (m, 1H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.65. (m, 1H).

    [0831] LCMS (Method A): 2.191 min, 100%, MS: ES+393.17 [M+H].sup.+

    Step-3

    [0832] To a stirred solution of 3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid (A63) (0.15 g, 0.38 mmol, 1.0 eq.) in DMF (1.5 Ml) was added HATU (0.21 g, 0.57 mmol, 1.5 eq.) at 0 C. Then after 10 min at same temperature DIPEA (0.2 MI, 1.14 mmol, 3.0 eq.) was added and stirred for 10 min. After 10 min of stirring, dimethyl amine (2M in THF) CAS: 124-40-3 (0.018 g, 0.42 mmol, 1.1 eq.) was added at 0 C. The resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice-cold water (10 Ml) and was extracted with EtOAc (10 Ml2). The combined layer was evaporated under vacuum and crude residue was purified by column chromatography using silica gel (60-120 mesh; 50% of EtOAc and hexane) to afford N-(3-(dimethylamino)-3-oxopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 75) (0.064 g, 0.155 mmol, Yield: 43.13%).

    [0833] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.84 (t, J=5.2 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 8.01-7.98 (m, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 3.52 (q, J=5.6 Hz, 2H), 2.97 (s, 3H), 2.88-2.77 (m, 5H), 2.71-2.62 (m, 3H), 2.32-2.24 (m, 1H), 2.09-2.07 (m, 1H), 1.74-1.63 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [0834] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.96 (dd, J=1.6 Hz, 7.6 Hz, 1H), 7.68-7.63 (m, 2H), 5.86 (br s, 1H), 3.73 (t, J=6.8 Hz, 2H), 3.11 (s, 3H), 2.98 (s, 3H), 2.80 (t, J=6.8 Hz, 3H), 2.75-2.64 (m, 2H), 2.55-2.50 (m, 1H), 2.40-2.37 (m, 1H), 2.17-2.15 (m, 1H), 1.92-1.88 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [0835] LCMS (Method A): 2.22 min, 99.25%, MS: ES+420.3 [M+H]

    [0836] HPLC (Method A): 7.98 min. 99.11%, 254 nm

    [0837] CHIRAL HPLC (Method A): 6.46+7.39 min. 49.63+49.80%, 242 nm

    Example 71Synthesis of N-(3-(methylamino)-3-oxopropyl)-8-(4-(trifluoro methyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 76)

    ##STR00295##

    Step-1

    [0838] To a stirred solution of 3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid A63 (0.15 g, 0.38 mmol, 1.0 eq.) in DMF (1.5 mL) was added HATU (0.21 g, 0.57 mmol, 1.5 eq.) at 0 C. Followed by addition of DIPEA (0.2 mL, 1.14 mmol, 3.0 eq.) and CAS: 74-89-5 methyl amine 2M in THF (0.28 mL, 0.57 mmol, 1.5 eq.). The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with ice-cold water (10 mL) and extracted with EtOAc (25 mL). The combined layer was evaporated under vacuum and crude residue was purified with silica column chromatography (60-120 mesh; 50% of EtOAc and hexane) to afford N-(3-(methylamino)-3-oxopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 76) (0.065 g, 0.155 mmol, Yield: 40.65%).

    [0839] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.88 (t, J=5.6 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.88-7.87 (m, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 3.55 (q, J=7.2 Hz, 2H), 2.85-2.75 (m, 1H), 2.74-2.65 (m, 1H), 2.58 (d, J=4.8 Hz, 3H), 2.42-2.39 (m, 3H), 2.18-2.07 (m, 1H), 1.74-1.63 (m, 1H). Note: 3H proton merged in DMSO solvent peak.

    [0840] .sup.1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.98-7.95 (m, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.72 (t, J=6.8 Hz, 2H), 2.75 (s, 3H), 2.68-2.64 (m, 2H), 2.57 (t, J=6.8 Hz, 2H), 2.51-2.49 (m, 1H), 2.40-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.89-1.85 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [0841] LCMS (Method A): 2.12 min, 98.87%, MS: ES+406.37 [M+H]

    [0842] HPLC (Method A): 7.49 min. 99.45%, 254 nm

    Example 72Synthesis of N((R)-4-acetamidobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 77)

    ##STR00296##

    Step-1

    [0843] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.2 g, 0.622 mmol, 1.0 eq.) in DMF (3 mL) was added HATU (0.355 g, 0.933 mmol, 1.5 eq.) and DIPEA (0.32 mL, 1.867 mmol, 3.0 eq.) at 0 C. under nitrogen atmosphere then stirred for 5 min, followed by addition of CAS: 1187927-71-4 (R)-1-Boc-amino-butyl-3-amine (0.129 g, 0.685 mmol, 1.1 eq.) under Nitrogen. The resulting mixture was stirred for 4 h at room temperature. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with DCM (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (50% EtOAc in Hexane) to afford tert-butyl ((3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butyl) carbamate (A64) (0.22 g, 0.448 mmol, Yield: 71.90%).

    [0844] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): 9.24 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.55 (d, J=8.0 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.65-7.63 (m, 2H), 6.80 (br s, 1H), 5.87 (br s, 1H), 4.11-4.08 (m, 1H), 3.02-2.97 (m, 2H), 2.73-2.68 (m, 3H), 2.33-2.25 (m, 2H), 2.09-2.07 (m, 1H), 1.73-1.65 (m, 3H), 1.36 (s, 9H), 1.20 (d, J=6.8 Hz, 3H).

    [0845] LCMS (Method A): 2.725 min, 96.87%, 254.0 nm, MS: ES+492.4 (M+1).

    Step-2:

    [0846] To a solution of tert-butyl ((3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butyl) carbamate (A64) (0.22 g, 0.448 mmol, 1.0 eq.) in MeOH (2 mL) was added 4 M HCl in Dioxane (0.22 mL, 0.895 mmol, 2.0 eq.) and stirred at RT for 3 h. TLC indicated the completion of reaction, the reaction mixture was concentrated under reduced pressure to afford the crude. The obtained crude material was purified by trituration with diethyl ether (5 mL) to afford N((R)-4-aminobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A65) (0.2 g, 0.511 mmol, Quantitative).

    [0847] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.28 (s, 1H), 8.87 (s, 1H), 8.78 (d, J=8.0 Hz, 1H), 8.03 (t, J=5.2 Hz, 3H), 7.87 (br s, 2H), 7.67-7.64 (m, 2H), 5.88 (br s, 1H), 4.19-4.16 (m, 1H), 3.72-3.46 (m, 5H), 2.89-2.86 (m, 2H), 2.76-2.68 (m, 2H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.86-1.82 (m, 2H), 1.75-1.69 (m, 1H), 0.85 (d, J=6.8 Hz, 3H). Note: Compound was isolated as HCl salt.

    [0848] LCMS (Method A): 1.853 min, 97.76%, 254.0 nm, MS: ES+392 (M+1)

    Step-3

    [0849] To a solution N((R)-4-aminobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A65) (0.18 g, 0.460 mmol, 1.0 eq.) and TEA (0.2 mL, 1.379 mmol, 3.0 eq.) in DCM (2 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added CH.sub.3COCl (0.036 mL, 0.460 mmol, 1.0 eq.) and the reaction mixture was stirred for another 4 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice cold water (10 mL) and extracted with DCM (10 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (50% EtOAc in Hexane) to afford N((R)-4-acetamidobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 77) (0.087 g, 0.201 mmol, Yield: 43.65%).

    [0850] .sup.1H NMR (DMSO-d.sub.6 400 MHz): ppm, 9.24 (s, 1H), 8.78 (s, 1H), 8.58 (d, J=7.6 Hz, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.63 (d, J=3.6 Hz, 2H), 5.87 (br s, 1H), 4.12-4.09 (m, 1H), 3.11-3.09 (m, 2H), 2.77-2.68 (m, 3H), 2.32-2.29 (m, 2H), 2.10-2.07 (m, 1H), 1.84 (s, 3H), 1.78-1.64 (m, 3H), 1.20 (d, J=6.4 Hz, 3H).

    [0851] LCMS (Method A): 2.198 min, 98.97%, 242.0 nm, MS: ES+434.3 (M+1)

    [0852] HPLC (Method A): 7.87 min, 97.93%, 254.0 nm

    [0853] CHIRAL HPLC: 4.93 min. 98%, 242 nm

    Example 73Synthesis of N-(3-acetamidopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 78)

    ##STR00297##

    Step-1

    [0854] A solution of propane-1,3-diamine (CAS: 109-76-2) (0.1 g, 1.348 mmol, 1.0 eq.), CH.sub.3COCl (0.105 g, 1.348 mmol, 1.0 eq.) and DIPEA (0.704 ml, 4.047 mmol, 3.0 eq.) in DCM (1 mL) at 78 C. under nitrogen atmosphere was stirred for 10 min then allowed to warm up to room temperature and stirring continued for 16 h at RT. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with 5% HCl (2 mL) and basified with Sat. NaHCO.sub.3 (310 mL) then extracted with DCM (10 mL) and the combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by trituration with n-Pentane to afford N-(3-aminopropyl) acetamide (A66) (0.1 g, 0.862 mmol, Yield: 63.79%).

    [0855] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 7.97-7.88 (m, 1H), 3.07-2.98 (m, 2H), 2.70 (t, J=6.8 Hz, 4H), 1.78 (s, 3H), 1.62-1.54 (m, 2H).

    [0856] LCMS (Method B): 1.25 min, 78%, 210.0 nm, MS: ES+117 (M+1)

    Step-2

    [0857] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.), HATU (0.17 g, 0.467 mmol, 1.5 eq.) and DIPEA (0.16 mL, 0.934 mmol, 3.0 eq.) in DMF (1 mL) at 0 C. under nitrogen atmosphere stirred for 10 min, was added A66 (0.039 g, 0.342 mmol, 1.1 eq.) and allowed to stirred for 7 h at room temperature. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with DCM (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (5% MDC in MeOH) to afford N-(3-acetamidopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 78) (0.033 g, 0.078 mmol, Yield: 25.28%).

    [0858] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.97 (dd, J=2.0 Hz J=7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.51 (t, J=6.8 Hz, 2H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.33 (m, 1H), 2.17-2.14 (m, 1H), 1.98 (s, 3H), 1.92-1.82 (m, 3H). Note: CONH proton exchanged in MeOD NMR.

    [0859] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): 9.24 (d, J=2.0 Hz, 1H), 8.80-8.78 (m, 1H), 8.02-7.99 (m, 1H), 7.90 (br s, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 3.12 (q, J=6.8 Hz, 2H), 2.80-2.67 (m, 3H), 2.33-2.32 (m, 1H), 2.10-2.07 (m, 1H), 1.81 (s, 3H), 1.76-1.64 (m, 3H). Note: CF.sub.3CH proton merged in DMSO solvent peak.

    [0860] LCMS (Method A): 2.150 min, 97.87%, 254.0 nm, MS: ES+420.38 (M+1)

    [0861] HPLC (Method A): 7.62 min, 97.0%, 254.0 nm

    Example 74Synthesis of N-(2-acetamidoethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 79)

    ##STR00298##

    Step-1

    [0862] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF (1 mL) was added HATU (0.17 g, 0.467 mmol, 1.5 eq.) and DIPEA (0.16 mL, 0.934 mmol, 3.0 eq.) at 0 C. under nitrogen atmosphere and stirred for 10 min, was added CAS: 1001-53-2 N-Acetylethylenediamine (0.034 g, 0.342 mmol, 1.1 eq.) under Nitrogen. The resulting mixture was stirred for 7 h at room temperature. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with DCM (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude which was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (5% MDC in MeOH) to afford N-(2-acetamidoethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 79) (0.038 g, 0.093 mmol, Yield: 30.12%).

    [0863] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.97 (dd, J=8.0 Hz, 7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.59-3.56 (m, 2H), 3.48-3.45 (m, 2H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.17-2.15 (m, 1H), 1.98 (s, 3H), 1.89-1.85 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [0864] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.86 (t, J=5.2 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.04-7.98 (m, 2H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 3.39-3.34 (m, 2H), 3.28-3.23 (m, 2H), 2.80-2.67 (m, 3H), 2.50-2.46 (m, 1H), 2.33-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.82 (s, 3H), 1.74-1.65 (m, 1H).

    [0865] LCMS (Method A): 2.122 min, 100%, 242.0 nm, MS: ES+406.22 (M+1)

    [0866] HPLC (Method A): 7.45 min, 99.69%, 254.0 nm

    Example 75Synthesis of N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 80)

    ##STR00299##

    Step-1

    [0867] To a stirred solution of 1-(1H-pyrazol-5-yl)ethan-1-one (CAS: 20583-33-9) (0.2 g, 1.81 mmol, 1.0 eq.) in 7M NH.sub.3 in MeOH (2.0 mL) was added Ti(O.sup.ipr) 4 (1.0 g, 3.63 mmol, 2.0 eq.) at 0 C. and stirred for 4 h. Followed by addition of sodium borohydride (0.13 g, 3.63 mmol, 2.0 eq.) and stirred for 6 h at RT. TLC indicated the completion of reaction, the resulting reaction mixture was concentrated under vacuum to obtain crude product 1-(1H-pyrazol-5-yl)ethan-1-amine (A67) (0.22 g, 1.97 mmol, Yield: Quantitative).

    [0868] LCMS (Method B): 1.22 min, 10.93%, 254 nm, MS: ES+112.2 (M+1)

    Step-2

    [0869] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.31 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.17 g, 0.46 mmol, 1.5 eq.) at 0 C. Followed by addition of DIPEA (0.16 mL, 0.934 mmol, 3.0 eq.) and stirred for another 10 min. After 10 min of stirring, 1-(1H-pyrazol-5-yl)ethan-1-amine (A67) (0.038 g, 0.342 mmol, 1.1 eq.) was added and reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured on to cold water (5 mL) to obtain precipitate. The precipitate was filtered through buckler funnel and washed with water (20 mL) and dried over high vacuum then purified by column chromatography (desired product eluted in 80% EtOAC in Hexane) to afford N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 80) (0.018 g, 0.043 mmol, Yield: 13.95%).

    [0870] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.57 (br s, 1H), 9.27 (d, J=2.0, 1H), 9.04 (br s, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.64-7.63 (m, 3H), 6.25 (s, 1H), 5.87 (s, 1H), 5.39-5.31 (m, 1H), 2.81-2.67 (m, 2H), 2.50-2.46 (m, 2H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.54 (d, J=6.8 Hz, 3H).

    [0871] LCMS (Method A): 2.293 min, 97.06%, 254 nm, MS: ES+415.2 (M+1)

    [0872] HPLC (Method A): 8.25 min, 95.14%, 254 nm

    Example 76Chiral separation of N((R)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 81 and Compound 82)

    ##STR00300##

    [0873] COLUMN ID: CHIRALPAK IG 25050 mm 5 um

    [0874] MOBILE PHASE A: LIQ. CO2

    [0875] MOBILE PHASE B: MEOH

    [0876] FLOW RATE (ML/MIN): 150

    [0877] INSTRUMENT ID: WATERS SFC 350 WITH 2489 UV Detector

    [0878] METHOD: TIME: FLOW: % A: % B (0.01:150:70:30), (24:150:70:30)

    [0879] Input Quantity: 0.1206 g.

    [0880] Output Quantity: Compound 81=0.044 g (% Yield=36.48%) and Compound 82=0.040 g (% Yield=33.17%)

    Compound 81:

    [0881] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.0 Hz, 1H), 8.47 (d, J=7.6 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.88 (br s, 1H), 4.79 (t, J=5.6 Hz, 1H), 4.10-4.07 (m, 1H), 3.53-3.49 (m, 1H), 3.42-3.37 (m, 1H), 2.73-2.68 (m, 3H), 2.33-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.72-1.67 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).

    [0882] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.97 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.31-4.26 (m, 1H), 3.71-3.68 (m, 2H), 2.78-2.65 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.83 (m, 1H), 1.32 (d, J=6.8 Hz, 3H).

    [0883] Note: CONH and OH proton exchanged in MeOD NMR.

    [0884] LCMS (Method A): 2.212 min, 99.64%, 254.0 nm, MS: ES+379.2 (M+1) HPLC (Method A): 7.88 min, 99.59%, 254.0 nm

    [0885] Chiral HPLC (Method A): 5.88 min, 99.76%, 240 nm

    Compound 82:

    [0886] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 8.47 (d, J=7.6 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.87 (br s, 1H), 4.79 (t, J=5.6 Hz, 1H), 4.10-4.07 (m, 1H), 3.52-3.48 (m, 1H), 3.42-3.38 (m, 1H), 2.81-2.68 (m, 3H), 2.33-2.29 (m, 2H), 2.10-2.07 (m, 1H), 1.72-1.67 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).

    [0887] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.97 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.31-4.26 (m, 1H), 3.71-3.68 (m, 2H), 2.78-2.65 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 1H), 1.32 (d, J=6.8 Hz, 3H).

    [0888] Note: CONH and OH proton exchanged in MeOD NMR.

    [0889] LCMS (Method A): 2.214 min, 100%, 254.0 nm, MS: ES+379.2 (M+1)

    [0890] HPLC (Method A): 7.87 min, 98.49%, 254.0 nm

    [0891] Chiral HPLC (Method A): 6.79 min, 98.70%, 240 nm

    Example 77Synthesis of N((R)-1-cyano-3-(methylamino)-3-oxopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 83)

    ##STR00301## ##STR00302##

    Step 1

    [0892] To a stirred solution of CAS: 51186-58-4 (0.5 g, 1.54 mmol, 1.0 eq.) in DMF (5.0 mL) was added HATU (0.88 g, 2.32 mmol, 1.5 eq.) at 0 C. and stirred for 1 h. followed by addition of aq. NH.sub.4OH (0.37 mL 28%). The resulting reaction mixture was stirred at RT for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtain crude product. The crude product was purified by manual column chromatography (desired product eluted in 35% Ethyl acetate in hexane) to afford benzyl(R)-4-amino-3-((tert-butoxy carbonyl)amino)-4-oxobutanoate (A68) (0.238, 0.739 mmol, Yield 47.75%).

    [0893] .sup.1H NMR (MeOD, 400 MHz): ppm 7.37-7.30 (m, 5H), 7.27 (s, 1H), 7.10 (s, 1H), 7.05 (d, J=8.4 Hz, 1H), 5.12-5.05 (m, 2H), 4.31-4.26 (m, 1H), 2.78-2.73 (dd, J=5.6 Hz, 16.0 Hz, 1H), 2.61-2.47 (dd, J=5.2, 16.0 Hz, 1H), 1.33 (d, J=24.0 Hz, 9H).

    [0894] LCMS (Method A): 1.821 min, 100.0% 210 nm, MS: ES+323.2 (M+1)

    Step-2

    [0895] To a stirred solution of benzyl(R)-4-amino-3-((tert-butoxycarbonyl)amino)-4-oxobutanoate (A68) (4.0 g, 12.4 mmol, 1.0 eq.) in 1,4 Dioxane (40.0 mL) was added pyridine (4.0 mL, 13.6 mmol, 1.1 eq.) at RT and stirred for 10 min. After 10 min, TFAA (2.8 mL, 55.9 mmol, 4.5 eq.) was added dropwise and resulting reaction mixture was stirred at RT for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with NaHCO.sub.3 (100 mL) and extracted with EtOAc (330 mL). The combined organic layer was dried over anhy Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained crude material. The crude material was purified by manual column chromatography silica gel (100-200 mesh) (desired product eluted in 30% Ethyl acetate in hexane) to afford benzyl(R)-3-((tert-butoxycarbonyl)amino)-3-cyanopropanoate (A69) (3.6 g, 11.82 mol, Yield 95.70%).

    [0896] .sup.1H NMR (MeOD, 400 MHz): ppm 7.84 (d, J=7.6 Hz, 1H), 7.38-7.30 (m, 5H), 5.12 (s, 2H), 4.70 (d, J=6.8 Hz, 1H), 3.02-2.87 (m, 2H), 1.30 (s, 9H).

    [0897] LCMS (Method A): 2.32 min, 90.42%, 220 nm, MS: ES+305.2 (M+1)

    Step-3

    [0898] To a stirred solution of benzyl(R)-3-((tert-butoxy carbonyl)amino)-3-cyanopropanoate (A69) (3.6 g, 11.82 mmol, 1.0 eq.) in THF (30 mL) was added CH.sub.3SO.sub.3H (5.22 mL, 59.14 mmol, 5.0 eq.) at RT and resulting reaction mixture was stirred at room temperature for 5 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with aq. NaHCO.sub.3 (100 mL) and extracted with EtOAc (330 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography silica gel (100-200 mesh) (desired product eluted in 30% Ethyl acetate in hexane) to afford benzyl(R)-3-amino-3-cyanopropanoate hydrochloride (A70) (1.2 g, 4.98 mmol, Yield 42.15%).

    [0899] .sup.1H NMR (DMSO, 400 MHz): ppm 7.39-7.31 (m, 5H), 5.14 (s, 2H), 4.01 (t, J=6.8 Hz, 1H), 2.88-2.74 (m, 2H); LCMS (Method A): Not supported the desired Mass.

    Step-4

    [0900] A stirred solution of benzyl(R)-3-amino-3-cyanopropanoate hydrochloride (A70) (0.5 g, 2.08 mmol, 1.0 eq.) in DMF (5.0 mL) was prepared. To this solution was added DIPEA (1.15 mL, 6.24 mmol, 3.0 eq.) and HATU (1.18 g, 3.12 mmol, 1.5 eq.) at RT under nitrogen atmosphere and stirred for 10 min. After 10 min, addition of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.801 g, 2.28 mmol, 1.1 eq.) at same temperature and again resulting reaction mixture stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography silica gel (100-200 mesh) (desired product eluted in 35% Ethyl acetate in hexane) to afford benzyl (3R)-3-cyano-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A71) (0.475, 0.936 mmol, Yield: 97.23%).

    [0901] .sup.1H NMR (DMSO, 400 MHz): ppm 9.60 (d, J=7.2 Hz, 1H), 9.22 (d, J=1.6 Hz, 1H), 8.81 (d, J=1.6 Hz, 1H), 8.04-8.02 (dd, J=2.4 Hz, & 6.8 Hz, 1H), 7.66 (t, J=7.2 Hz, 2H), 7.37 (d, J=6.8 Hz, 2H), 7.33-7.27 (m, 3H), 5.88 (br s, 1H), 5.32-5.27 (m, 1H), 5.18 (s, 2H), 3.34-3.15 (m, 2H), 2.81-2.78 (m, 1H), 2.70-2.65 (m, 2H), 2.46 (br s, 1H), 2.32-2.29 (m, 1H), 2.08-2.06 (m, 1H), 1.75-1.64 (m, 1H).

    [0902] LCMS (Method A): 2.823 min, 100.0%, 254 nm, MS: ES+508.4 (M+1).

    Step-5

    [0903] To a stirred solution of benzyl (3R)-3-cyano-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A71) (0.475 g, 0.931 mmol, 1.0 eq.) in MeOH:H.sub.2O (8:2) was added LiOH.Math.H.sub.2O (0.064 g, 2.80 mmol, 3.0 eq.) and reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was concentrated and residue was acidified by using 1N HCl up to pH acidic and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to afford (3R)-3-cyano-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid (A72) (0.380 g, 0.911 mmol, Yield 97.27%). Note: The crude product was directly used next step further without any purification.

    [0904] LCMS (Method A): 2.359 min, 28.84%, 254.0 nm, ES+418.3 (M+1).

    Step-6

    [0905] To a stirred solution of (3R)-3-cyano-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid (A72) (0.380 g, 0.911 mmol, 1.0 eq.) in DCM were added EDC.Math.HCl (0.26 g, 1.36 mmol, 1.5 eq.) and HOBt (0.246 g, 1.82 mmol, 2.0 eq.) at RT and stirred for 15 min. Followed by addition of methylamine (0.9 MI, 1.82 mmol, 2.0 eq., 2M in THF) at RT and resulting reaction mixture stirred for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 Ml) and extracted with EtOAc (320 Ml). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography (desired product eluted in 35% Ethyl acetate in hexane) to afford N((R)-1-cyano-3-(methylamino)-3-oxopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 83) (0.024 g, 0.056 mmol, Yield 47.75%)

    [0906] .sup.1H NMR (DMSO, 400 MHz): ppm 9.59 (d, J=7.2 Hz, 1H), 9.23 (d, J=2.4 Hz, 1H), 8.84 (d, J=2.4 Hz, 1H), 8.15 (d, J=4.8 Hz, 1H), 8.05-8.04 (dd, J=2.4, 6.8 Hz, 1H), 7.69-7.64 (m, 2H), 5.88 (br s, 1H), 5.26-5.20 (m, 1H), 2.92-2.90 (m, 1H), 2.85-2.80 (m, 2H), 2.69-2.67 (m, 2H), 2.62 (d, J=4.8 Hz, 3H), 2.33-2.25 (m, 2H), 2.08-2.04 (m, 1H), 1.73-1.67 (m, 1H).

    [0907] HPLC (Method A): 7.98 min, 96.11%, 254 nm.

    [0908] LCMS (Method A): 2.247 min, 100.0%, 254 nm, ES+431.3 (M+1).

    [0909] Chiral HPLC: 5.37 min, 50%, 245 nm, 6.51 min, 49.8%, 245 nm

    Example 78Synthesis of (R)N-(1-cyano-3-(methylamino)-3-oxopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 84)

    ##STR00303##

    Step-1

    [0910] A stirred solution of A25 (0.70 g, 2.91 mmol, 1.2 eq), HATU (1.39 g, 3.60 mmol, 1.5 eq) and DIPEA (1.34 ml, 7.34 mmol, 3.0 eq) in DMF (5.0 mL) was prepared at RT under nitrogen atmosphere and stirred for 10 min. After 10 min, benzyl(R)-3-amino-3-cyanopropanoate hydrochloride (A70) (0.5 g, 2.43 mmol, 1.0 eq) was added and resulting reaction mixture was stirred at RT for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with Aq. NaHCO.sub.3 (50 mL) and extracted with EtOAc (350 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.51 g crude product. The crude product was purified by manual column chromatography (desired product eluted in 35% Ethyl acetate in hexane) to afford benzyl(R)-3-cyano-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A73) (0.4 g, 0.842 mmol, Yield 34.53%)

    [0911] .sup.1H NMR (DMSO, 400 MHz): ppm 9.60 (d, J=7.2 Hz, 1H), 9.23 (d, J=2.4 Hz, 1H), 8.82 (d, J=2.0 Hz, 1H), 8.05-8.04 (dd, J=1.6 Hz & J=7.6 Hz, 1H), 7.72-7.63 (m, 2H), 7.37 (d, J=6.8 Hz, 2H), 7.33-7.28 (m, 3H), 5.77 (s, 1H), 5.29 (m, 1H), 5.17 (s, 2H), 3.34-3.15 (m, 2H), 2.90 (br's, 2H), 2.79 (t, J=14.4 Hz, 2H), 2.28-2.18 (m, 2H).

    [0912] LCMS (Method A): 2.616 min, 95.58%, 254 nm, MS: ES+476.34 (M+1).

    Step-2

    [0913] To a stirred solution of a benzyl(R)-3-cyano-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A73) (0.4 g, 0.842 mmol, 1.0 eq) in MeOH:H.sub.2O:THF (7:2:1.10.0 mL) was added LiOH.Math.H.sub.2O (0.06 g, 2.52 mmol, 3.0 eq) and resulting reaction mixture was stirred for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was concentrated to afford crude material which was acidified by using IN HCl (50.0 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, Filtered and concentrated under reduce pressure to afford (R)-3-cyano-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid (A74) (0.38 g, 0.987 mmol, Yield 97.75%).

    [0914] LCMS (Method A): 2.098 min, 71.57%, 254.0 nm, MS: ES+385.37 (M+1).

    Step-3

    [0915] To a stirred solution of (R)-3-cyano-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carbox amido) propanoic acid (A74) (0.38 g, 0.911 mmol, 1.0 eq) in DCM (5.0 mL) was added EDC.Math.HCl (0.26 g, 1.36 mmol, 1.5 eq) and HOBt (0.246 g, 1.82 mmol, 2.0 eq) at RT under nitrogen atmosphere. Then resulting reaction mixture stirred for 15 min. After 15 min, methylamine was added (0.9 mL, 1.82 mmol, 2.0 eq, 2M in THF) and again stirred for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford 0.4 g crude product. The crude product was purified by manual column chromatography (desired product eluted in 35% Ethyl acetate in hexane) to afford (R)N-(1-cyano-3-(methylamino)-3-oxopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 84) (0.238 g, 0.739 mmol, Yield 47.75% 1H NMR (MeOD, 400 MHz): ppm 9.56 (d, J=7.2 Hz, 1H), 9.26 (d, J=2.0 Hz, 1H), 8.86 (d, J=2.0 Hz, 1H), 8.5 (d, J=4.0 Hz, 1H), 8.05 (t, J=6.4 Hz & 1.2 Hz, 1H), 7.71-7.65 (m, 2H), 5.77 (br's, 1H), 5.26-5.21 (m, 1H), 3.39 (s, 2H), 2.96-2.76 (m, 6H), 2.76 (s, 3H), 2.26-2.19 (m, 2H).

    [0916] LCMS (Method A): 2.045 min, 100.0%, 244 nm, MS: ES+399.27 (M+1)

    [0917] HPLC (Method A): 7.05 min, 96.39. %, 254 nm

    Example 79Synthesis of N((R)-4-amino-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 85)

    ##STR00304##

    Step-1

    [0918] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.3 g, 0.934 mmol, 1.0 eq.) in DMF (2.0 mL) were added DIPEA (0.542 g, 2.80 mmol, 3.0 eq.), and HATU (0.532 g, 1.40 mmol, 1.5 eq.) at RT under Nitrogen atmosphere and stirred for 15 min. After 15 min (R)-Methyl 3-aminobutanoate hydrochloride CAS: 139243-54-2 (0.157 g, 1.03 mmol, 1.1 eq.) was added and reaction mixture was stirred RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, Filtered and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography silica gel (100-200) (desired product eluted in 20% Ethyl acetate in hexane) to afford methyl (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A75) (0.210 g, 0.499 mmol, Yield: 53.45%).

    [0919] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.21 (d, J=2.0 Hz, 1H), 8.75 (d, J=2.0 Hz, 1H), 8.70 (d, J=7.6 Hz, 1H), 8.00 (dd, J=4.0 Hz & 9.6 Hz, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.45-4.38 (m, 1H), 3.60 (s, 3H), 2.79 (d, J=12.4 Hz, 1H), 2.72-2.66 (m, 3H), 2.57 (d, J=6.8 Hz, 2H), 2.32-2.24 (m, 1H), 2.08 (d, J=8.0 Hz, 1H), 1.71-1.67 (m, 1H), 1.24 (d, J=6.8 Hz, 3H).

    [0920] LCMS (Method A): 2.487 min, 96.19%, 254 nm, MS: ES+421.2 (M+1)

    Step-2

    [0921] To a stirred solution of methyl (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A75) (0.21 g, 0.499 mmol, 1.0 eq.) in MeOH:H.sub.2O (3:1 mL), was added LiOH.Math.H.sub.2O (0.017 g, 0.749 mmol, 1.5 eq.) and resulting reaction mixture was stirred at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was concentrated followed by acidified using IN HCl solution up to pH 2-3 to obtain solid precipitate. Then precipitate was filtered on Buchner funnel and dried under reduce pressure to afford (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (A76) (0.1 g, 0.246 mmol, Yield: 49.26%).

    [0922] .sup.1H NMR (MeOD, 400 MHz): ppm 9.29 (d, J=2.4 Hz, 1H), 9.05 (d, J=1.6 Hz, 1H), 8.10 (dd, J=1.6 Hz & 8.0 Hz, 1H), 7.85-7.77 (m, 2H), 5.95 (br s, 1H), 4.62-4.57 (m, 1H), 2.78-2.70 (m, 2H), 2.69-2.55 (m, 3H), 2.44-2.41 (m, 1H), 2.22-2.19 (m, 1H), 2.19-1.88 (m, 1H), 1.40 (d, J=4.0 Hz, 3H). Note: CONH and COOH proton exchanged in MeOD NMR.

    [0923] HPLC (Method A): 4.431 min, 98.88%, 254 nm.

    [0924] LCMS (Method A): 2.268 min, 98.02%, 242.0 nm, MS: ES+407.3 (M+1).

    Step-3

    [0925] To a stirred solution of (3R)-3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (A76) (0.06 g, 0.147 mmol, 1.0 eq.) in DMF (2.0 mL) was added CDI (0.047 g, 0.295 mmol, 2.0 eq.) at 0 C. under nitrogen atmosphere. The resulting reaction mixture stirred at RT for 1 h. After 1 h, addition of Aq. Ammonia (1.0 mL, 28% NH.sub.4OH) at 0 C. and again stirred at RT for 12 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography (desired product eluted in 20% Ethyl acetate in hexane) to afford N((R)-4-amino-4-oxobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 85) (0.032 g, 0.078 mmol, Yield: 53.33%).

    [0926] .sup.1H NMR (MeOD, 400 MHz): ppm 9.22 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 7.96 (dd, J=2.0 Hz & 7.6 Hz, 1H), 7.68-7.64 (m, 2H), 5.86 (br s, 1H), 4.58-4.57 (m, 1H), 2.82-2.78 (m, 1H), 2.68-2.61 (m, 3H), 2.53-2.48 (m, 2H), 2.44-2.41 (m, 1H), 2.22-2.19 (m, 1H), 2.19-1.88 (m, 1H), 1.38 (d, J=6.8 Hz, 3H). Note: CONH and CONH.sub.2 proton exchanged in MeOD NMR.

    [0927] HPLC (Method A): 7.436 min, 98.69%, 254 nm.

    [0928] LCMS (Method A): 2.117 min, 100%, 210 nm, MS: ES+406.2 (M+1).

    Example 80Synthesis of N((R)-1-hydroxybutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 86)

    ##STR00305##

    Step-1

    [0929] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid Compound 15 (0.1 g, 0.31 mmol, 1.0 eq.) in DMF (2.0 mL) was added DIPEA (0.120 g, 0.93 mmol, 3.0 eq.) and HATU (0.177 g, 0.46 mmol, 1.5 eq.) at RT under nitrogen atmosphere and stirred for 15 min. followed by addition of CAS: 5856-63-6 (R)-()-2-Amino-1-butanol (0.030 g, 0.34 mmol, 1.1 eq.) and reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford the crude product. The crude was further purified by manual column chromatography on silica gel (100-200) (desired product eluted in 100% Ethyl acetate) to afford N((R)-1-hydroxybutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 86) (0.064 g, 0.16 mmol, Yield: 53.33%)

    [0930] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.25 (d, J=1.6 Hz, 1H), 8.81 (d, J=1.6 Hz, 1H), 8.39 (d, J=8.4 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.63 (d, J=4.4 Hz, 1H), 5.87 (br s, 1H), 4.74 (t, J=5.2 Hz, 1H), 3.93 (d, J=4.8 Hz, 1H), 3.52-3.46 (m, 2H), 2.77-2.67 (m, 3H), 2.32-2.28 (m, 1H), 2.08 (d, J=12.0 Hz, 1H), 1.73-1.67 (m, 2H), 1.50-1.48 (m, 1H), 0.91 (t, J=7.2 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [0931] .sup.1H NMR (MeOD, 400 MHz): ppm 9.26 (d, J=1.6 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.97 (d, J=6.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.13-4.10 (m, 1H), 3.69 (d, J=4.4 Hz, 2H), 3.01-2.88 (m, 1H), 2.84-2.65 (m, 4H), 2.55-2.37 (m, 3H), 2.18-2.15 (m, 2H), 1.93-1.82 (m, 2H), 1.79-1.65 (m, 1H), 0.91 (t, J=7.2 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [0932] LCMS (Method-A): 2.30 min, 99.54%, 220 nm, MS: ES+393.3 (M+1)

    [0933] HPLC (Method-A): 8.22 min, 95.85%, 210 nm

    Example 81Synthesis of N((R)-2-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 87)

    ##STR00306##

    Step-1

    [0934] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid Compound 15 (0.1 g, 0.311 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.236 g, 0.623 mmol, 2.0 eq.), DIPEA (0.120 g, 0.934 mmol, 3.0 eq.) at 0 C. and stirred reaction mixture for 15 min. After 15 min, addition of CAS: 2799-16-8 (R)-()-1-Amino-2-propanol (0.025 g, 0.342 mmol, 1.1 eq.) and stirred reaction mixture at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography using silica gel (100-200) (desired product eluted in 40% Ethyl acetate in hexane) to afford N((R)-2-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 87) (0.054 g, 0.142 mmol, Yield: 45.85%).

    [0935] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=1.6 Hz, 1H), 8.82-8.75 (m, 2H), 8.00 (t, J=5.2 Hz, 1H), 7.64-7.61 (m, 2H), 5.86 (br s, 1H), 4.82 (d, J=4.4 Hz, 1H), 3.86-3.81 (m, 1H), 3.31-3.22 (m, 2H), 2.80-2.77 (m, 1H), 2.72-2.69 (m, 2H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H), 1.11 (d, J=6.0 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [0936] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.6 Hz & 7.6 Hz, 1H), 7.68-7.62 (m, 2H), 5.86 (s, 1H), 4.08-4.00 (m, 1H), 3.57-3.49 (m, 1H), 3.43-3.37 (m, 1H), 2.78-2.75 (m, 1H), 2.68-2.64 (m, 2H), 2.55-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.17-2.15 (m, 1H), 1.92-1.82 (m, 1H), 1.26 (d, J=6.4 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [0937] LCMS (Method-A): 2.205 min, 99.21%, 220 nm, MS: ES+379.3 (M+1)

    [0938] HPLC (Method-A): 7.83 min, 97.48%, 254 nm

    [0939] Chiral HPLC: 2.98 min, 49.5%, 240 nm; 3.44 min, 49.5%, 240 nm

    Example 82Synthesis of N((S)-2-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 88)

    ##STR00307##

    Step-1

    [0940] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF (1 mL) were added HATU (0.177 g, 0.468 mmol, 1.5 eq.) and DIPEA (0.15 mL, 0.936 mmol, 3.0 eq.) at RT under nitrogen atmosphere, followed by cooling at 0 C. then(S)-1-aminopropan-2-ol CAS No: 2799-17-9 (0.026 g, 0.342 mmol, 1.1 eq.) was added into the reaction at 0 C. and stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and extracted with EtOAc (30 mL3) combined organic layer were dried over Na.sub.2SO.sub.4 and evaporated under vacuum to get crude product. The crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 45-50% Ethyl Acetate in Hexane) to afford N((S)-2-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 88) (0.014 g, 0.037 mmol, Yield: 11.57%).

    [0941] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.26 (d, J=2.0 Hz, 1H), 8.82 (d, J=2.0 Hz, 1H), 8.77 (t, J=5.2 Hz, 1H), 8.00 (q, J=4 Hz, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.82 (d, J=4.4 Hz, 1H), 3.86-3.81 (m, 1H), 3.29-3.23 (m, 2H), 2.80-2.67 (br s, 2H), 2.30-2.25 (br s, 1H), 2.08 (d, J=8.8 Hz, 1H), 1.74-1.64 (m, 2H), 1.11 (d, J=6.4 Hz, 2H). Note: CF3-CH proton merged with DMSO solvent peak.

    [0942] .sup.1H NMR (MeOD, 400 MHz): ppm 9.26 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.97 (dd, J=1.6 Hz, J=7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.04 (q, J=6.4 Hz, 1H), 3.54-3.49 (m, 1H), 3.41 (t, J=6.4 Hz, 2H), 2.78-2.75 (m, 1H), 2.66 (d, J=13.6 Hz, 2H), 2.54 (d, J=17.6 Hz 1H), 2.38 (d, J=13.6 Hz, 1H) 2.16 (d, J=10 Hz, 1H), 1.90-1.85 (m, 1H), 1.30 (s, 1H), 1.26 (d, J=6.4 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR

    [0943] HPLC (Method-A): 7.84 min, 96.09%, 254 nm

    [0944] LCMS (Method-A): 2.198 min, 97.68%, 254.0 nm, MS: ES+379.27 (M+1) Chiral HPLC: 6.3 min, 47.6%, 254 nm; 6.5 min, 47.5%, 254 nm

    Example 83Synthesis of N-((2R)-1-(((8-(4-(trifluoromethyl)cyclohex-1-en-1-yl) quinolin-3-yl)methyl)amino) propan-2-yl) acetamide and N((R)-2-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 89 and Compound 90)

    ##STR00308##

    Step-1

    [0945] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF (2 mL) were added HATU (0.177 g, 0.467 mmol, 1.5 eq.) and DIPEA (0.16 mL, 0.934 mmol, 3.0 eq.) under nitrogen atmosphere, followed by addition of CAS: 100927-10-4 (R)-tert-Butyl (1-aminopropan-2-yl) carbamate (0.065 g, 0.373 mmol, 1.2 eq.) and then reaction mixture was stirred at RT for 16 h TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and extracted with DCM (30 mL3), combined organic layer were dried over Na.sub.2SO.sub.3 and evaporate under vacuum to get crude product. The crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 70% Ethyl Acetate in Hexane) to afford tert-butyl ((2R)-1-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbox amido) propan-2-yl) carbamate (A77) (0.12 g, 0.251 mmol, Yield: 62.11%).

    [0946] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): 9.24 (s, 1H), 8.78 (br s, 2H), 7.99 (t, J=4.4 Hz, 1H), 7.65-7.61 (m, 2H), 6.81 (d, J=8.4 Hz, 1H), 5.87 (br s, 1H), 3.79-3.76 (m, 1H), 3.41-3.28 (m, 2H), 2.89-2.68 (m, 4H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.35 (s, 9H), 1.07 (d, J=6.8 Hz, 3H).

    [0947] LCMS (Method-A): 2.683 min, 99.16%, 242.0 nm, MS: ES+478.4 (M+1).

    Step-2

    [0948] To a solution tert-butyl ((2R)-1-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido) propan-2-yl) carbamate (A77) (0.12 g, 0.251 mmol, 1.0 eq.) in MeOH (4 mL) was added 4M HCl in Dioxane (0.13 mL, 0.502 mmol, 2.0 eq.) and stirred the reaction mixture at RT for 4 h. TLC indicated the completion of reaction, the reaction mixture was concentrated under reduced pressure to afford crude. The obtained crude material was purified by trituration with pentane to afford N((R)-2-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 90) (0.11 g, 0.291 mmol, quantitative).

    [0949] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.34 (d, J=1.6 Hz, 1H), 9.19 (t, J=5.6 Hz, 1H), 8.96 (s, 1H), 8.1 (brs, 3H), 8.05-8.02 (m, 1H), 7.68-7.65 (m, 2H), 5.88 (br s, 1H), 3.59-3.45 (m, 3H), 2.80-2.68 (m, 3H), 2.41-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.76-1.67 (m, 1H), 1.26 (d, J=6.4 Hz, 3H).

    [0950] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.57 (s, 1H), 9.49 (s, 1H), 8.34 (d, J=8.0 Hz, 1H), 8.07 (d, J=6.4 Hz, 1H), 8.00 (d, J=8.0 Hz, 1H), 6.07 (br s, 1H), 3.75-3.72 (m, 2H), 3.68-3.65 (m, 1H), 2.75-2.62 (m, 4H), 2.49-2.46 (m, 1H), 2.27-2.24 (m, 1H), 1.98-1.93 (m, 1H), 1.43 (d, J=6.4 Hz, 3H). Note: CONH and NH.sub.2 proton Exchanged in MeOD NMR.

    [0951] LCMS (Method A): 1.882 min, 98.14%, 254.0 nm, MS: ES+378.3 (M+1)

    [0952] HPLC (Method A): 9.61 min, 95.28%, 254.0 nm

    Step-3

    [0953] To the solution of N((R)-2-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 90) (0.05 g, 0.132 mmol, 1.0 eq.) in DCM (2 mL) was added TEA (0.55 mL, 0.397 mmol, 3.0 eq.) at 0 C. under nitrogen atmosphere and stirred for 10 min, then CH.sub.3COCl (0.009 mL, 0.132 mmol, 1.0 eq.) was added and the reaction mixture continued stirred for 4 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice cold water (5 mL) and extracted with DCM (10 mL) The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by column chromatography using silica gel (230-400 mesh) (gradient elution 5% MeOH in DCM) to afford N-((2R)-1-((8-(4-(trifluoromethyl)cyclohex-1-en-1-yl) quinolin-3-yl)methyl)amino)propan-2-yl) acetamide (Compound 89) (0.016 g, 0.038 mmol, Yield: 29.79%).

    [0954] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.23 (d, J=1.6 Hz, 1H), 8.80-8.78 (m, 2H), 8.00 (t, J=5.2 Hz, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.65-7.64 (m, 2H), 5.87 (br s, 1H), 4.05-4.01 (m, 1H), 2.81-2.68 (m, 4H), 2.35-2.29 (m, 1H), 2.10-2.07 (m, 1H), 1.81 (s, 3H), 1.75-1.66 (m, 1H), 1.08 (d, J=6.4 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [0955] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.73 (d, J=2.0 Hz, 1H), 7.99-7.97 (m, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.26-4.23 (m, 1H), 3.59-3.45 (m, 3H), 2.78-2.65 (m, 3H), 2.56-2.51 (m, 1H), 2.41-2.37 (m, 1H), 2.18-2.16 (m, 1H), 1.96 (s, 3H), 1.24 (d, J=6.8 Hz, 3H).

    [0956] LCMS (Method A): 2.192 min, 99.24%, 242.0 nm, MS: ES+420.4 (M+1)

    [0957] HPLC (Method A): 7.72 min, 97.80%, 254.0 nm

    Example 84Synthesis of N-(2-(methylsulfonamido)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 91)

    ##STR00309##

    Step-1

    [0958] A stirred solution of tert-butyl (2-aminoethyl) carbamate CAS: 57260-73-8 (1.0 g, 6.24 mmol, 1.0 eq) in THF (10 mL) was prepared in 30 mL glass vial at room temperature. To this reaction solution, NEt.sub.3 (0.5 g, 4.99 mmol, 0.8 eq) was added at room temperature. Followed by addition of methyl sulphonyl chloride (1.082 g, 7.48 mmol, 1.2 eq) at 0 C. The reaction mixture was stirred at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.3 and evaporated under vacuum to afford crude tert-butyl (2-(methylsulfonamido)ethyl) carbamate (A78) (1.1 g, 4.61 mmol, Yield: 74.32%).

    [0959] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 7.04 (bs, 1H), 6.88 (bs, 1H), 3.01 (t, J=6.0 Hz, 2H), 2.95 (t, J=5.6 Hz, 2H), 2.88 (s, 3H), 1.37 (s, 9H).

    [0960] LCMS (Method-A): not supported

    Step-2

    [0961] A stirred solution of tert-butyl (2-(methylsulfonamido)ethyl) carbamate (A78) (1.1 g, 4.61 mmol, 1.0 eq) in DCM (10.0 mL) was prepared in 30 mL glass vial at room temperature. To this reaction solution, 4M HCl in dioxane (6.89 mL, 13.84 mmol, 3.0 eq) was added at 0 C. and stirred the reaction mixture at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was distilled under vacuum to afford crude N-(2-aminoethyl) methanesulfonamide hydrochloride (A79) (0.8 g, 4.58 mmol, Yield: 85.99%).

    [0962] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.16 (bs, 3H) 7.39 (t, J=6 Hz, 1H), 3.21 (q, J=6.4 Hz, J=12.8 Hz, 2H), 2.96 (s, 3H) 2.90-2.88 (m, 2H), 1.37 (bs, 1H),

    [0963] LCMS (Method-A): not supported

    Step-3

    [0964] To a stirred solution of N-(2-aminoethyl) methane sulfonamide hydrochloride (A79), Compound 15 (0.1 g, 0.312 mmol, 1.0 eq.) in DMF in 10 mL glass vial was added HATU (0.216, 0.57 mmol, 1.5 eq), DIPEA (0.12 g, 0.936 mmol, 3.0 eq.) then reaction mixture was cooled up to 0 C. The N-(2-aminoethyl) methane sulfonamide hydrochloride (A79) (0.065 g, 0.374 mmol, 1.2 equiv) was added and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and the fallout precipitate was filtered and dried under vacuum. Crude obtained was purified by trituration with pentane to afford N-(2-(methylsulfonamido)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 91) (0.053 g, 0.120 mmol, Yield: 38%)

    [0965] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.26 (d, J=2 Hz, 1H), 8.90 (t, J=5.6 Hz, 1H), 8.81 (d, J=1.6 Hz, 1H), 8.02-8.01 (m, 1H), 7.65-7.62 (m, 2H), 7.22 (t, J=5.6 Hz, 1H), 5.87 (bs, 1H), 3.45-3.43 (t, J=6.0 Hz, 2H) 3.23-3.10 (m, 2H), 2.93 (s, 3H), 2.80-2.77 (m, 1H), 2.72-2.67 (m, 2H), 2.39-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.64 (m, 1H)

    [0966] .sup.1H NMR (MeOD, 400 MHz): ppm 9.26 (d, J=2 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.97 (dd, J=1.6 Hz, J=7.6 1H), 7.69-7.63 (m, 2H), 5.87 (bs, 1H), 3.61 (t, J=6.0 Hz, 2H), 2.99 (bs, 3H), 2.81-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.34 (m, 2H), 2.18-2.15 (m, 1H), 1.93-1.85 (m, 1H).

    [0967] LCMS (Method A): 2.260 min, 97.85%, MS: ES+442.88 [M+H]

    [0968] HPLC (Method B): 6.88 min, 95.71%, 254 nm

    Example 85Synthesis of methyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (Compound 92)

    ##STR00310##

    Step-1

    [0969] A stirred solution of tert-butyl (2-aminoethyl) carbamate CAS: 57260-73-8 (0.1 g, 0.624 mmol, 1.0 eq.) in THF (10 mL) was prepared in 30 mL glass vial at room temperature. To this reaction solution, NEt.sub.3 (0.05 g, 0.499 mmol, 0.8 eq.) was added followed by addition of methyl chloroformate (0.088 g, 0.936 mmol, 1.5 eq.) at 0 C. Then the reaction mixture was stirred at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL), extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.4 and evaporated under vacuum to afford to pure tert-butyl methyl ethane-1,2-diyldicarbamate (A80) (0.11 g, 0.504 mmol, Yield: 80.88%).

    [0970] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 7.11 (br s, 1H), 6.82 (br s, 1H), 3.50 (s, 3H), 2.96 (m, 4H), 1.37 (s, 9H); LCMS (Method A): not supported

    Step-2

    [0971] A stirred solution of tert-butyl methyl ethane-1,2-diyldicarbamate (A80) (0.11 g, 0.504 mmol, 1.0 eq.) in DCM (10 mL) were prepared in 10 mL glass vial at room temperature. To this reaction solution 4M HCl in dioxane (0.88 mL, 1.50 mmol, 3.0 eq.) was added at 0 C. and stirred the reaction mixture at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was distilled under vacuum to afford pure methyl (2-aminoethyl) carbamate hydrochloride (A81) (0.096 g, 0.620 mmol, Yield: 98.40%).

    [0972] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 7.97 (br s, 3H) 7.33 (br s, 1H), 3.54 (s, 3H), 3.38 (s, 3H) 3.23 (q, J=6 Hz, 2H), 2.84 (q, J=6 Hz, 2H) Note: Proton count is more due to HCl Salt.

    [0973] LCMS (Method A): not supported

    Step-3

    [0974] To the stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF was added DIPEA (0.15 mL, 0.924 mmol, 3.0 eq.) followed by addition of methyl (2-aminoethyl) carbamate hydrochloride (A81) (0.057 g, 0.373 mmol, 1.2 equiv) and resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and the fallout precipitate filtered and dried under vacuum then crude was purified by trituration with pentane to afford methyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (Compound 92) (0.047 g, 0.111 mmol, Yield: 35.87%)

    [0975] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.86 (t, J=5.2 Hz, 1H), 8.79 (d, J=2 Hz, 1H), 8.01-7.99 (m, 1H), 7.64-7.61 (m, 2H), 7.31 (t, J=5.6 Hz, 1H), 5.87 (br s, 1H), 3.53 (s, 3H) 3.22-3.18 (m, 2H), 2.80-2.61 (m, 3H), 2.21 (br s, 1H), 2.09-2.06 (m, 1H), 1.74-1.64 (m, 1H), 1.25-1.23 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak. 1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.75 (t, J=2.4 Hz, 1H), 7.97 (dd, J=1.6 Hz, J=7.6 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.65 (s, 3H), 3.57 (t, J=6 Hz, 2H), 3.41 (t, J=6.4 Hz, 3H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.4-2.34 (m, 1H), 2.16 (d, J=10.8 Hz, 1H), 1.93-1.83 (m, 1H). Note: CONH proton Exchanged in MeOD NMR.

    [0976] LCMS (Method A): 2.315 min, 98.12%, 241.0 nm MS: ES+422.53 [M+H]

    [0977] HPLC (Method A): 8.12 min, 95.61%, 254.0 nm

    Example 86Synthesis of N-(3-(methylsulfonamido)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 93)

    ##STR00311##

    Step-1

    [0978] A stirred solution of tert-butyl (3-aminopropyl)carbamate CAS: 75178-96-0 (0.5 g, 2.869 mmol, 1.0 eq.) in THF (10 mL) was prepared at room temperature. To this reaction solution, NEt.sub.3 (0.231 g, 2.295 mmol, 0.8 eq.) was added followed by addition of methyl sulfonyl chloride (0.39 g, 3.443 mmol, 1.2 eq.) at 0 C. and reaction mixture was stirred at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.4 and evaporated under vacuum to afford tert-butyl (3-(methylsulfonamido)propyl)carbamate (A82) (0.8 g, 3.174 mmol, Quantitative).

    [0979] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 6.93 (br s, 1H), 6.82 (br s, 1H), 4.18 (br s, 3H), 2.95-2.90 (m, 4H), 2.87 (s, 3H), 2.37 (s, 1H), 1.59-1.54 (m, 3H), 1.37 (s, 9H). Note: Exchangeable proton count is more.

    [0980] LCMS (Method A): not supported

    Step-2

    [0981] A stirred solution of tert-butyl (3-(methylsulfonamido)propyl)carbamate (A82) (0.8 g, 3.173 mmol, 1.0 eq.) in DCM (8 mL) were prepared in 30 mL glass vial at room temperature. To this reaction solution 4M HCl in dioxane (2.38 mL, 9.51 mmol, 3.0 eq.) was added at 0 C. and stirred the reaction mixture at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was distilled under vacuum to afford N-(3-aminopropyl) methane sulfonamide hydrochloride (A83) (0.7 g, 3.71 mmol, Yield: 95.03%).

    [0982] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.032 (br s, 3H) 7.17 (t, J=6 Hz, 1H), 3.03 (q, J=6.4 Hz, 2H), 2.90 (s, 3H) 2.85-2.77 (m, 2H) 1.79-1.74 (m, 2H).

    [0983] LCMS (Method A): not supported

    Step-3

    [0984] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF was added DIPEA (0.15 mL, 0.933 mmol, 3.0 eq.) and HATU (0.17 g, 0.466 mmol, 1.5 eq.) at RT. Followed by addition of N-(3-aminopropyl) methanesulfonamide hydrochloride (A83) (0.070 g, 0.373 mmol, 1.2 eq.) and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and the fallout precipitate was filtered then dried under vacuum. Crude obtained was purified by trituration with pentane to afford N-(3-(methylsulfonamido)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 93) (0.091 g, 0.199 mmol, Yield: 39.75%)

    [0985] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=2.4 Hz, 1H), 8.82-8.79 (m, 2H), 8.022-7.99 (m, 1H), 7.64-7.61 (m, 2H), 7.04 (t, J=5.6 Hz, 1H), 5.86 (br s, 1H), 3.05 (q, J=6.8 Hz, 2H), 2.91 (s, 3H), 2.80-2.77 (d, 1H), 2.72-2.67 (br s, 2H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.81-1.73 (m, 2H), 1.71-1.64 (m, 1H). Note: CH.sub.2 and CF.sub.3CH proton merged in DMSO solvent peaks.

    [0986] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 7.97 (dd, J=4 Hz, J=8 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.57 (t, J=6.8 Hz, 2H), 3.21 (t, J=6.8 Hz, 2H), 2.96 (s, 3H), 2.80 (d, 1H), 2.80-2.75 (m, 1H), 2.66-2.63 (m, 1H), 2.55-2.51 (m, 1H), 2.18-2.15 (m, 1H), 1.96-1.89 (m, 2H). Note: CONH and NHSO.sub.2Me protons are exchanged.

    [0987] LCMS (Method A): 2.297 min, 100%, 210 nm MS: ES+456.48 [M+H]

    [0988] HPLC (Method A): 8.03 min, 96.21%, 254 nm

    Example 87Synthesis of methyl (3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (Compound 94)

    ##STR00312##

    Step-1

    [0989] A stirred solution of tert-butyl (3-aminopropyl)carbamate CAS: 75178-96-0 (0.5 g, 2.869 mmol, 1.0 eq.) in DCM (10 mL) was prepared at room temperature. To this reaction mixture, NEt.sub.3 (0.230 g, 2.28 mmol, 0.8 eq.) was added followed by addition of methyl chloroformate (0.4 g, 4.30 mmol, 1.5 eq.) and stirred the reaction mixture at RT for 2 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (330 mL), organic layer was dried over Na.sub.2SO.sub.4 and evaporated under vacuum to afford tert-butyl methyl propane-1,3-diyldicarbamate (A84) (0.6 g, 2.58 mmol, Yield: 90.90%).

    [0990] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 7.055 (br s, 1H), 6.76 (br s, 1H), 3.59 (s, 2H), 2.96-2.88 (m, 4H), 1.53-1.42 (m, 2H), 1.37 (s, 9H).

    [0991] LCMS (Method A): not supported

    Step-2

    [0992] A stirred solution of tert-butyl methyl propane-1,3-diyldicarbamate (A84) (0.6 g, 2.58 mmol, 1.0 eq.) in DCM (8 mL) was prepared in 30 mL glass vial at room temperature. To this reaction solution, 4M HCl in dioxane (2.38 mL, 7.79 mmol, 3.0 eq.) was added at 0 C. Then stirred the reaction mixture at RT for 4 h. TLC indicated the completion of reaction, then solvent was removed under reduced pressure to afford methyl (3-aminopropyl)carbamate hydrochloride (A85) (0.7 g, 4.151 mmol, Yield: 95.03%).

    [0993] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 7.95 (br s, 2H) 7.28 (t, J=6.0 Hz, 1H), 3.52 (s, 3H), 3.06-3.03 (m, 2H), 2.78-2.73 (m, 2H), 1.79-1.68 (m, 2H).

    [0994] LCMS (Method A): not supported

    Step-3

    [0995] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.321 mmol, 1.0 eq.) in DMF (1.0 mL) was added DIPEA (0.15 mL, 0.936 mmol, 3.0 eq.) and HATU (0.177 g, 0.468 mmol, 1.5 eq.) at 0 C. followed by addition of methyl (3-aminopropyl)carbamate hydrochloride (A85) (0.062 g, 0.374 mmol, 1.2 equiv). The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and extracted with EtOAc (330 mL) organic layer was dried over Na.sub.2SO.sub.4 and evaporated under vacuum and obtained crude was purified by trituration with pentane to afford methyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (Compound 94) (0.020 g, 0.045 mmol, Yield: 15.26%)

    [0996] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.78 (d, J=2 Hz, 2H), 8.00 (q, J=4 Hz, J=5.6 Hz, 1H), 7.63 (t, J=2 Hz, 2H), 7.17 (br s, 1H), 5.86 (br s, 1H), 3.52 (s, 3H) 3.08 (q, J=6.4, J=12.8, 3H), 2.80-2.79 (m, 1H), 2.72-2.67 (m, 2H), 2.33-2.24 (m, 2H), 2.10-2.07 (m, 1H), 1.74-1.65 (m, 3H). Note: CF.sub.3CH proton merged in DMSO solvent peaks.

    [0997] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2 Hz, 1H), 8.76 (d, J=2 Hz, 2H), 7.97 (dd, J=2 Hz, 7.6 Hz 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 3.65 (s, 3H), 3.51 (t, J=6.8, 2H), 3.25 (t, J=6.8 Hz, 2H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 1H), 2.55-2.51 (m, 1H), 2.40-2.34 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.82 (m, 3H). Note: CONH protons are exchanged in MeOD NMR.

    [0998] LCMS (Method A): 2.362 min, 97.92%, 254.0 nm MS: ES+436.53 [M+H]

    [0999] HPLC (Method A): 8.31 min, 95.34%, 254.0 nm

    Example 88Synthesis of N-(3-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 95)

    ##STR00313##

    Step-1

    [1000] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.311 mmol, 1.0 eq.) in DMF (1 mL) was added DIPEA (0.15 mL, 0.936 mmol, 3.0 eq.) and HATU (0.177 g, 0.467 mmol, 1.5 eq.) at room temperature. Followed by addition of CAS: 156-87-6 3-Amino-1-propanol (0.026 g, 0.352 mmol, 1.1 equiv). The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was diluted with cold water (30 mL) and extracted with EtOAc (330 mL), organic layer was dried over Na.sub.2SO.sub.3 and evaporated under vacuum. crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 40% Ethyl Acetate in Hexane) to afford N-(3-hydroxypropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 95) (0.087 g, 0.229 mmol, Yield: 74.35%)

    [1001] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (d, J=2 Hz, 1H), 8.79 (d, J=1.6 Hz, 2H), 8.01-7.99 (m, 1H), 7.64-7.62 (m, 2H), 5.87 (br s, 1H), 4.52 (t, J=5.2 Hz, 1H), 3.50 (q, J=6 Hz, 2H), 3.41-3.38 (m, 2H), 2.80-2.67 (m, 3H), 2.47 (br s, 1H), 2.30 (d, J=14.4 Hz, 1H), 2.08 (d, J=12 Hz, 1H), 1.76-1.67 (m, 3H).

    [1002] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2 Hz, 1H), 8.75 (d, J=2 Hz, 1H), 7.97 (dd, J=2 Hz, J=8 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.71 (t, J=5.2 Hz, 2H), 3.57 (t, J=7.2 Hz, 2H), 2.81-2.75 (m, 3H), 2.65 (d, J=12.8 Hz, 1H), 2.40-2.33 (m, 1H), 2.17 (t, J=14.4 Hz, 1H), 1.94-1.88 (m, 3H).

    [1003] Note: CONH and OH protons are exchanged in MeOD NMR.

    [1004] LCMS (Method A): 2.182 min, 99.26%, 254.0 nm, MS: ES+379.32 [M+H]

    [1005] HPLC (Method A): 7.79 min, 98.27%, 254.0 nm

    Example 89Synthesis of N-(3-hydroxy-2-methylpropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 96)

    ##STR00314##

    Step-1

    [1006] To a stirred solution of 3-amino-2-methylpropanoic acid CAS: 144-90-1 (1.0 g, 9.70 mmol, 1.0 eq.) in THF (10 mL) was added BF.sub.3.Math.OEt.sub.3 (1.3 g, 9.70 mmol, 1.0 eq.) at room temperature. The reaction mixture was heated at reflux temperature for 3 h and then BH.sub.3SMe.sub.2 (0.88 g, 11.64 mmol, 1.2 eq.) was added at RT. Followed by heating the reaction mixture at reflux again for 5 h. TLC indicated the completion of reaction, the resulting reaction mixture was filtered and the filtrate concentrated under vacuum to yield 3-amino-2-methylpropan-1-ol (A86) (1.0 g, 11.21 mmol, Yield: 38.88%).

    [1007] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.04 (br s, 5H), 4.29 (br s, 3H), 3.55 (d, 7.6 Hz, 3H), 3.40-3.38 (m, 3H), 3.36-3.27 (m, 1H), 2.88-2.74 (m, 3H), 2.72-2.70 (m, 1H), 1.16 (d, J=7.2 Hz, 3H), 0.87 (d, J=6.8 Hz, 2H). Note: Proton count is more due to unconsumed SM.

    [1008] LCMS (Method A): 0.254 min, 43.27%, 254.0 nm, MS: ES+90.01 (M+1)

    Step-2

    [1009] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.1 g, 0.321 mmol, 1.0 eq.) in DMF (1 mL) was added HATU (0.177 g, 0.468 mmol, 1.5 eq.) and DIPEA (0.15 mL, 0.936 mmol, 3.0 eq.) at RT under nitrogen atmosphere, followed by addition of (A86) (0.033 g, 0.373 mmol, 1.2 eq.) and the reaction stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was extracted with cold water (30 mL) and EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.3 and evaporated under vacuum to get crude product. The crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 25% Ethyl Acetate in Hexane) to afford N-(3-hydroxy-2-methylpropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 96) (0.008 g, 0.204 mmol, Yield: 6.55%)

    [1010] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.24 (s, 1H), 8.79 (m, 2H), 8.01 (t, J=4 Hz, 1H), 7.63 (d, J=4 Hz, 2H), 5.86 (br s, 1H), 4.55 (t, J=5.2 Hz, 1H), 3.21-3.17 (m, 1H), 2.80-2.67 (m, 2H), 2.33-2.20 (m, 1H), 2.10-2.07 (m, 1H), 1.88-1.86 (m, 2H), 1.70-1.68 (m, 2H), 0.90 (d, J=6.8 Hz, 3H). Note: CH.sub.2 and CF.sub.3CH proton merged in DMSO solvent peak.

    [1011] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2 Hz, 1H), 8.76 (d, J=2 Hz, 2H), 7.97 (d, J=6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 3.55 (d, J=5.6 Hz, 2H), 3.51-3.47 (m, 1H), 3.43-3.32 (m, 1H), 2.78-2.75 (m, 1H), 2.66-2.65 (m, 1H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.17 (d, J=13.2 Hz, 1H), 2.05-2.00 (m, 1H), 1.91-1.85 (m, 1H), 1.04 (d, J=6.8 Hz, 3H). Note: CONH and OH protons are exchanged in MeOD NMR.

    [1012] LCMS (Method A): 2.322 min, 97.12%, 254.0 nm, MS: ES+393.37 (M+1)

    [1013] HPLC (Method A): 8.22 min, 95.24%, 254.0 nm

    Example 90Synthesis of (N-(3-hydroxybutyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 97)

    ##STR00315##

    Step-1

    [1014] To a stirred solution of 3-oxobutanamide (CAS: 5977-14-0) (2.0 g, 19.78 mmol, 1.0 eq.) in dry THF (20 mL), was added LiAlH.sub.4 solution (2M in THF) (49 mL, 5.0 eq.) slowly at 60 C. under the N.sub.2 atmosphere. The reaction mixture was allowed to warm up to room temperature over the period of 1 h. After 1 h, reaction mixture was refluxed for 3 h. then allowed to cool to room temperature and continued stirring for another 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with water (20 mL) also added saturated NaHCO.sub.3 solution (40 mL) and extracted with ethyl acetate (5100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 4-aminobutan-2-ol (A87) as yellowish oil. The crude was used for next step without any further purification (0.65 g, 7.29 mmol, Yield 36.86%).

    [1015] LCMS (Method-A): 0.232 min, 91.53%, 210.0 nm, MS: ES+90.0 (M+1)

    Step-2

    [1016] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.15 g, 0.467 mmol, 1.0 eq.) in DMF (1.0 mL), was added HATU (0.26 g, 0.700 mmol, 1.5 eq.) and DIPEA (0.18 g, 1.4 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C. 4-aminobutan-2-ol (A87) (0.045 g, 0.5135 mmol, 1.1 eq.) was added at same temperature and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (3.0 mL) and extracted with ethyl acetate (10 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 Mesh) as stationary phase (40% Ethyl acetate in Hexane) to afford N-(3-hydroxybutyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 97) (0.027 g, 0.069 mmol, Yield 14.73%)

    [1017] .sup.1H NMR (DMSO, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.78 (m, 2H), 8.0 (dd, J=4.0, 5.6 Hz, 1H), 7.64-7.63 (m, 2H), 5.86 (br s, 1H), 4.50-4.10 (m, 1H), 3.74-3.70 (m, 1H), 3.42-3.33 (m, 2H), 2.72-2.67 (m, 3H), 2.33-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.59 (m, 3H), 1.47 (s, 1H), 1.11 (d, J=6.0 Hz, 3H). CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in D.sub.2O.

    [1018] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.79 (d, J=2.4 Hz, 1H), 7.98 (dd, J=2.0, 8.0 Hz, 1H), 7.71-7.65 (m, 2H), 5.87 (br s, 1H), 3.93-3.88 (m, 1H), 3.63-3.55 (m, 2H), 2.81-2.65 (m, 3H), 2.65-2.51 (m, 1H), 2.41-2.32 (m, 1H), 2.19-2.13 (m, 1H), 1.90-1.76 (m, 3H), 1.26 (d, J=6.4 Hz, 3H). Note: CONH and OH protons are exchanged in MeOD NMR.

    [1019] LCMS (Method-A): 2.115 min, 99.68%, 254.0 nm, MS: ES+393.4 (M+1)

    [1020] HPLC (Method-A): 8.09 min, 99.22%, 254 nm.

    [1021] Chiral HPLC (Method-A): Peak-1: 1.92 min, 22.84%, 242.0 nm; Peak-2: 2.06 min, 26.38%, 242.0 nm; Peak-3: 3.18 min, 25.21%, 242.0 nm; Peak-4: 3.66 min, 24.85%, 242.0 nm.

    Example 91Synthesis of N((R)-4-(methylsulfonamido) butan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 98)

    ##STR00316##

    Step-1

    [1022] To a stirred solution of N((R)-4-aminobutan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 63) (0.04 g, 0.10 mmol, 1.0 eq.) in DCM (1.0 mL) was added TEA (0.031 g, 0.30 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred at 0 C. for 10 min. After 10 min of stirring at 0 C. methanesulfonyl chloride (CAS: No: 124-63-0) (0.017 g, 0.15 mmol, 1.5 eq.) was added then the resulting reaction mixture was stirred at RT for 1 h. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (5 mL) and extracted with DCM (10 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (30-40% Ethyl acetate in Hexane) to afford N((R)-4-(methylsulfonamido) butan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 98) (0.019 g, 0.04 mmol, Yield: 39.60%).

    [1023] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.60 (d, J=8.0 Hz, 1H), 8.01 (t, J=4.8 Hz, 1H), 7.64-7.63 (m, 2H), 6.99 (t, J=5.6 Hz, 1H), 5.87 (br s, 1H), 4.17-4.14 (m, 1H), 3.02 (q, J=6.8, 13.2 Hz, 2H), 2.89 (s, 3H), 2.80-2.67 (m, 3H), 2.33-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.80-1.67 (m, 3H), 1.21 (d, J=6.4 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in MeOD.

    [1024] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.23 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.98-7.96 (m, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.33 (q, J=6.8, 13.6 Hz, 1H), 3.24-3.18 (m, 2H), 2.95 (s, 3H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.55-2.51 (m, 1H), 2.40-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.83 (m, 2H), 1.35 (d, J=6.4 Hz, 3H). Note: CONH and NHSO.sub.2Me proton exchanged in MeOD NMR.

    [1025] LCMS (Method A): 2.358 min, 100%, 254.0 nm, MS: ES+470.4 (M+1).

    [1026] HPLC (Method A): 8.13 min, 98.02%, 210 nm.

    Example 92Synthesis of N-(2-(3-methylureido)ethyl)-8-(4-(trifluoromethylcyclohex-1-en-1-yl)quinoline-3-carboxamide and (Compound 99)

    ##STR00317## ##STR00318##

    Step-1

    [1027] To a stirred solution of Compound 15 (0.3 g, 0.93 mmol, 1.0 eq.) and CAS: 57260-73-8 1-Boc-ethylenediamine (0.19 g, 1.23 mmol, 1.3 eq.), in DMF (2 mL) was added HATU (0.53 g, 1.39 mmol, 1.5 eq.), DIPEA (0.48 mL, 2.79 mmol, 3.0 eq.), under the N.sub.2 atmosphere. The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was extracted with ethyl acetate (230 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (60-120 mesh) as stationary phase (100% EtOAC) to afford tert-butyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (A88) (0.28 g, 0.640 mmol, Yield 65.11%)

    [1028] .sup.1H NMR (DMSO, 400 MHz): ppm 9.24 (s, 1H), 8.80 (d, J=13.6 Hz, 2H), 7.97 (d, J=15.2 Hz, 1H), 7.64 (s, 2H), 6.99 (s, 1H), 5.87 (s, 1H), 3.16 (d, J=4.0 Hz, 2H), 2.77-2.69 (m, 4H), 2.32-1.67 (m, 4H), 1.37 (s, 9H), 1.25 (s, 1H).

    [1029] LCMS (Method A): 2.611 min, 87.31%, 210.0 nm

    Step-2

    [1030] To a stirred solution of (A88) (0.24 g, 0.51 mmol, 1.0 eq.) in Dioxane (1 mL) was added HCl in Dioxane (1.5 mL) and the reaction mixture was stirred under the N.sub.2 atmosphere for 2 h. TLC indicated the completion of reaction, the reaction mixture was concentrated under reduced pressure to afford N-(2-aminoethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A89) (0.21, 0.57 mmol, Yield 89.44%)

    [1031] .sup.1H NMR (DMSO, 400 MHz): ppm 9.31 (d, J=2.4 Hz, 1H), 9.11 (t, J=5.2 Hz, 1H), 8.91 (d, J=2.0 Hz, 1H), 8.03-8.01 (m, 4H), 7.66 (t, J=8.0 Hz, 2H), 5.87 (s, 1H), 3.60-3.07 (m, 5H), 2.89-2.69 (m, 6H), 2.29-2.07 (m, 2H), 1.72-1.67 (m, 1H), 1.29-1.23 (m, 2H). Note: Proton count is more due to HCl salt.

    Step-3

    [1032] To a stirred solution of (A89) (0.210 g, 0.57 mmol, 1.0 eq.) in DCM (2.0 mL) was added NaHCO.sub.3 (0.048 g, 0.57 mmol, 1.0 eq.) and Triphosgene (0.050 g, 0.18 mmol, 0.32 eq.) followed by addition of CH.sub.3NH.sub.2 2M in THF (2.0 mL, 1.5 eq.). The reaction mixture was stirred at 0 C. for 1 h under N.sub.2 atmosphere. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (20 ml) extracted with ethyl acetate (230 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography (using 100-200 silica gel), desired product eluted in 50% (DCM:MeOH) to afford 1-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carbonyl) imidazolidin-2-on (0.016 g, 0.041 mmol, Yield 6.95%); and N-(2-(3-methylureido)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 99) (0.010 g, Yield: 0.025 mmol, 7.1%)

    [1033] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.97 (dd, J=8.0, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.56-3.44 (m, 2H), 2.81-2.73 (m, 6H), 2.55-2.51 (m, 2H), 2.16 (d, J=10.4 Hz, 1H), 1.89-1.85 (m, 1H). Note: CONH protons are exchanged in MeOD NMR.

    [1034] .sup.1H NMR (DMSO, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.90-8.87 (m, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.65-7.63 (m, 2H), 6.10 (t, J=5.2 Hz, 1H), 5.86 (br s, 2H), 3.28-3.21 (m, 2H), 2.80-2.67 (m, 4H), 2.55-2.54 (m, 3H), 2.32-2.24 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.67 (m, 1H). Note: CF.sub.3CH proton merged in DMSO solvent peak.

    [1035] LCMS (Method A): 2.166 min, 100%, 242.0 nm

    [1036] HPLC (Method A): 7.37 min, 100%, 210.0 nm

    [1037] Chiral HPLC-Peak1: 6.51 min, 48.12%: Peak-2: 6.64 min, 51.87%, 240 nm Undesired product:

    [1038] .sup.1H NMR (MeOD, 400 MHz): ppm 8.96 (d, J=2.0 Hz, 1H), 8.54 (d, J=2.0 Hz, 1H), 7.94 (dd, J=7.6, 2.0 Hz, 1H), 7.67-7.59 (m, 2H), 5.85 (br s, 1H), 4.17-4.13 (m, 2H), 3.62-3.58 (m, 2H), 2.79-2.50 (m, 4H), 2.40-2.33 (m, 1H), 2.17-2.14 (m, 1H), 1.93-1.82 (m, 1H). Note: CONH proton exchanged in MeOD NMR.

    [1039] .sup.1H NMR (DMSO, 400 MHz): ppm 8.91 (d, J=2.4 Hz, 1H), 8.50 (d, J=2.0 Hz, 1H), 7.99 (dd, J=7.2, 6.8 Hz, 1H), 7.83 (s, 1H), 7.63-7.58 (m, 2H), 5.85 (br s, 1H), 4.00 (t, J=7.6 Hz, 2H), 3.45 (t, J=8.0 Hz, 2H), 2.80-2.67 (m, 2H), 2.33-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H). Note: CF.sub.3CH proton merged in DMSO solvent peak.

    [1040] LCMS (Method A): 2.32 min, 96.62%, 254.0 nm, M+H=390.32

    [1041] HPLC (Method A): 8.19 min, 98.33%, 254.0 nm

    Example 93Synthesis of N-(3-(3-methylureido) propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 100)

    ##STR00319##

    Step-1

    [1042] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.2 g, 0.62 mmol, 1.0 eq.) in DMF (2.0 mL), was added HATU (0.350 g, 0.93 mmol, 1.5 eq.) and DIPEA (0.31 mL, 1.86 mmol, 3.0 eq.) at 0 C. After 15 min of stirring at 0 C., tert-butyl (3-aminopropyl)carbamate (CAS: No: 75178-96-0) (0.140 g, 0.89 mmol, 1.3 eq.) was added and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction, the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica gel (60-120 Mesh) as a stationary phase (100% EtOAC) to afford tert-butyl (3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (A90) (0.120 g, 0.25 mmol, Yield: 40.37%).

    [1043] .sup.1H NMR (DMSO, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.79-8.76 (m, 2H), 8.01-7.99 (m, 1H), 7.65-7.61 (m, 2H), 6.87 (t, J=5.6 Hz, 1H), 5.86 (br s, 1H), 3.02-3.00 (m, 2H), 2.69-2.60 (m, 5H), 2.33-2.32 (m, 1H), 2.10-2.09 (m, 1H), 1.71-1.66 (m, 4H), 1.37-1.33 (m, 9H).

    [1044] LCMS (Method A): 2.72 min, 94.87%, 245.0 nm

    Step-2

    [1045] To a stirred solution of tert-butyl (3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (A90) (0.120 g, 0.25 mmol, 1.0 eq.) in 1,4-dioxane (2.0 mL), was added 4M HCl in Dioxane (2.0 mL) at 0 C. under N.sub.2 atmosphere. The resulting reaction mixture was stirred at room temperature for 4 h. TLC indicated the completion of reaction, the resulting mixture was concentrated under reduced pressure to afford N-(3-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A91) (0.060 g, 0.15 mmol, Yield 63.26%)

    [1046] .sup.1H NMR (DMSO, 400 MHz): ppm 9.29 (d, J=2.4 Hz, 1H), 9.07 (t, J=5.6 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.03-8.00 (m, 1H), 7.89 (br s, 3H), 7.67-7.63 (m, 2H), 3.44-3.39 (m, 2H), 2.92-2.67 (m, 2H), 2.57-2.50 (m, 3H), 2.42-2.33 (m, 1H), 2.32-2.28 (m, 1H), 1.90-1.69 (m, 2H), 1.67-1.23 (m, 1H). Note: Proton count is more due to HCl Salt.

    Step 3

    [1047] To a stirred solution of N-(3-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A91) (0.250 g, 0.66 mmol, 1.0 eq.) in DCM (2.5 mL), was added NaHCO.sub.3 (0.250 g, 0.66 mmol, 1.0 eq.) and Triphosgene (0.062 g, 0.21 mmol, 0.32 eq.) in DCM (2 mL), followed by addition of CH.sub.3NH.sub.2 2M in THF (2.0 mL, 1.5 eq.) and the reaction mixture was stirred at 0 C. for 1 h. TLC indicated the completion of reaction; the resulting reaction mixture was extracted with ethyl acetate (230 mL). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by reverse phase HPLC to afford N-(3-(3-methylureido) propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 100) (0.106 g, 0.243 mmol, Yield 51%)

    [1048] .sup.1H NMR (MeOD, 400 MHz): ppm 9.26 (d, J=2.0 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 7.98 (dd, J=1.6, 7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.52 (t, J=6.8 Hz, 2H), 3.27 (t, J=6.8 Hz, 2H), 2.78-2.76 (m, 1H), 2.72 (s, 3H), 2.69-2.65 (m, 2H), 2.52-2.50 (m, 1H), 2.40-2.37 (m, 1H), 2.17-2.15 (m, 1H), 1.89-1.81 (m, 1H). Note: CONH protons exchanged in MeOD NMR.

    [1049] .sup.1H NMR (DMSO, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.84-8.78 (m, 2H), 8.02-7.99 (m, 1H), 7.64-7.63 (m, 2H), 5.96 (t, J=5.6 Hz, 1H), 5.87 (br s, 1H), 5.80 (d, J=4.4 Hz, 1H), 3.09-3.07 (d, J=6.4 Hz, 2H), 2.80-2.67 (m, 3H), 2.51-2.59 (m, 6H), 2.33-2.29 (m, 1H), 2.12-2.16 (m, 1H), 1.67-1.64 (m, 3H).

    [1050] HPLC (Method A)-7.53 min, 95.33%, 215.0 nm

    [1051] LCMS (Method A)-2.17 min, 100%, 242.0 nm

    Example 94Synthesis of N-(2-((N-methylsulfamoyl)amino)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 101)

    ##STR00320##

    Step 1

    [1052] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.2 g, 0.623 mmol, 1.0 eq.) in DMF (5.0 mL) was added DIPEA (0.31 mL, 1.869 mmol, 3.0 eq.) and HATU (0.16 g, 0.934 mmol, 1.5 eq.) at 0 C. After 15 min of stirring at 0 C., tert-butyl (2-aminoethyl) carbamate (CAS: No: 57260-73-8) (0.119 g, 0.747 mmol, 1.2 eq.) was added and resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (80% EtOAc in Hexane) to afford tert-butyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (A92) (0.190 g, 0.410 mmol, Yield: 65%).

    [1053] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.81 (t, J=5.6 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.0-7.95 (m, 2H), 7.65-7.63 (m, 2H), 7.00-6.97 (t, J=5.6 Hz, 1H), 5.87 (s, 1H), 3.37-3.23 (m, 2H), 2.77-249 (m, 3H), 2.47-1.67 (m, 2H), 2.33-2.28 (m, 1H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.37 (s, 9H).

    [1054] LCMS (Method A): 2.639 min, 97.79%, 254.0 nm, MS: ES+464.53 (M+H)

    Step-2

    [1055] To a solution of tert-butyl (2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)ethyl) carbamate (A92) (0.190 g, 0.410 mmol 1.0 eq.) in DCM (2.0 mL), was added 4M HCl in 1,4-dioxane (1.9 mL, 10 V) at 0 C. under N.sub.2 atmosphere. The resulting reaction mixture was stirred at room temperature for 2 h. TLC indicated the completion of reaction; the reaction mixture was concentrated under reduced pressure to afford crude which was triturated with ether (5 mL2) to yield N-(2-aminoethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A93) (0.180 g, 0.495 mmol, Yield: quantitative).

    [1056] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.31 (d, J=2.0 Hz, 1H), 9.11 (t, J=5.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H), 8.03-8.01 (m, 3H), 7.67-7.64 (m, 2H), 5.87 (br s, 1H), 3.62-3.57 (m, 2H), 3.06-3.03 (m, 2H), 2.80-2.67 (m, 4H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.75-1.66 (m, 1H).

    [1057] LCMS (Method A): 1.853 min, 97.39%, 254.0 nm, MS: ES+364 (M+1)

    Step-3

    [1058] To a solution N-(2-aminoethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (A93) (0.140 g, 0.385 mmol, 1.0 eq.) in DCM (3.0 mL), was added TEA (0.13 mL, 0.77 mmol, 2.0 eq.) at 0 C. The reaction mixture was stirred at 0 C. for 10 min. followed by addition of methyl sulfamoyl chloride (0.490 g, 3.85 mmol, 10 eq.) and the resulting reaction mixture was stirred at 0 C. for 30 min and room temperature for 14.5 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (70% EtOAc in Hexane) to afford N-(2-((N-methylsulfamoyl)amino)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 101) (0.038 g, 0.083 mmol, Yield: 21.61%).

    [1059] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.86 (t, J=5.6 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 8.0 (dd, J=4.0, 6.0 Hz, 1H), 7.65-7.63 (m, 2H), 7.06 (t, J=5.6 Hz, 1H), 6.75 (m, 1H), 5.87 (br s, 1H), 3.47-3.43 (m, 2H), 3.06-3.01 (m, 2H), 2.80.2.62 (s, 3H), 2.45 (d, J=3.6 Hz, 3H), 2.32-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.67 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in MeOD.

    [1060] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 7.96 (dd, J=2.0, 7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.86 (br s, 1H), 3.62 (t, J=6.4 Hz, 2H), 3.26 (t, J=6.0 Hz, 2H), 2.78-2.68 (m, 2H), 2.63 (s, 3H), 2.55-2.51 (m, 1H), 2.40-2.33 (m, 1H), 2.17-2.15 (m, 1H), 1.92-1.83 (m, 1H). Note: CONH protons are exchanged in MeOD NMR.

    [1061] LCMS (Method A): 2.385 min, 100%, 254.0 nm, MS: ES+457.5 (M+1)

    [1062] HPLC (Method A): 7.92 min, 98.67%, 254.0 nm.

    [1063] Chiral HPLC: Peak-1: 4.06 min, 50.83.70%, 242.0 nm; Peak-2: 4.71 min, 49.16%, 242.0 nm.

    Example 95Synthesis of N-(3-((N-methylsulfamoyl)amino)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 102)

    ##STR00321##

    Step-1

    [1064] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (0.2 g, 0.623 mmol, 1.0 eq.) in DMF (2.0 mL) were added DIPEA (0.3 mL, 1.86 mmol, 3.0 eq.) and HATU (0.350 g, 0.934 mmol, 1.5 eq.) at 0 C. followed by addition of tert-butyl (3-aminopropyl)carbamate (CAS: 75178-96-0) (0.129 g, 0.747 mmol, 1.2 eq.) and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (80% EtOAc in Hexane) to afford tert-butyl (3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (A94) (0.185 g, 0.387 mmol, Yield: 61.21%).

    [1065] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.23 (d, J=2.4 Hz, 1H), 8.78-8.76 (m, 2H), 8.02-7.98 (m, 1H), 7.65-7.61 (m, 2H), 6.86 (t, J=5.6 Hz, 1H), 5.86 (br s, 1H), 3.04-2.99 (m, 2H), 2.80-2.67 (m, 3H), 2.33-2.32 (m, 1H), 2.10-2.06 (m, 1H), 1.73-1.65 (m, 3H), 1.37 (s, 9H).

    [1066] Note: CH.sub.2 proton merged with DMSO moisture peak which is clearly observed in D.sub.2O and CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in D.sub.2O.

    [1067] LCMS (Method A): 2.725 min, 84.36%, 210.0 nm, MS: ES+478.54 (M+1)

    Step-2

    [1068] To a solution of tert-butyl (3-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)carbamate (A94) (0.185 g, 0.387 mmol 1.0 eq.) in DCM (1.8 mL) was added 4 M HCl in 1,4-dioxane (1.8 mL, 10 v) at 0 C. under N.sub.2 atmosphere. The resulting reaction mixture was stirred at room temperature for 2 h. TLC indicated the completion of reaction; the reaction mixture was concentrated under reduced pressure to obtain the residue. The crude material was triturated with ether (5.0 mL2) to afford N-(3-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide hydrochloride (A95) (0.16 g, 0.424 mmol, Yield: Quantitative).

    [1069] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.4 Hz, 1H), 9.09 (t, J=5.6 Hz, 1H), 8.88 (d, J=2.4 Hz, 1H), 8.04-8.00 (m, 1H), 7.92 (br s, 3H), 7.68-7.64 (m, 2H), 5.87 (br s, 1H), 3.44-3.39 (q, J=7.2, 13.0 Hz, 2H), 2.92-2.87 (m, 2H), 2.79-2.67 (m, 2H) 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.91-1.83 (m, 2H), 1.74-1.68 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in D.sub.2O.

    [1070] LCMS (Method A): 1.86 min, 97.95%, 210.0 nm, MS: ES+378 (M+1)

    Step-3

    [1071] To a solution N-(3-aminopropyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide hydrochloride (A95) (0.120 g, 0.318 mmol, 1.0 eq.) in DCM (3.0 mL), was added TEA (0.01 mL, 0.636 mmol, 2.0 eq.) at 0 C. and stirred for 10 min. Followed by addition of methylsulfamoyl chloride (0.41 g, 3.1 mmol, 10 eq.) and reaction mixture was stirred at RT for 14.5 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (70% EtOAc in Hexane) to afford N-(3-((N-methylsulfamoyl)amino)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 102) (0.016 g, 0.034 mmol, Yield: 10.70%).

    [1072] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.98-7.96 (d, J=7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 3.57 (t, J=6.8 Hz, 2H), 3.09 (t, J=6.8 Hz, 2H), 2.79-2.68 (m, 3H), 2.63 (s, 3H), 2.55-2.51 (m, 1H), 2.41-2.37 (m, 1H), 2.16-2.15 (m, 1H), 1.96-1.85 (m, 3H). Note: Exchangeable proton are exchanged in MeOD NMR.

    [1073] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.81-8.78 (m, 2H), 8.02-7.99 (m, 1H), 7.64-7.61 (m, 2H), 6.88 (t, J=6.0 Hz, 1H), 6.71-6.69 (m, 1H), 5.87 (br s, 1H), 2.92-2.87 (m, 2H), 2.80-2.77 (m, 1H), 2.72-2.67 (m, 1H), 2.46-2.44 (m, 4H), 2.33-2.52 (m, 1H), 2.10-2.06 (m, 1H), 1.81-1.75 (m, 2H), 1.71-1.65 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak and CH.sub.2 proton merged with DMSO moisture peak which is clearly observed in MeOD spectrum.

    [1074] LCMS (Method A): 2.34 min, 100%, 254.0 nm, MS: ES+471.5 (M+1)

    [1075] HPLC (Method A): 8.00 min, 100%, 254.0 nm

    [1076] CHIRAL HPLC (Method A): Peak-1: 3.07 min, 49.43%, 240.0 nm; Peak-2: 3.61 min, 50.0%, 240.0 nm.

    Example 96Chiral separation of N((S)-1-hydroxy-3-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 103 and Compound 104)

    ##STR00322##

    Step-2: Chiral Separation of Compound 103 and Compound 104: N((S)-1-hydroxy-3-methoxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide

    [1077] COLUMN ID: YMC CELLULOSE, 25019 mm 5 um

    [1078] MOBILE PHASE A: 0.1% M.Math.NH3 IN n-HEPTANE

    [1079] MOBILE PHASE B: 0.1% M.Math.NH3 IN IPA-ACN (50:50)

    [1080] FLOW RATE (ML/MIN): 32

    [1081] INSTRUMENT ID: PHP-04 AGILENT 1260 INFINITY-II SERIES WITH UV DETECTOR

    [1082] METHOD: TIME: FLOW: % A: % B (0.00:32:87:13), (39:32:87:13)

    [1083] Input Quantity: 0.05 g.

    [1084] Output Quantity: Compound 103=0.0165 g (% Yield=32%), Compound 104, =0.017 g (% Yield=34%)

    Compound 103:

    [1085] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.82 (d, J=2.04 Hz, 1H), 8.83 (d, J=8.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.84 (t, J=11.6 Hz, 1H), 4.23-4.18 (m, 1H), 3.57-3.50 (m, 1H), 3.76-2.65 (m, 4H), 2.51 (s, 1H), 2.10-2.07 (m, 1H), 2.46-2.07 (m, 5H), 1.74-1.67 (m, 1H). 1.26-1.23 (m, 1H).

    [1086] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=1.6 Hz, 1H), 8.79 (d, J=2.04 Hz, 1H), 7.97 (dd, J=7.6 Hz, J=7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (s, 1H), 4.84 (t, J=11.6 Hz, 1H), 4.40-4.37 (m, 1H), 3.67-3.63 (m, 2H), 3.42-3.32 (m, 2H), 3.21 (s, 1H), 2.78-2.35 (m, 6H), 1.91-1.85 (m, 1H), 1.30 (s, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1087] LCMS (Method A): 2.192 min, 100%, 254.0 nm, MS: ES+409 (M+1)

    [1088] HPLC (Method A): 7.82 min, 99.74%, 254.0 nm

    [1089] Chiral HPLC: 5.44 min, %, 240.0 nm

    Compound 104:

    [1090] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.4 Hz, 1H), 8.82 (dd, J=8.0 Hz, 1H), 8.0-7.99 (m, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.84 (t, J=6.0 Hz, 1H), 4.21-4.18 (m, 1H), 3.55-3.28 (m, 4H), 2.51 (s, 3H), 2.10-2.07 (m, 1H), 2.51-2.01 (m, 3H), 1.71-1.67 (m, 1H).

    [1091] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.27 (d, J=2.0 Hz, 1H), 7.97 (dd, J=7.6 Hz, J=7.6 Hz, 1H), 7.69-7.63 (m, 2H), 5.87 (br s, 1H), 4.40-4.37 (t, J=6.0 Hz, 1H), 3.55-3.28 (m, 4H), 2.51 (s, 3H), 2.76-2.51 (m, 4H), 2.41-2.37 (m, 1H), 2.18-2.15 (m, 1H), 1.93-1.85 (m, 1H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1092] LCMS (Method A): 2.194 min, 100%, 254.0 nm, MS: ES+409 (M+1)

    [1093] HPLC (Method A): 7.82 min, 100%, 210.0 nm

    [1094] Chiral HPLC: 6.19 min, 96%, 240.0 nm

    Example 97Synthesis of (2R)-2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl dihydrogen phosphate (Compound 105)

    ##STR00323##

    Step-1

    [1095] To a stirred solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (1.0 g, 3.113 mmol, 1.0 eq.) in DMF (10 mL), was added CAS: 35320-23-1 D-Alaninol (0.234 g, 3.113 mmol, 1.0 eq.), DIPEA (1.2 g, 9.339 mmol, 3.0 eq.) and HATU (1.781 g, 4.687 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (300 mL) and extracted by EtOAc (2250 mL). The organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (30% EtOAc in Hexane) to afford N((R)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 7) (1.04 g, 2.74 mmol, 79%)

    [1096] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 8.49 (d, J=8.0 Hz, 1H), 8.01-7.95 (m, 1H), 7.64-7.61 (m, 2H), 5.87 (br s, 1H), 4.81 (t, J=8.4 Hz, 1H), 4.10-4.05 (m, 1H), 3.54-3.48 (m, 1H), 3.42-3.28 (m, 1H) 2.89 (br s, 1H), 2.80-2.73 (m, 3H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.73-1.67 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).

    [1097] LCMS (Method A): 2.219 min, 98.50%, 242.0 nm, MS: ES+379.17 (M+1)

    Step-2

    [1098] To a solution of N((R)-1-hydroxypropan-2-yl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 7) (0.9 g, 2.380 mmol, 1.0 eq.) and 1H-tetrazole (0.493 g, 7.135 mmol, 3.0 eq.) in DCM (25 mL) was added Di-tert-butyl N,N-Diisopropylphosphoramidite CAS: 137348-86-8 (1.95 g, 7.135 mmol, 3.0 eq.) and DMAP (0.145 g, 1.19 mmol, 0.5 eq.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 16 h. Then, H.sub.2O.sub.2 aq. (0.750 g, 7.135 mmol, 3.0 eq.) was added and reaction was stirred at room temperature for 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (70 mL) and extracted with ETOAc (275 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by column chromatography using silica gel (60-100 mesh) as stationary phase (40% EtOAc in Hexane) to afford di-tert-butyl ((2R)-2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)phosphate (A96) (0.230 g, 0.403 mmol, 16.10%)

    [1099] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 8.72 ( ) (d, J=7.6 Hz, 1H), 8.01-7.99 (m, 1H), 7.66-7.62 (m, 2H), 5.87 (br s, 1H), 4.32-4.28 (m, 1H), 3.96-3.88 (m, 2H), 2.80-2.67 (m, 3H), 2.33-2.28 (m, 2H), 2.10-2.07 (m, 1H), 1.71-1.67 (m, 1H), 1.40 (s, 9H), 1.37 (s, 9H) Note: CF.sub.3CH proton merged with DMSO solvent peak.

    [1100] LCMS (Method A): 2.785 min, 100%, 210.0 nm, MS: ES+571.3 (M+1)

    Step-3

    [1101] To a solution of di-tert-butyl ((2R)-2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl)phosphate (A96) (0.170 g, 0.298 mmol, 1.0 eq.) in DCM (5 mL) was added 4M HCl in Dioxane (1.5 mL) and stirred reaction mixture for 1 h. TLC indicated the completion of reaction; the reaction mixture was concentrated under reduced pressure to afford (2R)-2-(8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamido)propyl dihydrogen phosphate (Compound 105) (0.105 g, 0.215 mmol, Yield: 76.92%)

    [1102] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.86 (d, J=1.6 Hz, 1H), 8.79 (d, J=7.6 Hz, 1H), 8.03-8.01 (m, 1H), 7.67-7.66 (m, 2H), 5.88 (br s, 1H), 4.29-4.23 (m, 1H), 3.96-3.84 (m, 2H), 2.80-2.67 (m, 4H), 2.33-2.25 (m, 1H), 2.10-2.07 (m, 1H), 1.74-1.68 (m, 1H), 1.23 (d, J=6.4 Hz, 3H). Note: Phosphate OH protons are exchanging in DMSO solvent.

    [1103] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.61 (d, J=1.6 Hz, 1H), 9.45 (d, J=2.0 Hz, 1H), 8.35 (d, J=8.0 Hz, 1H), 8.12-8.10 (m, 1H), 8.05-8.01 (m, 1H), 6.08 (br s, 1H), 4.50-4.46 (m, 1H), 4.21-4.08 (m, 2H), 2.75-2.58 (m, 3H), 2.50-2.43 (m, 2H), 2.28-2.15 (m, 1H), 2.01-1.91 (m, 1H), 1.42 (d, J=6.4 Hz, 3H). Note: Phosphate OH and CONH protons are exchanged in MeOD solvent.

    [1104] HPLC (Method A): 3.649 min, 98.12%, 210.0 nm.

    [1105] LCMS (Method A): 1.822 min, 100%, 254.0 nm, MS: ES+459.1 (M+1)

    Example 98Chiral separation of N-((1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 106 and Compound 107)

    ##STR00324##

    Step-1

    [1106] To a solution of 8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (Compound 15) (7.0 g, 21.786 mmol, 1.0 eq.), HATU (12.42 g, 32.710 mmol, 1.5 eq.) and DIPEA (11.25 mL, 65.420 mmol, 3.0 eq.) in DMF (70 mL) at 0 C. under nitrogen atmosphere stirred for 20 min, was added CAS: 1196153-72-6 (1H-Pyrazol-3-yl) methanamine hydrochloride (2.91 g, 21.786 mmol, 1.0 eq.) under Nitrogen. The resulting mixture was stirred for 3 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (100 mL) and extracted with EtOAc (3100 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (90% Ethyl acetate in hexane as gradient) to afford N-((1H-pyrazol-5-yl)methyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 47) (3.0 g, 7.492 mmol, Yield: 34%).

    [1107] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.47 (s, 1H), 9.27-9.26 (m, 2H), 8.83 (d, J=2.4 Hz, 1H), 8.01-7.97 (m, 1H), 7.65-7.61 (m, 3H), 6.23 (s, 1H), 5.88 (br s, 1H), 4.54 (d, J=5.2 Hz, 2H), 3.40-3.28 (m, 1H), 2.80-2.67 (m, 3H), 2.51-1.88 (m, 2H), 1.74-1.64 (m, 1H).

    [1108] LCMS (Method A): 2.10 min, 98.39%, 254.0 nm, MS: ES+401 (M+1)

    [1109] HPLC (Method A): 7.44 min, 97.35%, 254.0 nm

    [1110] Chiral HPLC: 4.57 min, 47.798%, 5.11 min, 48.72%, 245.0 nm

    Step-2

    [1111] Chiral Separation of Compound 106 and Compound 107:

    [1112] COLUMN ID: IG-REPACK, 25030 mm 5 um

    [1113] MOBILE PHASE A: 0.1% M NH.sub.3 IN HEPTANE

    [1114] MOBILE PHASE B: MDC: IPA: CAN (80:10:10)

    [1115] FLOW RATE (ML/MIN): 40

    [1116] INSTRUMENT ID: WELCH PREP SAIL 1000 UV Detector

    [1117] METHOD: TIME: FLOW: % A: % B (INITIAL: 40:50:50), (45:40:50:40)

    [1118] Input Quantity: 3.0 g.

    [1119] Output Quantity: Compound 106=1.019 g (% Yield=33.97%) and Compound 107=1.081 g (% Yield=36%)

    Compound 106:

    [1120] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 12.47 (s, 1H), 9.28-9.27 (m, 2H), 8.84 (d, J=2.0 Hz, 1H), 8.01-7.97 (m, 1H), 7.65-7.61 (m, 3H), 6.23 (br s, 1H), 5.87 (br s, 1H), 4.54 (br s, 2H), 2.81-2.51 (m, 3H), 2.28-2.07 (m, 3H), 1.74-1.64 (m, 1H).

    [1121] LCMS (Method A): 2.219 min, 95.91%, 254.0 nm, MS: ES+401.3 (M+1)

    [1122] HPLC (Method A): 7.38 min, 95.02%, 254.0 nm

    [1123] Chiral HPLC (Method A): 4.74 min, 98.23%, 245 nm

    Compound 107:

    [1124] .sup.1H NMR (DMSO-d6, 400 MHz): ppm, 12.47 (s, 1H), 9.28-9.25 (m, 2H), 8.84 (d, J=2.0 Hz, 1H), 8.01-7.98 (m, 1H), 7.65-7.61 (m, 3H), 6.23 (s, 1H), 5.87 (br s, 1H), 4.54 (d, J=5.2 Hz, 2H), 2.81-2.67 (m, 3H), 2.33-2.07 (m, 2H), 1.73-1.67 (m, 1H). Note: CF.sub.3CH proton merged in DMSO solvent peak.

    [1125] LCMS (Method A): 2.218 min, 97.03%, 254.0 nm, MS: ES+401.27 (M+1)

    [1126] HPLC (Method A): 7.39 min, 97.45%, 254.0 nm

    [1127] Chiral HPLC (Method A): 5.35 min, 96.01%, 245 nm

    Example 99Synthesis of 6-methoxy-N((S)-1-(pyridin-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 108)

    ##STR00325##

    Step-1

    [1128] To a stirred solution of 5-Methoxy-2-aminobenzoic Acid (CAS: 6705-03-9) (1.0 g, 5.98 mmol, 1.0 eq.) in DMF (15.0 mL) was added NBS (1.28 g, 7.17 mmol, 1.2 eq.) at 0 C. The mixture was stirred at room temperature for 1 h. TLC indicated the completion of reaction; the reaction mixture was diluted with ice cold water (50.0 mL) and extracted by EtOAc (250 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude which was purified by flash column chromatography on silica gel (100-200 mesh) (desired product eluted in 20% EtOAc in Hexane) to afford 2-amino-3-bromo-5-methoxybenzoic acid (A97) (0.708 g, 2.87 mmol, Yield: 47.99%).

    [1129] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 7.38 (d, J=2.8 Hz, 1H), 7.33 (d, J=3.2 Hz, 1H), 3.69 (s, 3H).

    [1130] Note: NH.sub.2 and COOH protons might be exchange in DMSO solvent.

    [1131] LCMS (Method A): 1.812 min, 100%, 254.0 nm, MS: ES+248.1 (M+2)

    Step-2

    [1132] To a stirred solution of 2-amino-3-bromo-5-methoxybenzoic acid (A97) (0.7 g, 2.84 mmol, 1.0 eq.) in THF (5 mL) was added BH.sub.3. THF (10.0 mL, 9.95 mmol, 3.5 eq., 1M in THF) at 0 C. The reaction mixture was stirred at 70 C. for 12 h. TLC indicated the completion of reaction; the reaction mixture was quenched with MeOH (50 mL) to obtain precipitate. The precipitate was filtered and filtrate was concentrated under reduced pressure to obtain crude material. The crude material was stirred with water (30 mL) and filtered. The residue was dissolved in DCM and dried over anhy. Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford (2-bromo-6-(hydroxymethyl)-4-methoxyphenol (A98) (0.613 g, 2.64 mmol, 92.85% Yield) as a pale brown solid.

    [1133] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 6.93 (d, J=2.8 Hz, 1H), 6.82 (d, J=2.8 Hz, 1H), 5.27 (t, J=5.6 Hz, 1H), 4.61 (br s, 2H), 4.40 (d, J=5.6 Hz, 2H), 3.66 (s, 3H).

    [1134] LCMS (Method A): 1.505 min, 100%, 254.0 nm, MS: ES+234.0 (M+2)

    Step-3

    [1135] To a stirred solution of (2-amino-3-bromo-5-methoxyphenyl) methanol (A98) (0.6 g, 2.58 mmol, 1 eq.) in DCM (10.0 mL) was added MnO.sub.2 (2.28 g, 25.86 mmol, 10.0 eq.). The mixture was stirred at room temperature for 12 h. TLC indicated the completion of reaction; the reaction mixture was filtered on celite bed and filtrate was concentrated under reduced pressure to afford 2-amino-3-bromo-5-methoxybenzaldehyde (A99) (0.51 g, 2.21 mmol, Yield: 85.94%).

    [1136] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.83 (s, 1H), 7.45 (d, J=2.8 Hz, 1H), 7.33 (d, J=2.8 Hz, 1H), 6.71 (br s, 2H), 3.74 (s, 3H); LCMS (Method A): 2.037 min, 98.79%, 254.0 nm, MS: ES+232 (M+2)

    Step-4

    [1137] A stirred solution of 2-amino-3-bromo-5-methoxybenzaldehyde (A99) (0.50 g, 2.17 mmol, 1.0 eq.) in EtOH (10.0 mL) was prepared. To this solution were added L-proline (0.124 g, 1.08 mmol, 0.5 eq.) and CAS: 922-67-8 (0.237 g, 2.82 mmol, 1.3 eq.) at RT and resulting reaction mixture was stirred at 70 C. for 16 h. TLC indicated the completion of reaction; the reaction mixture was concentrated under reduced pressure to obtain crude material. The crude material was purified by column chromatography (desired product eluted in 30% Ethyl acetate in hexane) to afford methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (0.253 g, 0.854 mmol, 39.35% Yield).

    [1138] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.21 (d, J=1.6 Hz, 1H), 8.93 (s, 1H), 7.97 (d, J=2.4 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H).

    [1139] LCMS (Method A): 2.215 min, 100%, 254.0 nm, MS: ES+298.0 (M+2)

    Step-5

    [1140] To a stirred solution of methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (1.00 g, 3.37 mmol, 1.0 eq.) in 1,4-dioxane:water (4:1, 50 mL) were added 4, 4, 5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1, 3,2-dioxaborolane (A2) (1.39 g, 5.067 mmol, 1.5 eq.), and Cs.sub.2CO.sub.3 (3.29 g, 10.134 mmol, 3.0 eq.) at room temperature. The reaction mixture was stirred and degassed with N.sub.2 gas for 15 min. After then PdCl.sub.2(dppf).Math.DCM (0.413 g, 0.506 mmol, 0.15 eq.) was added at room temperature under N.sub.2 atmosphere. The resulting mixture was stirred at 100 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was filtered through celite bed and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (32% EtOAc in Hexane) to afford methyl (A101)methyl 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylate (1.25 g, 3.42 mmol, Yield: 45.01%).

    [1141] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.12 (d, J=2.4 Hz, 1H), 8.87 (d, J=2.4 Hz, 1H), 7.55 (d, J=2.8 Hz, 1H), 7.29 (d, J=2.8 Hz, 1H), 5.88 (br s, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.81-2.74 (m, 1H), 2.67-2.63 (m, 2H), 2.50-2.43 (m, 1H), 2.29-2.22 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.62 (m, 1H).

    [1142] LCMS (Method A): 2.923 min, 93.95%, 254.0 nm, MS: ES+366.3 (M+1).

    Step-6

    [1143] A solution of methyl 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylate (A101) (1.25 g, 3.42 mmol, 1.0 eq.) and LiOH.Math.H.sub.2O (0.410 g, 10.27 mmol, 3.0 eq.) in MeOH:H.sub.2O (20 mL, 7:3) was prepared at 0 C. under nitrogen atmosphere. The resulting mixture was stirred at 100 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was concentrated under reduced pressure and obtained residue was poured onto 10% citric acid solution, then filtered off to afford the desired product 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (1.03 g, 2.93 mmol, Yield: 85.72%).

    [1144] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.12 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 7.50 (d, J=2.8 Hz, 1H), 7.25 (d, J=2.8 Hz, 1H), 5.87 (br s, 1H), 3.90 (s, 3H), 2.78-2.75 (m, 1H), 2.68-2.65 (m, 2H), 2.50-2.43 (m, 1H), 2.29-2.22 (m, 1H), 2.07-2.05 (m, 1H), 1.70-1.64 (m, 1H). Note: Acid (COOH) proton exchanged with deuterium

    [1145] LCMS (Method A): 2.512 min, 94.61%, 254.0 nm, MS: ES+352.3 (M+1)

    Step 7

    [1146] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.900 g, 2.560 mmol, 1.0 eq.) in DMF (10 mL), was added DIPEA (0.998 g, 7.680 mmol, 3.0 eq.) and HATU (1.45 g, 3.840 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere for 10 minutes. After 10 min of stirring at 0 C. (S)-1-(237yridine-2-yl)ethan-1-amine (CAS: 27854-90-6) (0.312 mg, 2.56 mmol, 1.0 eq.) was added and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (100 mL) and extracted with ethyl acetate (125 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (32% EtOAc in Hexane) to afford 6-methoxy-N((S)-1-(237yridine-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 108) (0.527 g, 1.15 mmol, 45.24%).

    [1147] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.17-9.12 (m, 2H), 8.75 (d, J=2.0 Hz, 1H), 8.55 (d, J=4.0 Hz, 1H), 7.78 (d, J=6.8 Hz, 1H), 7.48-7.46 (d, J=8.0 Hz, 1H), 7.40 (d, J=2.4 Hz, 1H), 7.29-7.25 (m, 2H), 5.89 (br s, 1H), 5.29-5.23 (m, 1H), 3.91 (s, 3H), 2.89-2.67 (m, 3H), 2.50-2.44 (m, 1H), 2.32-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.66 (m, 1H), 1.64 (d, J=6.8 Hz, 3H).

    [1148] HPLC (Method A): 9.24 min, 95.12%, 210.0 nm.

    [1149] LCMS (Method A): 9.915 min, 96.52%, 254.0 nm, MS: ES+456.5 (M+1).

    Example 100Synthesis of 6-methoxy-N((R)-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 109)

    ##STR00326##

    Step-1

    [1150] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.75 g, 2.13 mmol, 1.0 eq.) in DMF (10 mL) was added DIPEA (0.82 g, 6.40 mmol, 3.0 eq.) and HATU (1.21 g, 3.20 mmol, 1.5 eq.) at 0 C. Followed by addition of (R)-1-(oxazol-2-yl)ethan-1-amine (A61) (0.238 g, 2.13 mmol, 1.0 eq.) and the resulting reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (100 mL) and extracted with ethyl acetate (125 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (40% EtOAc in Hexane) to afford 6-methoxy-N((R)-1-(oxazol-2-yl)ethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 109) (0.264 g, 0.593 mmol, 29.81%).

    [1151] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.32 (d, J=8.0 Hz, 1H), 9.10 (d, J=1.6 Hz, 1H), 8.73 (d, J=1.6 Hz, 1H), 8.08 (s, 1H), 7.39 (d, J=2.8 Hz, 1H), 7.25 (d, J=2.8 Hz, 1H), 7.18 (s, 1H), 5.89 (br s, 1H), 5.40-5.33 (m, 1H), 3.90 (s, 3H), 3.78-2.66 (m, 3H), 2.47-2.44 (m, 1H), 2.30-2.26 (m, 1H), 2.23-2.08 (m, 1H), 1.75-1.61 (m, 1H), 1.60 (d, J=6.8 Hz, 3H).

    [1152] LCMS (Method A): 2.46 min, 98.31%, 254.0 nm, MS: ES+446.3 (M+1).

    [1153] HPLC (Method A): 8.77 min, 99.62%, 254.0 nm.

    [1154] Chiral HPLC: Peak-1: 3.11 min, 48.01%, 248.0 nm; Peak-2: 3.83 min, 48.04%, 248.0 nm

    Example 101Synthesis of N((R)-1-hydroxypropan-2-yl)-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 110)

    ##STR00327##

    Step-1

    [1155] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.750 g, 2.13 mmol, 1.0 eq.) in DMF (10 mL) was added DIPEA (0.82 g, 6.40 mmol, 3.0 eq.) and HATU (1.21 g, 3.20 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C. (R)-2-aminopropan-1-ol (CAS: 35320-23-1) (0.159 g, 2.13 mmol, 1.0 eq.), was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (100 mL) and extracted with ethyl acetate (125 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (60% EtOAc in Hexane) to afford N((R)-1-hydroxypropan-2-yl)-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 110) (0.281 g, 0.688 mmol, 34.59%)

    [1156] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.07 (d, J=1.6 Hz, 1H), 8.67 (d, J=1.6 Hz, 1H), 8.42 (d, J=8.0 Hz, 1H), 7.38 (d, J=2.8 Hz, 1H), 7.24 (d, J=2.4 Hz, 1H), 5.89 (br s, 1H), 4.78 (t, J=6.0 Hz, 1H), 4.10-4.03 (m, 1H), 3.96 (s, 3H), 3.53-3.47 (m, 2H), 2.77-2.67 (m, 3H), 2.33-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.65 (m, 1H), 1.17 (d, J=6.8 Hz, 3H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in D.sub.2O spectrum.

    [1157] LCMS (Method A): 2.25 min, 99.03%, 254.0 nm, MS: ES+409.4 (M+1)

    [1158] HPLC (Method A): 8.02 min, 98.79%, 254.0 nm.

    [1159] Chiral HPLC: Peak-1: 3.64 min, 45.42%, 246.0 nm. Peak-2: 3.95 min, 52.76%, 246.0 nm.

    Example 102Synthesis of 6-methoxy-N-(oxazol-2-ylmethyl)-8-(4-(trifluoro methyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 111)

    ##STR00328## ##STR00329##

    Step-1

    [1160] To a stirred solution of oxazole-2-carbaldehyde (A58) (5.0 g, 51.5 mmol, 1.0 eq) in DMF (10 mL) was added 2-Methylpropane-2-sulfinamide CAS: 146374-27-8 (7.4 g, 61.8 mmol, 1.2 eq), and Piperidine-1-carbaldehyde CAS: 3087-36-3 (25.5 ml, 10.3 mmol, 2.0 eq) at 0 C. under Nitrogen atmosphere. Then reaction mixture was stirred at RT for 16 h. TLC (50% EtOAc in Hexane as a mobile phase) indicated the completion of reaction. The resulting reaction mixture was poured onto water (100 mL) and extracted with EtOAc (3200 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude. The resulting crude product was purified by column chromatography using silica gel 230-400 mesh size and desired product eluted in 40% EtOAc in hexane to afford (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A103) (4.9 g, 24.46 mmol, Yield: 47.50%).

    [1161] .sup.1H NMR (DMSO, 400 MHz): ppm 8.45 (s, 1H), 8.28 (s, 1H), 7.62 (s, 1H), 1.27 (s, 9H).

    [1162] LCMS (Method A): LCMS does not support the desired product mass.

    Step-2

    [1163] To a stirred solution of (E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A103) (4.9 g, 29.9 mmol, 1.0 eq) in MeOH (20 mL) was added NaBH.sub.4 (1.7 g, 44.9 mmol, 2.0 eq) at 0 C. The reaction mixture was stirred at RT for 30 min and monitored on TLC (5% DCM: MeOH as mobile phase). The resulting reaction mixture was poured into water (400 mL) and extracted with EtOAc (3200 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude. The resulting crude product was purified by column chromatography (desired product eluted in 2% MeOH in DCM) to afford 2-methyl-N-(oxazol-2-ylmethyl) propane-2-sulfinamide (A104) (4.1 g, 20.26 mmol, Yield: 82.84%).

    [1164] LCMS (Method A): 1.303 min, 100.0%, 210.0 nm MS: ES+203.0 (M+1).

    [1165] .sup.1H NMR (DMSO, 400 MHz): ppm 7.64 (s, 1H), 7.09 (s, 1H), 4.49-4.37 (m, 2H), 3.94 (t, J=8.8 Hz 1H), 1.24 (s, 9H).

    Step-3

    [1166] To a stirred solution of 2-methyl-N-(oxazol-2-ylmethyl) propane-2-sulfinamide (A104) (9.0 g, 44.4 mmol, 1.0 eq) in MeOH (90 mL) was added 4M HCl in Dioxane (11.68 g, 31.1 mmol, 7.0 v) at 0 C. and reaction mixture was stirred at RT for 1 h. The reaction was monitored on TLC (using; 5% DCM:MeOH as mobile phase). After completion, the resulting reaction mixture was directly concentrated under reduced pressure to obtained the crude material which was triturated using pentane to afford oxazol-2-ylmethanamine hydrochloride (A105) (7.0 g, 52.02 mmol, Yield: 87.88%).

    [1167] LCMS (Method A): LCMS does not support the desired product mass

    [1168] .sup.1H NMR (DMSO, 400 MHz): ppm 8.94 (s, 3H), 8.23 (s, 1H), 7.30 (s, 1H), 4.22 (s, 2H).

    Step-4

    [1169] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.35 g, 0.996 mmol, 1.0 eq.) in DMF (15 mL) were added DIPEA (0.38 g, 2.99 mmol, 3.0 eq.) and HATU (0.568 g, 1.49 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C. Oxazol-2-ylmethanamine (A105) (0.097 g, 0.996 mmol, 1.0 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (50 mL) and extracted with ethyl acetate (100 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (55% EtOAc in Hexane) to afford 6-methoxy-N-(oxazol-2-ylmethyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 111) (0.165 g, 0.382 mmol, 44.74%).

    [1170] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.48 (t, J=5.6 Hz, 1H), 9.00 (d, J=2.0 Hz, 1H), 8.72 (d, J=2.0 Hz, 1H), 8.09 (s, 1H), 7.40 (d, J=2.4 Hz, 1H), 7.26 (d, J=2.8 Hz, 1H), 7.19 (s, 1H), 5.89 (br s, 1H), 4.66 (d, J=5.6 Hz, 2H), 3.91 (s, 3H), 2.79-2.67 (m, 3H), 2.33-2.23 (m, 2H), 2.09-2.06 (m, 1H), 1.72-1.63 (m, 1H).

    [1171] LCMS (Method C): 2.413 min, 96.37%, 254.0 nm, MS: ES+432.3 (M+1)

    [1172] HPLC (Method B): 6.93 min, 95.22%, 210.0 nm.

    [1173] Chiral HPLC: Peak-1: 4.81 min, 47.98%, 246.0 nm; Peak-2: 5.33 min, 49.82%, 246.0 nm.

    Example 103Synthesis of N-((1H-pyrazol-3-yl)methyl)-6-methoxy-8-(4-(trifluoro methyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 112)

    ##STR00330##

    Step-1

    [1174] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.1 g, 0.28 mmol, 1.0 eq.), in DMF (2.0 mL) was added HATU (0.123 g, 0.56 mmol, 2.0 eq.) and DIPEA (0.110 g, 0.85 mmol, 3.0 eq.) at 0 C. Followed by addition of (1H-pyrazol-3-yl) methanamine hydrochloride (CAS: No: 1196153-72-6) (0.056 g, 0.42 mmol, 1.5 eq.) and the resulting reaction mixture was stirred at room temperature for 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (20 mL) and extracted with ethyl acetate (50 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica (230-400 Mesh) as stationary phase (45-50% Ethyl Acetate in Hexane) to afford N-((1H-pyrazol-3-yl)methyl)-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 112) (0.067 g, 0.155 mmol, Yield: 54.69%).

    [1175] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.63 (br s, 1H), 9.20 (br s, 1H), 9.10 (d, J=2.0 Hz, 1H), 8.70 (d, J=2.0 Hz, 1H), 7.66 (br s, 1H), 7.38 (d, J=2.8 Hz, 1H), 7.24 (d, J=2.8 Hz, 1H), 6.22 (s, 1H), 5.88 (s, 1H), 4.53 (br s, 2H), 3.93 (s, 3H), 2.78-2.67 (m, 3H), 2.33-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.62 (m, 1H). Note: CF.sub.3CH proton merged with DMSO solvent peak which is clearly observed in MeOD.

    [1176] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.09 (d, J=2.0 Hz, 1H), 8.67 (d, J=2.4 Hz, 1H), 7.61 (br s, 1H), 7.30 (d, J=1.2 Hz, 2H), 6.37 (s, 1H), 5.86 (s, 1H), 4.70 (s, 2H), 4.01 (s, 3H), 2.74-2.71 (m, 3H), 2.65-2.49 (m, 1H), 2.39-2.31 (m, 1H), 2.16-2.13 (m, 1H), 1.91-1.80 (m, 1H). Note: CONH and NH protons exchanged in MeOD NMR.

    [1177] LCMS (Method A): 2.30 min, 98.42%, 254 nm, MS: ES+431.7 (M+1)

    [1178] HPLC (Method A): 8.07 min, 98.25%, 254 nm.

    Example 104Synthesis of N((S)-1-hydroxy-3-methoxypropan-2-yl)-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 113)

    ##STR00331##

    Step-1

    [1179] To a solution 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.09 g, 0.256 mmol, 1.0 eq.) in DMF (1 mL), was added HATU (0.14 g, 0.38 mmol, 1.5 eq.) and DIPEA (0.13 mL, 0.76 mmol, 3.0 eq.) at 0 C. under the N.sub.2 atmosphere. After 10 min of stirring at 0 C., (S)-2-amino-3-methoxypropan-1-ol (A50) (0.053 g, 0.51 mmol, 2.0 eq.) was added and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with ethyl acetate (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 Mesh) as stationary phase (70% EA in Hexane) to afford N((S)-1-hydroxy-3-methoxypropan-2-yl)-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 113) (0.04 g, 0.091 mmol, Yield: 35.62%).

    [1180] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.07 (d, J=2.0 Hz, 1H), 8.66 (d, J=2.0 Hz, 1H), 7.30 (dd, J=2.8, 5.2 Hz, 2H), 5.87 (br s, 1H), 4.39-3.36 (m, 1H), 3.97 (s, 3H), 3.78 (dd, J=1.2, 5.6 Hz, 2H), 3.68-3.62 (m, 2H), 3.42 (s, 3H), 2.75-2.62 (m, 3H), 2.54-2.50 (m, 1H), 2.39-2.36 (m, 1H), 2.16-2.14 (m, 1H), 1.88-1.84 (m, 1H). Note: CONH and OH protons exchanged in MeOD NMR.

    [1181] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.08 (d, J=2.0 Hz, 1H), 8.69 (d, J=2.0 Hz, 1H), 8.47 (d, J=8.4 Hz, 1H), 7.38 (d, J=2.8 Hz, 1H), 7.24 (d, J=2.8 Hz, 1H), 5.89 (m, 1H), 4.82 (t, J=5.6 Hz, 1H), 4.21-4.16 (m, 1H), 3.91 (s, 3H), 3.54-3.47 (m, 4H), 3.25 (s, 3H), 2.78-2.67 (m, 3H), 2.46-2.44 (m, 1H), 2.33-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.62 (m, 1H).

    [1182] LCMS (Method A): 2.270 min, 99.48%, 254.0 nm, MS: ES+439.6 (M+1).

    [1183] HPLC (Method A): 6.89 min, 95.15%, 254.0 nm.

    [1184] CHIRAL HPLC (Method A): Peak-1: 20.361 min, 48.11%, 246.0 nm; Peak-2: 24.125 min, 48.83%, 246.0 nm.

    Example 105Synthesis of 6-methoxy-N-(3-(methylsulfonamido)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 114)

    ##STR00332##

    Step-1

    [1185] To a stirred solution of 6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A102) (0.050 g, 0.142 mmol, 1.0 eq.) in DMF (5 mL), was added N-(3-aminopropyl) methanesulfonamide (A83) (0.026 mg, 0.142 mmol, 1.0 eq.), TEA (0.043 g, 0.426 mmol, 3.0 eq.) and HATU (0.080 g, 0.213 mmol, 1.5 eq.). The resulting reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (100 mL) and extracted by EtOAc (2125 mL). The organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (10% MeOH in DCM) to afford 6-methoxy-N-(3-(methylsulfonamido)propyl)-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 114) (0.029 g, 0.060 mmol, 45.84%)

    [1186] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.06 (d, J=2.0 Hz, 1H), 8.82 (br s, 1H), 8.65 (d, J=2.0 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H), 5.86 (br s, 1H), 4.02 (s, 3H), 3.60-3.56 (m, 2H), 3.21 (t, J=6.4 Hz, 2H), 2.98 (s, 3H), 2.75-2.62 (m, 3H), 2.54-2.50 (m, 1H), 2.9-2.36 (m, 1H), 2.17-2.14 (m, 1H), 1.96-1.87 (m, 3H). Note: CONH and MeSO.sub.2NH-proton exchanged in MeOD NMR.

    [1187] .sup.1H NMR (DMOS-d.sub.6, 400 MHz): ppm, 9.06 (d, J=2.0 Hz, 1H), 8.76 (t, J=5.6 Hz, 1H), 8.66 (d, J=2.0 Hz, 1H), 7.39 (d, J=2.4 Hz, 2H), 7.25 (d, J=2.8 Hz, 2H), 7.04 (t, J=5.6 Hz, 2H), 5.86 (br s, 1H), 3.92 (s, 3H), 3.06-3.01 (m, 2H), 2.91 (s, 3H), 2.88-2.73 (m, 4H), 2.33-2.23 (m, 1H), 2.08-2.06 (m, 1H), 1.80-1.65 (m, 2H).

    [1188] HPLC (Method B): 7.18 min, 96.09%, 254.0 nm,

    [1189] LCMS (Method A): 2.357 min, 97.41%, 254.0 nm, MS: ES+486.89

    Example 106Synthesis of N-isopropyl-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 115)

    ##STR00333##

    Step-1

    [1190] To the stirred solution of methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (0.2 g, 0.675 mmol, 1.0 eq.) in MeOH:H.sub.2O (5.0 mL, 7:3) was added LiOH (0.270 g, 6.75 mmol, 10.0 eq.) and reaction mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was directly concentrated under reduced pressure to obtained crude product. The crude product was neutralized by using aq. 10% citric acid solution to obtained precipitate. The precipitate was collected by filtration and dried under reduce pressure to afford 8-bromo-6-methoxyquinoline-3-carboxylic acid (A106) (0.156 g, 0.553 mmol, Yield: 81.92%).

    [1191] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.38 (br s, 1H), 9.21 (d, J=1.6 Hz, 1H), 8.89 (d, J=1.6 Hz, 1H), 7.95 (d, J=2.4 Hz, 1H), 7.68 (d, J=2.4 Hz, 1H), 3.92 (s, 3H).

    [1192] LCMS (Method A): 1.851 min, 100%, 254.0 nm, MS: ES+284.0 (M+2)

    Step-2

    [1193] A stirred solution of 8-bromo-6-methoxyquinoline-3-carboxylic acid (A106) (0.15 g, 0.531 mmol, 1.0 eq.) in DMF (2.5 mL) was prepared. To this solution, isopropyl amine CAS: 75-31-0 (0.03 g, 0.531 mmol, 1.0 eq.), DIPEA (0.20 g, 1.593 mmol, 3.0 eq.) and HATU (0.30 g, 0.796 mmol, 1.5 eq.) was added and resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (75 mL) and again stirred at RT for another 1 h to obtained solid material. The obtained solid material was filtered on Buchner funnel and dried under high vacuum to afford 8-bromo-N-isopropyl-6-methoxyquinoline-3-carboxamide (A107) (0.11 g, 0.340 mmol, 67%).

    [1194] .sup.1H NMR (DMSO-.sub.6, 400 MHz): ppm, 9.15 (d, J=2.0 Hz, 1H), 8.72 (d, J=1.6 Hz, 1H), 8.62 (d, J=7.2 Hz, 1H), 7.92 (d, J=2.4 Hz, 1H), 7.54 (d, J=2.8 Hz, 1H), 4.18-4.13 (m, 1H), 3.93 (s, 3H), 1.22 (d, J=6.8 Hz, 6H).

    [1195] LCMS (Method A): 1.946 min, 99.51%, 254.0 nm, MS: ES+325.1 (M+2)

    Step-3

    [1196] A stirred solution of 4, 4, 5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1, 3,2-dioxaborolane (A2) (0.084 g, 0.306 mmol, 1.1 eq.), 8-bromo-N-isopropyl-6-methoxyquinoline-3-carboxamide (A107) (0.09 g, 0.278 mmol, 1.0 eq.) and Na.sub.2CO.sub.3 (0.058 g, 0.556 mmol, 2.0 eq.) in Dioxane (4.0 mL) and water (1.0 mL) at RT was prepared. The resulting reaction mixture was purged under Nitrogen atmosphere for 10-15 min. Then added Pd(dppf)Cl.sub.2.Math.DCM (0.004 g, 0.042 mmol, 0.15 eq.) and stirred at 100 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was filtered through celite bed and filtrate was concentrated under reduced pressure to obtain crude product. The obtained crude product was purified by flash column chromatography (desired product eluted in 35% EtOAc in Hexane) to afford N-isopropyl-6-methoxy-8-(4-(trifluoromethyl)cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 115) (0.026 g, 0.066 mmol, Yield: 21.65%).

    [1197] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.06 (d, J=2.0 Hz, 1H), 8.65 (d, J=2.4, Hz, 1H), 8.53 (d, J=7.6 Hz, 1H), 7.38 (d, J=2.8, Hz, 1H), 7.23 (d, J=2.8, Hz, 1H), 5.89 (br s, 1H), 4.19-4.10 (m, 1H), 3.95 (s, 3H), 2.77-2.67 (m, 3H), 2.49-2.44 (m, 1H), 2.33-2.23 (m, 1H), 2.08-2.05 (m, 1H), 1.72-1.62 (m, 1H), 1.16 (d, J=7.2 Hz, 6H).

    [1198] HPLC (Method A): 9.46 min, 97.20%, 254.0 nm,

    [1199] LCMS (Method A): 2.576 min, 97.02%, 254.0 nm, MS: ES+393.4 (M+1).

    Example 107Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 116)

    ##STR00334##

    Step-1

    [1200] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.1 g, 0.34 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.18 mL, 1.03 mmol, 3.0 eq.) and HATU (0.19 g, 0.51 mmol, 1.5 eq.) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (R)-2-aminopropan-1-ol (CAS: 35320-23-1) (0.025 g, 0.34 mmol, 1.0 eq.) was added and the resulting reaction mixture was stirred from 0 C. to RT for 1 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (desired product eluted in 70% EtOAc in Hexane) afforded (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 116) (0.065 g, 0.18 mmol, Yield: 54.62%).

    [1201] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.0 Hz, 1H), 8.48 (d, J=8.0 Hz, 1H), 8.02 (dd, J=7.2 Hz, 2.0 Hz, 1H), 7.67-7.63 (m, 2H), 5.76 (br s, 1H), 4.80 (t, J=6.0 Hz, 1H), 4.08-4.06 (m, 1H), 3.52-3.49 (m, 1H), 3.41-3.37 (m, 1H), 2.90 (br s, 2H), 2.80-2.75 (m, 2H), 2.25-2.18 (m, 2H), 1.17 (d, J=6.8 Hz, 3H).

    [1202] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.4 Hz, 1H), 7.98 (dd, J=8.0 Hz, 1.6 Hz, 1H), 7.69-7.62 (m, 2H), 5.75 (br s, 1H), 4.28 (q, J=6.0 Hz, 1H), 3.67 (t, J=5.2 Hz, 2H), 2.89-2.86 (m, 2H), 2.78 (m, 2H), 2.34-2.24 (m, 2H), 1.30 (t, d=6.4 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1203] LCMS (Method A): 1.948 min, 97.77%, 254 nm, MS: ES+347.1 (M+1) HPLC (Method A): 7.04 min, 96.92%, 254 nm

    [1204] Chiral HPLC (Method A): 3.27 min, 100%, 242 nm

    Example 108Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 117)

    ##STR00335##

    Step-1

    [1205] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.1 g, 0.345 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.262 g, 0.691 mmol, 2.0 eq.) and DIPEA (0.16 mL, 1.037 mmol, 3.0 eq.) at 0 C. After 10 min of stirring, (R)-1-(oxazol-2-yl)ethan-1-amine hydrochloride (A61) (0.046 g, 0.414 mmol, 1.2 eq.) was added and the resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) and dried under reduced pressure and purified by column chromatography (desired product eluted in 0-2% MeOH in DCM) to afford (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 117) (0.026 g, 0.067 mmol, Yield: 19.62%).

    [1206] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.28 (s, 1H), 8.82 (s, 1H), 8.08 (s, 1H), 7.98 (d, J=8.0 Hz, 1H), 7.92 (s, 1H), 7.70-7.63 (m, 2H), 7.18 (s, 1H), 5.75 (br s, 1H), 5.50-5.48 (m, 1H), 2.88 (br s, 2H), 2.77 (t, J=14.8 Hz, 2H), 2.32-2.25 (m, 2H), 1.72 (d, J=6.8 Hz, 3H).

    [1207] LCMS (Method A): 2.190 min, 100%, 254 nm, MS: ES+384.17 (M+1)

    [1208] HPLC (Method A): 7.81 min, 100%, 254 nm

    [1209] Chiral HPLC: 5.14 min, 100%, 240 nm

    Example 109Synthesis of(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 118)

    ##STR00336##

    Step-1

    [1210] A stirred solution of oxazole-2-carbaldehyde (A58) (CAS: 65373-52-6) (0.4 g, 4.120 mmol, 1.0 eq) in THF (4 mL, 10 v) was prepared in 50 mL three neck round bottom flask at room temperature. To this solution was added (R)-2-methylpropane-2-sulfinamide (CAS: 196929-78-9) (0.599 g, 4.944 mmol, 1.2 eq) at same temperature. Then dropwise addition of Ti(OEt).sub.4 (1.88 g, 8.240 mmol, 2.0 eq) at 0 C. The resulting reaction mixture was stirred at RT for 16 h. The reaction was monitored by TLC (50% EtOAc in Hexane as a mobile phase), After completion, the resulting reaction mixture was dilute with brine solution (3 mL), EtOAc (20 mL) and stirred for 15 min. After 15 min, solid material was filtered through celite bed and washed with EtOAc (10 mL). The organic layer was separated, dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained the crude. The crude material was purified by flash column chromatography using silica 230-400 mesh size and desired product eluted in 22% EtOAc in Hexane to afford (R,E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A108) brown sticky liquid (0.4 g, 1.997 mmol, Yield: 48.48).

    [1211] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.45 (s, 1H), 8.28 (s, 1H), 7.63 (s, 1H), 1.19 (s, 9H).

    [1212] LCMS (Method A): 1.298 min, 100%, 254.0 nm, MS: ES+201.0 (M+1)

    Step-2

    [1213] A stirred solution of (R,E)-2-methyl-N-(oxazol-2-ylmethylene) propane-2-sulfinamide (A108) (0.4 g, 1.997 mmol, 1.0 eq) in DCM (8 mL, 20 v) was prepared in 50 mL three neck round bottom flask at 78 C. To this reaction mixture dropwise added MeMgBr (0.8 mL, 2.936 mmol, 1.2 eq) at 78 C. and stirred for 1.5 h. at same temperature. After 1.5 h, reaction mixture was warm to RT and again stirred for another 1.5 h. Then second time dropwise addition of MeMgBr (0.8 mL, 2.936 mmol, 1.2 eq) at 78 C. and stirred 1.5 h. at same temperature. After 1.5 h, again reaction mixture was warm to RT and stirred for another 1.5 h. Then third time dropwise addition of MeMgBr (0.4 mL, 1.468 mmol, 1.2 eq) at 78 C. and resulting reaction mixture was stirred at RT for another 16 h. The TLC indicated (100% EtOAc as a mobile phase) completion of reaction after 16 h of stirring at RT. The resulting reaction mixture was quenched with aq. NH.sub.4Cl solution (10 mL) and extracted with EtOAc (220 mL). The combine organic layer was separated, dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to obtained crude material. The crude material was purified by trituration with 20% Diethyl ether and n-pentane to afford (R)-2-methyl-N((S)-1-(oxazol-2-yl)ethyl) propane-2-sulfinamide (A109) Light yellow solid (0.21 g, 0.970 mmol, Yield: 48.61).

    [1214] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.07 (s, 1H), 7.15 (s, 1H), 5.94 (d, J=7.6 Hz, 1H), 4.51-4-48 (m, 1H), 1.49 (d, J=6.8 Hz, 3H), 1.08 (s, 9H).

    [1215] LCMS (Method A): 1.379 min, 100%, 210 nm, MS: ES+217.0 (M+1)

    Step-3

    [1216] A stirred solution of (R)-2-methyl-N((S)-1-(oxazol-2-yl)ethyl) propane-2-sulfinamide (A109) (0.1 g, 0.462 mmol, 1.0 eq) in MeOH (0.8 mL) was prepared in 10 mL glass vail at room temperature. To this reaction mixture was dropwise added 4M HCl in Dioxane (0.24 mL, 0.970 mmol, 2.1 eq) at RT. The resulting reaction mixture was stirred for 16 h. at same temperature. The reaction was monitored by TLC (100% EtOAc as a mobile phase) which confirmed that the reaction got completed after 16 h of stirring at room temperature. The resulting reaction mixture was directly concentrated under reduced pressure to obtained 0.075 g material as a(S)-1-(oxazol-2-yl)ethan-1-amine hydrochloride yellowish sticky liquid (A110) (0.075 g, 0.668 mmol, Yield: 48.48%).

    [1217] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 8.85 (br s, 3H), 8.24 (s, 1H), 7.32 (s, 1H), 4.66-4.64 (m, 1H), 1.56 (d, J=6.8 Hz, 3H).

    [1218] LCMS (Method A): 0.185 min, 100.0%, 210 nm, MS: ES+113.1 (M+1)

    Step-4

    [1219] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.172 mmol, 1.0 eq.) in DMF (0.8 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.15 mL, 0.864 mmol, 5.0 eq.) and HATU (0.098 g, 0.259 mmol, 1.5 eq.) were added under nitrogen atmosphere. After 10 min of stirring, (S)-1-(oxazol-2-yl)ethan-1-amine hydrochloride (A110) (0.026 g, 0.172 mmol, 1.0 eq.) was added and the resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured onto cold water (20 mL) and extracted with ethyl acetate (202), organic layer was dried over Na.sub.2SO.sub.4 and concentrated under reduce pressure to obtain crude product which was purified by normal phase column chromatography using silica (100-200 mesh) desired product was eluted at 42% ethyl acetate in hexane to afford(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 118) (0.039 g, 0.101 mmol, Yield: 59.09%).

    [1220] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.36 (d, J=7.6 Hz, 1H), 9.28 (d, J=2.0 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 8.03 (dd, J=7.6, 2.0 Hz, 1H), 7.69-7.63 (m, 2H), 7.19 (s, 1H), 5.77 (br s, 1H), 5.40-5.36 (m, 1H), 2.90 (br s, 2H), 2.83-2.27 (m, 2H), 2.27-2.17 (m, 2H), 1.61 (d, J=7.2 Hz, 3H).

    [1221] LCMS (Method A): 2.181 min, 98.92%, 245 nm, MS: ES+384.12 (M+1)

    [1222] HPLC (Method A): 7.78 min, 99.09%, 210 nm

    Example 110Synthesis of N-((1H-pyrazol-5-yl)methyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 119)

    ##STR00337##

    Step-1

    [1223] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.17 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.15 mL, 0.86 mmol, 5.0 eq.) and HATU (0.098 g, 0.25 mmol, 1.5 eq.) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (1H-pyrazol-5-yl) methenamine hydrochloride (CAS: 11961153-72-6) (0.023 g, 0.17 mmol, 1.0 eq.) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (2% MeOH in DCM) to afford as a N-((1H-pyrazol-5-yl)methyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 119) (0.023 g, 0.062 mmol, Yield: 36.50%).

    [1224] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.64 (s, 1H), 9.28 (d, J=2.0 Hz, 2H), 8.85 (d, J=2.0 Hz, 1H), 8.01 (d, J=7.6 Hz, 1H), 7.67-7.41 (m, 3H), 6.23 (s, 1H), 5.76 (br s, 1H), 4.54 (s, 2H), 2.89 (s, 2H), 2.83-2.73 (m, 2H), 2.27-2.21 (m, 2H),

    [1225] LCMS (Method A): 2.020 min, 100%, 254 nm, MS: ES+369.2 (M+1)

    [1226] HPLC (Method A): 7.02 min, 97.98%, 254 nm

    Example 111Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((4-methyl-1H-pyrazol-5-yl)methyl)quinoline-3-carboxamide (Compound 120)

    ##STR00338##

    Step-1

    [1227] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.17 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.09 mL, 0.51 mmol, 3.0 eq.) and HATU (0.098 g, 0.25 mmol, 1.5 eq.) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (4-methyl-1H-pyrazol-5-yl) methanamine (CAS: 2173991-88-1) (0.031 g, 0.17 mmol, 1.0 eq.) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford the crude product. The obtained crude material was purified by RFC using (0-30% water in ACN) to afford as an 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((4-methyl-1H-pyrazol-5-yl)methyl)quinoline-3-carboxamide (Compound 120) (0.018 g, 0.047 mmol, Yield: 27.27%).

    [1228] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.39 (s, 1H), 9.28 (s, 1H), 9.10 (s, 1H) 8.84 (s, 1H), 8.00 (d, J=6.8 Hz, 1H), 7.67-7.61 (m, 2H), 7.45 (br s, 1H), 5.75 (br s, 1H), 4.52 (d, J=4.8 Hz, 2H), 2.89 (br s, 2H), 2.82-2.75 (m, 2H), 2.25-2.18 (m, 2H), 2.02 (s, 3H).

    [1229] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 7.97 (d, J=6.8 Hz, 1H), 7.69-7.62 (m, 2H), 7.42 (br s, 1H), 5.75 (br s, 1H), 4.68 (s, 2H), 2.87 (br s, 2H), 2.81-2.74 (m, 2H), 2.32-2.25 (m, 2H), 2.15 (s, 3H). Note: CONH and NH protons exchanged in MeOD NMR.

    [1230] LCMS (Method A): 2.101 min, 95.53%, 254 nm, MS: ES+383.2 (M+1) HPLC (Method A): 7.36 min, 98.50%, 254 nm

    Example 112Synthesis of(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-methoxy propan-2-yl)quinoline-3-carboxamide (Compound 121)

    ##STR00339##

    Step-1

    [1231] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.1 g, 0.34 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.18 mL, 1.03 mmol, 3.0 eq.) and HATU (0.19 g, 0.51 mmol, 1.5 eq.) were added at 0 C. under nitrogen atmosphere. After 30 min of stirring at 0 C., (S)-1-methoxypropan-2-amine (CAS: 99636-32-5) (0.025 g, 0.34 mmol, 1.0 eq.) was added at same temperature. The resulting reaction mixture was stirred from 0 C. to RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (desired product eluted in 30% EtOAc in Hexane) to afford(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 121) (0.052 g, 0.14 mmol, Yield: 41.93%).

    [1232] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 8.61 (d, J=8.0 Hz, 1H), 8.03 (dd, J=7.6, 2.0 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (s, 1H), 4.27-4.24 (m, 1H), 3.47-3.40 (m, 2H), 3.26 (s, 3H), 2.90 (br s, 2H), 2.83-2.75 (m, 2H), 2.25-2.18 (m, 2H), 1.19 (d, J=6.8 Hz, 3H).

    [1233] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.75 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.0 Hz, 1.6 Hz, 1H), 7.69-7.62 (m, 2H), 5.75 (br s, 1H), 4.42-4.40 (m, 1H), 3.57-3.53 (m, 1H), 3.42 (s, 3H), 3.50-3.46 (m, 1H), 2.89-2.86 (m, 2H), 2.81-2.74 (m, 2H), 2.32-2.25 (m, 2H), 1.31 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [1234] LCMS (Method A): 2.178 min, 95.62%, 254 nm, MS: ES+361.2 (M+1)

    [1235] HPLC (Method A): 8.17 min, 100%, 254 nm

    [1236] Chiral HPLC: 2.96 min, 100% 242 nm

    Example 113Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((5-oxopyrrolidin-2-yl)methyl)quinoline-3-carboxamide (Compound 122)

    ##STR00340##

    Step-1

    [1237] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.172 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.098 g, 0.259 mmol, 1.5 eq.) and DIPEA (0.066 mL, 0.518 mmol, 3.0 eq.) at 0 C. After 10 min of stirring, 5-(aminomethyl) pyrrolidin-2-one hydrochloride (CAS: 115307-13-6) (0.028 g, 0.190 mmol, 1.1 eq.) was added and the resulting reaction mixture was stirred at RT for 6 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain the precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) and dried under reduced pressure then crude obtained was purified by column chromatography (and eluted with 0-2% MeOH in DCM to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((5-oxopyrrolidin-2-yl)methyl)quinoline-3-carboxamide (Compound 122) (0.039 g, 0.101 mmol, Yield: 58.64%).

    [1238] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.87-8.82 (m, 2H), 8.03 (dd, J=2.0, 7.2 Hz, 1H), 7.83 (s, 1H), 7.68-7.62 (m, 2H), 5.76 (br s, 1H), 3.76 (t, J=6.0 Hz, 1H), 3.40-3.32 (m, 2H), 2.90-2.83 (m, 2H), 2.79-2.67 (m, 2H), 2.26-2.10 (m, 5H), 1.82-1.79 (m, 1H).

    [1239] LCMS (Method A): 1.914 min, 98.09%, 254 nm, MS: ES+386.17 (M+1)

    [1240] HPLC (Method A): 6.52 min, 98.44%, 254 nm

    [1241] Chiral HPLC: Peak-1 3.67 min, 49.95% 240 nm; Peak-2 4.80 min, 50.04%, 240 nm

    Example 114Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((6-oxo-1,6-dihydropyridin-2-yl)methyl)quinoline-3-carboxamide (Compound 123)

    ##STR00341##

    Step-1

    [1242] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.172 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.098 g, 0.259 mmol, 1.5 eq.) and DIPEA (0.066 g, 0.518 mmol, 3.0 eq.) at 0 C. After 10 min of stirring, 6-(aminomethyl)pyridin-2 (1H)-one hydrochloride (CAS: 95878-02-7) (0.030 g, 0.190 mmol, 1.1 eq.) was added and the resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (5 mL) to obtain precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) then concentrated under reduced pressure. The obtained crude was purified by column chromatography on silica gel (230-400 mesh) (desired product eluted in 0-4% MeOH in DCM) to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((6-oxo-1,6-dihydropyridin-2-yl)methyl)quinoline-3-carboxamide (Compound 123) (0.036 g, 0.091 mmol, Yield: 52.68%).

    [1243] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 11.63 (br s, 1H), 9.34-9.30 (m, 2H), 8.88 (d, J=2.0 Hz, 1H), 8.05 (dd, J=7.6, 1.6 Hz, 1H), 7.69-7.64 (m, 2H), 7.40-7.38 (m, 1H), 6.22-6.13 (m, 2H), 5.77 (br s, 1H), 4.39 (d, J=5.6 Hz, 2H), 2.95-2.87 (m, 2H), 2.83-2.76 (m, 2H), 2.28-2.17 (m, 2H).

    [1244] LCMS (Method A): 1.954 min, 98.46%, 254 nm, MS: ES+396.27 (M+1)

    [1245] HPLC (Method A): 6.53 min, 98.41%, 254 nm

    Example 115Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((2-oxo-1,2-dihydro pyridin-3-yl)methyl)quinoline-3-carboxamide (Compound 124)

    ##STR00342##

    Step-1

    [1246] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.17 mmol, 1.0 eq.) in DMF (1 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.089 mL, 0.51 mmol, 3.0 eq.) and HATU (0.098 g, 0.25 mmol, 1.5 eq.) were added at same temperature under nitrogen atmosphere. After 30 min of stirring at 0 C., CAS: 85468-38-8 (0.033 g, 0.20 mmol, 1.2 eq.) was added and the resulting reaction mixture was stirred from 0 C. to RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (5 mL) to obtain the precipitate. The obtained precipitate was filtered through Buchner funnel, washed with water (5 mL2) and concentrated under reduced pressure to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-((2-oxo-1,2-dihydropyridin-3-yl)methyl)quinoline-3-carboxamide (Compound 124) (0.040 g, 0.10 mmol, Yield: 58.53%).

    [1247] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 11.7 (br s, 1H), 9.31 (d, J=2.4 Hz, 1H), 9.15 (t, J=6.8 Hz, 1H), 8.88 (d, J=2.0 Hz, 1H), 8.03 (dd, J=1.6, 6.0 Hz, 1H) 7.67-7.64 (m, 2H), 7.38 (d, J=6.4 Hz, 1H), 7.32 (d, J=5.2 Hz, 1H), 6.43 (t, J=6.4 Hz, 1H), 5.77 (br s, 1H), 4.31 (d, J=5.2 Hz, 2H), 2.90 (br s, 2H), 2.81-2.79 (m, 2H), 2.24-2.21 (m, 2H).

    [1248] .sup.1H NMR (MeOD, 400 MHz): ppm 9.29 (d, J=2.0 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 7.99 (dd, J=1.6, 6.4 Hz, 1H), 7.70-7.63 (m, 3H), 7.40 (dd, J=4.8 Hz, 1.6, 1H), 6.43 (t, J=6.4 Hz, 1H), 5.75 (br s, 1H), 4.25 (s, 2H), 2.90-2.87 (m, 2H), 2.81-2.74 (m, 2H), 2.34-2.24 (m, 2H). Note: CONH proton exchanged in MeOD NMR.

    [1249] LCMS (Method A): 1.95 min, 100%, 210.0 nm, MS: ES+396.2 (M+1)

    [1250] HPLC (Method A): 6.63 min, 97.89%, 210.0 nm

    Example 116Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(hydroxy methyl)cyclopropyl)quinoline-3-carboxamide (Compound 125)

    ##STR00343##

    Step-1

    [1251] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.05 g, 0.17 mmol, 1.0 eq.) in DMF (0.5 mL) was prepared in 10 mL of glass vial and cooled to 0 C. To this reaction solution, HATU (0.09 g, 0.26 mmol, 1.5 eq.) and DIPEA (0.07 g, 0.51 mmol, 3.0 eq.) was added followed by addition of 1-amino-cyclopropanemethanol hydrochloride (CAS: 115652-52-3) (0.02 g, 0.17 mmol, 1.0 eq.) and the resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured onto cold water (20 mL) and precipitated out which were filtered and washed with water (50 mL) and dried under reduced pressure to obtain the crude which was purified by reverse phase column chromatography on silica gel (230-400 mesh), desired product eluted in 45% water in acetonitrile to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-(hydroxymethyl)cyclopropyl)quinoline-3-carboxamide (Compound 125) (0.045 g, 0.12 mmol, Yield: 72.65%).

    [1252] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 9.03 (s, 1H), 8.82 (d, J=2.0 Hz, 1H), 7.99 (dd, J=7.2, 1.6 Hz, 1H), 7.67-7.61 (m, 2H), 5.77 (s, 1H), 4.84 (t, J=4.8 Hz, 1H), 3.58 (d, J=4.8 Hz, 2H), 2.89 (m, 2H), 2.79-2.70 (m, 2H), 2.26-2.17 (m, 2H), 0.81-0.76 (m, 4H)

    [1253] LCMS (Method A): 1.982 min, 98.29%, 254.0 nm, MS: ES+359.12 (M+1)

    [1254] HPLC (Method B): 7.00 min, 98.60%, 254.0 nm

    Example 117Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(4-(methylamino)-4-oxobutan-2-yl)quinoline-3-carboxamide (Compound 126)

    ##STR00344##

    Step-1

    [1255] A stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.5 g, 1.73 mmol, 1.0 eq.) in DMF (5 mL) was prepared in 50 mL of single neck at room temperature. To this reaction solution, DIPEA (0.8 mL, 5.19 mmol, 3.0 eq.) and HATU (0.98 g, 2.59 mmol, 1.5 eq.) were added at same temperature under nitrogen atmosphere. After 30 min of stirring at 0 C., CAS: 139243-54-2 (R)-Methyl 3-aminobutanoate hydrochloride (0.29 g, 1.90 mmol, 1.1 eq.) was added at same temperature. The resulting reaction mixture was stirred from 0 C. to RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain precipitate. Precipitate was filtered through Buchner funnel, washed with water and dried over high vacuum to afford as methyl (R)-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A111) (0.35 g, 0.90 mmol, Yield: 52.13%).

    [1256] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.23 (d, J=2.0 Hz, 1H), 8.77 (d, J=2.0 Hz, 1H), 8.70 (d, J=7.6 Hz, 1H), 8.03 (d, J=5.6 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (br s, 1H), 4.59-4.39 (m, 1H), 3.64 (s, 3H), 2.90 (br s, 2H), 2.82-2.72 (m, 2H), 2.70-2.66 (m, 2H), 2.62-2.54 (m, 2H), 2.25-2.18 (m, 2H), 1.24 (d, J=6.8 Hz, 3H).

    [1257] LCMS (Method A): 2.21 min, 93%, 254.0 nm, MS: ES+389.3 (M+1)

    Step-2

    [1258] A stirred solution of methyl (R)-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A111) (0.35 g, 0.90 mmol, 1.0 eq.) in THF (3.5 Ml) was prepared in 25 Ml of single neck at room temperature. To this reaction solution, aq. solution of LiOH in water (3.5 Ml) (0.113 g, 2.70 mmol, 3.0 eq.) was added and resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was neutralized with solution of citric acid to obtain precipitate. Precipitate was filtered through Buchner funnel, washed with water and dried over high vacuum to afford as a (R)-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (A112) (0.25 g, 0.66 mmol, Yield: 53.20%).

    [1259] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.73 (d, J=1.6 Hz, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.68-7.62 (m, 2H), 5.75 (br s, 1H), 4.57 (q, J=6.8 Hz, 1H), 2.87-2.55 (m, 7H), 2.32-2.25 (m, 2H), 1.38 (d, J=6.8 Hz, 3H). Note: COOH proton might be exchanged in MeOD NMR.

    [1260] LCMS (Method A): 1.99 min, 93%, 254.0 nm, MS: ES+375.1 (M+1)

    Step-3

    [1261] A stirred solution of (R)-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoic acid (A112) (0.100 g, 0.26 mmol, 1.0 eq.) in DMF (1 mL) was prepared in 25 mL of single neck at room temperature. To this reaction solution, CDI (0.086 g, 0.53 mmol, 2.0 eq.) were added at RT. The methylamine solution (2M in THF) (10 vol) was added dropwise into the reaction. The resulting reaction mixture stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (90% Ethyl acetate in hexane) to afford (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(4-(methylamino)-4-oxobutan-2-yl)quinoline-3-carboxamide (Compound 126) (0.045 g, 0.11 mmol, Yield: 33.51%).

    [1262] .sup.1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.4 Hz, 1H), 8.73 (d, J=2.4 Hz, 1H), 7.98 (dd, J=1.6, 7.6 Hz, 1H), 7.69-7.62 (m, 2H), 5.75 (br s, 1H), 4.58-4.53 (m, 1H), 2.89-2.86 (m, 2H), 2.81-2.78 (m, 2H), 2.75 (s, 3H), 2.62-2.57 (m, 1H), 2.51-2.46 (m, 1H), 2.32-2.25 (m, 2H), 1.36 (d, J=6.8 Hz, 3H). Note: CONH proton exchanged in MeOD NMR.

    [1263] LCMS (Method A): 1.948 min, 100%, 210.0 nm, MS: ES+388.4 (M+1)

    [1264] HPLC (Method A): 6.83 min, 100%, 254 nm

    Example 118Synthesis of N-(cyanomethyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 127)

    ##STR00345##

    Step-1

    [1265] To a stirred solution of A25 (0.20 g, 0.691 mmol, 1.0 eq.) in DMF (2.0 mL) was added HATU (0.394 g, 1.037 mmol, 1.5 eq.) and DIPEA (0.57 mL, 2.074 mmol, 3.0 eq.) at 0 C. After 10 min of stirring, 2-aminoacetonitrile hydrochloride (CAS: 6011-14-9) (0.06397 g, 0.6914 mmol, 1.0 eq.) was added and reaction stirred for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with NaHCO.sub.3 (50 mL) and extracted with EtOAc (320 mL). The combined organic layers extracted with EtOAc (250 mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (gradient elution 35% Ethyl acetate in hexane) to afford N-(cyanomethyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 127) (0.109 g, 0.333 mmol, Yield 48.16%)

    [1266] .sup.1H NMR (DMSO, 400 MHz): ppm 9.57 (t, J=5.2 Hz, 1H), 9.27 (d, J=2.4 Hz, 1H), 8.87 (d, J=2.4 Hz, 1H), 8.05 (dd, J=1.6, 7.6 Hz, 1H), 7.71-7.65 (m, 2H), 5.76 (d, J=3.6 Hz, 1H), 4.42 (d, J=5.2 Hz, 2H), 2.90 (t, J=5.2 Hz, 2H), 2.80 (t, J=14.0 Hz, 2H), 2.26-2.19 (m, 2H).

    [1267] LCMS (Method A): 2.122 min, 254 nm, 100%, m/z=328.2 (M+H)+

    [1268] HPLC (Method A): 7.76 min, 254 nm, 100%

    Example 119Synthesis of N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 128)

    ##STR00346##

    Step-1

    [1269] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.15 g, 0.519 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.295 g, 0.778 mmol, 1.5 eq.) and DIPEA (0.27 mL, 0.1.556 mmol, 3.0 eq.) followed by addition of (1H-pyrazol-5-yl)ethan-1-amine (A67) (CAS: 1179072-43-5) (0.063 g, 0.57 mmol, 1.1 eq.) and the resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) and dried over high vacuum and purified by column chromatography and eluted with 50% EtOAC in Hexane to afford N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 128) (0.029 g, 0.076 mmol, Yield: 14.62%).

    [1270] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.58 (br s, 1H) 9.28 (d, J=2.4, 1H), 9.02 (s, 1H), 8.82 (d, J=2.0 Hz, 1H), 7.97 (t, J=5.2 Hz, 1H), 7.63-7.60 (m, 3H), 6.25 (s, 1H), 5.76 (br s, 1H), 5.34 (br s, 1H), 2.90-2.89 (m, 2H), 2.83-2.69 (m, 2H), 2.32-2.19 (m, 2H), 1.52 (d, J=7.2 Hz, 3H).

    [1271] LCMS (Method A): 2.053 min, 96.82%, 254 nm, MS: ES+383.3 (M+1)

    [1272] HPLC (Method A): 7.32 min, 95.76%, 254 nm

    Example 120Synthesis of (R)N-(4-amino-4-oxobutan-2-yl)-8-(4,4-difluoro cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 129)

    ##STR00347##

    Step-1

    [1273] A stirred solution of (R)-3-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoic acid (A112) (0.10 g, 0.26 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 25 mL of single neck RBF at room temperature. To this reaction solution was added CDI (0.086 g, 0.53 mmol, 2.0 eq.) at RT. Then dropwise addition of aq. ammonia solution (10 vol) and reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude product. The obtained crude material was purified by flash column chromatography (desired product eluted in 90% Ethyl acetate in hexane) to afford (R)N-(4-amino-4-oxobutan-2-yl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 129) (0.040 g, 0.10 mmol, Yield: 40.11%).

    [1274] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 7.98 (dd, J=2.0 Hz & 8.0 Hz, 1H), 7.70-7.62 (m, 2H), 5.75 (br s, 1H), 4.59-4.57 (m, 1H), 2.89-2.86 (m, 2H), 2.81-2.74 (m, 2H), 2.66-2.61 (m, 1H), 2.53-2.48 (m, 1H), 2.32-2.25 (m, 2H), 1.38 (d, J=6.8 Hz, 3H). Note: CONH and CONH.sub.2 protons exchanged in MeOD NMR.

    [1275] LCMS (Method A): 1.895 min, 100%, 210.0 nm, MS: ES+374.4 (M+1)

    [1276] HPLC (Method A): 6.59 min, 100%, 210.0 nm

    Example 121Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxy butan-2-yl)quinoline-3-carboxamide (Compound 130)

    ##STR00348##

    Step-1

    [1277] To a stirred solution of A25 (0.1 g, 0.34 mmol, 1.0 eq.) in DMF (2.0 mL) was added DIPEA (0.133 g, 1.03 mmol, 3.0 eq.) and HATU (0.197 g, 0.51 mmol, 1.5 eq.) at RT under N.sub.2 atmosphere and stirred reaction for 10 min. After 10 min, addition of CAS: 5856-63-6 (R)-()-2-Amino-1-butanol (0.033 g, 0.38 mmol, 1.1 eq.) and resulting reaction was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography (desired product eluted in 100% Ethyl acetate) to afford (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxybutan-2-yl)quinoline-3-carboxamide (Compound 130) (0.068 g, 0.18 mmol, Yield: 56.6%).

    [1278] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.27 (s, 1H), 8.82 (s, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.02 (d, J=7.2 Hz, 1H), 7.63 (t, J=7.6 Hz, 2H), 5.76 (br s, 1H), 4.74 (t, J=5.6 Hz, 1H), 3.93 (d, J=5.2 Hz, 1H), 3.53-3.46 (m, 2H), 2.90 (br s, 2H), 2.79-2.76 (m, 2H), 2.24-2.18 (m, 2H), 1.70-1.68 (m, 1H), 1.50-1.47 (m, 1H), 0.91 (t, J=7.2 Hz, 3H).

    [1279] .sup.1H NMR (MeOD, 400 MHz): ppm 9.27 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.98 (dd, J=7.6 Hz & 7.6 Hz, 1H), 7.69-7.64 (m, 2H), 5.75 (s, 1H), 4.13-4.10 (m, 1H), 3.70-3.68 (m, 2H), 2.87 (m, 2H), 2.83-2.74 (m, 2H), 2.34-2.24 (m, 2H), 1.83-1.77 (m, 1H), 1.67-1.59 (m, 1H), 1.07 (t, J=7.6 Hz, 3H).

    [1280] Note: CONH and OH protons exchanged in MeOD NMR.

    [1281] LCMS (Method-A): 2.047 min, 95.99%, 210 nm, MS: ES+361.2 (M+1)

    [1282] HPLC (Method-A): 7.33, 95.88%, 220 nm

    [1283] Chiral HPLC (Method): 3.60, 100%, 240 nm

    Example 122Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(2-hydroxy propyl)quinoline-3-carboxamide (Compound 131)

    ##STR00349##

    Step-1

    [1284] To a stirred solution of A25 (0.1 g, 0.345 mmol, 1.0 eq.) in DMF (1 mL) were added HATU (0.262 g, 0.691 mmol, 2.0 eq.) and DIPEA (0.133 g, 1.03 mmol, 3.0 eq.) at RT under nitrogen atmosphere. Followed by addition of (R)-1-aminopropan-2-ol (CAS: No: 2799-16-8) (0.028 g, 0.380 mmol, 1.1 eq.) at 0 C. and then stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 ml) extracted with EA (20 mL2), combined organic layers were concentrated under reduced pressure to obtain the crude which was purified by column chromatography using silica gel (230-400 mesh) (50% ethyl acetate in hexane as gradient) to afford (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(2-hydroxypropyl)quinoline-3-carboxamide (Compound 131) (0.040 g, 0.115 mmol, Yield: 33.41%).

    [1285] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.28 (d, J=2.0 Hz, 1H), 8.85-8.81 (m, 2H), 8.0 (q, J=2.0 Hz, 7.2 Hz 1H), 7.67-7.62 (m, 2H), 5.76 (br s, 1H), 4.85 (br s, 1H), 3.84 (d, J=8.0 Hz, 1H), 3.29-3.21 (m, 2H), 2.90 (br s, 2H), 2.79 (t, J=14.0 Hz, 2H), 2.25-2.17 (m, 2H), 1.11 (d, J=6.4 Hz, 3H).

    [1286] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.99 (d, J=8 Hz, 1H), 7.69-7.63 (m, 2H), 5.75 (s, 1H), 4.06-4.02 (m, 1H), 3.54-3.49 (m, 1H), 3.43-3.38 (m, 2H), 2.28 (br s, 2H), 2.78 (t, J=14.4 Hz, 2H), 2.34-2.24 (m, 2H), 1.26 (d, J=6.4 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1287] LCMS (Method A): 1.96, 100%, 254 nm, MS: ES+347.3 (M), (M+1)

    [1288] HPLC (Method-A): 7.30 min, 100%, 210 nm

    Example 123Synthesis of(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(2-hydroxypropyl)quinoline-3-carboxamide (Compound 132)

    ##STR00350##

    Step-1

    [1289] To the stirred solution of A25 (0.1 g, 0.345 mmol, 1.0 eq.) in DMF (1 mL) was added HATU (0.196 g, 0.517 mmol, 1.5 eq.) and DIPEA (0.15 mL, 1.035 mmol, 3.0 eq.) at RT under Nitrogen atmosphere, followed by addition of(S)-1-aminopropan-2-ol CAS: 2799-17-9 (0.028 g, 0.380 mmol, 1.1 eq.) and then stirred at RT for 16 h. The resulting reaction mixture was stirred at RT for 16 h. Water (30 mL) was added and extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.4 and evaporate under vacuum to get crude product. The crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 45-50% Ethyl Acetate in Hexane) to afford(S)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(2-hydroxypropyl)quinoline-3-carboxamide (Compound 132) (0.016 g, 0.046 mmol, Yield: 11.97%)

    [1290] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.27 (d, J=2 Hz, 1H), 8.82 (d, J=2 Hz, 1H), 8.77 (t, J=5.6 Hz, 1H), 8.02 (dd, J=2.0 Hz, 7.6 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (br s, 1H), 4.82 (d, J=4.8 Hz, 1H), 3.85-3.82 (m, 1H), 3.29-3.25 (m, 2H), 2.90 (br s, 2H), 2.79 (t, J=14.8 Hz, 2H), 2.27-2.17 (m, 2H), 1.10 (d, J=2.8 Hz, 3H).

    [1291] .sup.1H NMR (MeOD, 400 MHz): ppm 9.27 (d, J=2 Hz, 1H), 8.79 (d, J=2.4 Hz, 1H), 7.99 (dd, J=1.6 Hz, 7.6 Hz, 1H), 7.70-7.63 (m, 2H), 5.75 (s, 1H), 4.04-4.02 (m, 1H), 3.54-3.49 (m, 1H), 3.42 (d, J=7.2 Hz, 1H), 2.88 (t, J=5.2 Hz, 2H), 2.83-2.74 (m, 2H), 2.32-2.25 (m, 2H), 1.26 (d, J=6.4 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1292] LCMS (Method A): 1.939 min, 95.12%, 254.0 nm MS: ES+347.21 [M+H]

    [1293] HPLC (Method-A)-6.95 min, 96.10%, 210 nm

    Example 124Synthesis of (R)N-(2-acetamidopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 133)

    ##STR00351##

    Step-1

    [1294] To a stirred solution of (R)N-(2-aminopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 134) (0.1 g, 0.28 mmol, 1.0 eq.) in DCM (5 mL) was added acetyl chloride (0.02 mL, 0.28 mmol, 1.0 eq.) and NEt.sub.3 (0.12 mL, 0.86 mmol, 3.0 eq.) at RT under Nitrogen atmosphere and stirred for 1 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 ml) and extracted with ethyl acetate (230 mL). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (60-120 Mesh) as stationary phase (3% MDC in MeOH) to afford (R)N-(2-acetamidopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 133) (0.03 g, 0.077 mmol, 34.54%).

    [1295] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.4 Hz, 1H), 8.72 (d, J=2.0 Hz, 1H), 7.99 (dd, J=8.0 Hz, 8.0 Hz, 1H), 7.70-7.63 (m, 2H), 5.75 (br s, 1H), 4.26-4.21 (m, 1H), 3.6-3.54 (m, 1H), 3.48-3.43 (m, 1H), 2.88 (t, J=6 Hz, 2H), 2.78-2.75 (m, 2H), 2.34-2.23 (m, 2H), 1.93 (s, 3H), 1.24 (d, J=6.8 Hz, 3H). Note: CONH proton Exchanged in MeOD NMR.

    [1296] .sup.1H NMR (DMSO, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.79 (m, 2H), 8.02 (dd, J=7.6, 1.6 Hz, 1H), 7.81 (d, J=8.0 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (s, 1H), 4.06-3.99 (m, 1H), 2.90 (br s, 2H), 2.79 (t, J=14.4 Hz, 2H), 2.26-2.17 (m, 2H), 1.80 (s, 3H), 1.08 (d, J=6.8 Hz, 3H).

    [1297] LCMS (Method A) 1.94 min, 97.18%, 254.0 nm, MS: ES+388.37 (M), (M+1)

    [1298] HPLC (Method A) 6.87 min, 96.26%, 220 nm

    [1299] Chiral HPLC-3.73 min, 95.54%, 240.0 nm

    Example 125Synthesis of (R)N-(2-aminopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 134)

    ##STR00352##

    Step-1

    [1300] To a stirred solution of A25 (0.3 g, 1.03 mmol, 1.0 eq.) in DMF (2.0 mL) was added HATU (0.59 g, 1.55 mmol, 1.5 eq.) and DIPEA (0.53 mL, 3.11 mmol, 3.0 eq.) at RT under nitrogen atmosphere, followed by addition of(S)-1-aminopropan-2-ol CAS: 100927-10-4 (0.21 g, 1.24 mmol, 1.2 eq.) at 0 C. stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (30 mL) and extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.3 and evaporated under vacuum to get crude product. The crude was purified by column chromatography using silica gel (230-400 mesh) (eluting with 30% Ethyl Acetate in Hexane) to afford tert-butyl (R)-(1-(8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamido) propan-2-yl) carbamate (A113) (0.22 g, 0.49 mmol, Yield 47.82%)

    [1301] LCMS-(Method A): 2.47 min, 96.11%, 254.0 nm MS: ES+446.38 (M+1)

    [1302] .sup.1H NMR (DMSO, 400 MHz): ppm 9.25 (s, 1H), 8.78 (s, 2H), 8.00 (d, J=6.0 Hz, 1H), 7.64 (t, J=14.4 Hz, 2H), 6.81 (d, J=8.0 Hz, 1H), 5.76 (br s, 1H), 3.77 (br s, 1H), 3.15 (s, 2H), 2.89 (br s, 2H), 2.83-2.67 (m, 2H), 2.25-2.20 (m, 2H), 1.35 (s, 9H), 1.05 (d, J=6.4 Hz, 3H).

    Step-2

    [1303] To a stirred solution of A113 (0.22 g, 0.49 mmol, 1.0 eq.) in dioxane (2.0 mL) was added 4M HCl in Dioxane (4 mL, 2.0 eq.) to the reaction mixture under the N.sub.2 atmosphere. The resulting mixture was stirred at room temperature for 4 h. TLC indicated the completion of reaction; the reaction mixture was concentrated under reduced pressure to yield (R)N-(2-aminopropyl)-8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 134) (0.047 g, 0.140 mmol, Yield 27.56%)

    [1304] .sup.1H NMR (MeOD, 400 MHz): ppm 9.47 (s, 2H), 8.30 (d, J=8.0 Hz, 1H), 8.03 (d, J=7.2 Hz, 1H), 7.96 (t, J=8.0 Hz, 1H), 5.93 (s, 1H), 3.75-3.61 (m, 3H), 2.91-2.33 (m, 4H), 2.42-2.33 (m, 2H), 1.42 (d, J=6.8 Hz, 3H).

    [1305] Note: CONH and NH.sub.2 proton exchanged in MeOD NMR.

    [1306] .sup.1H NMR (DMSO, 400 MHz): ppm 9.33 (d, J=2.0 Hz, 1H), 9.15 (t, J=5.2 Hz, 1H), 8.92 (d, J=1.6 Hz, 1H), 8.04 (d, J=7.2 Hz, 4H), 7.70-7.64 (m, 2H), 5.77 (s, 1H), 2.90-2.67 (m, 4H), 2.28-2.17 (m, 2H), 1.25 (d, J=6.4 Hz, 3H). Note: CH.sub.2 proton merged in DMSO solvent peak.

    [1307] LCMS(Method A): 1.66 min, 98.72%, 254.0 nm

    [1308] HPLC (Method A): 8.13 min, 97.58%, 254.0 nm

    [1309] Chiral HPLC5.65 min, 95.87%, 254.0 nm

    Example 126Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxypropyl)quinoline-3-carboxamide (Compound 135)

    ##STR00353##

    Step-1

    [1310] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.150 g, 0.51 mmol, 1.0 eq.) in DMF (1.0 mL), was added DIPEA (0.20 g, 1.55 mmol, 3.0 eq.) and HATU (0.295 g, 0.77 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., 3-aminopropan-1-ol (CAS: No: 156-87-6) (0.042 g, 0.57 mmol, 1.1 eq.) was added at same temperature and the resulting reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (15 mL) and extracted with ethyl acetate (15 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 Mesh) as a stationary phase (50% Ethyl acetate in Hexane) to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxypropyl)quinoline-3-carboxamide (Compound 135) (0.060 g, 0.173 mmol, Yield 33.40%).

    [1311] .sup.1H NMR (DMSO, 400 MHz): ppm 9.25 (s, 1H), 8.79 (s, 2H), 8.02 (d, J=6.0 Hz, 1H), 7.65-7.63 (m, 2H), 5.75 (br s, 1H), 4.52 (br s, 1H), 3.50 (d, J=4.8 Hz, 2H), 3.38 (d, J=5.6 Hz, 2H), 2.90 (s, 2H), 2.79-2.75 (m, 2H), 2.22 (s, 2H), 1.74-173 (m, 2H).

    [1312] LCMS (Method A): 1.963 min, 95.50%, 254.0 nm, MS: ES+347.4 (M+1)

    [1313] HPLC (Method B): 7.06 min, 100%, 254 nm.

    Example 127Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxy-2-methylpropyl)quinoline-3-carboxamide (Compound 136)

    ##STR00354##

    Step-1

    [1314] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.1 g, 0.34 mmol, 1.0 eq.) in DMF (2.0 mL) was added HATU (0.19 g, 0.51 mmol, 1.5 eq.) and DIPEA (0.13 g, 1.037 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., 3-amino-2-methylpropan-1-ol (A86) (0.034 g, 0.381 mmol, 1.1 eq.) was added and the resulting reaction mixture was stirred from 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (3.0 mL) and extracted with ethyl acetate (10 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (50% Ethyl acetate in Hexane) to afford light brown gummy 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxy-2-methylpropyl)quinoline-3-carboxamide (Compound 136) (0.012 g, 0.033 mmol, Yield: 4.81%).

    [1315] .sup.1H-NMR (DMSO, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 8.76 (t, J=5.6 Hz, 1H), 8.03 (dd, J=2.0, 7.2 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (s, 1H), 4.55 (t, J=5.2 Hz, 1H), 3.22-3.16 (m, 1H), 2.90 (br s, 2H), 2.83-2.75 (m, 2H), 2.27-2.17 (m, 2H), 1.90-1.85 (m, 1H), 0.90 (d, J=6.4 Hz, 3H). Note: 3H merged in moisture peak which is clearly visible in D.sub.2O NMR.

    [1316] LCMS (Method A): 2.047 min, 95.84%, 254.0 nm, MS: ES+361.3 (M+1)

    [1317] HPLC (Method A): 7.31 min, 95.64%, 254 nm.

    Example 128Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxybutyl)quinoline-3-carboxamide (Compound 137)

    ##STR00355##

    Step-1

    [1318] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A25) (0.1 g, 0.34 mmol, 1.0 eq.), in DMF (1.0 mL), was added DIPEA (0.130 g, 1.03 mmol, 3.0 eq.) and HATU (0.19 g, 0.51 mmol, 1.5 eq.), at 0 C. under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., 4-aminobutan-2-ol (A87) (0.046 g, 0.51 mmol, 1.5 eq.) was added at same temperature and the resulting reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (5 mL) and extracted with ethyl acetate (15 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica (230-400 mesh) as stationary phase (40% Ethyl acetate in Hexane) to afford light brown 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-hydroxy butyl)quinoline-3-carboxamide (Compound 137) (0.037 g, 0.10 mmol, Yield 26.69%).

    [1319] .sup.1H NMR (DMSO, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.79-8.75 (m, 2H), 8.02 (dd, J=2.0, 7.6 Hz, 1H), 7.67-7.62 (m, 2H), 5.76 (s, 1H), 4.55 (d, J=4.8 Hz, 1H), 3.73-3.70 (m, 1H), 3.42-3.37 (m, 2H), 2.90 (br s, 2H), 2.78 (t, J=14.2 Hz, 2H), 2.25-2.18 (m, 2H), 1.66-1.59 (m, 2H), 1.10 (d, J=6.4 Hz, 3H).

    [1320] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 7.98 (dd, J=1.6, 8.0 Hz, 1H), 7.69-7.62 (m, 2H), 5.76 (br s, 1H), 3.94-3.86 (m, 1H), 3.64-3.50 (m, 2H), 2.89-2.86 (t, J=4.8 Hz, 2H), 2.78 (t, J=14.0 Hz, 2H), 2.34-2.19 (m, 2H), 1.88-1.72 (m, 2H), 1.25 (d, J=6.0 Hz, 3H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1321] LCMS (Method A): 2.033 min, 95.63%, 254.0 nm, MS: ES+361.4 (M+1) HPLC (Method B): 7.19 min, 95.11%, 220 nm Chiral HPLC: Peak-1: 5.68 min, 49.42%, 240 nm; Peak-2:6.38 min, 49.84%, 240 nm.

    Example 129Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-isopropyl-6-methoxyquinoline-3-carboxamide (Compound 138)

    ##STR00356##

    Step-1

    [1322] To a stirred solution of 2-(4,4-difluorocyclohex-1-en-1-yl)-4, 4, 5,5-tetramethyl-1, 3, 2-dioxaborolane (2.72 g, 11.14 mmol, 1.5 eq.), methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (2.20 g, 7.43 mmol, 1.0 eq.) and Na.sub.2CO.sub.3 (1.56 g, 14.86 mmol, 2.0 eq.) in Dioxane (40 mL) and water (10 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (0.543 g, 0.743 mmol, 0.1 eq.) under N.sub.2. The resulting mixture was stirred at 100 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (200 mL) and extracted with EtOAc (2250 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford the crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (32% EtOAc in Hexane) afforded methyl 8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylate (A114) (1.66 g, 4.98 mmol, Yield: 67.02%).

    [1323] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.13 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.8 Hz, 1H), 7.56 (d, J=2.8 Hz, 1H), 7.32 (d, J=2.8 Hz, 1H), 5.79 (br s, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 2.88-2.85 (m, 2H), 2.81-2.74 (m, 2H), 2.74-2.59 (m, 2H).

    [1324] LCMS (Method A): 2.654 min, 97.43%, 254.0 nm, MS: ES+334.3 (M+1)

    Step-2

    [1325] A solution of methyl 8-(4,4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylate (A114) (1.66 g, 4.98 mmol, 1.0 eq.) and LiOH (0.627 g, 14.94 mmol, 3.0 eq.) in THF:H.sub.2O (10 mL, 7:3) was prepared at room temperature. The resulting mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was concentrated under reduced pressure and obtained residue was poured onto 1 N HCl solution, then filtered off to afford the desired product (A115) 8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (0.925 g, 2.89 mmol, Yield: 58.16%).

    [1326] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.46 (s, 1H), 9.13 (d, J=2.0 Hz, 1H), 8.83 (d, J=2.0 Hz, 1H), 7.54 (d, J=2.8 Hz, 1H), 7.30 (d, J=2.8 Hz, 1H), 5.78 (br s, 1H), 3.91 (s, 3H), 2.88-2.86 (m, 2H), 2.81-2.67 (m, 2H), 2.25-2.20 (m, 2H).

    [1327] LCMS (Method A): 2.066 min, 100%, 254.0 nm, MS: ES+320.3 (M+1)

    Step-3

    [1328] To a stirred solution of 8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (A115) (0.100 g, 0.313 mmol, 1.0 eq.) in DMF (10 mL), was added isopropyl amine CAS: 75-31-0 (0.023 mg, 0.313 mmol, 1.0 eq.), DIPEA (0.122 g, 0.939 mmol, 3.0 eq.) and HATU (0.178 g, 0.470 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice cold water (50 mL), and solid obtained was filtered and vacuum dried to afford 8-(4, 4-difluorocyclohex-1-en-1-yl)-N-isopropyl-6-methoxyquinoline-3-carboxamide (Compound 138) (0.027 g, 0.074 mmol, 23.64%)

    [1329] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.08 (d, J=2.0 Hz, 1H), 8.67 (d, J=2.0 Hz, 1H), 8.54 (d, J=7.4 Hz, 1H), 7.40 (d, J=2.8 Hz, 1H), 7.26 (d, J=2.8 Hz, 1H), 5.78 (br s, 1H), 4.17-4.12 (m, 1H), 3.91 (s, 3H), 2.89-2.88 (m, 2H), 2.78-2.73 (m, 2H), 2.24-2.17 (m, 2H), 1.21 (d, J=6.4 Hz, 6H).

    [1330] HPLC (Method A): 8.29 min, 99.22%, 254.0 nm.

    [1331] LCMS (Method A): 2.346 min, 97.75%, 254.0 nm, MS: ES+361.47 (M+1)

    Example 130Synthesis of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 139)

    ##STR00357##

    Step-1

    [1332] To a stirred solution of 8-(4,4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (A115) (0.10 g, 0.313 mmol, 1.0 eq.) in DMF (15 mL), was added D-alinol CAS: 35320-23-1 (0.023 g, 0.313 mmol, 1.0 eq.), DIPEA (0.122 g, 0.939 mmol, 3.0 eq.) and HATU (0.178 g, 0.470 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (40 mL) and stirred for 15 mins. The solid obtained was filtered and concentrated under vacuum to afford (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 139) (0.036 g, 0.088 mmol, 28.15%)

    [1333] .sup.1H NMR (DMSO-d.sub.6 400 MHz): ppm, 9.09 (d, J=2.0 Hz, 1H), 8.68 (d, J=2.0 Hz, 1H), 8.43 (d, J=8.0 Hz, 1H), 7.40 (d, J=2.8 Hz, 1H), 7.26 (d, J=2.8 Hz, 1H), 5.78 (br s, 1H), 4.78 (t, J=5.6 Hz, 1H), 4.10-4.05 (m, 1H), 3.91 (s, 3H), 3.53-3.47 (m, 1H), 3.47-3.33 (m, 1H), 2.88 (br s, 2H), 2.81-2.78 (m, 2H), 2.25-2.19 (m, 2H), 1.22 (d, J=6.8 Hz, 3H). Note: one proton merged in DMSO moisture peak.

    [1334] HPLC (Method A): 7.104 min, 95.77%, 254.0 nm.

    [1335] LCMS (Method A): 1.914 min, 97.10%, 254.0 nm, MS: ES+377.4 (M+1)

    Example 131Synthesis of N-((1H-pyrazol-3-yl)methyl)-8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxamide (Compound 140)

    ##STR00358##

    Step-1

    [1336] To a stirred solution of A115 (0.15 g, 0.383 mmol, 1.0 eq.) in DMF (2 mL) was added HATU (0.291 g, 0.766 mmol, 2.0 eq.) and DIPEA (0.148 g, 1.14 mmol, 3.0 eq.) respectively at 0 C. Followed by addition of CAS No: 1196153-72-6 (1H-Pyrazol-3-yl) methanamine hydrochloride) (0.076 g, 0.574 mmol, 1.5 eq.) and was maintained for 2 h at RT. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (350 mL), combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford the crude. The crude was purified by flash column chromatography by eluting with 50% Ethyl Acetate in Hexane to afford N-((1H-pyrazol-3-yl)methyl)-8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxamide (Compound 140) (0.114 g, 0.286 mmol, Yield: 60.91%).

    [1337] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.63 (br s, 1H), 9.21 (br s, 1H), 9.11 (d, J=2.0 Hz, 1H), 8.71 (d, J=2.4 Hz, 1H), 7.65 (d, J=6.8 Hz, 1H), 7.40 (d, J=2.8 Hz, 1H), 7.26 (d, J=3.2 Hz, 1H), 6.22 (d, J=1.6 Hz, 1H), 5.77 (d, J=6.8 Hz, 1H), 4.53 (d, J=3.6 Hz, 2H), 3.91 (s, 3H), 2.86-2.83 (m, 2H) 2.74 (t, J=1.6 Hz, 2H) 2.26-2.15 (m, 2H).

    [1338] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.10 (d, J=2.4 Hz, 1H), 8.67 (d, J=2.4 Hz, 1H), 9.21 (br. s, 1H), 7.32-7.29 (m, 2H), 6.37 (d, J=2.0 Hz, 1H), 5.75 (br. s, 1H), 4.70 (s, 2H), 3.97 (s, 3H), 2.86-2.83 (m, 2H), 2.80-2.73 (m, 2H), 2.33-2.22 (m, 2H). Note: CONH and NH proton exchanged in MeOD NMR.

    [1339] LCMS (Method-A): 2.04 min, 96.98%, 254 nm, MS: ES+399 (M), (M+1)

    [1340] HPLC (Method-A): 7.16 min, 99.27%, 254 nm,

    Example 132Synthesis of (R)-8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 141)

    ##STR00359##

    Step-1

    [1341] To a stirred solution of A115 (0.1 g, 0.313 mmol, 1.0 eq.), in DMF (1.0 mL) was added HATU (0.178 g, 0.469 mmol, 1.5 eq.), at 0 C. under the N.sub.2 atmosphere. The resulting mixture was stirred at 0 C. for 15 min. then DIPEA (0.121 g, 0.939 mmol, 3.0 eq.), was added and stirred at RT for 15 min. After 15 minutes A61 (0.069 g, 0.469 mmol, 1.5 eq.) was added and resulting mixture was allowed to stirred at RT for 16 h. TLC indicated the completion of reaction; water (3 mL) was added and extracted with ethyl acetate (210 mL). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (35% Ethyl acetate in Hexane) to afford (R)-8-(4, 4-difluorocyclohex-1-en-1-yl)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 141) (0.041 g, 0.099 mmol, Yield 31.66%)

    [1342] .sup.1H NMR (DMSO, 400 MHz): ppm 9.31 (d, J=7.6 Hz, 1H), 9.11 (d, J=1.6 Hz, 1H), 8.73 (d, J=1.6 Hz, 1H), 8.08 (br. s, 1H), 7.42 (d, J=2.4 Hz, 1H), 7.28 (d, J=2.4 Hz, 1H), 7.19 (s, 1H), 5.79 (br. s, 1H), 5.40-5.33 (m, 1H), 3.91 (s, 3H), 2.88 (br. s, 2H), 2.82-2.74 (m, 2H), 2.24-2.17 (m, 2H), 1.60 (d, J=6.8 Hz, 3H).

    [1343] LCMS (Method A): 2.093 min, 95.44%, 254.0 nm, MS: ES+414.4 (M+1)

    [1344] HPLC (Method A): 7.94 min, 98.97%, 254 nm

    [1345] Chiral HPLC: 8.25 min, 98.63%, 254 nm

    Example 133Synthesis of 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-(methyl sulfonamido)propyl)quinoline-3-carboxamide (Compound 142)

    ##STR00360##

    Step-1

    [1346] To a stirred solution of, A25 (0.1 g, 0.346 mmol, 1.0 eq.), in DMF in a 10 mL glass vial, was added DIPEA (0.15 mL, 1.035 mmol, 3.0 eq.) and HATU (0.197 g, 0.517 mmol, 1.5 eq.) at 0 C. Followed by addition of (A83) N-(3-aminopropyl) methanesulfonamide hydrochloride (0.078 g, 0.414 mmol, 1.2 equiv). The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (30 mL) and extracted with EtOAc (30 mL) three times, organic layer was dried over Na.sub.2SO.sub.4 and evaporated under vacuum. Crude was purified by flash column chromatography on silica gel (100-200 mesh) (desired product eluted in 25% EtOAc in hexane) to afford 8-(4,4-difluorocyclohex-1-en-1-yl)-N-(3-(methylsulfonamido)propyl)quinoline-3-carboxamide (Compound 142) (0.103 g, 0.229 mmol, Yield: 74.54%)

    [1347] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.26 (d, J=2 Hz, 1H), 8.79 (d, J=1.6 Hz, 2H), 8.03 (dd, J=4 Hz, J=7.2 Hz, 1H), 7.67-7.62 (m, 2H), 7.04 (t, J=6 Hz, 1H), 5.76 (br s, 1H), 3.44-3.39 (m, 2H), 3.04 (q, J=6.8 Hz, 2H), 2.91 (s, 3H), 2.83-2.67 (m, 2H), 2.27-2.17 (m, 2H), 1.81-1.74 (m, 2H), 1.81-1.74 (m, 2H).

    [1348] .sup.1H NMR (MeOD, 400 MHz); ppm 9.26 (d, J=2 Hz, 1H), 8.76 (d, J=1.6 Hz, 1H), 7.98 (dd, J=4 Hz, J=7.2 Hz, 1H), 7.70-7.63 (m, 2H), 5.75 (br s, 1H), 3.57 (t, J=6.8 Hz, 2H), 3.21 (t, J=8.5 Hz, 2H), 3.01 (s, 3H), 2.87 (m, J=12.8 Hz, 2H), 2.78 (t, J=14.8 Hz, 2H), 2.34-2.25 (m, 2H). 1.96-1.89 (m, 2H).

    [1349] LCMS (Method A): 2.065 min, 95.39%, 254.0 nm MS: ES+424.68 [M+H]

    [1350] HPLC (Method A): 7.09 min, 95.12%, 254.0 nm

    Example 134Synthesis of (R)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 143)

    ##STR00361##

    Step-1

    [1351] A solution of methyl 8-bromoquinoline-3-carboxylate (A13) (0.5 g, 1.87 mmol, 1.0 eq.), 2-(4, 4-dimethylcyclohex-1-en-1-yl)-4,4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (CAS: 859217-67-7) (purchased from combi block) (0.44 g, 1.87 mmol, 1.0 eq.) and Na.sub.2CO.sub.3 (0.594 g, 5.61 mmol, 3.0 eq.) in Dioxane:water (4:1) was prepared in 30 mL of glass vial at room temperature under N.sub.2 atmosphere. The reaction solution was degassed by N.sub.2 for 15 minutes at room temperature. To this reaction solution, PdCl.sub.2dppf (0.136 g, 0.187 mmol, 0.1 eq.) was added at same temperature. The glass vial was sealed with cap and heated to 110 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was cooled to room temperature, diluted with EtOAc (10 mL), filtered it through celite bed, washed it with EtOAc (30 mL) and filtrate was concentrated under reduced pressure to afford crude product. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as a stationary phase (desired product eluted in hexane) to afford methyl 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylate (A116) (0.243 g, 0.822 mmol, Yield: 43.78%).

    [1352] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.29 (d, J=2.0 Hz, 1H), 8.99 (d, J=2.0 Hz, 1H), 8.10 (dd, J=7.2 Hz, 2.0 Hz, 1H), 7.68-7.62 (m, 2H), 5.74 (br s, 1H), 3.95 (s, 3H), 2.60 (d, J=1.6 Hz, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.04 (s, 6H).

    [1353] LCMS (Method A): 2.174 min, 98.68%, 254 nm, MS: ES+296.2 (M+1)

    Step-2

    [1354] A stirred solution of methyl 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylate (A116) (0.243 g, 0.823 mmol, 1.0 eq.) in MeOH:water (7:3) was prepared in 30 mL of glass vial at room temperature. To this reaction solution, NaOH (0.065 g, 1.647 mmol, 2.0 eq.) was added at same temperature. The glass vial was sealed with cap and heated to 50 C. for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was directly concentrated under reduced pressure and acidified by using aq. solution of citric acid until pH became acidic to yield precipitate. The precipitate was filtered through Buchner funnel, washed with water (10 mL) and dried under vacuum to afford 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A117) (0.150 g, 0.533 mmol, Yield: 64.913).

    [1355] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 13.49 (br s, 1H), 9.28 (d, J=2.4 Hz, 1H), 8.93 (d, J=2.0 Hz, 1H), 8.07 (dd, J=2.4 Hz & 7.2 Hz, 1H), 7.76-7.61 (m, 2H), 5.74 (br s, 1H), 2.60 (br s, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.04 (s, 6H).

    [1356] LCMS (Method A): 2.734 min, 100%, 254 nm, MS: ES+282.2 (M+1)

    Step 3

    [1357] A stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A117) (0.09 g, 0.319 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.16 mL, 0.959 mmol, 3.0 eq.) and HATU (0.182 g, 0.479 mmol, 1.5 eq.) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, (R)-2-Aminopropan-1-ol, CAS: 35320-23-1 (0.024 g, 0.319 mmol, 1.0 eq.) was added at 0 C. Then the resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (15 mL) and extracted with ethyl acetate (202), and the combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to obtain crude product which was purified by normal phase column chromatography using hexane and ethyl acetate (desired product was eluted at 48% ethyl acetate in hexane) further purified by preparative TLC (100% EtOAc as mobile phase) to afford (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 143) (0.034 g, 0.100 mmol, Yield: 31.48%).

    [1358] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.26 (d, J=2.0 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.46 (d, J=7.6 Hz, 1H), 7.98-7.95 (m, 1H) 7.61-760 (m, 2H), 5.74 (br s, 1H), 4.79 (t, J=5.6 Hz, 1H), 4.09-4.06 (m, 1H), 3.53-3.47 (m, 1H), 3.41-3.35 (m, 1H), 2.61 (br s, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.0 Hz, 2H), 1.17 (d, J=6.8 Hz, 3H), 1.05 (s, 6H).

    [1359] LCMS (Method A): 2.411 min, 100%, 254 nm, MS: ES+339.16 (M+1)

    [1360] HPLC (Method A): 8.81 min, 98.61%, 210 nm

    Example 135Synthesis of (R)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 144)

    ##STR00362##

    Step-1

    [1361] To a stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.1 g, 0.355 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.270 g, 0.710 mmol, 2.0 eq.) and DIPEA (0.18 mL, 1.066 mmol, 3.0 eq.) at 0 C. After 10 min of stirring, (R)-1-(oxazol-2-yl)ethan-1-amine hydrochloride (A61) (0.048 g, 0.426 mmol, 1.2 eq.) was added at 0 C. and the resulting reaction mixture was stirred at RT for 6 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) and dried under reduced pressure then purified by column chromatography and eluted with 0-2% MeOH in DCM to afford (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 144) (0.023 g, 0.061 mmol, Yield: 17.23%).

    [1362] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.33 (d, J=8.0 Hz, 1H), 9.28 (d, J=2.4 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 7.98 (t, J=4.8 Hz, 1H), 7.62 (d, J=4.8 Hz, 2H), 7.18 (s, 1H), 5.75 (br s, 1H), 5.39-5.36 (m, 1H), 2.43-2.40 (m, 2H), 2.016 (br s, 2H), 1.60 (d, J=6.8 Hz, 3H), 1.54 (t, J=6.4 Hz, 2H), 1.05 (s, 6H).

    [1363] LCMS (Method A): 2.694 min, 95.96%, 254 nm, MS: ES+376.22 (M+1)

    [1364] HPLC (Method A): 9.80 min, 96.80%, 254 nm

    [1365] Chiral HPLC: 7.72 min, 97.48%, 240 nm

    Example 136Synthesis of(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 145)

    ##STR00363##

    Step-1

    [1366] A stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.05 g, 0.177 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.15 mL, 0.884 mmol, 5.0 eq.) and HATU (0.101 g, 0.266 mmol, 1.5 eq.) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, A110 (0.026 g, 0.177 mmol, 1.0 eq.) was added at 0 C. Then the resulting reaction mixture was stirred at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (25 mL) and extracted with ethyl acetate (302), and combined organics were dried over Na.sub.2SO.sub.4 and filtered, then filtrate was concentrated under reduce pressure to obtain crude product which was purified by normal phase column chromatography (Desired product was eluted at 40% ethyl acetate in hexane) to afford(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 145) (0.029 g, 0.077 mmol, Yield: 43.93%).

    [1367] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.34 (d, J=7.6 Hz, 1H), 9.28 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.08 (s, 1H) 7.98 (t, J=4.8 Hz, 1H), 7.62 (d, J=4.8 Hz, 2H), 7.19 (s, 1H), 5.74 (s, 1H), 5.37-5.34 (m, 1H), 2.61-2.50 (m, 2H), 2.08 (br s, 2H), 1.70 (d, J=6.8 Hz, 3H), 1.52 (t, J=6.0 Hz, 2H), 1.04 (s, 6H).

    [1368] LCMS (Method A): 2.679 min, 100%, 254 nm, MS: ES+376.17 (M+1)

    [1369] HPLC (Method A): 9.780 min, 98.73%, 210 nm

    Example 137Synthesis of N-((1H-pyrazol-5-yl)methyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 146)

    ##STR00364##

    Step-1

    [1370] A stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.05 g, 0.17 mmol, 1.0 eq.) in DMF (1.0 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.15 mL, 0.88 mmol, 5.0 eq.) and HATU (0.10 g, 0.26 mmol, 1.5 eq.) were added under nitrogen atmosphere. After 30 min of stirring at 0 C., (1H-pyrazol-5-yl) methenamine hydrochloride (CAS: 1196153-72-6) (0.023 g, 0.17 mmol, 1.0 eq.) was added at same temperature. Then the resulting reaction mixture was stirred from 0 C. to RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with cold water (5 mL) and extracted with EtOAc (35 mL). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as a stationary phase (desired product eluted in 2% MeOH in DCM) to afford N-((1H-pyrazol-5-yl)methyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 146) (0.033 g, 0.09 mmol, Yield: 51.56%).

    [1371] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.63 (s, 1H), 9.28-9.23 (m, 2H two signals merged together), 8.82 (d, J=2.4 Hz, 1H), 7.96 (t, J=4.8 Hz, 1H), 7.66-7.60 (m, 3H), 6.23 (s, 1H), 5.74 (br s, 1H), 4.54 (br s, 1H), 2.61 (br s, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.04 (s, 6H).

    [1372] VT .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.45 (s, 1H), 9.28 (d, J=1.6 Hz, 1H), 8.97 (br s, 1H), 8.78 (d, J=1.6 Hz, 1H), 7.94-7.92 (m, 1H), 7.61-7.58 (m, 3H), 6.24 (s, 1H), 5.77 (s, 1H), 4.57 (d, J=4.4 Hz, 2H), 2.64-2.59 (br s, 2H), 2.04 (br s, 1H), 1.56 (t, J=6.4 Hz, 2H), 1.07 (s, 6H).

    [1373] LCMS (Method A): 2.450 min, 100%, 254 nm, MS: ES+361.2 (M+1)

    [1374] HPLC (Method A): 8.80 min, 100%, 254 nm

    Example 138Synthesis of 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-((4-methyl-1H-pyrazol-5-yl)methyl)quinoline-3-carboxamide (Compound 147)

    ##STR00365##

    Step-1

    [1375] A stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.05 g, 0.177 mmol, 1.0 eq.) in DMF (0.5 mL) was prepared in 10 mL of glass vial at room temperature. To this reaction solution, DIPEA (0.09 mL, 0.533 mmol, 3.0 eq.) and HATU (0.101 g, 0.266 mmol, 1.5 eq.) were added at same temperature under nitrogen atmosphere. After 10 min of stirring, CAS: 2173991-88-1 (4-Methyl-1H-pyrazol-3-yl) methanamine dihydrochloride, (0.032 g, 0.177 mmol, 1.0 eq.) was added at 0 C. The resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured into cold water (15 mL) to obtain precipitate. The precipitate was filtered through Bchner funnel and washed with water (20 mL) and dried over high vacuum then crude obtained was purified by preparative TLC (100% EtOAc as mobile phase) to afford 8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-((4-methyl-1H-pyrazol-5-yl)methyl)quinoline-3-carboxamide (Compound 147) (0.017 g, 0.045 mmol, Yield: 25.54%)

    [1376] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.38 (s, 1H), 9.27 (d, J=2.0 Hz, 1H), 9.09 (br s, 1H), 8.81 (d, J=2.0 Hz, 1H), 7.95 (t, J=4.8 Hz, 1H) 7.60 (d, J=7.6 Hz, 2H), 7.44 (br s, 1H), 5.92-5.73 (m, 1H), 4.60-4.51 (m, 2H), 2.02 (s, 5H), 1.52 (t, J=6.0 Hz, 2H), 1.04 (s, 6H). (Note: 2H merged with DMSO solvent peak).

    [1377] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.0 Hz, 1H), 8.74 (s, 1H), 7.92-7.90 (m, 1H), 7.62-7.59 (m, 2H) 7.43 (br s, 1H), 5.77 (br s, 1H), 4.67 (br s, 2H), 2.61 (br s, 2H), 2.14 (s, 3H), 2.08 (br s, 2H), 1.63 (t, J=6.4 Hz, 2H), 1.09 (s, 6H). Note: CONH and NH proton exchanged in MeOD NMR.

    [1378] LCMS (Method A): 2.540 min, 99.36%, 254 nm, MS: ES+375.17 (M+1)

    [1379] HPLC (Method A): 9.20 min, 98.70%, 210 nm

    Example 139Synthesis of(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 148)

    ##STR00366##

    Step-1

    [1380] A stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.1 g, 0.35 mmol, 1 eq.) in THF (1 mL) were prepared in 10 mL glass vial at room temperature. To this reaction solution, DIPEA (0.13 g, 1.06 mmol, 3 eq.) was added at same temperature followed by addition of HATU (0.19 g, 0.52 mmol, 1.5 eq.) at 0 C. and reaction mixture stirred for 10 min. Then (CAS: 99636-32-5) (S)-(+)-1-methoxy-2-propylamine (0.03 g, 0.35 mmol, 1 eq.) was added and resulting reaction mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was extracted by EtOAc (20 mL3), combined organic layer was dried over Na.sub.2SO.sub.4, concentrated under reduced pressure to afford the crude. The obtained crude was purified by flash column chromatography using silica gel (230-400 mesh). (Eluent gradient 10% EtOAc:Hexane) to afford(S)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 148) (0.034, 0.096 mmol, Yield: 27.2%).

    [1381] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.25 (d, J=2 Hz, 1H), 8.77 (d, J=2 Hz, 1H), 8.59 (d, J=4 Hz, 1H), 7.99-7.96 (m, 1H), 7.63-7.60 (m, 2H), 5.74 (br s, 1H), 4.29-4.22 (m, 1H), 3.47-3.43 (m, 1H), 3.35-3.30 (m, 1H), 3.29 (s, 3H), 2.68-2.33 (m, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.18 (d, J=2.8 Hz, 3H), 1.10 (s, 6H).

    [1382] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.22 (s, 1H), 8.72 (s, 1H), 7.93-7.91 (m, 1H), 7.63-7.59 (m, 2H), 5.78 (br s, 1H), 4.43-4.38 (m, 1H), 3.57-3.53 (m, 1H), 3.50-3.46 (m, 1H), 3.36 (s, 3H), 2.63-2.61 (m, 2H), 2.08 (br s, 2H), 1.64 (t, J=6.4 Hz, 2H), 1.30 (d, J=6.8 Hz, 3H), 0.92 (s, 6H). Note: CONH proton exchanged in MeOD NMR.

    [1383] LCMS (Method A): 2.735 min, 100%, 254 nm, MS: ES+275M+1)

    [1384] HPLC (Method A): 10.22 min, 100%, 254 nm

    Example 140Synthesis of (R)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(4-(methylamino)-4-oxobutan-2-yl)quinoline-3-carboxamide (Compound 149)

    ##STR00367##

    Step-1

    [1385] A stirred solution of A121 (0.09 g, 0.245 mmol, 1.0 eq.) in DCM (1.0 mL) was prepared in 10 mL glass vial at 0 C. To this reaction solution was added TEA (0.1 mL, 0.368 mmol, 1.5 eq.), Ethylchloroformate (0.040 g, 0.368 mmol, 1.5 eq.) at 0 C. and stirred for 1 h. followed by addition of methyl amine (0.18 mL, 0.368 mmol, 1.5 eq.) at same temperature and resulting reaction mixture was again stirred at RT for 2 h. TLC indicated the completion of reaction. The resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (220 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtain crude product. The crude product was purified by combi-flash column chromatography using 230-400 mesh size silica and product was eluted at 25% EtOAc:Hexane to afford as a (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(4-(methylamino)-4-oxobutan-2-yl)quinoline-3-carboxamide (Compound 149) (0.065 g, 0.171 mmol, Yield: 69.89%).

    [1386] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.23 (d, J=1.6 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 8.61 (d, J=7.6 Hz, 1H), 7.98-7.96 (m, 1H), 7.86-7.85 (d, J=4.4 Hz, 1H), 7.61-7.60 (m, 1H), 5.74 (br s, 1H), 4.40-4.37 (m, 1H), 2.67-2.57 (m, 5H), 2.46-2.42 (m, 1H), 2.32-2.28 (m, 1H), 2.01 (br s, 2H), 1.52 (t, J=6.0 Hz, 2H), 1.19 (d, J=6.4 Hz, 3H), 1.05 (s, 6H).

    [1387] .sup.1H NMR (MeOD-d.sub.3, 400 MHz): ppm, 9.18 (d, J=2.0 Hz, 1H), 8.67 (d, J=2.0 Hz, 1H), 7.99 (br s, 1H), 7.90-7.88 (m, 1H), 7.61-7.58 (m, 2H), 5.76-5.74 (m, 1H), 4.56-4.50 (m, 1H), 3.23-3.17 (m, 1H), 2.72 (d, J=4.4 Hz, 3H), 2.60-2.54 (m, 3H), 2.48-2.43 (m, 1H), 2.05-2.05 (m, 2H), 1.61 (t, J=6.4 Hz, 2H), 1.33-1.28 (m, 3H), 1.05 (s, 6H). Note: CONH proton exchanged in MeOD NMR.

    [1388] LCMS (Method A): 2.336 min, 100.00%, 254 nm, MS: ES+380.27 (M+1)

    [1389] HPLC (Method B): 8.60 min, 100.00%, 254.0 nm

    [1390] Chiral HPLC (Method B): 9.06 min, 100.00%, 240.0 nm

    Example 141Synthesis of N-(cyanomethyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 150)

    ##STR00368##

    Step-1

    [1391] A stirred solution of A26 (0.05 g, 0.177 mmol, 1.0 eq.) in DMF (1 mL) was prepared in 10 mL glass vial at room temperature. To this reaction solution was added DIPEA (0.15 mL, 0.888 mmol, 5.0 eq.) and HATU (0.067 g, 0.177 mmol, 1.0 eq.) at RT and stirred for 10 min. Then addition of 2-aminoacetonitrile hydrochloride (CAS: 6011-14-9) (0.019 g, 0.213 mmol, 1.2 eq.) at same temperature and resulting reaction mixture was stirred at RT for 16 h, TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (230 mL). The combined organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtain crude product. The crude product was purified by combi-flash column chromatography using 230-400 mesh size silica and product was eluted at 0-30% EtOAc:Hexane to afford as a N-(cyanomethyl)-8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 150) (0.021 g, 0.065 mmol, Yield: 36.98%).

    [1392] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.55 (t, J=5.2 Hz, 1H), 9.25 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.64-7.61 (m, 2H), 5.74 (s, 1H), 4.41 (d, J=5.2 Hz, 2H), 2.61 (br s, 2H), 2.01 (br s, 2H), 1.53 (t, J=6.4 Hz, 2H), 1.05 (s, 6H).

    [1393] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.77 (d, J=2.4 Hz, 1H), 7.94 (dd, J=2.0 Hz and 5.2 Hz, 2H), 5.78 (s, 1H), 4.44 (s, 2H), 2.62 (d, J=2.0 Hz, 2H), 2.08 (d, J=2.8 Hz, 2H), 1.64 (d, J=6.4 Hz, 2H), 1.10 (s, 6H). Note: CONH proton exchanged in MeOD NMR.

    [1394] LCMS (Method A): 2.651 min, 100.0%, 254 nm, MS: ES+320.16 (M+1)

    [1395] HPLC (Method A): 9.66 min, 97.73%, 254 nm

    Example 142Synthesis of N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 151)

    ##STR00369##

    Step-1

    [1396] To a stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.1 g, 0.35 mmol, 1.0 eq.) in DMF (1.0 mL) was added HATU (0.20 g, 0.533 mmol, 1.5 eq.) at 0 C. Then after 10 min at same temperature DIPEA (0.18 mL, 0.106 mmol, 3.0 eq.) was added and stirred for another 10 min. After 10 min of stirring, 1-(1H-pyrazol-5-yl)ethan-1-amine (A67) (CAS: 1179072-43-5) (0.043 g, 0.390 mmol, 1.1 eq.) was added at 0 C. The resulting reaction mixture was stirred at RT for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was poured in cold water (5 mL) to obtain precipitate. The precipitate was filtered through Buchner funnel and washed with water (20 mL) and dried over high vacuum and purified by column chromatography and eluted with 50% EtOAC in Hexane to afford N-(1-(1H-pyrazol-5-yl)ethyl)-8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 151) (0.025 g, 0.066 mmol, Yield: 18.93%).

    [1397] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.58 (br s, 1H) 9.28 (d, J=2.4, 1H), 9.02 (br s, 1H), 8.82 (d, J=2.0 Hz, 1H), 7.97 (t, J=5.2 Hz, 1H), 7.63-7.60 (m, 3H), 6.25 (s, 1H), 5.74 (br s, 1H), 5.34-5.32 (m, 1H), 2.65-2.60 (m, 2H), 2.02-2.01 (m, 2H), 1.52 (t, J=6.8 Hz, 5H), 1.05 (s, 6H).

    [1398] LCMS (Method A): 2.486 min, 98.95%, 254 nm, MS: ES+375.27 (M+1)

    [1399] HPLC (Method A): 9.20 min, 98.06%, 254 nm

    Example 143Synthesis of (R)N-(1-cyano-3-(methylamino)-3-oxopropyl)-8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 152)

    ##STR00370##

    Step-1

    [1400] To a stirred solution of A26 (0.49 g, 1.75 mmol, 1.0 eq.) in DMF (5.0 mL) was added HATU (1.0 g, 2.63 mmol, 1.5 eq.) and DIPEA (0.98 g, 5.28 mmol, 3.0 eq.) at RT and stirred for 15 min. After 15 min, addition of A70 (0.55 g, 2.28 mmol, 1.3 eq.) at same temperature. Then the resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to afford crude product. The crude product was purified by manual column chromatography (desired product eluted in 3% MDC in MeOH) to afford benzyl(R)-3-cyano-3-(8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoate (A118) (0.32 g, 0.68 mmol, Yield: 40%)

    [1401] LCMS: 3.033 min, 40.35%, 220 nm, MS: ES+468.5 (M+1)

    Step-2

    [1402] To a stirred solution of A118 (0.32 g, 0.68 mmol, 1.0 eq.) in THF:MeOH (3.0 mL, 2:1 vol) was added aq. LiOH (1.0 mL, 1 vol of 1N solution). Then the resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 mL) acidified with 1N HCl and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to afford crude product (R)-3-cyano-3-(8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamido) propanoic acid (A119) (0.13 g, 0.34 mmol, Yield: 52%)

    [1403] LCMS: 2.43 min, 23.73%, 254 nm, MS: ES+378.4 (M+1)

    Step-3

    [1404] To a stirred solution of (A119) (0.12 g, 0.31 mmol, 1.0 eq.) in DCM (2.0 mL) were added EDC.Math.HCl (0.12 g, 4.75 mmol, 2.0 eq.) and HOBt (0.085 g, 6.34 mmol, 2.0 eq.) at RT and stirred for 10 min. After 10 min, addition of CH.sub.3NH.sub.2 (2 M solution in THF) (0.37 mL, 6.34 mmol, 2 eq.)) at RT and resulting mixture was again stirred at same temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 mL) and extracted with EtOAc (320 mL). The combined organic layer was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude product. The crude product was purified by Prep HPLC purification (Method-A) to afford (R)N-(1-cyano-3-(methylamino)-3-oxopropyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 152) (0.0075 g, 0.019 mmol, Yield: 6.25%). 1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.75 (d, J=2.4 Hz, 1H), 7.94 (dd, J=2.4 Hz & 7.6 Hz, 1H), 7.67-7.63 (m, 2H), 5.78 (s, 1H), 5.14 (t, J=7.2 Hz, 1H), 2.98 (t, J=6.0 Hz, 2H), 2.78 (s, 3H), 2.62 (d, J=1.6 Hz, 2H), 2.08 (d, J=3.2 Hz, 2H), 1.64 (t, J=6.4 Hz, 2H), 1.10 (s, 6H). Note: CONH proton exchanged in MeOD NMR.

    [1405] HPLC (Method A): 8.81 min, 97.45%, 254 nm.

    [1406] LCMS (Method A): 2.511 min, 100%, 254 nm, MS: ES+391.3 (M+1)

    Example 144Synthesis of (R)N-(4-amino-4-oxobutan-2-yl)-8-(4, 4-dimethyl cyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 153)

    ##STR00371##

    Step-1

    [1407] A stirred solution of A26 (0.25 g, 0.888 mmol, 1.0 eq.) in DMF (4.0 mL) was prepared in 30 mL glass vial at room temperature. To this reaction solution were added DIPEA (0.45 mL, 2.665 mmol, 3.0 eq.), HATU (0.36 g, 0.888 mmol, 1.0 eq.) at RT and stirred for 10 min. Then addition of methyl (R)-3-aminobutanoate hydrochloride (CAS: 139243-54-2) (0.20 g, 1.332 mmol, 1.5 eq.) at same temperature and resulting reaction mixture was stirred at 0 C. to RT 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (230 mL). The combined organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtain crude product. The crude product was purified by combi-flash column chromatography (desired product eluted in 25% EtOAc:Hexane) to afford methyl (R)-3-(8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamido) butanoate (A120) (0.15 g, 0.394 mmol, Yield: 44.37%).

    [1408] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 8.67 (d, J=7.6 Hz, 1H), 8.00-7.97 (m, 1H), 7.63-7.67 (m, 2H), 5.74 (br s, 1H), 4.46-4.39 (m, 1H), 3.60 (s, 3H), 2.71-2.66 (m, 3H), 2.61 (br s, 3H), 2.58-2.56 (m, 3H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.30-1.15 (m, 3H), 1.05 (s, 6H).

    [1409] LCMS (Method A): 2.713 min, 94.72%, 254 nm, MS: ES+381.27 (M+1)

    Step-2

    [1410] A stirred solution of (A120) (0.15 g, 0.394 mmol, 1.0 eq.) in THF:H.sub.2O (1:1, 3.0 Ml, 2 vol) was prepared in 10 Ml glass vial at 0 C. To this reaction solution was added LiOH.Math.2H.sub.2O (0.05 g, 1.182 mmol, 3.0 eq.) and stirred the reaction mixture at RT for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 Ml) and extracted with diethyl ether (230 Ml). Then aqueous layer was acidified by aq. citric acid up to Ph 4 and again extracted with EtOAc (310 Ml). Then combined organic layer (after acidified) was dried over anhy. Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford (R)-3-(8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamido)butanoic acid (A121) (0.07 g, 0.191 mmol, Yield: 41.66%).

    [1411] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.25 (br s, 1H), 9.24 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 8.66 (d, J=7.6 Hz, 1H), 7.98-7.96 (m, 1H), 7.65-7.60 (m, 2H), 5.74 (s, 1H), 4.43-4.36 (m, 1H), 3.60 (s, 3H), 2.73-2.61 (m, 2H), 2.01 (br s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.30-1.15 (m, 3H), 1.24 (s, 6H).

    [1412] LCMS (Method A): 2.427 min, 99.45%, 254 nm, MS: ES+367.32 (M+1)

    Step-3

    [1413] A stirred solution of (A121) (0.06 g, 0.163 mmol, 1.0 eq.) in DCM (0.6 mL) was prepared in 10 mL glass vial at 0 C. To this reaction solution were added TEA (0.025 g, 0.245 mmol, 1.5 eq.), Ethylchloroformate (0.027 g, 0.245 mmol, 1.5 eq.) at 0 C. and stirred for 1 h. Then addition of aq. NH.sub.4OH (0.6 g, 10 vol) at same temperature and resulting reaction mixture was again stirred at 0 C. to RT 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (30 mL) and extracted with EtOAc (210 mL). The combined organic layer was dried on Na.sub.2SO.sub.4, filtered and concentrated under high vacuum to obtained crude product. The crude product was purified by combi-flash column chromatography (desired product eluted in 25% EtOAc:Hexane) to afford (R)N-(4-amino-4-oxobutan-2-yl)-8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxamide (Compound 153) (0.021 g, 0.057 mmol, Yield: 35.09%).

    [1414] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.4 Hz, 1H), 8.61 (d, J=8.0 Hz, 1H), 7.97 (dd, J=4.0 Hz & 6.0 Hz, 1H), 7.61-7.60 (m, 2H), 7.38 (br s, 1H), 6.87 (br s, 1H), 5.74 (s, 1H), 4.39 (m, 1H), 2.62-2.61 (m, 2H), 2.47-2.42 (m, 1H), 2.22-2.26 (m, 1H), 2.01 (d, J=3.2 Hz, 2H), 1.52 (t, J=6.8 Hz, 2H), 1.23-1.20 (m, 3H), 1.05 (s, 6H).

    [1415] .sup.1H NMR (MeOD-d.sub.3, 400 MHz): ppm, 9.22 (d, J=2.0 Hz, 1H), 8.71 (d, J=2.4 Hz, 1H), 7.92 (dd, J=2.8 Hz & 6.8 Hz, 1H), 7.64-7.61 (m, 2H), 6.87 (br s, 1H), 5.79-5.77 (m, 1H), 4.60-4.55 (m, 1H), 2.66-2.59 (m, 3H), 2.53-2.48 (m, 1H), 2.08 (d, J=3.6 Hz, 2H), 1.64 (t, J=6.4 Hz, 2H), 1.39-1.37 (m, 3H), 1.10 (s, 6H). Note: CONH and CONH2 protons exchanged in MeOD NMR.

    [1416] LCMS (Method A): 2.273 min, 99.73%, 254 nm, MS: ES+366.4 (M+1)

    [1417] HPLC (Method A): 8.25 min, 98.94%, 254.0 nm

    Example 145Synthesis of(S)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 154)

    ##STR00372##

    Step-1

    [1418] To a solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)quinoline-3-carboxylic acid (A26) (0.08 g, 0.284 mmol, 1.0 eq.) in DMF (2.0 mL), were added HATU (0.162 g, 0.42 mmol, 1.5 eq.) and DIPEA (0.15 mL, 0.85 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under N.sub.2 atmosphere. After 15 min of stirring at 0 C., (S)-2-amino-3-methoxypropan-1-ol (A50) (0.060 g, 0.568 mmol, 2.0 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with ethyl acetate (10 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (60% Ethyl acetate in hexane as gradient) to afford(S)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 154) (0.031 g, 0.084 mmol, Yield: 29.59%).

    [1419] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.27 (s, 1H), 8.80 (s, 1H), 8.51 (d, J=7.6 Hz, 1H), 7.98 (s, 1H), 7.62-7.61 (d, J=3.6 Hz, 2H), 5.75 (br s, 1H), 4.83 (s, 1H), 4.21-4.20 (m, 1H), 3.54-3.50 (m, 4H), 3.29 (s, 3H), 2.75-2.62 (m, 2H), 2.02 (s, 2H), 1.53 (s, 2H), 1.05 (s, 6H).

    [1420] LCMS (Method A): 2.40 min, 96.55%, 254.0 nm, MS: ES+369.4 (M+1)

    [1421] HPLC (Method A): 8.73 min, 96.49%, 254.0 nm

    [1422] Chiral HPLC (Method A): 8.73 min, 95.03%, 242.0 nm.

    Example 146Synthesis of 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-isopropyl-6-methoxyquinoline-3-carboxamide (Compound 155)

    ##STR00373##

    Step-1

    [1423] To a stirred solution of 2-(4, 4-dimethylcyclohex-1-en-1-yl)-4,4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane CAS: 859217-67-7 (1.84 g, 8.442 mmol, 1.0 eq.), methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (2.50 g, 8.442 mmol, 1.0 eq.) and Na.sub.2CO.sub.3 (1.77 g, 16.88 mmol, 2.0 eq.) in Dioxane (40 mL) and water (10 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (1.21 g, 1.688 mmol, 0.2 eq.) under N.sub.2. The resulting mixture was stirred at 110 C. for 8 h. TLC indicated the completion of reaction; the resulting reaction mixture was filtered through celite bed and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (85% EtOAc in Hexane) to afford (A122) 8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (1.2 g, 3.85 mmol, Yield: 45.60%). (Note: -observed one pot coupling and hydrolysis) .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.42 (br s, 1H), 9.11 (d, J=2.4 Hz, 1H), 8.80 (d, J=2.0 Hz, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.23 (d, J=2.8 Hz, 1H), 5.76 (br s, 1H), 3.91 (s, 3H), 2.57 (br s, 2H), 1.98 (br s, 2H), 1.50 (t, J=6.0 Hz, 2H), 1.02 (s, 6H).

    [1424] LCMS (Method A): 2.57 min, 78%, 254.0 nm, MS: ES+312

    Step-2

    [1425] To a stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (A122) (0.100 g, 0.321 mmol, 1.0 eq.) in DMF (10 mL), was added isopropylamine CAS: 75-31-0 (0.024 g, 0.321 mmol, 1.0 eq.), DIPEA (0.125 g, 0.963 mmol, 3.0 eq.) and HATU (0.182 g, 0.481 mmol, 1.5 eq.) then stirring continued at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted by EtOAc (275 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (26% EtOAc in Hexane) to afford 8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-isopropyl-6-methoxyquinoline-3-carboxamide (Compound 155) (0.041 g, 0.116 mmol, 36.23%)

    [1426] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.08 (d, J=2.4 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H), 8.51 (d, J=7.6 Hz, 1H), 7.36 (d, J=2.8 Hz, 1H), 7.19 (d, J=2.8 Hz, 1H), 5.75 (br s, 1H), 4.17-4.12 (m, 1H), 3.89 (s, 3H), 2.59 (br s, 2H), 1.99 (br s, 2H), 1.50 (t, J=6.0 Hz, 2H), 1.18 (d, J=9.2 Hz, 6H), 1.04 (s, 6H).

    [1427] HPLC (Method A): 8.50 min, 95.33%, 254.0 nm.

    [1428] LCMS (Method A): 2.796 min, 99.71%, 254.0 nm, MS: ES+353.4.

    Example 147Synthesis of N-isopropyl-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 156)

    ##STR00374##

    Step-1

    [1429] To a stirred solution of 4,4, 5, 5-tetramethyl-2-(spiro[2.5]oct-5-en-6-yl)-1, 3, 2-dioxaborolane (A40) (1.97 g, 8.442 mmol, 1.0 eq.), methyl 8-bromo-6-methoxyquinoline-3-carboxylate (A100) (2.50 g, 8.442 mmol, 1.0 eq.) and Na.sub.2CO.sub.3 (1.77 g, 16.884 mmol, 2.0 eq.) in Dioxane (40 mL) and water (10 mL) was added Pd(dppf)Cl.sub.2.Math.DCM (1.23 g, 1.688 mmol, 0.2 eq.) under N.sub.2 Atmosphere. The resulting mixture was stirred at 110 C. for 8 h. TLC indicated the completion of reaction; the resulting reaction mixture was filtered through celite bed and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (100-200 mesh) as stationary phase (desired product eluted in 78% EtOAc in Hexane) to afford 6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A123) (0.67 g, 2.16 mmol, Yield: 25.65%).

    [1430] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 13.42 (br s, 1H), 9.14 (d, J=2.4 Hz, 1H), 8.82 (d, J=2.4 Hz, 1H), 7.50 (d, J=2.8 Hz, 1H), 7.28 (d, J=2.8 Hz, 1H), 5.90 (br s, 1H), 3.91 (s, 3H), 2.66 (br s, 2H), 2.11 (br s, 2H), 1.54 (t, J=6.0 Hz, 2H), 0.39 (br s, 4H).

    [1431] LCMS (Method A): 2.496 min, 97.37%, 254.0 nm, MS: ES+310.4.

    Step 2

    [1432] To a stirred solution of 6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A123) (0.075 g, 0.242 mmol, 1.0 eq.) in DMF (10 mL), was added isopropyl amine (0.018 g, 0.242 mmol, 1.0 eq.), DIPEA (0.095 g, 0.726 mmol, 3.0 eq.) and HATU (0.138 g, 0.363 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted by EtOAc (275 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (100-200 mesh) as stationary phase (desired product eluted in 26% EtOAc in Hexane) to afford N-isopropyl-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 156) (0.014 g, 0.04 mmol, 16.52%)

    [1433] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.08 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H), 8.51 (d, J=7.6 Hz, 1H), 7.36 (d, J=2.8 Hz, 1H), 7.22 (d, J=2.8 Hz, 1H), 5.90 (br s, 1H), 4.17-4.12 (m, 1H), 3.90 (s, 3H), 2.67-2.61 (m, 2H), 2.12 (br s, 2H), 1.54 (t, J=6.0 Hz, 2H), 1.21 (d, J=6.4 Hz, 6H), 0.39 (br s, 4H).

    [1434] HPLC (Method A): 9.874 min, 96.18%, 254.0 nm.

    [1435] LCMS (Method A): 2.618 min, 97.24%, 254.0 nm, MS: ES+351.4.

    Example 148Synthesis of (R)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 157)

    ##STR00375##

    Step-1

    [1436] To a stirred solution of A122 (0.1 g, 0.321 mmol, 1.0 eq.), in DMF (2 mL), was added HATU (0.244 g, 0.643 mmol, 2.0 eq.) and DIPEA (0.124 g, 0.963 mmol, 3.0 eq.) respectively at 0 C., followed by addition of CAS No: 35320-23-1 (R)-2- Aminopropan-1-ol (0.036 g, 0.481 mmol, 1.5 eq.) and allow the reaction mixture to stir at RT for 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice water (50 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by flash column chromatography on silica gel (100-200 mesh) (Desired product eluted in 45% Ethyl Acetate in Hexane) to afford (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 157) (0.040 g, 0.108 mmol, Yield: 33.80%).

    [1437] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.09 (d, J=1.6 Hz, 1H), 8.65 (d, J=1.6 Hz, 1H), 8.39 (d, J=7.6 Hz, 1H), 7.35 (d, J=2.4 Hz, 1H), 7.19 (d, J=2.8 Hz, 1H), 5.75 (br s, 1H), 4.77 (t, J=5.6 Hz, 1H), 4.09-4.05 (m, 1H), 3.90 (s, 3H), 3.51-3.47 (m, 1H), 2.60 (br s, 2H), 2.00 (br s, 2H), 1.50 (t, J=6.0 Hz, 1H), 1.23 (s, 2H), 1.16 (d, J=6.4 Hz, 3H), 1.04 (s, 6H).

    [1438] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.06 (d, J=2.4 Hz, 1H), 8.62 (d, J=2.0 Hz, 1H), 7.27-7.23 (m, 2H), 5.78 (br. s, 1H), 4.31-4.24 (m, 1H), 3.96 (s, 3H), 3.67-3.65 (m, 2H), 2.59 (br. s, 1H), 2.07 (br. s, 2H), 1.62 (t, J=6.4 Hz, 1H), 1.32-1.30 (d, J=6.4 Hz, 4H), 1.09 (s, 6H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1439] LCMS (Method A): 2.40, 97.75%, 254 nm, MS: ES+369 (M), (M+1)

    [1440] HPLC (Method A): 8.96, 100%, 254 nm,

    Example 149Synthesis of N-((1H-pyrazol-4-yl)methyl)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxamide (Compound 158)

    ##STR00376##

    Step-1

    [1441] To a stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (A122) (0.100 g, 0.321 mmol, 1.0 eq.) in DMF (10 mL), was added (1H-pyrazol-4-yl) methanamine CAS: 1196153-72-6 (0.042 g, 0.321 mmol, 1.0 eq.), DIPEA (0.125 g, 0.963 mmol, 3.0 eq.) and HATU (0.182 g, 0.481 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted by EtOAc (275 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (100-200 mesh) as stationary phase (desired product eluted in 26% EtOAc in Hexane) to afford N-((1H-pyrazol-4-yl)methyl)-8-(4,4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxamide (Compound 158) (0.019 g, 0.048 mmol, Yield: 15.15%) 1H NMR (MeOD, 400 MHz): ppm, 9.09 (d, J=2.4 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H), 7.64 (m, 1H), 7.27 (dd, J=9.6, 2.8 Hz, 2H), 6.37 (br s, 1H), 5.79 (br s, 1H), 4.70 (br s, 2H), 3.99 (s, 3H), 2.59 (br s, 2H), 2.07 (br s, 2H), 1.63 (t, J=6.4 Hz, 2H), 1.08 (s, 6H). Note: CONH and NH proton exchanged in MeOD NMR.

    [1442] .sup.1H NMR (DMSO-d.sub.6 400 MHz): ppm, 12.62 (br s, 1H), 9.18 (br s, 1H), 9.10 (d, J=1.6 Hz, 1H), 8.69 (d, J=2.0 Hz, 1H), 7.66 (br s, 1H), 7.35 (d, J=2.4 Hz, 1H), 7.20 (d, J=2.8 Hz, 1H), 6.22 (br s, 1H), 5.77 (br. s, 1H), 4.53 (br s, 2H), 3.90 (s, 3H), 2.67-2.59 (m, 2H), 1.99 (br s, 2H), 1.51 (t, J=6.4 Hz, 2H), 1.04 (s, 6H).

    [1443] HPLC (Method A): 8.862 min, 95.24%, 254.0 nm.

    [1444] LCMS (Method A): 2.462 min, 95.89%, 254.0 nm, MS: ES+391.5 (M+1)

    Example 150Synthesis of (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 159)

    ##STR00377##

    Step-1

    [1445] To a stirred solution of A122 (0.07 g, 0.22 mmol, 1.0 eq.), (A61) (0.03 g, 0.27 mmol, 1.2 eq.) in DMF (4 mL), was added HATU (0.128 g, 0.337 mmol, 1.5 eq.) and DIPEA (0.11 mL, 0.67 mmol, 3.0 eq.), under the N.sub.2 atmosphere. Then the resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; After 16 h. water (20 mL) was added and resulting reaction mixture was extracted with ethyl acetate (330 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (10% MDC:MeOH) to afford (R)-8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 159) (0.019 g, 0.04 mmol, Yield 20.6%)

    [1446] .sup.1H NMR (MeOD, 400 MHz): ppm 9.08 (d, J=2.0 Hz, 2H), 8.67 (d, J=2.0 Hz, 2H), (7.92 (s, 1H), 7.26 (d, J=2.8 Hz, 2H), 7.24 (d, J=2.8 Hz, 2H) 7.18 (s, 1H), 5.79 (br. s, 1H), 5.51-5.45 (m, 1H), 3.96 (s, 3H), 2.59 (br. d, J=2.0 Hz, 2H), 2.80 (br. s, 2H), 1.72 (d, J=7.2 Hz, 3H), 1.63 (t, J=2.8 Hz, 2H), 1.09 (s, 6H).

    [1447] Note: CONH proton exchanged in MeOD NMR.

    [1448] .sup.1H NMR (DMSO, 400 MHz): ppm 9.28 (d, J=8.0 Hz, 1H), 9.10 (d, J=2.0 Hz, 1H), 8.70 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 7.37 (d, J=2.8 Hz, 1H), 7.20 (d, J=2.8 Hz, 1H), 7.18 (s, 1H), 5.76 (br s, 1H), 5.38-5.34 (m, 1H), 3.90 (s, 3H), 2.00 (s, 2H), 1.59 (d, J=7.2 Hz, 3H), 1.51 (t, J=6.4 Hz, 2H), 1.04 (s, 6H). Note: CH.sub.2 proton merged in DMSO Solvent peak.

    [1449] LCMS (Method A): 2.68 min, 99.83%, 210 nm M+H=406.37

    [1450] HPLC (Method A): 9.88 min, 99.19%, 254 nm

    [1451] Chiral HPLC: 3.90 min, 98.73%, 248 nm

    Example 151Synthesis of(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 160)

    ##STR00378##

    Step-1

    [1452] To a stirred solution of 8-(4, 4-dimethylcyclohex-1-en-1-yl)-6-methoxyquinoline-3-carboxylic acid (A122) (0.09 g, 0.289 mmol, 1.0 eq.) and HATU (0.16 g, 0.433 mmol, 1.5 eq.) along with DIPEA (0.15 mL, 0.867 mmol, 3.0 eq.) in DMF (1 mL) at 0 C. under nitrogen atmosphere was added (A50) (S)-2-amino-3-methoxypropan-1-ol (0.060 g, 0.578 mmol, 2.0 eq.) and resulting mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice-cold water (10 mL) and extracted with EA (320 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (100-200 mesh) as stationary phase (desired product eluted in 80% EA in Hex) to afford(S)-8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)-6-methoxyquinoline-3-carboxamide (Compound 160) (0.022 g, 0.055 mmol, Yield: 19%).

    [1453] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.06 (d, J=2.4 Hz, 1H), 8.63 (d, J=2.0 Hz, 1H), 8.44 (d, J=8.0 Hz, 1H), 7.23 (d, J=2.8 Hz, 1H), 5.76 (br s, 1H), 4.39-4.36 (m, 1H), 3.90 (s, 3H), 3.54-3.34 (m, 4H), 3.28 (s, 3H), 2.59-2.58 (m, 2H). 2.07 (s, 2H), 1.62 (t, J=12.4 Hz, 3H), 1.09 (s, 6H). Note: CONH and OH proton exchanged in MeOD NMR.

    [1454] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.10 (d, J=2.0 Hz, 1H), 8.67 (d, J=1.6 Hz, 1H), 8.44 (d, J=8.0 Hz, 1H), 7.36 (d, J=2.8 Hz, 1H), 7.20 (d, J=2.8 Hz, 2H), 5.76 (br s, 1H), 4.81 (t, J=11.2 Hz, 1H), 4.21-4.16 (m, 1H), 3.90 (s, 3H), 3.54-3.46 (m, 4H), 3.28 (s, 3H), 2.67-2.57 (m, 1H), 2.00 (br s, 2H), 1.50 (t, J=12.8 Hz, 2H), 1.10 (s, 6H).

    [1455] LCMS (Method A): 2.417 min, 100%, 254.0 nm, MS: ES+399 (M+1)

    [1456] HPLC (Method A): 8.90 min, 100%, 254.0 nm

    [1457] CHIRAL HPLC (Method A): 4.29 min, 99.17%, 248.0 nm

    Example 152Synthesis of 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(3-(methyl sulfonamido)propyl)quinoline-3-carboxamide (Compound 161)

    ##STR00379##

    Step-1

    [1458] To a stirred solution of A26 (0.07 g, 0.24 mmol, 1.0 eq.), A83 N-(3-aminopropyl) methanesulfonamide hydrochloride (0.056 g, 0.29 mmol, 1.2 eq.), in DMF (2 mL), HATU (0.12 g, 0.36 mmol, 1.5 eq.), DIPEA (0.16 mL, 0.72 mmol, 3.0 eq.), was added to the reaction mixture under the N.sub.2 atmosphere. The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was extracted with ethyl acetate (230 mL). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (60-120 Mesh) as stationary phase (30% EtOAc:Hexane) to afford 8-(4,4-dimethylcyclohex-1-en-1-yl)-N-(3-(methylsulfonamido)propyl)quinoline-3-carboxamide (Compound 161) (0.019 g, 0.045 mmol, Yield 18.44%)

    [1459] .sup.1H NMR (MeOD, 400 MHz): ppm 9.24 (d, J=2.0 Hz, 1H), 8.73 (d, J=2.4 Hz, 1H), 7.93 (dd, J=6.8, 6.8 Hz, 1H), 7.64-7.62 (m, 2H), 5.78 (br s, 1H), 3.57 (t, J=13.6 Hz, 2H), 3.21 (t, J=13.6 Hz, 2H), 2.61 (d, J=1.6 Hz, 2H), 2.09 (s, 2H), 1.94-1.91 (m, 2H), 1.64 (t, J=12.4 Hz, 2H), 1.10 (s, 6H). Note: CONH proton exchanged in MeOD NMR.

    [1460] .sup.1H NMR (DMSO, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.80-8.77 (m, 2H), 7.99-7.96 (m, 1H), 7.61 (t, J=5.2 Hz, 2H), 7.03 (t, J=12.0 Hz, 1H), 5.74 (br s, 1H), 3.41-3.34 (m, 2H), 3.06-3.01 (m, 2H), 2.91 (s, 3H), 2.67-2.60 (m, 2H), 2.01 (br s, 2H), 1.79-1.74 (m, 2H), 1.52-1.49 (m, 2H), 1.05 (s, 6H).

    [1461] LCMS (Method A)-2.504 min, 98.69%, 254.0 nm

    [1462] HPLC (Method A)-8.96 min, 99.49%, 210 nm

    Example 153Synthesis of 8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-isopropyl quinoline-3-carboxamide (Compound 162)

    ##STR00380##

    Step 1

    [1463] To a stirred solution of A36 (0.3 g, 1.945 mmol, 1.0 eq.) & ZnCu couple (1.254 g, 9.727 mmol, 5.0 eq.), in DME (5.0 mL) was added Cl.sub.3CCOCl (0.56 mL g, 5.058 mmol, 2.6 eq.) dropwise to the reaction mixture under the N.sub.2 atmosphere at RT. Then the resulting mixture was continue stirred at RT for 18 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched using aq. NH.sub.4Cl then extracted with EtOAc (30 mL4). The combined organic layers were washed with brine (40 mL) dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (15% Ethyl acetate in hexane) to afford 1, 1-dichloro-8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecan-2-one (A124) (0.12 g, 0.453 mmol, Yield: 23.27%)

    [1464] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 3.99-3.96 (m, 4H), 2.88-2.81 (m, 2H), 1.97-1.69 (m, 8H).

    Step 2

    [1465] To a stirred solution of 1, 1-dichloro-8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecan-2-one (A124) (0.1 g, 0.377 mmol, 1.0 eq.), in Methanol (1.0 mL) and Saturated aq. NH.sub.4Cl (1.0 mL) was added Zn Dust (0.247 g, 3.773 mmol, 10.0 eq.) at RT and resulting reaction mixture was continue stirred for 16 h. TLC indicated the completion of reaction; After 16 h. reaction mixture was filtered through celite bed washed with EtOAc (20 mL). Combined ethyl acetate layer washed with water (20 mL) dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (desired product eluted in 15% EtOAc in Hexane) to afford 8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecan-2-one (A125) (0.04 g, 0.204 mmol, Yield 54.02%).

    [1466] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm, 3.87 (s, 4H), 2.78 (s, 4H), 1.72-1.69 (m, 4H), 1.57-1.54 (m, 4H).

    Step 3

    [1467] To a stirred solution of 8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecan-2-one (A125) (0.2 g, 1.019 mmol, 1.0 eq.) in DCM (5 Ml) was added DAST (0.34 MI, 2.548 mmol, 2.5 eq.) at 0 C. Then the resulting mixture was stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched using ice cold water (20 Ml) and extracted with ethyl acetate (30 Ml4). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 18% EtOAc in Hexane) to afford 2, 2-difluoro-8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecane (A126) (0.06 g, 0.275 mmol, Yield: 26.98%).

    [1468] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 3.96 (m, 4H), 2.36 (t, J=5.6 Hz, 4H), 1.76-1.73 (m, 4H), 1.63-1.59 (m, 4H).

    Step 4

    [1469] To a stirred solution of 2, 2-difluoro-8, 11-dioxadispiro[3.2.4.sup.7.2.sup.4]tridecane (A126) (0.06 g, 0.275 mmol, 1.0 eq.) in THF (1.0 mL) was added IN HCl solution (1.0 mL) to the reaction mixture at room temperature. Then reaction mixture stirred at 70 C. for 3 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica (230-400 Mesh) as stationary phase (desired product eluted in 10% EtOAc in Hexane) to afford 2,2-difluorospiro[3.5]nonan-7-one (A127) (0.020 g, 0.114 mmol, Yield: 41.76%)

    [1470] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 2.52 (t, J=6 Hz, 4H), 2.36 (t, J=6.8 Hz, 4H), 2.00 (t, J=6.8 Hz, 4H).

    Step 5

    [1471] To a stirred solution of 2, 2-difluorospiro[3.5]nonan-7-one (A127) (0.025 g, 0.144 mmol, 1.0 eq.) in THF (3 mL) was added LiHMDS (0.158 mL, 0.158 mmol, 1.1 eq.) under the N.sub.2 atmosphere at 0 C. and stirred for 1 h. Followed by addition of CAS: 37595-74-7 (0.056 g, 0.158 mmol, 1.1 eq.), was added to the reaction mixture. Then reaction mixture stirred at RT for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched using H.sub.2O extracted with ethyl acetate (45 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (230-400 mesh) as stationary phase (desired product eluted in 20% Ethyl acetate in hexane) to afford 2, 2-difluorospiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (A128) (0.005 g, 0.0163 mmol, Yield: 11.38%).

    [1472] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 5.74-5.72 (m, 1H), 2.46-2.35 (m, 8H), 1.90 (t, J=6.4 Hz, 2H).

    Step 6

    [1473] To a stirred solution of 2, 2-difluorospiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (A128) (0.1 g, 0.327 mmol, 1.0 eq.) in Dioxane (2 mL) was added B.sub.2Pin.sub.2 (0.91 g, 0.359 mmol, 1.1 eq.) and KOAc (0.096 g, 0.980 mmol, 3.0 eq.) under N.sub.2 atmosphere at room temperature. Then the reaction mixture was purged with N.sub.2 gas for 5 min. followed by addition of PdCl.sub.2 (dppf). DCM (0.014 g, 0.0195 mmol, 0.06 eq.) and the reaction was allowed to run overnight at 100 C. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 5% Ethyl acetate in hexane) to afford 2-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-4,4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (A129) (0.02 g, 0.074 mmol, Yield: 21.56%)

    [1474] .sup.1H NMR (CDCl.sub.3, 400 MHz): ppm 6.48 (s, 1H), 2.37-2.28 (m, 4H), 2.25-2.24 (m, 2H), 2.22-2.18 (m, 2H), 1.67 (t, J=6.0 Hz, 2H). 1.25 (s, 12H).

    Step 7

    [1475] To a stirred solution of 2-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-4,4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (A129) (0.302 g, 1.126 mmol, 1.1 eq.), A4 (0.3 g, 1.023 mmol, 1.0 eq.) in Dioxane (2 Ml) & H.sub.2O (0.5 Ml), was added K.sub.3PO.sub.4 (0.652 g, 3.069 mmol, 3.0 eq.) and purged reaction mixture with N.sub.2 gas for 5 min. Then PdCl.sub.2 (dppf). DCM (0.037 g, 0.051 mmol, 0.05 eq.) was added to the reaction mixture under the N.sub.2 atmosphere at room temperature and the reaction was allowed to run overnight at 110 C. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (20 Ml) & extracted with ethyl acetate (320 Ml). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by flash column chromatography using silica (230-400 mesh) as stationary phase (desired product eluted in 30% Ethyl acetate in hexane) to afford 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-isopropylquinoline-3-carboxamide (Compound 162) (0.084 g, 0.227 mmol, Yield: 21.48%).

    [1476] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.25 (s, 1H), 8.77 (s, 1H), 8.57 (d, J=7.6 Hz, 1H), 7.98 (t, J=4.8 Hz, 1H), 7.61 (d, J=4.8 Hz, 2H), 5.79 (br s, 1H), 4.19-4.14 (m, 1H), 2.69 (br s, 2H), 2.46-2.38 (m, 6H), 1.85 (t, J=6.0 Hz, 2H), 1.22 (d, J=6.8 Hz, 6H).

    [1477] .sup.1H NMR (MeOD, 400 MHz): ppm 9.23 (d, J=2.4 Hz, 1H), 8.72 (d, J=2.0 Hz, 1H), 7.94 (dd, J=2.8, 6.4 Hz, 1H), 7.65-7.62 (m, 2H), 5.81 (br s, 1H), 4.33-4.26 (m, 1H), 2.69-2.68 (m, 2H), 2.53-2.45 (m, 6H), 1.97 (t, J=6.0 Hz, 2H), 1.33 (d, J=6.4 Hz, 6H).

    [1478] LCMS (Method A): 2.637 min, 99.25%, 254.0 nm, MS: ES+371.2 (M+1).

    [1479] HPLC (Method-A): 9.45 min, 99.04%, 254.0 nm

    Example 154Synthesis of(S)-8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 163)

    ##STR00381## ##STR00382##

    Step-1

    [1480] To a stirred solution of methyl 8-bromoquinoline-3-carboxylate (A13) (0.45 g, 1.691 mmol, 1.0 eq.), A129 (0.5 g, 1.860 mmol, 1.1 eq.) in Dioxane (4 mL) and H.sub.2O (2 mL) was added K.sub.3PO.sub.4 (1.074 g, 5.062 mmol, 3.0 eq.) and then reaction mixture purged with N.sub.2 gas for 5 min, followed by addition of PdCl.sub.2 (dppf).DCM complex (0.619 g, 0.844 mmol, 0.5 eq.) and resulting mixture was stirred at 110 C. for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (330 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (30% Ethyl acetate in hexane) to afford methyl 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylate (A130) (0.3 g, 0.874 mmol, Yield: 49.65%)

    [1481] .sup.1H NMR (MeOD, 400 MHz): ppm 9.35 (d, J=2.0 Hz, 1H), 8.95 (d, J=2.4 Hz, 1H), 7.99 (dd, J=1.6, 8.0 Hz, 1H), 7.70-7.62 (m, 2H), 5.80 (br s, 1H), 4.03 (s, 3H), 2.70-2.67 (m, 2H), 2.53-2.45 (m, 6H), 1.97 (t, J=6.0 Hz, 2H).

    [1482] LCMS (Method A): 2.900 min, 91.28%, 254.0 nm, MS: ES+344.2 (M+1).

    Step-2

    [1483] To a stirred solution of methyl 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylate (A130) (0.3 g, 0.874 mmol, 1.0 eq.) in MeOH (2.4 mL) and H.sub.2O (0.3 mL) was added NaOH (0.175 g, 4.368 mmol, 5.0 eq.). Then the resulting mixture was stirred at 40 C. for 4 h. TLC indicated the completion of reaction; the resulting reaction mixture was concentrated under reduced pressure then obtained residue was acidified by 1N HCl (10 mL) and extracted with EtOAc (430 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.23 g, 0.699 mmol, Yield 79.93%)

    [1484] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 13.51 (br s, 1H), 9.29 (d, J=2.0 Hz, 1H), 8.95 (d, J=2.0 Hz, 1H), 8.10-8.08 (m, 1H), 7.67-7.62 (m, 2H), 5.79 (br s, 1H), 2.68 (s, 2H), 2.51-2.38 (m, 4H), 1.84 (t, J=6.0 Hz, 2H).

    [1485] .sup.1H NMR (MeOD, 400 MHz): ppm 9.36 (d, J=2.0 Hz, 1H), 8.96 (d, J=1.6 Hz, 1H), 7.99 (d, J=6.8 Hz, 1H), 7.69-7.62 (m, 2H), 5.81 (br s, 1H), 2.69-2.68 (m, 2H), 2.53-2.45 (m, 6H), 1.97 (t, J=6.4 Hz, 2H

    [1486] LCMS (Method A): 2.476 min, 91.40%, 254.0 nm, MS: ES+330.3 (M+1).

    Step-3

    [1487] To a solution of 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.07 g, 0.213 mmol, 1.0 eq.), HATU (0.242 g, 0.638 mmol, 3.0 eq.) and DIPEA (0.22 mL, 1.275 mmol, 6.0 eq.) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 5 min, was added CAS: 40154-78-7 (0.049 g, 0.468 mmol, 2.2 eq.) under Nitrogen. The resulting mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 80% Ethyl acetate in hexane) to afford(S)-8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-(pyridin-2-yl)ethyl)quinoline-3-carboxamide (Compound 163) (0.034 g, 0.078 mmol, Yield: 36.90%).

    [1488] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.31 (d, J=2.0 Hz, 1H), 9.19 (d, J=7.6 Hz, 1H), 8.87 (d, J=2.0 Hz, 1H), 8.54 (d, J=4.4 Hz, 1H), 8.00 (t, J=4.8 Hz, 1H), 7.78 (t, J=6.0 Hz, 1H), 7.63 (d, J=4.8 Hz, 2H), 7.48 (d, J=7.6 Hz, 1H), 7.29-7.26 (m, 1H), 5.79 (br s, 1H), 5.30-5.22 (m, 1H), 2.70-2.68 (m, 4H), 2.43-2.33 (m, 4H), 1.86 (t, J=6.0 Hz, 2H), 1.56 (d, J=7.2 Hz, 3H).

    [1489] LCMS (Method A): 2.284 min, 95.81%, 254.0 nm, MS: ES+434.4 (M+1)

    [1490] HPLC (Method A): 9.19 min, 98.56%, 254.0 nm

    Example 155Synthesis of 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 164)

    ##STR00383##

    Step-1

    [1491] To a solution of 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.07 g, 0.213 mmol, 1.0 eq.), HATU (0.242 g, 0.638 mmol, 3.0 eq.) and DIPEA (0.22 mL, 1.275 mmol, 6.0 eq.) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 5 min, was added (A105) oxazol-2-ylmethanamine (0.063 g, 0.468 mmol, 2.2 eq.) and stirred for another 16 h at room temperature. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (80% Ethyl acetate in hexane as gradient) to afford 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-(oxazol-2-ylmethyl)quinoline-3-carboxamide (Compound 164) (0.033 g, 0.078 mmol, Yield: 37.92%).

    [1492] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.52 (t, J=6.0 Hz, 1H), 9.28 (d, J=2.4 Hz, 1H), 8.85 (d, J=2.4 Hz, 1H), 8.09 (d, J=0.4 Hz, 1H), 8.01-7.99 (m, 1H), 7.65-7.62 (m, 2H), 7.19 (d, J=0.8 Hz, 1H), 5.79 (br s, 1H), 4.67 (d, J=6.0 Hz, 2H), 2.68-2.67 (m, 4H), 2.43-2.33 (m, 4H), 1.85 (t, J=6.0 Hz, 2H).

    [1493] .sup.1H NMR (MeOD, 400 MHz): ppm 9.29 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 7.97-7.93 (m, 2H), 7.67-7.62 (m, 2H), 7.18 (d, J=0.4 Hz 1H), 5.82-5.80 (m, 1H), 4.80 (s, 2H), 2.71-2.67 (m, 2H), 2.53-2.45 (m, 6H), 1.97 (t, J=6.0 Hz, 2H).

    [1494] LCMS (Method A): 2.385 min, 99.10%, 254.0 nm, MS: ES+410.4 (M+1)

    [1495] HPLC (Method A): 8.39 min, 97.95%, 254.0 nm

    Example 156Synthesis of (R)-8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 165)

    ##STR00384##

    Step-1

    [1496] To a solution of 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.07 g, 0.213 mmol, 1.0 eq.), HATU (0.242 g, 0.638 mmol, 3.0 eq.) and DIPEA (0.22 mL, 1.275 mmol, 6.0 eq.) in DMF (2 mL) at 0 C. under nitrogen atmosphere stirred for 5 min, was added CAS: 35320-23-1 (R)-2-Aminopropan-1-ol (0.035 g, 0.468 mmol, 2.2 eq.) and resulting mixture was stirred for 16 h at room temperature. TLC indicated the completion of reaction; after completion water (10 mL) was added and extracted with EtOAc (310 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 mesh) as stationary phase (desired product eluted in 70% Ethyl acetate in hexane) to afford (R)-8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-hydroxypropan-2-yl)quinoline-3-carboxamide (Compound 165) (0.045 g, 0.116 mmol, Yield: 54.79%).

    [1497] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.26 (br s, 1H), 8.79 (br s, 1H), 8.46 (d, J=6.8 Hz, 1H), 7.98 (br s, 1H), 7.62 (br s, 2H), 5.79 (br s, 1H), 4.79 (br s, 1H), 4.08 (br s, 1H), 3.51-3.49 (m, 1H), 2.69 (br s, 3H), 2.43-2.38 (m, 3H), 1.85 (br s, 2H), 1.23-1.16 (m, 4H)

    [1498] .sup.1H NMR (MeOD, 400 MHz): ppm 9.26 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.94 (dd, J=2.8, 6.8 Hz, 1H), 7.64-7.62 (m, 2H), 5.80 (br s, 1H), 4.30-4.27 (m, 1H), 3.67 (d, J=4.8 Hz, 2H), 2.69-2.67 (m, 2H), 2.53-2.45 (m, 6H), 1.97 (t, J=6.0 Hz, 2H), 1.31 (d, J=6.8 Hz, 4H);

    [1499] LCMS (Method A): 2.214 min, 95.77%, 254.0 nm, MS: ES+387.4 (M+1)

    [1500] HPLC (Method A): 6.99 min, 96%, 254.0 nm

    Example 157Synthesis of (R)N-(1-(oxazol-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 166)

    ##STR00385##

    Step-1

    [1501] To a stirred solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.090 g, 0.32 mmol, 1.0 eq.) in DMF, were added DIPEA (0.120 g, 0.96 mmol, 3.0 eq.) and HATU (0.180 g, 0.48 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., (R)-1-(oxazol-2-yl)ethan-1-amine (A61) (0.050 g, 0.38 mmol, 1.2 eq.), was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with ethyl acetate (30 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (60-120 Mesh) as stationary phase (100% Ethyl acetate) to afford (R)N-(1-(oxazol-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 166) (0.018 g, 0.048 mmol, Yield 15%)

    [1502] .sup.1H NMR (DMSO, 400 MHz): ppm 9.34 (d, J=8.0 Hz, 1H), 9.28 (d, J=2.4 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 7.99-7.97 (m, 1H), 7.67-7.61 (m, 2H), 7.19 (s, 1H), 5.89 (s, 1H), 5.38 (t, J=7.2 Hz, 1H), 2.68 (br s, 2H), 2.13 (br s, 2H), 1.61 (d, J=7.2 Hz, 3H), 1.55 (t, J=6.0 Hz, 2H), 0.40 (s, 4H).

    [1503] LCMS (Method A): 2.52 min, 99.45%, 244.0 nm, MS: ES+374.3 (M+1)

    [1504] HPLC (Method B): 9.17 min, 99.52%, 210 nm

    [1505] Chiral HPLC-4.37 min, 97.70%, 242 nm

    Example 158Synthesis of (R)N-(1-hydroxypropan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 167)

    ##STR00386##

    Step-1

    [1506] To a stirred solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.090 g, 0.32 mmol, 1.0 eq.) in DMF (4.0 mL), were added DIPEA (0.120 g, 0.96 mmol, 3.0 eq.) and HATU (0.180 g, 0.48 mmol, 1.5 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., 2-aminoethan-1-ol (CAS No: 35320-23-1) (0.020 g, 0.38 mmol, 1.2 eq.), was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10.0 mL) and extracted with ethyl acetate (10 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (60-120 Mesh) as stationary phase (100% Ethyl acetate) to afford (R)N-(1-hydroxypropan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 167) (0.027 g, 0.080 mmol, Yield 24.91%)

    [1507] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.93 (d, J=6.4 Hz, 1H), 7.68-7.63 (m, 2H), 5.89 (br s, 1H), 4.29-4.27 (m, 1H), 3.67 (dd, J=2.0, 6.0 Hz, 2H), 2.67 (br s, 2H), 2.19 (br s, 2H), 1.67 (t, J=6.0 Hz, 2H), 1.31 (d, J=6.8 Hz, 3H), 0.44 (s, 4H).

    [1508] .sup.1H NMR (DMSO, 400 MHz): ppm 9.27 (d, J=2.0 Hz, 1H), 8.79 (d, J=2.0 Hz, 1H), 8.45 (d, J=7.6 Hz, 1H), 7.97 (dd, J=2.0, 7.6 Hz, 1H), 7.64-7.59 (m, 2H), 5.88 (s, 1H), 4.79 (t, J=6.0 Hz, 1H), 4.10-4.06 (m, 1H), 3.52-3.48 (m, 1H), 3.41-3.38 (m, 1H), 2.68 (br s, 2H), 2.13 (br s, 2H), 1.55 (t, J=6.0 Hz, 2H), 1.18 (d, J=6.8 Hz, 3H) 0.40 (s, 4H).

    [1509] LCMS (Method A): 2.25 min, 98.19%, 239.0 nm. MS: ES+337.4 (M+1)

    [1510] HPLC (Method B): 8.14 min, 99.09%, 210.0 nm.

    [1511] Chiral HPLC: 5.53 min, 97.09%, 242.0 nm

    Example 159Synthesis of (R)N-(4-(methylamino)-4-oxobutan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 168)

    ##STR00387##

    Step-1

    [1512] To a stirred solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.3 g, 1.07 mmol, 1.0 eq.) in DMF (4.0 mL), were added HATU (0.16 g, 1.60 mmol, 1.5 eq.) and DIPEA (0.120 g, 0.32 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., methyl (R)-3-aminobutanoate hydrochloride (CAS: No: 139243-54-2) (0.190 g, 1.2 mmol, 1.2 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (30 mL) and extracted with ethyl acetate (30 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (60-120 Mesh) as stationary phase (100% Ethyl acetate) to afford methyl (R)-3-(8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamido) butanoate (A132) (0.260 g, 0.68 mmol, Yield 65%).

    [1513] .sup.1H NMR (DMSO, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.75 (d, J=2.4 Hz, 1H), 8.68 (d, J=8.0 Hz, 1H), 7.98 (dd, J=2.0, 7.6 Hz, 1H), 7.65-7.60 (m, 2H), 5.88 (s, 1H), 4.44-4.40 (m, 1H), 3.60 (s, 3H), 2.72-2.66 (m, 3H), 2.13 (s, 2H), 1.55 (t, J=5.2 Hz, 2H), 1.24 (d, J=6.8 Hz, 3H), 0.40 (s, 4H). Note: one proton merged with DMSO solvent peak.

    [1514] LCMS (Method A): 2.589 min, 100%, 254.0 nm.

    Step 2

    [1515] To a stirred solution of methyl (R)-3-(8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamido) butanoate (A132) (0.02 g, 0.0524 mmol, 1.0 eq.), LiOH (0.0006 g, 0.158 mmol, 3.0 eq.), in THF:H.sub.2O (3:1) (0.3 mL), was added to the reaction mixture and stirred at room temperature for 3 h. The reaction was monitored by TLC, which indicated the completion of reaction; the resulting reaction mixture was extracted with ethyl acetate (230 m L). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford 0.03 g crude: (R)-3-(8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamido)butanoic acid (A133) Note: crude used as such for next step without further purification.

    [1516] LCMS (Method A): 2.253 min, 96.82%, 254.0 nm.

    Step 3

    [1517] To a stirred solution of (R)-3-(8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamido)butanoic acid (A133) (0.120 g, 0.32 mmol, 1.0 eq.) in DCM (2.0 mL), were added EDC.Math.HCl (0.090 g, 0.49 mmol, 1.5 eq.) and HOBt (0.08 g, 0.65 mmol, 2.0 eq.) at 0 C. followed by addition of CH.sub.3NH.sub.2 (0.020 g, 0.65 mmol, 2.0 eq.) in DCM (2.0 mL), was added to the reaction mixture under the N.sub.2 atmosphere. Then the resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was extracted with DCM (30 mL2). The combined organic layers dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (60-120 Mesh) as stationary phase (30% MDC in methanol) to afford (R)N-(4-(methylamino)-4-oxobutan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 168) (0.015 g, 0.04 mmol, Yield: 12.5%).

    [1518] .sup.1H-NMR (MeOD, 400 MHz): ppm 9.22 (d, J=2.4 Hz, 1H), 8.76 (d, J=1.6 Hz, 1H), 7.94 (dd, J=1.6, 8.0 Hz, 1H), 7.69-7.61 (m, 2H), 5.89 (s, 1H), 4.65-4.53 (m, 1H), 2.75 (s, 3H), 2.67 (br d, J=1.6 Hz, 2H), 2.62-2.57 (m, 1H), 2.51-2.46 (m, 1H) 2.19 (d, J=3.2 Hz, 2H), 1.67 (t, J=6.0 Hz, 2H), 1.36 (d, J=6.8 Hz, 3H), 1.31 (s, 1H), 0.44 (s, 4H).

    [1519] 1H-NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.24 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 8.63 (d, J=8.0 Hz, 1H), 7.98 (d, J=5.6, 1H), 7.87 (br s, 1H), 7.65-7.59 (m, 2H), 5.88 (s, 1H), 4.41-4.39 (m, 1H), 2.67 (br s, 2H), 2.62-2.57 (m, 4H), 2.13 (s, 2H), 1.55 (t, J=6.0 Hz, 2H), 1.19 (d, J=6.8 Hz, 3H), 0.40 (s, 4H).

    [1520] LCMS (Method A): 2.205 min, 98.46%, 254.0 nm

    [1521] HPLC (Method A): 8.00 min, 100%, 254.0 nm

    [1522] Chiral HPLC (Method): 4.53 min, 98.27%, 242.0 nm

    Example 160Synthesis of N-((1H-pyrazol-3-yl)methyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 169)

    ##STR00388##

    Step-1

    [1523] To a stirred solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.1 g, 0.35 mmol, 1.0 eq.) in DMF (2.0 mL) was added DIPEA (0.138 g, 1.07 mmol, 3.0 eq.) and HATU (0.271 g, 0.71 mmol, 2.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., (1H-pyrazol-3-yl) methenamine hydrochloride (CAS: No: 1196153-72-6) (0.071 g, 0.53 mmol, 1.5 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (20 mL) and extracted with ethyl acetate (30 mL2). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (45-50% Ethyl acetate in Hexane) to afford N-((1H-pyrazol-3-yl)methyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 169) (0.064 g, 0.17 mmol, Yield: 49.88%).

    [1524] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.65 (br s, 1H), 9.29 (d, J=1.6 Hz, 1H), 9.24 (s, 1H), 8.82 (d, J=1.6 Hz, 1H), 7.97 (d, J=6.4 Hz, 1H), 7.65-7.59 (m, 3H), 6.23 (s, 1H), 5.87 (s, 1H), 4.55 (d, J=4.8 Hz, 2H), 2.68 (s, 2H), 2.13 (s, 2H), 1.56-1.53 (t, J=6.0 Hz, 2H), 0.39 (s, 4H).

    [1525] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.27 (d, J=2.0 Hz, 1H), 8.76 (d, J=2.4 Hz, 1H), 7.93-7.91 (dd, J=1.6, 8.0 Hz, 1H), 7.68-7.60 (m, 3H), 6.37 (d, J=2.4 Hz, 1H), 5.88 (s, 1H), 4.70 (s, 2H), 2.66 (d, J=1.6 Hz, 2H), 2.18 (d, J=2.8 Hz, 2H), 1.66 (t, J=6.0 Hz, 2H), 0.44 (s, 4H).

    [1526] LCMS (UC02_FAR1): 2.178 min, 98.61%, 254.0 nm, MS: ES+359.3 (M+1).

    [1527] HPLC (HP04-BR1): 8.22 min, 98.47%, 210.0 nm.

    Example 161Synthesis of(S)N-(1-hydroxy-3-methoxypropan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 170)

    ##STR00389##

    Step-1

    [1528] To a solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.08 g, 0.28 mmol, 1.0 eq.) in DMF (2.0 mL) were added HATU (0.163 g, 0.42 mmol, 1.5 eq.) and DIPEA (0.15 mL, 0.859 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., (S)-2-amino-3-methoxypropan-1-ol (A50) (0.060 g, 0.573 mmol, 2.0 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with ethyl acetate (10 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 mesh) as stationary phase (70% Ethyl acetate in hexane as gradient) to afford(S)N-(1-hydroxy-3-methoxypropan-2-yl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 170) (0.035 g, 0.096 mmol, Yield: 33.35%).

    [1529] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.28 (d, J=1.6 Hz, 1H), 8.81 (d, J=1.6 Hz, 1H), 8.50 (d, J=8.0 Hz, 1H), 7.98 (d, J=5.6 Hz, 1H), 7.64-7.60 (m, 2H), 5.89 (s, 1H), 4.83 (t, J=5.6 Hz, 1H), 4.21-4.20 (m, 1H), 3.56-3.50 (m, 4H), 3.29 (s, 3H), 2.69 (s, 2H), 2.14 (s, 2H), 1.56 (t, J=5.6 Hz, 2H), 0.40 (s, 4H).

    [1530] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.26 (d, J=2.4 Hz, 1H), 8.78 (d, J=2.4 Hz, 1H), 7.94 (dd, J=1.6, 8.0 Hz, 1H), 7.69-7.62 (m, 2H), 5.90 (s, 1H), 4.39 (t, J=5.6 Hz, 1H), 3.79-3.77 (m, 2H), 3.69-3.63 (m, 2H), 3.43 (s, 3H), 2.68 (s, 2H), 2.19 (d, J=2.8 Hz, 2H), 1.67 (t, J=6.0 Hz, 2H), 0.45 (s, 4H).

    [1531] LCMS (Method A): 1.241 min, 98.90%, 244.0 nm, MS: ES+367.3 (M+1)

    [1532] HPLC (Method A): 8.11 min, 99.09%, 254.0 nm

    [1533] Chiral HPLC (Method A): 3.95 min, 99.08%, 242.0 nm.

    Example 162Synthesis of (R)N-(1-hydroxypropan-2-yl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 171)

    ##STR00390##

    Step-1

    [1534] To a stirred solution of A123 (0.10 g, 0.323 mmol, 1.0 eq.), in DMF (2 mL), was added HATU (0.246 g, 0.647 mmol, 2.0 eq.) and DIPEA (0.125 g, 969 mmol, 3.0 eq.) respectively at 0 C. followed by addition of CAS No: 35320-23-1 (R)-2-Aminopropan-1-ol (0.036 g, 0.484 mmol, 1.5 eq.) and reaction mixture was maintained at RT for 2 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with ice water (20 mL) and extracted with EtOAc (350 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by flash column chromatography (desired product was eluted in 50% Ethyl acetate in Hexane) to afford (R)N-(1-hydroxypropan-2-yl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 171) (0.057 g, 0.155 mmol, Yield: 48.12%).

    [1535] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.10 (br s, 1H), 8.66 (br s, 1H), 8.40 (d, J=7.6 Hz, 1H), 7.36 (br s, 1H), 7.23 (br s, 1H), 5.90 (br s, 1H), 4.78 (t, J=5.6 Hz, 1H), 4.08-4.04 (m, 1H), 3.90 (s, 3H), 3.51-3.47 (m, 1H), 2.67 (br s, 2H), 2.12 (br s, 2H), 1.55 (br s, 2H), 1.17 (d, J=6.4 Hz, 3H), 0.39 (s, 4H),

    [1536] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.07 (br s, 1H), 8.64 (br s, 1H), 7.27 (br s, 2H), 5.89 (br s, 1H), 4.29-4.25 (m, 1H), 3.97 (br s, 3H), 3.66 (br s, 2H), 2.64 (s, 2H), 2.17 (br s, 2H), 1.65 (t, J=6 Hz, 2H), 1.31 (d, J=6.4 Hz, 3H), 0.44 (s, 4H)

    [1537] LCMS (Method-A): 2.26, 96.58%, 254 nm, MS: ES+367 (M), (M+1)

    [1538] HPLC (Method-A): 8.17, 98.62%, 254 nm.

    Example 163Synthesis of N-((1H-pyrazol-4-yl)methyl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 172)

    ##STR00391##

    Step-1

    [1539] To a stirred solution of 6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A123) (0.100 g, 0.323 mmol, 1.0 eq.) in DMF (10 mL), was added (1H-pyrazol-4-yl) methanamine CAS: 1196153-72-6 (0.047 g, 0.323 mmol, 1.0 eq.), DIPEA (0.125 g, 0.969 mmol, 3.0 eq.) and HATU (0.184 g, 0.484 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted by EtOAc (250 mL). Combined organic phase was dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (100-200 mesh) as stationary phase (desired product eluted in 26% EtOAc in Hexane) to afford N-((1H-pyrazol-4-yl)methyl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 172) (0.014 g, 0.039 mmol, 12.36%)

    [1540] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 12.62 (br s, 1H), 9.18 (br s, 1H), 9.12 (d, J=2.4 Hz, 1H), 8.69 (d, J=2.4 Hz, 1H), 7.66 (br s, 1H), 7.36 (d, J=2.8 Hz, 1H), 7.23 (d, J=2.8 Hz, 1H), 6.23 (br s, 1H), 5.90 (s, 1H), 4.53 (br s, 2H), 3.90 (s, 3H), 2.67 (br s, 2H), 2.15 (br s, 2H), 1.54 (t, J=6.0 Hz, 2H), 0.39 (s, 4H).

    [1541] HPLC (Method A): 8.374 min, 96.51%, 254.0 nm.

    [1542] LCMS (Method A): 2.342 min, 97.30%, 254.0 nm, MS: ES+389.4 (M+1)

    Example 164Synthesis of (R)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 173)

    ##STR00392##

    Step-1

    [1543] To a stirred solution of (A123) 6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (0.1 g, 3.21 mmol, 1.0 eq.) and (A61) (0.05 g, 0.38 mmol, 1.2 eq.), in DMF (4 mL), HATU (0.18 g, 4.8 mmol, 1.5 eq.) and DIPEA (0.16 mL, 0.96 mmol, 3.0 eq.), was added to the reaction mixture under N.sub.2 atmosphere. The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; water (20 mL) was added and extracted with ethyl acetate (230 mL). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica (100-200 mesh) as stationary phase (desired product was eluted in 50% EtOAc:Hexane) to afford (R)-6-methoxy-N-(1-(oxazol-2-yl)ethyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 173) (0.013 g, 0.032 mmol, Yield: 10.15%) 1H NMR (MeOD, 400 MHz): ppm 9.09 (d, J=2.0 Hz, 1H), 8.68 (d, J=2.4 Hz, 1H), 7.92 (s, 1H), 7.29 (s, 2H), 7.18 (s, 1H), 5.90 (br s, 1H), 5.49-5.47 (m, 1H), 3.97 (s, 3H), 2.65 (d, J=1.6 Hz, 2H), 2.18 (d, J=3.2 Hz, 2H), 1.72 (d, J=7.2 Hz, 3H), 1.66 (t, J=6.0 Hz, 2H), 0.40 (s, 4H).

    [1544] .sup.1H NMR (DMSO, 400 MHz): ppm 9.29 (d, J=7.6 Hz, 1H), 9.11 (d, J=2.0 Hz, 1H), 8.71 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 7.37 (d, J=2.8 Hz, 1H), 7.24 (d, J=2.8 Hz, 1H), 7.18 (s, 1H), 5.91 (br s, 1H), 5.38-5.35 (m, 1H), 3.91 (s, 2H), 2.67-2.50 (m, 2H), 2.12 (br s, 2H), 1.61-1.52 (m, 4H), 0.39 (s, 3H).

    [1545] LCMS2.50 min, 98.37%, 254 nm

    [1546] HPLC9.25 min, 99.23%, 254 nm

    Example 165-Synthesis of(S)N-(1-hydroxy-3-methoxypropan-2-yl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 174)

    ##STR00393##

    Step-1

    [1547] To a stirred solution of 6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A123) (0.100 g, 0.323 mmol, 1.0 eq.) in DMF (10 mL), was added(S)-2-amino-3-methoxypropan-1-ol (A50) (0.047 g, 0.323 mmol, 1.0 eq.), DIPEA (0.125 g, 0.969 mmol, 3.0 eq.) and HATU (0.176 g, 0.465 mmol, 1.5 eq.). The resulting mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was diluted with water (50 mL) and extracted by EtOAc (250 mL). Organic phase was dried over Na.sub.2SO.sub.4 and concentrated under vacuum to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (100-200 mesh) as stationary phase (desired product eluted in 7% MeOH in DCM) to afford(S)N-(1-hydroxy-3-methoxypropan-2-yl)-6-methoxy-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 174) (0.015 g, 0.042 mmol, 13.25%)

    [1548] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.10 (d, J=2.0 Hz, 1H), 8.70 (d, J=2.0 Hz, 1H), 8.47 (d, J=8.0 Hz, 1H), 7.36 (d, J=2.8 Hz, 1H), 7.24 (d, J=2.8 Hz, 1H), 5.91 (br s, 1H), 4.21-4.16 (m, 1H), 3.94 (s, 3H), 3.56-3.47 (m, 4H), 3.29 (s, 3H), 2.67 (br s, 2H), 2.12 (br s, 2H), 1.54 (t, J=6.0 Hz, 2H), 0.39 (s, 4H), 1H is merging in solvent

    [1549] .sup.1H NMR (MeOD, 400 MHz): ppm, 9.10 (d, J=2.4 Hz, 1H), 8.83 (br s, 1H), 7.38-7.36 (m, 2H), 5.95 (br s, 1H), 4.45-4.35 (m, 1H), 3.99 (s, 3H), 3.80-3.76 (m, 2H), 3.75-3.61 (m, 2H), 3.44 (s, 3H), 2.63 (br s, 2H), 2.20 (br s, 2H), 1.68 (t, J=6.0 Hz, 2H), 0.46 (s, 4H).

    [1550] HPLC (Method A): 8.263 min, 98.34%, 254.0 nm.

    [1551] LCMS (Method A): 2.249 min, 96.60%, 254.0 nm, MS: 397.2 (M+1)

    Example 166Synthesis of N-(3-(methylsulfonamido)propyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 175)

    ##STR00394##

    Step-1

    [1552] To a stirred solution of 8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxylic acid (A42) (0.100 g, 0.35 mmol, 1.0 eq.) in DMF (2.0 mL), were added HATU (0.190 g, 0.52 mmol, 1.5 eq.) and DIPEA (0.18 mL, 1.05 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., N-(3-aminopropyl) methane sulfonamide hydrochloride (A83) (0.088 g, 0.46 mmol, 1.3 eq.) was added at same temperature. The resulting reaction mixture was stirred from 0 C. to room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The crude was purified by manual column chromatography using silica gel (60-120 Mesh) as a stationary phase (10% MDC: Methanol) to afford N-(3-(methylsulfonamido)propyl)-8-(spiro[2.5]oct-5-en-6-yl)quinoline-3-carboxamide (Compound 175) (0.052 g, 0.125 mmol, Yield 37.14%)

    [1553] .sup.1H NMR (MeOD, 400 MHz): ppm 9.25 (d, J=2.4 Hz, 1H), 8.74 (d, J=2.0 Hz, 1H), 7.94 (dd, J=1.6, 8.0 Hz, 1H), 7.69-7.61 (m, 2H), 5.89 (s, 1H), 3.57 (t, J=6.8 Hz, 2H), 3.21 (t, J=6.8 Hz, 2H), 2.98 (s, 3H), 2.67 (br s, 2H), 2.19 (d, J=2.8 Hz, 2H), 1.96-1.89 (m, 2H), 1.67 (t, J=6.0 Hz, 2H), 0.44 (s, 4H).

    [1554] .sup.1H NMR (DMSO, 400 MHz): ppm 9.26 (d, J=2.4 Hz, 1H), 8.81-8.77 (m, 2H), 7.98 (dd, J=2.0, 7.6 Hz, 1H), 7.65-7.59 (m, 2H), 7.04 (t, J=5.8 Hz, 1H), 3.41-3.34 (m, 3H), 3.04 (q, J=6.4 Hz, 13.2 Hz, 2H), 2.91 (s, 3H), 2.68 (br s, 2H), 2.13 (br s, 2H), 1.78 (t, J=6.8 Hz, 2H), 1.55 (t, J=6.0 Hz, 2H), 0.40 (s, 4H).

    [1555] LCMS (Method A)-2.31 min, 98.88%, 254.0 nm, MS: ES+414.3 (M+1)

    [1556] HPLC (Method A)-8.28 min, 99.24%, 254.0 nm

    Example 167Synthesis of (R)-8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 176)

    ##STR00395##

    Step-1

    [1557] To a solution of 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.060 g, 0.182 mmol, 1.0 eq.) in DMF (2.0 mL), were added DIPEA (0.19 mL, 1.093 mmol, 6.0 eq.) and HATU (0.208 g, 0.547 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., (R)-1-(oxazol-2-yl)ethan-1-amine hydrochloride (A61) (0.059 g, 0.401 mmol, 2.2 eq.) was added at same temperature and the resulting reaction mixture was stirred at 0 C. to room temperature for 8 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (10 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to afford crude. The crude was purified by column chromatography using silica gel (230-400 Mesh) as a stationary phase (70% Ethyl acetate in hexane as gradient) to afford (R)-8-(2,2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-(oxazol-2-yl)ethyl)quinoline-3-carboxamide (Compound 176) (0.022 g, 0.052 mmol, Yield: 28.52%).

    [1558] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): ppm 9.34 (d, J=7.6 Hz, 1H), 9.28 (d, J=2.0 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.08 (s, 1H), 7.99 (t, J=5.6 Hz, 1H), 7.63-7.60 (m, 2H), 7.19 (s, 1H), 5.79 (br s, 1H), 5.37 (t, J=7.2 Hz, 1H), 2.67 (br s, 3H), 2.38-2.33 (m, 5H), 1.85 (t, J=6.0 Hz, 2H), 1.61 (d, J=7.2 Hz, 3H).

    [1559] HPLC (Method A): 8.82 min, 98.79%, 254.0 nm.

    [1560] LCMS (Method A): 2.447 min, 98.19%, 254.0 nm, MS: ES+424.4 (M+1).

    [1561] Chiral HPLC: 3.96 min, 97.99%, 242.0 nm.

    Example 168Synthesis of(S)-8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 177)

    ##STR00396##

    Step-1

    [1562] To a solution 8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)quinoline-3-carboxylic acid (A131) (0.070 g, 0.212 mmol, 1.0 eq.) in DMF (1.0 mL), were added HATU (0.121 g, 0.319 mmol, 1.5 eq.) and DIPEA (0.10 mL, 0.636 mmol, 3.0 eq.) at 0 C. The reaction mixture was stirred under the N.sub.2 atmosphere. After 15 min of stirring at 0 C., (S)-2-amino-3-methoxypropan-1-ol (A50) (0.044 g, 0.424 mmol, 2.0 eq.) was added at same temperature. Then the reaction mixture was stirred at room temperature for 16 h. TLC indicated the completion of reaction; the resulting reaction mixture was quenched with ice-cold water (10 mL) and extracted with EtOAc (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to afford crude. The obtained crude material was purified by flash column chromatography using silica gel (230-400 Mesh) as stationary phase (5% MDC in MeOH) to afford(S)-8-(2, 2-difluorospiro[3.5]non-6-en-7-yl)-N-(1-hydroxy-3-methoxypropan-2-yl)quinoline-3-carboxamide (Compound 177) (0.025 g, 0.06 mmol, Yield: 25.99%).

    [1563] .sup.1H-NMR (MeOD, 400 MHz): ppm, 9.25 (d, J=2.4 Hz, 1H), 8.76 (d, J=2.0 Hz, 1H), 7.94 (dd, J=2.8 Hz, 7.2 Hz, 1H), 7.65-7.62 (m, 2H), 5.80 (s, 1H), 4.40-4.37 (m, 1H), 3.77 (dd, J=1.6 Hz, 5.6 Hz, 2H), 3.66-3.64 (m, 2H), 3.42 (s, 3H), 2.68 (br s, 2H), 2.52-2.44 (m, 6H), 1.96 (t, J=6.0 Hz, 2H).

    [1564] .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): ppm, 9.27 (d, J=2.4 Hz, 1H), 8.81 (d, J=2.4 Hz, 1H), 8.51 (d, J=8.4 Hz, 1H), 7.98 (t, J=5.0 Hz, 1H), 7.61 (d, J=4.4 Hz, 2H), 5.79 (br s, 1H), 4.82 (t, J=5.6 Hz, 1H), 4.23-4.18 (m, 1H), 3.55-3.50 (m, 4H), 3.28 (s, 3H), 2.69 (br s, 2H), 2.46-2.38 (m, 4H), 2.33 (br s, 2H), 1.85 (t, J=6 Hz, 2H).

    [1565] LCMS (Method A): 2.240 min, 100%, 254.0 nm, MS: ES+417.5 (M+1)

    [1566] HPLC (Method A): 7.91 min, 100%, 254.0 nm

    [1567] CHIRAL HPLC (Method A): 3.88 min, 98.79%, 260.0 nm

    BIOLOGICAL EXAMPLES

    [1568] Prior art TEAD inhibitors 1-1, 1-2, 1-3, and 1-4 (structures provided in Table 3) are used as reference compounds throughout Biological Examples 169-179.

    TABLE-US-00003 TABLE 3 Prior art TEAD inhibitors Compound Number Structure 1-1 [00397]embedded image 1-2 [00398]embedded image 1-3 [00399]embedded image 1-4 [00400]embedded image

    Example 169NCI-H226 and H28 Proliferation and Cell Viability Assay

    [1569] Cell proliferation of a TEAD dependent NF2-null mesothelioma cell line, NCI-H226, and a TEAD-non-dependent mesothelioma cell line, NCI-H28 was assayed using two different protocols: [1570] a) CellTiter-Glo 2.0 (Promega #G9243). The effect of the TEAD inhibitors disclosed herein on cell proliferation was determined in TEAD1-genetically dependent cell line NCI-H226 (responder cell line) and TEAD-independent cell lines (NCI-H23, HEK293T), as non-responder, negative control. Cells were seeded in 96-well plates (Thermo Scientific #167008) in growth media (RPMI-1640, Gibco #61870-010) for NCI-H226 and NCI-H23 or DMEM (Gibco #31966-021, HEK293T) with 10% Heat Inactivated Fetal Bovine Serum (Gibco 10500-064) at 800 (NCI-H226 and HEK-293T) or 2000 (NCI-H23) cells per well at 37 C., 5% CO.sub.2, humidified incubator; 24 hours later, fresh growth media containing test compound or DMSO vehicle was added and incubated with the cells for 144 hrs. TEAD inhibitor stocks were made at a 1000 fold excess in DMSO, and a dose response test compound dose range of 10,000 to 0.1 nM was used. Each treatment was carried out in triplicate. After 144 hrs of treatment, relative cell viability numbers were determined using the CellTiter-Glo 2.0 assay following the manufacturer's instructions. Test plates and CellTiter-Glo 2.0 reagent were allowed to equilibrate to room temperature. CellTiter-Glo 2.0 reagent was added at 1:1 reagent to media ratio to the 96-well cell plates, plates were placed on a plate shaker for 2 minutes and then incubated at room temperature for a further 10 minutes to allow complete cell lysis to occur. The mix was then transferred to white, 96-well luminometer assay plates (Greiner Bio One #655075). Luminescence was quantified using a CLARIOStar Plus multi-mode plate reader (BMG Labtech) in luminescence detection mode with the recommended settings (ultra-Glo pre-set: emission 545-50 nm with autofocus and enhanced dynamic range on). Relative cell density was expressed as a function of inhibitor concentration, with respect to DMSO-only control wells. Data where plotted using GraphPad Prism and IC.sub.50 values for the biological effect were calculated using the EC.sub.50 non-linear fit function using a sigmoidal, 4-parameter logistic, least squares fit with no constraints. [1571] b) Cell Titer One (Promega, #G3582). The effect of the TEAD inhibitors disclosed herein on cell proliferation was also determined using the Promega Substrate Cell Titer Aqueous One Solution Reagent. The TEAD inhibitors were evaluated for the effects on cell proliferation responder (H226) and non-responder negative control cancer cell lines (CAMA1, H28), as well as non-transformed normal human cells (HUVEC, NHDF). Dissociated cells were resuspend in media (depending on cell line, either in DMEM, RPMI, or EMEM all with 10% FBS, with gentamicin as an antibiotic). Cells were seeded at 100 L/well at 750 cells per well in 96-well plates and allowed to settle and attach. After an incubation of 24 hrs (37 C., 5% CO.sub.2, humidified incubator), 100 L of test compound-containing media was added. A dilution series of 2000 concentrated stock of test compounds was prepared in DMSO, for final concentrations from 0.1 to 10,000 nM. After addition of test compound-containing media, cells were incubated for 6 days at 37 C., 5% CO.sub.2, humidified incubators). To measure cell density, 20 L of Promega Substrate Cell Titer 96 Aqueous One Solution Reagent (Promega, #G3582) to each well was added according to the manufacturer's instructions. Plates were incubated at 37 C. for usually 3-8 hrs, to reach in the control cells (without compound) an OD of 1.5 at 490 nm. The OD was measured using Vmax [Molecular Devices] spectrophotometer plate reader. Media only-wells were used as background controls and cell densities normalized to DMSO vehicle control. ECs were taken as the concentration achieving 50% of maximal growth inhibition.

    [1572] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00004 TABLE 4 Cytotoxic potency measured by CTG assay for the H226-responder and H23-non-responder cell lines Cmpd No. NCI-H226 IC.sub.50 NCI-H23 IC.sub.50 1 A C 2 A C 5 A C 6 A C 7 A C 11 A C 16 A ND 19 A C 20 A C 21 B C 22 A C 26 A ND 27 A ND 29 B ND 30 A ND 31 A ND 12 A C 13 A C 38 A ND 39 A ND 40 A ND

    TABLE-US-00005 TABLE 5 Cytotoxic potency measured by CTG assay for the H226-responder cell line Compound EC50 Number (nM) 1-2 A 1-3 A 7 A 11 A 19 A 47 A 62 A 165 A 166 A 109 A 110 A

    TABLE-US-00006 TABLE 6 Cytotoxic potency measured by Cell Titer One assay for the H226 and H28 cell lines Cmpd No. NCI-H226 IC.sub.50 NCI-H28 IC.sub.50 1 A C 2 A C 5 A ND 6 A C 7 A C 11 A C 16 A C 19 A C 20 A C 21 B C 22 B C 26 A ND 27 A ND 29 C ND 30 A ND 31 C ND 35 B ND 36 C ND 37 C ND 12 B ND 13 A ND 38 B ND 39 A ND 40 B ND

    Example 170Mero14 Proliferation and Cell Viability Assay

    [1573] Mero14 cells were trypsinised, counted and plated at 400 cells/well in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 144 hours (6 days) at 37 C., 5% CO.sub.2. Following compound treatment the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate.

    [1574] Luminescence at 545 nm was read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control is plotted against compound concentration and a curve fitted with non-linear regression in GraphPad Prism software. IC.sub.50 values were calculated using GraphPad Prism software as follows: For Relative IC.sub.50 values, a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computed area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1575] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00007 TABLE 7 Cytotoxic potency measured by CTG assay for Mero14 cell line Compound EC50 Number (nM) 1-2 B 1-3 A 7 A 11 A 19 A 47 A 62 A 165 A 166 A 109 A 110 A

    Example 171Mero82 Proliferation and Cell Viability Assay

    [1576] Mero 82 cells were trypsinised, counted and plated at 400 cells/well in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 144 hours (6 days) at 37 C., 5% CO.sub.2. Following compound treatment, the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate. Luminescence at 545 nm was read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control is plotted against compound concentration and a curve fitted with non-linear regression in GraphPad Prism software. IC.sub.50 values were calculated using GraphPad Prism software as follows: For Relative IC.sub.50 values a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computes area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1577] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00008 TABLE 8 Cytotoxic potency measured by CTG assay for Mero82 cell line Compound EC50 Number (nM) 1-2 C 1-3 A 7 A 11 A 19 A 47 A 62 A 165 A 166 A 109 A 110 A

    Example 172BHY Proliferation and Cell Viability Assay

    [1578] BHY cells were trypsinised, counted and plated at the specified cell density in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 144 hours (6 days) at 37 C., 5% CO.sub.2. Following compound treatment, the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate. Luminescence at 545 nm was read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control was plotted against compound concentration and a curve fitted with non-linear regression in GraphPad

    [1579] Prism software. EC.sub.50 and IC.sub.50 values are calculated using GraphPad Prism software as follows: For EC.sub.50 values, a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computes area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1580] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00009 TABLE 9 Cytotoxic potency measured by CTG assay for BHY cell line Compound EC50 Number (nM) 1-2 C 1-3 A 7 A 19 A 20 A 47 A 62 A 81 A 82 B 109 A 103 A 104 A

    Example 173LOU-NH91 Proliferation and Cell Viability Assay

    [1581] LOU-NH91 cells were trypsinised, counted and plated at the specified cell density in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 216 hours (9 days) at 37 C., 5% CO.sub.2. Following compound treatment, the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate. Luminescence at 545 nm was read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control was plotted against compound concentration and a curve fitted with non-linear regression in GraphPad Prism software. EC.sub.50 and IC.sub.50 values were calculated using GraphPad Prism software as follows: For EC.sub.50 values a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computes area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1582] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00010 TABLE 10 Cytotoxic potency measured by CTG assay for LOU-NH91 cell line Compound EC50 Number (nM) 1-2 A 1-3 A 7 A 19 A 20 A 47 A 62 A 81 A 82 A 109 A 103 A 104 A

    Example 174MSTO-211H Proliferation and Cell Viability Assay

    [1583] MSTO-211H cells were trypsinised, counted and plated at the specified cell density in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 144 hours (6 days) at 37 C., 5% CO.sub.2. Following compound treatment, the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate. Luminescence at 545 nm is read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control was plotted against compound concentration and a curve fitted with non-linear regression in GraphPad Prism software. IC.sub.50 values were calculated using GraphPad Prism software as follows: For Relative IC.sub.50 values a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computes area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1584] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00011 TABLE 11 Cytotoxic potency measured by CTG assay for MSTO-211H cell line Compound EC50 Number (nM) 1-2 A 1-3 A 7 A 11 A 19 A 47 A 62 A 165 A 166 A 109 A 110 A

    Example 175SDM103T2 Proliferation and Cell Viability Assay

    [1585] SDM103T2 cells were trypsinised, counted and plated at the specified cell density in 200 l of growth media in 96 well flat bottom tissue culture treated plates. The plated cells were incubated overnight at 37 C., 5% CO.sub.2 before being treated with compounds in triplicate for each assay point. 50 l of the serially diluted compound was added to each well giving a final DMSO concentration of 0.5% per well and a total volume of 250 l per well. The treated cells were incubated for 144 hours (6 days) at 37 C., 5% CO.sub.2. Following compound treatment the remaining viable cells were detected using the Promega CellTiter-Glo 2.0 assay as follows: 150 l of media was removed from each of the wells to be assayed and 100 l of room temperature CellTiter-Glo 2.0 reagent was added. The plate was placed on an orbital shaker at 500 rpm at room temperature for 2 minutes, and then incubated without shaking for a further 10 minutes at room temperature. 150 l of cell lysate was removed from each well and dispensed into a single well of a white opaque 96 well plate. Luminescence at 545 nm was read using a BMG CLARIOstar plate reader. The luminescent signal was directly proportional to number of viable cells, the percent of viable cells relative to the DMSO control was then calculated for each assay point. Percent viability relative to DMSO control was plotted against compound concentration and a curve fitted with non-linear regression in GraphPad Prism software. EC.sub.50 and IC.sub.50 values were calculated using GraphPad Prism software as follows: For EC.sub.50 values a non-constrained four-parameter logistic curve fit was used (Sigmoidal, 4PL, X is concentration). For Absolute IC.sub.50 values the baseline was constrained to Y=0 (Absolute IC.sub.50, X is concentration). Area Under the Curve (AUC): Prism computes area-under-the-curve by the trapezoidal method. The analysis sees a fitted curve as simply a series of connected XY points. Prism simply computes the area under the curve defined by connecting the points by straight lines. The units of the AUC are the units of the Y axis times units of the X axis.

    [1586] For IC.sub.50 and EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M. ND: no data.

    TABLE-US-00012 TABLE 12 Cytotoxic potency measured by CTG assay for SDM103T2 cell line Compound EC50 Number (nM) 1-1 A 1-2 C 1-3 A 7 A 11 A 19 A 47 A 62 A 165 A 166 A 109 A 110 A

    Example 176Cell-Based TEAD-Promoter Transcriptional Activity Assay

    [1587] Luciferase based TEAD-transcriptional cell-based reporter assay: To measure the effect of the TEAD inhibitors disclosed herein on TEAD transcriptional activity in cell-based systems, we employed a stable MCF7 cell line expressing luciferase under a consensus synthetic TEAD/YAP promoter element (MCF7-Luc, BPS Bioscience, Catalog #60618). This MCF7-TEAD-Luc cell line has been extensively validated with both genetic and pharmacological intervention, showing inhibition of luciferase expression and luminescence in response to ablation of the TEAD/YAP pathway. MCF7-Luc cells were plated at 10,000 cells per well in white 384-well plates and settled by a quick spin. The media was MEM (Gibco) supplemented with 10% fetal bovine serum (ExCell), selenium-transferrin-insulin mix (Gibco), 1 non-essential amino acids (Gibco) and sodium pyruvate (Gibco). Cells were allowed to attach and grow overnight (37 C., 5% CO.sub.2 in humidified incubator), and test compounds were added the next day. Compounds were dissolved at 1000 fold excess in DMSO and made into 2-fold serial dilution, and added to media at 30 L of media per well. A DMSO-only well serves a vehicle control. The highest concentration of drug in media was 1,000 nM. Positive control compounds include K975 (pan-TEAD inhibitor) and negative control (Actinomycin). Cells were incubated for 24 hrs with test compounds and positive controls, after which time, the luminescence was measured by the One-Glo luciferase kit (Promega). 30 L of One-Glo reagent was added to each well and shaken for 8 minutes to lyse the cells. The plates were centrifugated at 1000 RPM for 1 minute to settle all liquid in the well and eliminate bubbles. Luminescence was quantified using an ENVision plate reader (Perkin Elmer). Percent inhibition of luminescence by test compound was expressed as a function of test compound concentration, with the no-test compound DMSO only wells serving as baseline. EC.sub.50 values for each compound were calculated with a non-linear asymptotic line fit.

    [1588] For EC.sub.50 data A indicates a value of less than 0.2 M; the symbol B indicates a value in the range of from 0.2 M up to 1 M; and the symbol C indicates a value of greater than 1 M.

    TABLE-US-00013 TABLE 13 MCF-7 TEAD Luciferase Assay Cmpd No. MCF-7 Luc EC.sub.50 1 A 2 A 11 A 19 A 20 A

    Example 177TEAD Thermal Shift Assay (TSA)

    [1589] Thermal shift assay (TSA) is a biophysical method to evaluate stability of proteins with change in temperature. The assay measures thermal denaturation temperature in varying conditions such as different drug concentration. For this example, fluorogenic dye was used that bind to unfolded proteins. SYPRO Orange binds non-specifically to hydrophobic surfaces, and water strongly quenches its fluorescence. When the protein unfolds, the exposed hydrophobic surfaces bind the dye, resulting in an increase in fluorescence by excluding water. Detergent micelles also bind the dye and increase background noise dramatically. Binding of small molecules to proteins leads to a stabilization against to thermal denaturation with the degree of thermal stabilization proportional to the strength of binding.

    [1590] The study described in this example investigated the change in melting temperature (Tm) of TEAD isoforms 14 when treated with TEAD inhibitors. Compound 1-1-a known strong TEAD1 and weak TEAD2 inhibitor; as well as Compound 1-4-a pan-TEAD inhibitor were used as controls. As expected, Compound 1-1 showed pronounced thermal shift only for TEAD1 whilst Compound 1-4 showed thermal shifts for all four TEAD isoforms. As shown in Table 14, compounds of the disclosure uniformly displayed TEAD1 binding and significantly divergent binding to TEAD2-4 Experimental Parameters/Conditions

    TABLE-US-00014 Parameters Conditions Assay Format Biophysical, 96-well Bio-Rad plate Protein Human TEADs Sypro Orange 5X Conc. DMSO 1% Ramp rate 1 C./min Assay Buffer 20 mM Tris-HCL (pH: 8), 200 mM NaCl, 2 mM TCEP, 10% Glycerol, 0.01% Tween 20 Assay Volume 25 L Assay Readout Melt Curve 20-95 C. Instrument Bio-Rad family of CFX Real-time PCR systems

    Assay Buffer Preparation

    TABLE-US-00015 Component Final Weighed Total Name Source Cat # Conc. quantity Volume Trizma Sigma T5941- 20 mM 31.52 mg 10 mL hydrochloride 500G NaCl Sd fine- 20241 200 mM 116.88 mg chem ltd TCEP Sigma C4706-2G 2 mM 5.73 mg Glycerol Sigma G5516- 10% 1 mL 100ML Tween 20 Sigma P9416- 0.01% 1 L 100ML Cell culture Hi-media TCL019- grade water 500ML

    [1591] Tris-HCL was dissolved in 5 mL of Cell culture grade water and allowed to dissolve completely. The pH was adjusted to 8 using NaOH. Additional assay buffer components were added in the order listed above. The buffer was mixed slowly.

    Assay Flow

    [1592] Assay buffer was prepared according to the procedures outlined above and dispensed into test wells. Spyro orange was added to a concentration of 5 in the assay buffer, followed by test compound stock solution which was added to a concentration of 10 M or 30 M in the assay buffer.

    [1593] The melt cycle was performed in Bio-RAD PCR instrument from 20-95 C. with ramp rate of 1 C./min.

    [1594] Thermal shift data are provided in Table 14.

    TABLE-US-00016 TABLE 14 Thermal shift assay data Ratio of Protein to TEAD1 TEAD2 TEAD3 TEAD4 Compound Compound Tm( C.) 1-1 1:1 2 1 0 0 1-1 1:3 8 1 0 1 1-4 1:1 10 5 5 5 1-4 1:3 12 7 9 9 2 1:1 10 1 2 2 2 1:3 12 1.5 3 4 7 1:1 9 2 2 1.5 7 1:3 11 3 2 3 11 1:1 11 3 3.5 1.5 11 1:3 11.5 3 3 2.5 19 1:1 12 2 2 2 19 1:3 12 3 4 3 20 1:1 10 1 2 1.5 20 1:3 13 3 4.5 3 47 1:1 9 2 2 3 47 1:3 11 2 3 3 62 1:1 9 3 1 2 62 1:3 11 3 2 3 81 1:1 9 2 4 5 81 1:3 10 3 5 7 109 1:1 13 3 2 1 109 1:3 14 2 3 2 110 1:1 14 2 2 2 110 1:3 16 3 3 3

    Example 178Inhibition of mouse xenograft MSTO-211H tumors with TEAD inhibitors

    [1595] This study evaluated the in vivo anti-tumor efficacy of test compounds in BALB/c nude mice for treatment of MSTO-211H xenograft of lung cancer.

    Abbreviations

    [1596] AAALAC Association for Assessment and Accreditation of Laboratory Animal Care [1597] BW Body Weight [1598] g gram [1599] IACUC Institutional Animal Care and Use Committee [1600] kg kilogram [1601] mg milligram [1602] mL milliliter [1603] mm millimeter [1604] PO Per Os [1605] R&D Research and Development [1606] RT Room Temperature [1607] RTV Relative Tumor Volume [1608] SEM Standard Error of the Mean [1609] TGI Tumor Growth Inhibition [1610] TV Tumor Volume [1611] TW Tumor Weight [1612] UL microliter [1613] dd H.sub.2O double distilled water [1614] T/C Relative tumor proliferation rate [1615] AA Antibiotic-Antimycotic [1616] CMC-Na Carbokyl Methyl Cellulose-Na [1617] BID Bis in Die [1618] Tween 80 Tween 80

    Animals and Housing Conditions

    [1619] Species: Mus Musculus [1620] Strain: BALB/c nude [1621] Age: 6-8 weeks [1622] Sex: female [1623] Body weight: 18-22 g [1624] Number of animals inoculated with tumor: 80 mice [1625] Number of animals enrolled in the treatment: 36 mice [1626] Number of unenrolled animals: 44 mice [1627] Animal supplier: Beijing Vital River Biotechnology Experimental Animal Co. Ltd
    Certification number: 20170011010591

    Study Design

    TABLE-US-00017 Dosing Dosage Volume.sup.b Dosing Dosing Dosing Group N.sup.a Compound (mg/kg) (L/g) route Frequency.sup.c Schedule.sup.c 1 4 Vehicle 10 PO BID 27 3 4 7 12.5 10 PO BID 27 5 4 110 12.5 10 PO BID 27 7 4 166 12.5 10 PO BID 27 8 4 109 12.5 10 PO BID 27 9 4 62 12.5 10 PO BID 27 Note: .sup.aN, animal number in each group. .sup.bDose volume: adjust dose volume based on body weight 10 L/g. .sup.cTreatment schedule was adjusted if body weight loss >15%.

    Cell Culture

    [1628] The MSTO-211H tumor cells were maintained in RPMI 1640 medium supplemented with 10% Fetal bovine serum and 1% Antibiotic-Antimycotic at 37 C. in an atmosphere of 5% CO.sub.2 in air. The tumor cells were routinely subcultured twice weekly by trypsin-EDTA. The cells growing in an exponential growth phase with 95% cell survival or above were harvested, and counted for tumor inoculation.

    Tumor Cell Information

    TABLE-US-00018 Cell lines Cancer Type Species Vendor Cat. No. MSTO-211H Lung cancer human ATCC CRL-2081

    Tumor Inoculation

    [1629] Each mouse was inoculated subcutaneously at the right flank with MSTO-211H tumor cells (510.sup.6+50% matrigel/0.2 mL) for tumor development. Animals were marked with earrings with unique 6 significant figure number for identification. The treatments were started when the average tumor volume reached an average size of 181 mm.sup.3.

    Tumor Measurement

    [1630] The major endpoint was to see if the tumor growth could be delayed or mice could be cured. Tumor volume was measured twice a week in two dimensions using a caliper, and the volume was expressed in mm.sup.3 using the formula: V=0.5 ab.sup.2 where a and b are the long and short diameters of the tumor, respectively. The tumor size was then used for calculations of T/C value. The TGI value (in percent) or the T/C value (in percent) is an indication of antitumor effectiveness; T and C are the mean tumor volumes or tumor weights of the treated and control groups, respectively, on a given day.

    [1631] TGI was calculated for each group using the formula: TGI (%)=[1(T.sub.iT.sub.0)/(V.sub.iV.sub.0)]100; Ti is the average tumor volume of a treatment group on a given day, To is the average tumor volume of the treatment group on the day of treatment start, V.sub.i is the average tumor volume of the vehicle control group on the same day with T.sub.i, and V.sub.0 is the average tumor volume of the vehicle group on the day of treatment start.

    [1632] Relative T/C (%)=T.sub.RTV/C.sub.RTV100 (RTV(%)=V.sub.t/V.sub.0100, V.sub.t is the average tumor volume on a given day, V.sub.0 is the average tumor volume on the first day of treatment. T.sub.RTV is the RTV of a treatment group, and the C.sub.RTV is the RTV of the vehicle control group.)

    Statistical Analysis

    [1633] Summary statistics, including mean and the standard error of the mean (SEM), were provided for the tumor volume of each group at each time point.

    [1634] Statistical analysis of difference in tumor volume among the groups was conducted on the data obtained at the end of the study.

    [1635] One-tailed T test was performed to compare tumor volumes between two groups. All data are analyzed using GraphPad Prism 6.0. p<0.05 is considered to be statistically significant.

    [1636] The antitumor effectiveness of the study was analyzed on PG-D27 when vehicle group reached 588 mm.sup.3.

    Tumor Volume Trace

    [1637] The change in tumor volume over the course of the study is provided in Table 15.

    TABLE-US-00019 TABLE 15 Tumor size over course of study. Days after the start of treatment.sup.a Gr. Treatment 0 3 6 10 13 17 20 23 27 1 Vehicle, PO, BID 181 249 287 327 363 392 431 489 588 5 23 32 48 43 51 51 54 73 3 Compound 7, 12.5 181 245 219 124 99 86 109 117 126 mg/kg, PO, BID 12 31 29 8 7 6 12 20 16 5 Compound 110, 12.5 181 207 179 107 75 51 42 53 50 mg/kg, PO, BID 9 11 24 16 9 5 4 8 2 7 Compound 166, 12.5 181 192 177 153 145 139 148 184 219 mg/kg, PO, BID 7 11 36 18 8 25 21 26 25 8 Compound 109, 12.5 181 216 174 89 59 44 44 46 58 mg/kg, PO, BID 11 21 18 5 3 3 4 4 8 9 Compound 62, 12.5 181 224 228 149 111 82 88 101 104 mg/kg, PO, BID 10 14 30 14 2 9 9 7 3 Note: .sup.aMean SEM

    Tumor Growth Inhibition Analysis

    [1638] Tumor growth inhibition rate for the test compounds was calculated based on tumor volume measurement at day 27 after the start of treatment. The T/C values calculated according to tumor volume are close to each other, and the trend is shown in Table 16.

    TABLE-US-00020 TABLE 16 Tumor size on day 27. Tumor P value Volume T/CD.sup.b TGI.sup.b compared Gr. Treatment (mm.sup.3).sup.a (%) (%) With vehicle.sup.c 1 Vehicle , 588 PO, BID 73 3 Compound 126 21.4 113.6 p < 0.001 7, 12.5 16 mg/kg, PO, BID 5 Compound 50 8.5 132.4 p < 0.001 110, 12.5 2 mg/kg, PO, BID Compound 219 38.1 90.7 p < 0.01 7 166, 12.5 25 mg/kg, PO, BID 8 Compound 58 10.1 130.2 p < 0.001 109, 12.5 8 mg/kg, PO, BID 9 Compound 104 17.9 119.1 p < 0.001 62, 12.5 3 mg/kg, PO, BID .sup.aMean + SEM. .sup.bT/C(%) = TRTV / CRTV 100, TGI = [1 (T.sub.i T.sub.0)/ (V.sub.i V.sub.0)] 100. .sup.cOne-tailed T test analysis was performed to compare tumor volumes between two groups.

    Example 179Inhibition of Mouse Xenograft NCI-H226 Tumors with TEAD Inhibitors

    [1639] This study evaluated the in vivo therapeutic efficacy of TEAD inhibitors in the treatment of the subcutaneous lung cancer NCI-H226 xenograft model in female BALB/c nude mice.

    Abbreviations

    [1640] ANOVA Analysis of variance [1641] BW Body weight [1642] BWL Body weight loss [1643] FFPE Formalin fixed paraffin embedded [1644] IACUC Institutional animal care and use committee [1645] MTV Mean tumor volume [1646] N/A Not available or not applicable [1647] p.o. Oral (ly) [1648] QD Once a day [1649] REG REG=[(T0Ti)/T0]100%; [1650] Ti as the mean tumor volume of the treatment group on the measurement day; [1651] T0 as the mean tumor volume of the treatment group on Day 0. [1652] ROA Route of administration [1653] RT Room temperature [1654] RTV Relative tumor volume [1655] SD Standard deviation [1656] SEM Standard error of mean [1657] SOC Standard of care used in clinical setting for a specific disease [1658] TBD To be determined [1659] T/C The Ti/Ci value (%): T/C %=Ti/Ci100; [1660] Ti and Ci are the mean tumor volumes of the treatment and control groups, respectively, on a given day. [1661] TGI Tumor growth inhibition; TGI %=(1Ti/Ci)100; [1662] Ti and Ci are the mean tumor volumes of the treatment and control groups, respectively, on a given day. [1663] TV Tumor volume [1664] PK/PD Pharmacokinetics/Pharmacodynamics [1665] Inhibition Mean % Inhibition=((CiC0)(TiT0))/(CiC0)*100% [1666] Ti and Ci are the mean tumor volumes of the treatment and control groups, respectively, on a given day. T0 and C0 as the mean tumor volumes of the treatment and vehicle groups on Day 0.

    Animal and Model

    [1667] Species Mus musculus [1668] Strain Balb/c nude [1669] Supplier GemPharmatech Co., Ltd [1670] Gender Female [1671] No. of Animals Ordered 68 (45 plus 23 spare) [1672] No. of Animals Assigned 45 [1673] to Study [1674] Average Age of Animals 6-8 weeks [1675] at Study Initiation

    Tumor Cell Information

    TABLE-US-00021 Cell line Cancer Type NCI-H226 Lung cancer

    Study Design

    TABLE-US-00022 Dose Dosing Dosing Dosing No. of level Solution Volume Frequency Group mice Compound (mg/kg) (mg/ml) (mL/kg) ROA & Duration 1 5 Vehicle 10 p.o. QD 28 days 2 5 No treatment QD 28 days 3 5 1-1 3 0.3 10 p.o. QD 28 days 4 5 2 25 2.5 10 p.o. QD 28 days 5 5 2 10 1 10 p.o. QD 28 days 6 5 2 3 0.3 10 p.o. QD 28 days 7 5 11 25 2.5 10 p.o. QD 28 days 8 5 11 10 1 10 p.o. QD 28 days 9 5 11 3 0.3 10 p.o. QD 28 days

    Cell Culture

    [1676] The NCI-H226 cells (CL-00364) cancer cells were maintained in vitro with RPMI1640 medium supplemented with 10% fetal bovine serum at 37 C. in an atmosphere of 5% CO.sub.2 in the air. The cells in exponential growth phase were harvested and quantitated by cell counter before tumor inoculation.

    Tumor Inoculation

    [1677] Each mouse was inoculated subcutaneously in the right front flank region with NCI-H226 tumor cells (110.sup.7) in 0.2 ml of PBS mixed with Matrigel (1:1) for tumor development.

    Randomization

    [1678] The randomization was performed when the mean tumor size reached 138.81 mm.sup.3. 45 mice were enrolled in the study. All animals were randomly allocated to 9 study groups, 5 mice in each group. Randomization was performed based on Matched distribution method/Stratified method (StudyDirector software, version 3.1.399.19)/randomized block design. The date of randomization was denoted as day 0.

    Test Compound Administration

    [1679] The treatment was initiated on the same day of randomization (day 0) per study design.

    Observation and Data Collection

    [1680] After tumor cells inoculation, the animals were checked daily for morbidity and mortality. During routine monitoring, the animals were checked for any effects of tumor growth and treatments on behavior such as mobility, food and water consumption, body weight gain/loss (Body weights were measured twice per week after randomization), eye/hair matting and any other abnormalities. Mortality and observed clinical signs were recorded for individual animals in detail.

    [1681] Tumor volumes were measured twice per week after randomization in two dimensions using a caliper, and the volume was expressed in mm.sup.3 using the formula: V=(LWW)/2, where V is tumor volume, L is tumor length (the longest tumor dimension) and W is tumor width (the longest tumor dimension perpendicular to L). Dosing as well as tumor and body weight measurements were conducted in a Laminar Flow Cabinet.

    [1682] The body weights and tumor volumes were measured by using StudyDirector software (version 3.1.399.19).

    Statistical Analysis

    [1683] To compare tumor volumes of different groups at a pre-specified day, Bartlett's test was first used to check the assumption of homogeneity of variance across all groups. When the p-value of Bartlett's test was >=0.05, one-way ANOVA was performed to test overall equality of means across all groups. If the p-value of the one-way ANOVA was <0.05, post hoc testing was performed by running Tukey's HSD (honest significant difference) tests for all pairwise comparisons, and Dunnett's tests for comparing each treatment group with the vehicle group. When the p-value of Bartlett's test was <0.05, Kruskal-Wallis test was performed to test overall equality of medians among all groups. If the p-value the Kruskal-Wallis test was <0.05, post hoc testing was performed by running Conover's non-parametric test for all pairwise comparisons or for comparing each treatment group with the vehicle group, both with single-step p-value adjustment.

    [1684] In addition, pairwise comparisons were performed without multiple comparison correction and report nominal/uncorrected p-values directly from Welch's t-test or Mann-Whitney U test. Specifically, Bartlett's test was first used to check the assumption of homogeneity of variance for a pair of groups. When the p-value of Bartlett's test was 0.05, Welch's t-test was performed; otherwise Mann-Whitney U test was performed, to obtain nominal p-values.

    [1685] All statistical analyses were performed in R-a language and environment for statistical computing and graphics (version 3.3.1). All tests were two-sided unless otherwise specified, and p-values of <0.05 were regarded as statistically significant.

    ResultsTumor Growth Inhibition

    TABLE-US-00023 TABLE 17 TGI and T/C calculation on Day 27 Dose Day 27 Level Tumor Volume T/C TGI Group Compound (mg/kg) (mm.sup.3, mean SEM) (%) (%) P Value 1 Vehicle 534.18 57.34 2 No 636.87 179.23 119.22 19.22 1 treatment 3 1-1 3 66.85 12.17 12.51 87.49 5.49e07 4 2 25 105.03 13.17 19.66 80.34 3.12e05 5 2 10 243.78 74.70 45.64 54.36 0.1 6 2 3 345.21 85.33 64.62 35.38 0.605 7 11 25 112.73 17.20 21.10 78.90 6.14e05 8 11 10 194.94 42.44 36.49 63.51 0.0201 9 11 3 479.84 96.60 89.83 10.17 1 Note: Bartlett's test was performed to test homogeneity of variance and normality, P = 4.09e06, significant, non-parametric test was used to compare groups. P < 0.05 was considered to be statistically significant.